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Abstract 
The research outlined in this thesis describes methodologies for the synthesis of 
functionalised heterocycles through the use of C1-ammonium enolate catalysis utilising 
isothiourea organocatalysts. 
Chapter 2: Initial work demonstrated a DHPB-mediated Michael addition-
lactamisation/PhSH elimination/N- to O-sulfonyl transfer one-pot cascade for the synthesis of 
2,4,6-substituted pyridine sulfonates. Applying (phenylthio)acetic acid and a range of α,β-
unsaturated ketimines, pyridine sulfonates were obtained in moderate to good yield (40-69%) 
with the functionalisation of the incorporated sulfonate group examined through various 
derivatisations. 
 Chapter 3: The established isothiourea-mediated pyridine methodology was expanded 
into the synthesis of 2,3- and 2,3,5-substituted pyridine 6-tosylates through a three-stage 
Michael addition-lactamisation, S-oxidation-sulfoxide elimination and N- to O-sulfonyl transfer 
protocol. Using (phenylthio)acetic acids and 2-N-tosyliminoacrylates a range of pyridine 
products were provided in moderate to good yield over the three-stage process (44-72%). 
Derivatisation of the installed sulfonate group allowed access into 2,3-, 2,3,5-, 2,3,6 and 2,3,5,6-
substituted pyridines. 
 Chapter 4: Subsequent studies expanded the scope of dihydropyranone and 
dihydropyridinone products accessible through isothiourea-catalysis using 2-aroyl acrylates or 
2-N-tosyliminoacrylates in an enantioselective Michael addition-cyclisation process. It was 
discovered that the use of homoanhydride enolate precursors was necessary when applying 2-
aroyl acrylates to ensure high enantioselectivity (up to 99%) and reproducibility of the 
dihydropyranone products, while carboxylic acids can be used with 2-N-tosyliminoacrylates, 
providing dihydropyridinones in high enantioselectivity (typically >90% ee). 
 Chapter 5: Enantioselective Michael addition-lactonisation of 2-aryl and 2-
alkenylacetic acids and α,β-unsaturated trichloromethyl ketones, catalysed by (2S,3R)-
HyperBTM was shown to give dihydropyranones with subsequent ring opening and substitution 
of the CCl3 group providing a range of diesters and diamides in high diastereo- and 
enantioselectivity (up to 95:5 and up to >99% ee).  
 Chapter 6: The pyrrolizine core is present in many biologically relevant molecules. It 
was demonstrated that an isothiourea-catalysed enantioselective Michael addition-
lactonisation/ring opening process gives access to these important molecules with exquisite 
diastereo- and enantioselectivity (typically >95:5 dr and >99% ee). A novel synthetic route into 
the synthesis of the pyrrole enone-acid substrates was established, hence making the overall 
methodology more efficient and reproducible. Computational studies are provided to 
Abstract 
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compliment the synthetic studies with investigations into the origin of the high stereocontrol 
observed in this process. 
 Chapter 7: Saccharin-derived Michael acceptors have been shown as useful substrates 
in isothiourea-catalysis. (2R,3S)-HyperBTM catalyses the Michael addition-lactamisation of 
carboxylic acids and saccharin-derived Michael acceptors to give 8,9-dihydro-7H 
benzo[4,5]isothiazolo[2,3-a]pyridin-7-one 5,5-dioxides in good to excellent stereocontrol 
(80:20->95:5 dr and 71->99% ee). Furthermore, these Michael acceptors can be utilised with 1-
(1H-imidazol-1-yl)-2-(phenylthio)ethan-1-one in a Michael addition-lactamisation/PhSH 
elimination process giving access to the corresponding 1,2-benzoisothiazolopyridone 1,1-
dioxide heterocycle in a chromatography-free procedure. 
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Chapter 1: Introduction 
1.1 Organocatalysis 
For many decades scientists have been stimulated by the exquisite manner and elegance 
in which Nature produces complex chiral molecules with impressive levels of selectivity and 
specificity. Endeavours by synthetic chemists have elegantly demonstrated the performance, 
selectivity and tuneability of bio- and transition metal-based catalysts to mediate a wide range 
of complex and enantioselective transformations. Only in recent decades has the use of small 
organic molecule catalysts (organocatalysts) emerged alongside the use of enzymes and metal-
based complexes at the forefront of asymmetric catalysis. Despite sporadic reports of 
organocatalysed processes that date from the early 20th century, it was not until the late 1990s 
that organocatalysis was conceptualised and acknowledged as a general field with enormous 
potential, with the result being a rapid evolution in the reported application of organocatalysts in 
>100 discrete reaction types.[1] The remarkable recent growth observed in this area builds upon 
the exploratory findings of Bredig,[2] Pracejus,[3] Wynberg,[4] Hajos[5] and Wiechert,[6] Inoue,[7] 
Juliá and Colonna,[8] who all documented the use of cinchona alkaloid or amino acid derivatives 
as organic catalysts. However, the highly specific nature of these reactions, combined with poor 
mechanistic understanding, contributed to a slow realisation of the potential of organocatalysis 
as an approach to synthesis. These initial articles also did not emphasise the potential benefits of 
using organic molecules in catalysis, or the general concepts that underpin these reaction 
processes.  
At the core of the modern interest in organocatalysis are the inherent advantages it 
presents to that of alternative enantioselective catalytic processes. Practically, most 
organocatalysts are insensitive to oxygen and moisture thus eliminating the need for strict 
experimental techniques, reagents, anhydrous solvents and equipment. From an economic 
standpoint, many organocatalysts are easy and cheap to prepare in large quantities, with most 
derived from chiral pool reagents and other single-enantiomer compounds available from 
Nature. Not only may this present lower process expenses for industrial projects but also lower 
costs for academic researchers entering the area of asymmetric catalysis. They can be used in a 
wide range of reaction processes for the preparation of diverse enantiomerically pure 
compounds of enormous complexity. Paramount to the development and widespread utilisation 
of catalysis in the modern day is the safety and environmental impact of these processes. One 
potential beneficial feature of small organic catalysts is their generally low/non-toxic effects 
with typically low levels of environmental damage.  
To establish organocatalysis as a general catalytic concept it is necessary to determine 
and identify the key reactivity modes available. Improved understanding of these reactivity 
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modes allows us to apply organocatalysis to a wide range of examples in a systematic manner 
with predictable origins of selectivity. Commonly, the most powerful methodologies for 
enantioselective organocatalysis can be placed under the categories of Brønsted acid, Brønsted 
base, Lewis acid and Lewis base catalysis. 
1.1.1 Brønsted Acid Catalysis 
The role of a Brønsted acid catalyst is based on similar fundamentals to that of a Lewis 
acid catalysis whereby C=X bonds (where X is O, NR, CR2) can be activated through non-
covalent interactions with the reaction catalyst thus lowering the LUMO energy and increasing 
the electrophilicity of the substrate.[9] A proton is therefore considered the smallest and simplest 
Lewis acid, with the ability to activate the substrate in two ways (Figure 1). The first approach, 
referred to as general/neutral Brønsted acid catalysis, utilises a hydrogen bonding (H-bonding) 
interaction between the chiral catalyst (H-bond donor) and the substrate (H-bond acceptor) 
promoting selectivity during a nucleophilic attack on the substrate. The second approach, 
referred to as specific/stronger Brønsted acid catalysis, exploits the relative acidities of the 
chiral catalyst (Brønsted acid) and the substrate (Brønsted base) resulting in the formation of a 
tight ion pair that can impart enantioselectivity when attacked by a nucleophile. Typically, this 
second class of reaction is most effective at pH near or below the pKaH of the substrate. In both 
these strategies it is believed that nucleophilic attack on the Brønsted acid activated species is 
the turnover-limiting step in the mechanistic cycle.  
 
 
 
 
 
 
 
 
Figure 1 - General concepts for Brønsted acid catalysis. 
The research group of Takemoto has made a significant contribution to this area 
through the application of urea and thiourea-based H-bonding catalysts. One such prominent 
example is the enantioselective Michael addition of malonates 1 into nitroolefins 2 catalysed by 
thiourea 3 (10 mol%) (Scheme 1). The Michael adduct products 4 are provided in excellent 
yield (74-95%) and typically excellent enantioselectivity (>90% ee) for a range of aryl and alkyl 
substituted substrates.[10]  
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Scheme 1 - Enantioselective H-bonding catalysed Michael addition into nitroolefins. 
The application of much stronger Brønsted acid catalysts that can protonate the 
substrate and form a close ion pair has attracted significant interest from the research 
community. The seminal work by Akiyama[11] and Terada[12] launched the development of a 
new class of chiral phosphoric Brønsted acid catalyst based upon the core structure of (R)-
BINOL. These phosphoric acid catalysts are ideally designed to remain conformationally rigid, 
maximizing the communication of stereoselectivity to the substrate. A tightly associated ion 
pair between catalyst and substrate results from the high Brønsted acidity[13] of the P(O)O−H, 
with the phosphoryl P=O also available as a Lewis basic point of binding.[14] Various 
derivatives have emerged containing different stereodirecting groups situated at the ortho-
position of the binaphthyl backbone that allows fine-tuning of enantioselectivity. 
The founding work from Akiyama applies catalyst 7 (10 mol%) into the Mannich 
reaction between imines 5 and silyl enol ethers 6 to produce amino esters 8 with typically 
excellent levels of enantioselectivity (81-96% ee) (Scheme 2). The 2-phenol N-substituent on 
the imine is crucial for obtaining high enantioselectivity. Theoretical experiments have 
attributed the high enantioselectivity to the efficient association between the protonated imine 
and deprotonated catalyst 7 providing an ion-ion interaction, with a second favourable H-
bonding interaction between phenol O−H and phosphoryl oxygen defining the Re-facial 
selectivity of the subsequent nucleophilic attack.  
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Scheme 2 - Phosphoric acid-catalysed enantioselective Mannich reaction. 
1.1.2 Brønsted Base Catalysis 
Deprotonation of a molecule by a Brønsted base constitutes a key step in many 
carbon−carbon and carbon−heteroatom forming reactions in organic synthesis. Classically, 
reactions instigated by a Brønsted base deprotonation of a substrate have been unselective. With 
the advent of asymmetric organocatalysis, a significant research direction has applied chiral 
Brønsted bases to mediate stereoselective transformations. The concept resides on the 
deprotonation of a pro-nucleophilic substrate (NuH) by a chiral Brønsted base catalyst (BB), 
generating a tight ion pair, which subsequently directs a bond-forming reaction in the presence 
of an electrophile (E) with induction of stereocontrol (Figure 2).[15] Catalyst design usually 
includes nitrogen-based functional groups with tertiary amines (most commonly cinchona 
alkaloids),[16] guanidines[17] and amidines[18] proving most abundant in research reports with 
properties of high basicity and moreover good accessibility from chiral pool reagents. In recent 
times, the preparation of bifunctional catalysts bearing both Brønsted base units (for nucleophile 
activation) and Brønsted acid units (for electrophile activation) has become widely researched. 
 
 
 
 
 
 
 
Figure 2 - General concepts of Brønsted base catalysis. 
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A transformation that has proven well suited for Brønsted base catalysis is the Michael 
addition of nucleophiles into α,β-unsaturated systems. A new and state-of-the-art method is the 
use of highly basic (pKBH+ = 26.9) cyclopropenimine compounds that present strong properties 
for application as Brønsted base catalysts. A modern example from Lambert uses 
cyclopropenimine catalyst 11 (10 mol%) to mediate the enantioselective Michael addition of 
glycine derived imines 9 into Michael acceptors 10 with high stereocontrol (89-99% ee) 
(Scheme 3).[19] Computational studies suggest the reaction to proceed via transition state 13, 
with both the nucleophile and electrophile directed by the catalyst to dictate the excellent 
enantioselectivity of the reaction.[20] 
 
 
 
 
 
 
 
 
 
Scheme 3 - Enantioselective Michael addition catalysed by cycloprenimine catalyst 11. 
1.1.3 Lewis Acid Catalysis 
Activation of a substrate via metal-based Lewis acid catalysis is the foundation of many 
organic reactions. Through the maturity of organocatalysis, many of these functions have been 
revisited in recent times with the intention that organic Lewis acids can emulate the versatility 
and reactivity of their metal counterparts. Typically a chiral Lewis acid (LA) can activate a 
substrate (S) via the acceptance of a pair of electrons to form an associated adduct (S+−LA−) 
that can subsequently undergo a reaction and release the product (S−R) (Figure 3). To facilitate 
the need for a Lewis acid to have a vacant orbital to accept a lone pair of electrons, molecules 
such as ammonium, carbenium, silyl and phosphonium cations have attracted attention. Perhaps 
the most popular area to emerge within this area of Lewis acid organocatalysis is that of 
asymmetric phase transfer catalysis (PTC).[21] 
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Figure 3 - General concepts of Lewis acid catalysis. 
One PTC transformation studied recently by Smith and co-workers is enantioselective 
electrocyclisation.[22] Phase transfer catalyst 15 (10 mol%) can mediate the enantioselective 6π-
electrocyclisation reaction of imines generated in situ from amines 14 and a range of aldehydes 
into indolines 16 with typically excellent stereoselectivity (85-98% ee). Stereochemical 
rationale has been assigned based on the tight ion pair model proposed by Corey and co-
workers.[23] Inputting 14 into this model, it is proposed that the enolate oxygen forms a close 
association with ammonium catalyst 15 inducing a number of non-covalent interactions that 
dictate the torquoselectivity of the ring-closing step.  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4 - Enantioselective 6π-electrocyclisation reaction catalysed by 15 (one ester group removed 
for clarity). 
1.1.4 Lewis Base Catalysis 
Lewis base activation represents the largest area of organocatalysis and can be broadly 
defined as the ability of a Lewis base catalyst (LB) to activate a substrate (S) through the 
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donation of a lone pair of electrons (Figure 4).[24] Enhancement of a reaction occurs from the 
increased electron density present in the newly formed Lewis adduct (LB+−S−), how this 
electron density is distributed is determined by the constituent atoms and dictates the 
nucleophilic or electrophilic character of the reactive species when reacted with reactant (R) to 
form product (R−S). With a wide availability of chiral Lewis bases encompassing a number of 
complimentary reactivity modes, this field has progressed to the forefront of asymmetric 
catalysis. 
 
 
 
 
 
 
Figure 4 - General concepts of Lewis base catalysis. 
Enamine Catalysis 
Enamine catalysis consists of the condensation of a secondary amine catalyst with a 
carbonyl containing substrate, followed by deprotonation of the intermediate iminium cation to 
generate the key nucleophilic enamine species (Figure 5).[25] This newly formed enamine 
species has a raised highest occupied molecular orbital (HOMO) energy and therefore lower 
HOMO-LUMO energy gap compared to the starting ketone. 
 
 
 
 
 
Figure 5 - Enamine formation by Lewis base catalyst. 
Now realised as one of the first applications of asymmetric organocatalysis, the Hajos-
Parrish-Eder-Sauer-Wiechert cyclisation reported in 1971 is one of the earliest examples of 
enamine catalysis (Scheme 5).[26] Enantioselective intramolecular aldol reaction of triketone 17 
catalysed by (S)-proline 18 (3 mol%) gives bicyclic ketone 19 with excellent diastereo- and 
enantiocontrol (>95:5 dr and 93% ee). Following the generation of the enamine intermediate, it 
is proposed that the carboxylic acid substituent derived from (S)-proline 18 can H-bond with 
one of the ketone groups to define the selectivity of the cyclisation. 
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Scheme 5 - Hajos-Parrish-Eder-Sauer-Wiechert cyclisation 
In 2000, List and co-workers revisited the use of the amino acid (S)-proline 18 in 
enamine catalysis with a piece of work that has since become celebrated as one of the founding 
examples of organocatalysis as a field in organic chemistry.[27] This work also displayed an 
enantioselective aldol reaction, but this time in a more challenging intermolecular system 
(Scheme 6). Applying acetone 20 as the enamine precursor with a range of aldehydes 21 
catalysed by 18 (3 mol%) produces hydroxyl ketones 22 with typically moderate to excellent 
enantioselectivity (54-94% ee) and served as a solid proof of concept for the exploration of 
asymmetric enamine catalysis. 
 
 
 
 
 
 
Scheme 6 - (S)-Proline-catalysed enantioselective aldol reaction. 
Iminium Catalysis 
Similarly to enamine catalysis, iminium catalysis involves the condensation of a 
secondary amine catalyst with a carbonyl containing substrate this time giving the electrophilic 
intermediate iminium cation (Figure 6). Here the key reactive species is LUMO activated, thus 
bringing the energy of the LUMO nearer to the HOMO of the nucleophile.[28]  
 
 
 
 
 
Figure 6 - Iminium formation by Lewis base catalyst. 
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In 2000, MacMillan and co-workers showed that the iminium intermediate generated 
from the condensation of imidazolidinone catalyst 25 (20 mol%) and enals 23 can be 
intercepted to give an enantioselective Diels-Alder reaction with dienes 24 (Scheme 7).[29] It’s 
proposed that the geminal methyl groups on the catalyst favour the formation of an (E)-iminium 
ion, with the stereodirecting Bn substituent blocking the Si-face upon approach of the diene in 
an endo selective manner. Along with the prioneering enamine chemistry reported by List, this 
methodology was a founding example of the field of organocatalysis. 
 
 
 
 
 
 
 
Scheme 7 - Iminium-catalysed Diels-Alder reaction. 
SOMO Catalysis 
 Singularly occupied molecular orbital (SOMO) catalysis is one of the newest reactivity 
modes to enter the field of organocatalysis in recent years. The concept is based upon one 
electron oxidation of an electron-rich enamine, generated as described previously, to form a 
reactive radical cation with three π-electrons (Figure 7).[30] The electrophilicity of these SOMO 
intermediates allows them to react with a range of weak nucleophiles that are typically 
incompatible with other reactivity modes.  
 
 
 
 
 
Figure 7 - Generation of SOMO activated intermediates. 
The area of SOMO catalysis has been introduced and explored by the MacMillan group 
with their seminal work on the enantioselective α-alkylation of aldehydes (Scheme 8). 
Treatment of aldehydes 27 with imidazolidinone catalyst 29 (20 mol%) in the presence of 
allylsilanes 28 and ceric ammonium nitrate (CAN) as the oxidant gives products 30 in good 
yield (70-88%) and excellent enantioselectivity (87-95% ee). Computational studies suggest the 
(E)-configuration of the three π-system to minimise non-bonding interactions between the 
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catalyst t-Bu substituent and the substrate. Furthermore, enantiofacial discrimination arises from 
the blocking of the Re face by the benzyl group leaving the Si-face exposed for the reaction. 
 
 
 
 
 
 
 
Scheme 8 - Enantioselective α-alkylation of aldehydes applying SOMO catalysis 
1.1.5 Ammonium Enolate/Acyl Ammonium Catalysis 
Nucleophilic tertiary amine catalysts have been classically used in a range of 
amidations, esterifications and acyl transfer reactions through their ability to effectively undergo 
N-acylation. In the last decade a number of research groups have elaborated on this function 
with the interception of a Lewis base generated N-acyl species with a selection of further 
transformations (Figure 8). Most commonly, the adopted focus is the complimentary methods of 
deprotonation of the N-acyl species to form a nucleophilic enolate equivalent or reaction of the 
N-acyl species as an in situ generated electrophile. Modern methods have utilised a number of 
chiral, non-racemic catalysts in these processes with the purpose of establishing enantioselective 
reactions. 
 
 
 
 
 
 
 
 
 
Figure 8 - Concepts of ammonium enolate and acyl ammonium catalysis. 
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Ammonium enolate catalysis 
The generation of nucleophilic ammonium enolates can be considered closely related to 
that of Lewis base generated enamine species. However, many enamine catalysis methods are 
limited by the use of aldehydes and ketones as substrates with common functional groups such 
as esters, amides, carboxylic acids and nitriles proving incompatible in most cases. To expand 
the methodologies of organocatalytically generated enolate equivalents, a number of ammonium 
enolate strategies has been devised. As defined by Gaunt, there are three main branches of 
ammonium enolate catalysis dependent on the position at which the catalyst is covalently 
bonded to the substrate (Figure 9).[31] 
 
 
 
 
 
 
 
Figure 9 - Classification of ammonium enolates. 
In 2001, Romo and co-workers showcased one of the first proof of principle reports that 
ammonium enolate catalysis could be used in asymmetric catalysis with high levels of 
enantiocontrol (Scheme 9).[32] Activation of carboxylic acid 31 with Mukaiyama’s reagent 32 
and treatment with O-acetyl quinidine catalyst 33 (10 mol%) and Et3N promotes the 
intramolecular nucleophile-catalysed-aldol-lactonisation (NCAL) reaction to give bicyclic β-
lactone 34 in excellent diastereo- and enantioselectivity (>95:5 dr and 92% ee). A proposed 
stereochemical model suggests the approach of the aldehyde onto the Si-face of the ammonium 
enolate leading to a cis-aldolate with ring closure of the oxetane. 
 
 
 
 
Scheme 9 - Nucleophile-catalysed-aldol-lactonisation reaction. 
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Enantioselective cyclopropanations via C2-ammonium enolate catalysis was reported 
by Gaunt and co-workers (Scheme 10). For example, the intramolecular cyclisation of diketones 
35 catalysed by cinchona alkaloid 36 (20 mol%) gives bicyclic products 37 in typically good 
enantioselectivity (93-99% ee).[33] Following the isolation and X-ray crystal analysis of the 
intermediate N-acyl species, a proposed stereochemical rationale was shown with cyclisation 
occurring via a boat conformation onto the face opposite to the catalyst bulk. Further catalyst 
optimisation discovered that the inclusion of a methyl substituent at the 2-position of the 
quinolone heterocycle was necessary to deter any competitive quinoline N-acylation. 
 
 
 
 
 
 
 
Scheme 10 - Cinchona alkaloid-catalysed intramolecular cyclopropanation. 
C3-Ammonium enolate catalysis is slightly less explored than other organocatalytic 
reactivity modes, but a significant contribution has been made to the area of enantioselective 
Morita-Baylis-Hillman (MBH) reactions. Traditionally, MBH reactions with high 
enantioselectivity have proven difficult, however ammonium enolate routes have provided 
powerful advances in this area. An innovative example was reported by Hatakeyama and co-
workers using β-isocupreidine 40 (10 mol%) as the catalyst, giving hydroxyl ester products 41 
in excellent enantioselectivity and as one of the first examples of enantiomeric excesses >90% 
(Scheme 11).[34] Key for this reaction was the presence of the free hydroxyl group on the 
catalyst that can H-bond to the substrate, pre-organising the transition state toward the 
enantioselective reaction. 
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Scheme 11 - β-Isocupreidine 40-catalysed enantioselective Morita-Baylis-Hillman reaction. 
1.2 Isothioureas as Lewis Base Organocatalysts 
1.2.1 Development of Isothioureas as Organocatalysts 
The use of the isothiourea motif in asymmetric synthesis draws its origins from the 
seminal work by Birman and co-workers on the kinetic resolution of secondary alcohols.[35] The 
work initially investigated the use of amidines as acyl transfer catalysts in the kinetic resolution 
of alcohol 42 using propionic anhydride (Figure 10). Good selectivity factors (S) were observed 
(S =28, c = 47%) with catalyst 45 and it was proposed that the pyridinium ring could offer a 
favourable π-stacking interaction within the transition state and hence explain the high 
enantioselectivity. Based on this proposal, annulated amidine 46 was trialled and gave slightly 
higher selectivity (S = 33, c = 51%). This study was extended to look at catalysts with the 
structurally related isothiourea scaffold. (−)-TetramisoleHCl 47 is a commercial drug used to 
treat parasitic worm infections in animals and presents a cheap, readily available catalyst for 
asymmetric catalysis. Interestingly, the application of 47 provided comparable results with the 
amidines (S = 27, c = 45%), implying that the pyridinium ring in the amidine catalysts is not 
essential to obtain high selectivity factors. However, based on the previous proposal that π-
stacking is an important feature in the selectivity of this reaction, (+)-benzotetramisole (BTM) 
was explored. The use of this benzannulated catalyst proved even more superior with improved 
enantiodiscrimination (S = 57, c = 49%).  
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Figure 10 - Investigation into amidine and isothiourea-based catalysts in the kinetic resolution of 
42. 
From these initial studies it was clear that there exists a difference in reactivity and 
selectivity between amidine and isothiourea catalysts. It was proposed that the high selectivity 
from isothioureas originates from a stabilising interaction between the lone pair of the acyl 
ammonium oxygen and the σ* orbital of the C−S bond (Figure 11). This favourable interaction 
is believed to stabilise the transition state, leading to a more rigid conformation and higher 
enantiodiscrimination. 
 
 
 
 
 
 
Figure 11 - Proposed transition state assembly for (+)-BTM catalysed kinetic resolution of 42. 
This phenomenon has previously been reported in a number of systems where oxygen 
and sulfur are situated 1,5 to each other.[36] A notable example was the X-ray crystallographic 
results reported by Nagoa and co-workers with multiple (acylimino)thiadiazoline derivatives 
showing interatomic distances between oxygen and sulfur of 2.670 Å, which is smaller than the 
sum of their Van der Waals radii of 3.320 Å (Figure 12).[37] The resulting effect is a stabilising 
influence and a rigid cis conformation.  
 
 
 
 
Figure 12 - Observed 1,5-S−O interaction in the X-ray analysis of (acylimino)thiadiazolines 
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Wu and Greer have conducted theoretical studies on this feature within the antitumor 
antibiotic, leinamycin (Figure 13). Density functional theory (DFT) calculations showed that the 
1,5-S−O non-bonding interaction stabilises the conformation of the thiosulfinate ester 
heterocycle and leads to a lowering in energy of 6 kcalmol-1.[38] 
 
 
 
 
 
 
Figure 13 - Computational studies into the 1,5-S−O interactions in leinamycin. 
1.2.2 Application of Isothioureas within the Smith Group 
Since the seminal work with isothioureas on the kinetic resolution of alcohols these 
powerful Lewis base catalysts have been applied to range of enantioselective processes, in 
particular by the Smith research group. An early transformation to be explored was the 
asymmetric Steglich rearrangement.[39] The isothiourea catalyst (2S,3R)-HyperBTM 53 (10 
mol%) operates as an efficient carboxyl transfer agent in the rearrangement of oxazolyl 
carbonate 52 into C-carboxyazlactone 54 in good to excellent enantioselectivity (70-93% ee) 
and typically excellent yield (91-96%) (Scheme 12). The proposed mechanism starts with 
acylation of catalyst 53 via nucleophilic attack into the carbonate group of 52 to give ion-
pairing 55. Attack of the enolate through the C(4) position transfers the carboxyl group from the 
catalyst with enantiodiscrimination giving product 54. 
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Scheme 12 - Isothiourea-catalysed Steglich rearrangement and proposed mechanism. 
The Smith group has since expanded the use of isothiourea catalysts into the area of C1-
ammonium enolate catalysis. The seminal work in this methodology arose in 2010 with the 
report from Romo and co-workers on the nucleophile-catalysed aldol lactonisation (NCAL) 
reaction of a range of cyclic tethered keto-acids (Scheme 13). One example involved the acid 
activation of 56 using p-tosylchloride and i-Pr2NEt followed an aldol-lactonisation catalysed by 
the isothiourea homobenzotetramisole (HBTM) 57 (20 mol%) and using LiCl as an additive to 
give tricyclic lactone 58 in 93% yield, >95:5 dr and 90% ee.[40] It was proposed that in transition 
state 59, the LiCl additive enforces the conformation via a Li−S chelation leading to higher 
enantioselectivity. 
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Scheme 13 - Isothiourea-catalysed enantioselective NCAL reaction. 
At that time, the Smith group also published an isothiourea-catalysed intramolecular 
cascade with a Michael addition-lactonisation process (Scheme 14). Treatment of enone-acids 
60 with i-Pr2NEt, pivaloyl chloride and (−)-TetramisoleHCl 47 (20 mol%) gives tricyclic 
dihydropyranones 61 in moderate to excellent yield (43-99%) and excellent stereoselectivity 
(>95:5 dr and 90-99% ee). A number of examples were subjected to an in situ ring opening with 
either MeOH or i-Pr2NH to provide the corresponding dihydrobenzofurans and indanes 62 with 
maintenance of the high stereoselectivity. 
 
 
 
 
 
 
Scheme 14 - Isothiourea-catalysed intramolecular Michael addition-lactonisation. 
This work was also extended to a state-of-the-art application of C1-ammonium enolate 
catalysis with an intermolecular variant (Scheme 15).[41] Commercially available and bench 
stable aryl acetic acids 63 are used as enolate precursors through treatment with pivaloyl 
chloride, i-Pr2NEt and isothiourea catalyst 53 (10 mol%). Addition of ketoester Michael 
acceptors facilitates a Michael addition-lactonisation cascade to afford anti-dihydropyranones 
65 with excellent enantioselectivity. A key feature of isothiourea catalysts is the formation of a 
favourable oxygen to sulfur interaction (no to σ*C-S) that can stabilise and define the transition 
state assembly and account for the high stereocontrol.  
 
 
 
 
 
 
 
 
Scheme 15 - Isothiourea-catalysed intermolecular Michael addition-lactonisation. 
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It’s proposed that the mechanism begins with formation of mixed anhydride 66 from 
carboxylic acid 63, i-Pr2NEt and pivalolyl chloride (Figure 14). Interception of 66 with catalyst 
53 gives acyl ammonium 67 that undergoes subsequent deprotonation to generate ammonium 
enolate 68. In the presence of Michael acceptor 64, this undergoes Michael addition to give 69 
that cyclises to provide product 65 and regenerate the catalyst. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 - Propsed mechanism for intermolecular isothiourea-catalysed Michael addition-
lactonisation. 
The methodology has proven broad in scope with a diverse range of carboxylic acids 
and electron-deficient Michael acceptors investigated giving a range of dihydropyranones,[42] 
dihydropyridinones[43],[44] and oxadiazinones,[45] all in excellent enantioselectivity (Figure 15). 
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Figure 15 - Range of chiral heterocycles accessed using isothiourea-catalysed Michael addition-
lactonisation/lactamisation protocol. 
The process has also been expanded beyond that of formal [4+2] cycloaddition 
reactions to a formal [2+2] protocol (Scheme 16). In this system, the use of carboxylic acids as 
enolate precursors was problematic as purification of the desired products was difficult. Instead, 
homoanhydrides 74 were applied with (2S,3R)-HyperBTM 53 (5 mol%) and i-Pr2NEt in the 
presence of aldimines 75 to give β-lactams 76 in moderate to good yield (44-74%), good to 
excellent diastereoselectivity (typically >95:5) and enantioselectivity (68-90% ee).  
 
 
 
 
 
Scheme 16 - Enantioselective synthesis of β-lactams using isothiourea-catalysis. 
The use of isothiourea-generated enolates has also been applied to a formal [3+2] 
process with oxaziridine substrates (Scheme 17). Homoanhydrides were also tried in this system 
due to side-reactions occurring from a carboxylic acid and pivalolyl chloride activation method. 
Reaction of homoanhydrides 77 with (R,R)-oxaziridine 78, Cs2CO3 and (2S,3R)-HyperBTM 53 
(10 mol%) gave the corresponding products 79 in moderate to excellent yield (49-95%) and 
typically excellent diastereoselectivity (94:6->95:5 dr) and excellent enantioselectivity (97-
>99% ee). 
 
 
 
 
 
Scheme 17 - Enantioselective isothiourea-catalysed synthesis of oxazolidin-4-ones. 
In the context of asymmetric catalysis the use of acyl ammonium species is relatively 
new with much of the attention directed towards α,β-unsaturated acyl species that can undergo 
enantioselective Michael addition reactions. A primary methodology in this area was displayed 
by Smith and co-workers in 2014 (Scheme 18).[46] Reaction of isothiourea catalyst 53 (5 mol%) 
with homoanhydrides 80 gives an intermediate α,β-unsaturated acyl ammonium species that can 
be attacked by diketones 81 in an enantioselective Michael addition at the Re-face, with 
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subsequent proton transfer and lactonisation giving dihydropyranones 82 in excellent 
enantioselectivity (89-96% ee) with many examples being subject to an in situ ring opening to 
provide products 83 (where R2 = R3).  
 
 
 
 
 
 
 
 
 
Scheme 18 - Application of isothiourea-generated α,β-unsaturated acyl ammonium intermediates. 
1.3 Aims of the Project 
Isothiourea-generated enolate equivalents can provide a powerful strategy for the 
construction of chiral heterocycles with high levels of stereocontrol. However, at the beginning 
of this PhD, there was no truly organocatalytic formal cycloaddition processes for the synthesis 
of functionalised heteroaromatics. Based on the absence of such methodologies, the initial aim 
of this work was to create efficient, organocatalytic protocols for the preparation of 
heteroaromatic products of biological relevance. It was proposed that C1-ammonium enolates 
derived from cheap, readily available carboxylic acid precursors would form appealing building 
blocks for this undertaking. Additionally, with the still ever growing need for stereodefined 
molecules and highly enantioselective catalytic processes to provide them, it was also intended 
to target further chiral heterocyclic products using isothiourea-catalysed Michael addition-
cyclisation processes. Through variation in the substrates applied to this method, the scope, 
stereoselectivity and robustness of such systems can be assessed.  
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Chapter 2: One-Pot Synthesis of Functionalised Pyridines 
This chapter describes the discovery of a one-pot Lewis base-mediated procedure for 
the preparation of 2,4,6-substituted pyridines. This one-pot organocatalytic cascade is broad in 
scope and incorporates a synthetically valuable functional handle that can be easily derivatised. 
The cascade reaction is initiated with a DHPB 86 catalysed Michael addition-lactamisation 
between (phenylthio)acetic acid 84 and α,β-unsaturated ketimines 85 in the presence of pivaloyl 
chloride and i-Pr2NEt, giving the corresponding dihydropyridinone, which readily undergoes 
elimination of PhSH and a thermal-assisted N- to O-sulfonyl transfer affording functionalised 
pyridine sulfonates 87 (Scheme 19).[47] 
 
 
 
 
 
 
 
 
 
Scheme 19 - Isothiourea-catalysed one-pot synthesis of functionalised pyridines. 
2.1 Introduction 
The pyridine motif is a heterocyclic class present at the core of many biologically active 
molecules and has found widespread function within many agrochemical and pharmaceutical 
products (Figure 16).[48]  
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Figure 16 - Biologically relevant pyridine molecules. 
Specifically, the pyridine core has found a prevalent place within many of the top 
commercially approved pharmaceuticals. A recent study by Njardarson and co-workers 
explored the structural trends within a database of 1,086 U.S. FDA-approved drugs, and found 
that 59% of all small molecules contain a nitrogen heterocycle. Pyridine features in this list as 
the second most abundant heterocycle behind piperidine hence making it the most prevalent 
heteroaromatic motif (Figure 17).[48b] 
 
 
 
 
 
Figure 17 - Prevalence of pyridine within U.S. FDA-approved pharmaceuticals. 
2.1.1 Classical Routes to Synthesise Functionalised Pyridines: Condensation Reactions 
Due to the privileged status of these heterocycles there has been much attention directed 
towards new methodologies that can provide these molecules efficiently and in high yield.[49] 
Classical routes to construct pyridines focused on the condensation of carbonyl compounds with 
a nitrogen source. Historical examples include the [5+1] condensation,[50] Hantzsch ester 
pyridine synthesis,[51] and also the [3+2+1] condensation (Figure 18).[52] 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 - Classical and early condensation routes towards the synthesis of pyridines. 
Condensation approaches such as the Bohlmann-Rahtz synthesis have been used in 
recent times by Moody and co-workers in their successful synthesis of promothiocin A (Scheme 
20).[53] After the preparation of the oxazole amino ester 88, alkynone 89 was added in EtOH at 
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50 °C to give conjugate addition intermediate 90. Increasing the temperature to 140 °C resulted 
in cyclisation to give pyridine 91 in 83% yield. 
 
 
 
 
 
 
 
Scheme 20 - Bohlmann-Rahtz reaction used in the synthesis of promothiocin A. 
2.1.2 Classical Routes to Synthesise Functionalised Pyridines: Cycloaddition Strategies 
Cycloaddition chemistry is an effective tool for building cyclic structures, its use as a 
strategy to produce pyridines should therefore be considered. For example, Diels-Alder reaction 
between an alkene (or alkyne) and an azadiene, followed by oxidation into the desired pyridine 
is conceivable but examples are rare. This strategy commonly encounters a number of 
difficulties originating from various disfavoured electronic, conformational and thermodynamic 
issues found with the pericyclic reaction. As a result, modifications have been developed that 
incorporate electron-donating substituents onto the nitrogen of the azadiene. This gives a more 
electron-rich azadiene, which is preferable for a conventional Diels-Alder reaction and 
additionally allows elimination of this group to facilitate the final formal oxidation into the 
pyridine. As a representative example of this strategy, Boger and co-workers applied this 
methodology to the synthesis of Rubrolone aglycon (Scheme 21).[54] Exposure of azadiene 92, 
bearing the N-OMe functionality, to high temperatures (185 °C) gave pyridine 94 in 70% yield 
via intermediate 93, followed by elimination of MeOH. 
 
 
 
 
Scheme 21 - Cycloaddition-elimination strategy applied by Boger and co-workers. 
The most commonly-applied strategy involves an inverse electron demand Diels-Alder 
reaction followed by extrusion.[55] One notable example arose from Weinreb and co-workers in 
their synthesis of eupolauramine in 1984 (Scheme 22).[56] Oxazole 95 underwent an 
intramolecular hetero Diels-Alder reaction to give intermediate adduct 96. This species was then 
dehydrated to provide pyridine 97 in 76% yield. Applying oxazoles in this approach is 
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commonly referred to as the Kondrat’eva reaction.[57],[58] The use of oxazoles in this manor can, 
however, lead to complex product distributions occurring from multiple possible fragmentations 
of the oxo-bridged intermediate or other potential side-reactions.  
 
 
 
 
 
Scheme 22 - Kondrat’eva reaction used in the synthesis of eupolauramine. 
More common is the use of heterocycles assigned to the 6-membered nitrogen 
containing structural family. Pyrimidines, for example, are capable of undergoing Diels-
Alder/retro-Diels-Alder sequences with regioselectivity dependent on the substituents 
present.[59] Related attempts using pyridazine are known, although not as prevalent. Perhaps the 
most useful protocol in this area is to apply 1,2,4-triazines, as these readily undergo inverse 
electron demand Diels-Alder reactions with a wide range of electron-rich dienes. Boger and co-
workers have made a prominent contribution to this approach (Scheme 23).[60] Treatment of 
ketone 98 with pyrrolidine 100 generates an enamine in situ that subsequently reacts in an 
inverse electron demand hetero Diels-Alder reaction with triazine 99 to give adduct 101. This 
intermediate then collapses with extrusion of N2 and elimination of pyrrolidine 100 to provide 
pyridine 102 in typically moderate to good yields.  
 
 
 
 
 
 
 
Scheme 23 - Boger pyridine synthesis. 
2.1.3 Modern State-of-the-Art Strategies for the Synthesis of Functionalised Pyridines 
With many stoichiometric methods established, the largest drive in this area has been 
towards the development of efficient catalytic methodologies. Predominantly, many transition 
metal-catalysed processes have dominated the area of pyridine synthesis over the last decade.  
Notably, the emergence of ring-closing metathesis (RCM) has allowed further routes to 
construct the cyclic pyridine framework. Donohoe and co-workers reported an example where 
an RCM approach was used to access dihydropyridones, which can subsequently be 
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transformed into 2,6-substituted pyridines 108 (Scheme 24). RCM of oxime ester 103 with 
Hoveyda-Grubbs second generation catalyst 104 gives dihydropyridone 105.[61] Treatment of 
105 with DBU promotes elimination to give pyridone 106 that, following triflation with 
Comin’s reagent 107, yields pyridine 108 in excellent yield. 
 
 
 
 
 
 
 
 
 
 
Scheme 24 - Pyridine formation via RCM step-wise protocol. 
In 2013 Rovis and co-workers described a Rh(III)-catalysed [4+2] cycloaddition 
protocol for the synthesis of 2,3,4,6-substituted pyridines (Scheme 25).[62] Reaction of pivaloyl 
ketoxime 109 and olefin 110 with catalyst [RhCp*Cl2]2 111 and AgOAc proceeds, via 
rhodacycle 113, to give substituted pyridine 112 in typically high yield. This work provides an 
excellent method for the rapid construction of pyridines with excellent regioselectivity (>20:1 
for all examples).  
 
 
 
 
Scheme 25 - Rh(III)-catalysed pyridine construction. 
More recently Dong and co-workers have reported a further Rh-catalysed pyridine 
synthesis.[63] C−H activation of sulfonyl ketimine 114 with Rh-catalyst 116 and subsequent 
formal cycloaddition with alkyne 115 produces pyridine 117 in excellent 80-99% yields 
(Scheme 26). Coordination of the Rh catalyst to the imine nitrogen of 114 allows for C−H 
activation at the β-position giving rhodacycle 118. Subsequent coordination of 115 to the Rh 
species promotes an alkyne insertion into the C−Rh bond of 119 to generate intermediate 120. 
Following reductive elimination, the catalytic process is proposed to proceed via chelation of 
the sulfonyl group to the Rh(I) centered species 121 with subsequent S=O insertion to 122 and 
O
N
OBn
MeO2C
103
i) 104  (10 mol%)
PhMe, 95 °C N O
OBn
MeO2C
R1
N
H
OMeO2C
R1
DBU (5.0 eq)
N OTfMeO2C
R1 107  (2.0 eq)
KHMDS (2.0 eq)
THF, -78 °C
RuCl
Cl
O
i-Pr
NNMes Mes
N NTf2
Cl
107
104
THF
105
106
R1
R2 R2
R2 R2
108
7 examples
48-81% yield
R4O2C
R1
R2
N
+
CO2R4 NR1
R2
CO2R4
[RhCp*Cl2]2 (2.5 mol%)
AgOAc (2.1 eq)
DCE/AcOH
85 °C
109
(1.0 eq)
110
(1.0 eq)
Rh
N
R1
R2
Cp*
PivO
113OPiv
R3 R3 R3
112
18 examples
33-96% yield
>20:1 regioselectivity
Chapter 2: One-Pot Synthesis of Functionalised Pyridines 
 30 
cleavage of the N−S bond to give 123. During this step, the Rh(I) species 121 may be oxidized 
to give Rh(III) 122 with sulfur reduced from oxidation state (VI) to (IV). This suggests the N−S 
bond is acting as an internal oxidant. Finally, the Rh species can dissociate by protonolysis to 
give pyridine 117. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 26 - Synthesis of pyridines using Rh-catalysis and N-sulfonyl ketimines and proposed 
mechanism. 
Following the report from Movassaghi and co-workers[64] in 2007 on the application of 
enamides towards the synthesis of polysubstituted pyridines (Scheme 27a), the group of 
Wang[65] successfully developed a catalytic protocol, also from enamides (Scheme 27b). The 
procedure applies a formal dehydrative [4+2] cycloaddition using enamides 128 and alkynes 
129, catalysed by [(p-cymene)RuCl2]2, giving pentasubstituted pyridines 130 in typically 
excellent yield. The scope of this reaction is broad and includes many highly functionalised 
pyridines and a number of polycyclic or annulated examples.   
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Scheme 27 - Application of enamides towards pyridine synthesis by a.) Movassaghi, 2007 and b.) 
Wang, 2015. 
Despite the dominance of metal-catalysed processes, an initial endeavor to apply 
organocatalytic reactivity modes towards pyridine synthesis was the synergistic protocol by 
Yoshikai and co-workers reported in 2013.[66] Reduction of oxime 131 with Cu(I)I generates 
copper enamide intermediate 134; simultaneously, iminium intermediate 135 is formed from 
enal 132 and pyrrolidine catalyst 100. Once formed, these reactive intermediates can undergo a 
Michael addition/cyclisation/Cu(II)-mediated oxidation cascade to provide pyridine 133 in good 
yield (Scheme 28). 
 
 
 
 
 
 
 
Scheme 28 - Synergistic iminium and copper catalysis. 
Lee and co-workers have taken inspiration from the work by Yoshikai and advanced 
this strategy to a solely organcatalytic procedure (Scheme 29).[67] Iminium ion 139, generated 
from the condensation of enals 137 with catalytic proline 18, is attacked by the enol form of 140 
giving alkylated intermediated 141. Reaction with ammonium acetate gives imine 142 that 
undergoes proton migration and subsequent intramolecular cyclisation into 143. Pyridine 138 is 
formed from oxidative aromatisation and regenerates the proline catalyst 18. Yields are 
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generally good for many examples bearing aryl groups at R2 and R3, and show excellent 
regioselectivity in the cases where R1 ≠ R2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 29 - Organocatalysed oxidative N-annulation for the synthesis of pyridines and proposed 
mechanism. 
Only recently have metal-free and organocatalytic methods emerged as serious 
competition for the more developed transition metal-catalysed processes. A notable example 
was reported in 2013 by Loh and co-workers who presented an aza-Rauhut-
Currier/cyclisation/desulfonation cascade route to functionalised pyridines (Scheme 30).[68] 
Treatment of allenoate 145 with ketimine 144 in the presence of catalytic, commercially 
available, TMEDA 146 provides a one-pot cascade to 2,3,4,6-substituted pyridines 147 in 
excellent yield (up to 88%). 
 
 
 
 
 
 
Scheme 30 - Aza-Rauhut/cyclisation/desulfonation cascade route to pyridines. 
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In 2014 Loh expanded his pyridine work with a protocol based on the ring expansion of 
2-allyl 2H-azirines.[69] Treatment of azirine 148 with DBU opens the ring to generate azatriene 
intermediate 150, that at the elevated temperature of 130 °C undergoes a 6π–electrocyclisation 
and oxidation to provide pyridines 149 (Scheme 31). Overall, the pyridine yields are good to 
excellent for this process however the multiple steps required to synthesise the azirine substrates 
may limit applications of this methodology.  
 
 
 
 
 
Scheme 31 - Metal-free synthesis of pyridines from 2-allyl 2H-aziridines. 
2.2 Initial Discovery of Isothiourea Catalysed Pyridine Synthesis 
Nitrogen containing heterocycles have been prepared previously in the Smith group via 
isothiourea-catalysed intermolecular Michael addition-cyclisation protocols.[70] In 2012 Smith 
and co-workers reported the synthesis of anti-dihydropyridinones 153 in high yield, dr and ee 
using chalcone derived α,β-unsaturated ketimines 152 and aryl acetic acids 151, catalysed by 
benzotetramisole (+)-(BTM) 48 (Scheme 32). This builds upon the Smith group’s work on the 
use of carboxylic acids as ammonium enolate precursors in Lewis base catalysis, through the 
use of pivaloyl chloride and i-Pr2NEt to produce a mixed anhydride in situ that can then be 
intercepted by a Lewis base catalyst. 
 
 
 
 
 
 
Scheme 32 - Isothiourea-catalysed Michael addition-lactamisation. 
 Following this, the Smith group extended the scope of accessible dihydropyridinones by 
applying β-ester-α,β-unsaturated ketimines 154 in the methodology.[44] Application of these 
Michael acceptors proved successful, however the reaction of (phenylthio)acetic acid 84 gave 
an undesired elimination of PhSH to yield a mixture of pyridone 155 and pyridine 156 (≈50:50). 
A small portion of 156 could be isolated and the constitution confirmed by X-ray 
crystallography to be that of pyridine 156. Following the Michael addition-lactamisation 
process it can be assumed that the intermediate dihydropyridinone undergoes elimination of 
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PhSH to yield 155 with some pyridone undertaking a further isomerisation to pyridine sulfonate 
156. [71] 
 
 
 
 
 
Scheme 33 - Previously observed formation of pyridine sulfonate 156 (P.-P. Yeh, Smith Group). 
 It was anticipated that this observation could be optimised to provide a concise route to 
functionalised aromatic heterocycles. Particularly the presence of the N- to O-sulfonyl transfer 
step would present a succinct and efficient route into substituted pyridine sulfonates, with the 
attractive feature of introducing a useful functional handle for further elaboration. This 
appealing N- to O-sulfonyl transfer process has been reported sporadically over the past few 
decades, although to date this isomerisation is traditionally considered as an undesirable side-
product. For example Mahmood and Afarinkia reported in 1998 that the desired Diels-Alder 
reaction between pyridone 160 and olefin 161 gave a ratio of the expected adduct 162 and the 
corresponding pyridine mesylate 163 arising from N- to O-sulfonyl transfer (Scheme 34). 
 
  
 
 
 
Scheme 34 - Literature precedent for N- to O-sulfonyl transfer. 
Building upon these results, the aim of this project, therefore, was to exploit these 
observations and optimise an isothiourea-catalysed Michael addition-lactamisation/PhSH 
elimination/N- to O-sulfonyl transfer one-pot cascade, towards functionalised pyridine synthesis 
(Scheme 35). 
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Scheme 35 - Proposed isothiourea-mediated route to functionalised pyridines. 
2.3 Reaction Optimisation 
Firstly, the reaction described above was repeated with achiral isothiourea DHPB 86 as 
the catalyst (Scheme 36). Full consumption of ketimine 154 was observed after 4 h providing a 
4:1 mixture of the pyridone 155 and the desired pyridine 156 (155:156) as determined by 1H 
NMR analysis. 155 and 156 were not separable by column chromatography and could therefore 
not be fully characterised at this point. 
 
 
 
 
 
 
Scheme 36 - Initial result. 
Optimisation of this process was initiated to selectively favour the synthesis of the 
desired pyridine products. As no stereoinduction was required in this reaction, a range of 
commercially available achiral and racemic Lewis base catalysts were screened (Table 1). This 
catalyst screen found that DHPB 86 provided 156 in the highest yield (30%). Typically 
reactions with 47 and 167 gave a mixture of dihydropyridinone 164, pyridone 155 and 
decomposition material. In all cases no ketimine 154 was observed by 1H NMR spectroscopic 
analysis after 4 h. 
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Entry Catalyst Yield (%)a Ratio (155:156)b 
1 86  30 4:1 
2 165 13 5:1 
3 166 4 7:1 
4 47 −c −c 
5 167 −c −c 
aIsolated yield following column chromatography. bDetermined by 1H NMR analysis.  
cDid not yield 156 
Table 1 - Reaction optimisation: Lewis base catalyst screen. 
The key observation from this initial study was the higher ratio of pyridone 155 
compared with pyridine 156 present in the crude mixture. This was apparent from the 1H NMR 
spectroscopic analysis of the crude mixture with pyridone C(3)H and C(5)H signals present at 
6.65 and 6.96 ppm, respectively (Figure 19). Additionally, the distinct 1H NMR signals for the 
ester CH2 of pyridone 155 and pyridine 156 provided a good guide for the 155:156 ratio and 
hence an indication for the extent of the cascade process. Ratios were typically in the region of 
4:1-7:1 (pyridone:pyridine) for entries 1-3 (Table 1). From these results two main deductions 
were made (i) elimination 164 into 155 proceeds quickly, with observation of 164 difficult to 
obtain by TLC analysis in many cases (ii) the poor ratio of 155:156 shows the N- to O-sulfonyl 
transfer to be sluggish under the reaction conditions. 
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Figure 19 - Typical 1H NMR spectra of a crude reaction mixture(4.15-4.6 and 6.55-7.00 ppm 
shown). 
 DHPB 86 (20 mol%) was carried forward as the optimum catalyst with the focus on 
driving the reaction from pyridone 155 through to pyridine 156. Varying the reaction time and 
temperature were next investigated (Table 2). Longer reaction times at rt was not beneficial with 
a time of 24 h giving only 8% isolated yield of 156 and 168 h giving no observable 156. The 
reactions were able to reach intermediate dihydropyridinone 164 and pyridone 155 (evaluated 
by 1H NMR spectroscopic analysis) but, over the increased reaction time period these 
intermediate species degraded before being converted into 156. Decreasing the reaction 
temperature to 0 °C and −78 °C in an attempt to minimise decomposition gave poor conversion 
into 156 at 0 °C and no observable 156 at −78 °C. Increasing the temperature to 40 °C and 60 
°C did not provide any significant improvement over that of the reaction at rt. Gratifyingly, at 
the elevated temperature of 80 °C in THF in a screw-top vial, 1H NMR spectroscopic analysis of 
the crude mixture indicated only trace pyridone 155 and what appeared to be less degradation 
than observed previously. This made isolation of 156 via column chromatography considerably 
easier. Further experimentation showed that allowing the initial Michael addition-lactamisation 
and elimination to occur at rt over 4 h followed by heating to 80 °C for 16 h led to a much 
improved 67% isolated yield of pyridine 156 with no pyridone 155 observed in the crude 
reaction mixture. It is logical to assume that the increased temperature aids the final N- to O-
sulfonyl transfer step, thus being driven by the formation of the thermodynamically favourable 
pyridine product. This result also correlates with the literature reports of this process, with 
elevated reaction temperatures affording higher conversion into the isomerisation product. 
Analysis of the crude mixture by 1H NMR spectroscopy from the reaction at 80 °C showed the 
desired pyridine 156 in addition to some decomposition, which accounted for the remainder of 
the theoretical yield.  
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Entry Solvent T (°C) Yield (%)a Ratio (155:156)b 
1 CH2Cl2 −78 −c −
c 
2 CH2Cl2 0 7 7:1 
3 CH2Cl2 rt 30 4:1 
4 THF 40 −d 1:1 
5 THF 60 −d 1:1 
6 THF rt-80 67 −e 
7 THFf 80 10 4:1 
8 THF 120 35 2:1 
aIsolated yield following column chromatography.. bDetermined by 1H NMR analysis. cDid not yield 156. dNot 
pursued further. eNo pyridone observed. f[0.06 M] (typically [0.6 M]. 
Table 2 - Reaction optimisation: solvent and temperature screen. 
In an attempt to assist the N- to O-sulfonyl transfer a microwave reactor was 
investigated as an alternative energy source (Table 3). A Biotage Initiator with a program of 
heating to 80 °C at 150 W using low absorption settings was used for this.  Two reactions were 
conducted at different reaction times of 1 h and 4 h in 1,4-dioxane (recommended as the 
optimum solvent for this instrument). Both reactions produced promising results with 156 
isolated in 45% and 52% yield for 1 h and 4 h reaction, respectively. However, as the 
microwave heating source showed no significant advantage over the conventional heating 
methods this option was not pursued any further.  
 
 
 
 
Entry MW reaction time (h) Yield (%)a 
1 1 45 
2 4 52 
aIsolated yield following column chromatography. MW = Biotage Initiator with a 
program of heating to 80 °C at 150 W using low absorption settings. 
Table 3. - Microwave-assisted reaction. 
HO O
SPh
Ph N
CO2Et
SO2Ph
+
84
(1.0 eq)
154
(1.0 eq)
t-BuCOCl (1.5 eq)
i-Pr2NEt (1.5 eq)
solvent, 0 °C, 10 min
then DHPB 86 (20 mol%)
i-Pr2NEt (1.5 eq)
T (°C), 16 h
N OSO2PhPh
CO2Et
156
HO O
SPh
Ph N
CO2Et
SO2Ph
+
84
(1.0 eq)
154
(1.0 eq)
t-BuCOCl (1.5 eq)
i-Pr2NEt (1.5 eq)
1,4-dioxane, 0 °C, 10 min
then DHPB 86 (20 mol%)
i-Pr2NEt (1.5 eq)
MW, t (h)
N OSO2PhPh
CO2Et
156
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Next a catalyst loading screen was conducted (Table 4). The reaction tolerates catalyst 
loadings down to 1 mol%, however there was a significant decrease in isolated yield compared 
with use of 20 mol% DHPB 86. It can be tentatively suggested that the Michael addition-
lactamisation proceeds at a slower reaction rate when using lower catalyst loadings, allowing 
more time for ketimine 154 and other potential intermediates to decompose before conversion 
to products. 
 
 
 
 
 
Entry Catalyst (mol%) Yield (%)a 
1 20 67 
2 10 20 
3 5 15 
2 1 10 
aIsolated yield following column chromatography. 
Table 4 - Reaction optmisation: catalyst loading screen. 
2.4 Substrate Scope: Variation of β-Ester-α,β-Unsaturated Ketimines 
2.4.1 Synthesis of β-Ester-α,β-Unsaturated Ketimines 
With the optimum conditions for the isothiourea-catalysed Michael addition-
lactamisation/PhSH elimination/N- to O-sulfonyl transfer cascade in hand the generality of this 
protocol was investigated. To extend the scope beyond the parent Michael acceptor, a range of 
β-ester-α,β-unsaturated ketimines was prepared from the corresponding γ-keto-α,β-unsaturated 
esters. Employing the synthesis from Lu and co-workers, phosphoranes 169 were prepared from 
the corresponding α-bromo ketones 168 (Table 5a).[72] Next the requisite glyoxylates were 
prepared in situ from an oxidative cleavage of the corresponding tartrate 170 with periodic acid. 
Treatment of these glyoxylate intermediates with phosphoranes 169 in a Wittig reaction gave 
keto esters 171. Treatment of keto ester 171 with the requisite sulfonamide in the presence of 
TiCl4 and Et3N affords β-ester-α,β-unsaturated ketimines 172 (Table 5b). Keto esters 173-178 
were obtained in typically good yield whereas the ketimines 179-184 proved challenging to 
purify and in most cases were used as crude mixtures of 80-90% purity (as determined by 1H 
NMR spectroscopic analysis). Additional substrates applied in the substrate scope were 
available within the Smith Group.[73] 
HO O
SPh
Ph N
CO2Et
SO2Ph
+
84
(1.0 eq)
154
(1.0 eq)
t-BuCOCl (1.5 eq)
i-Pr2NEt (1.5 eq)
THF, 0 °C, 10 min
then DHPB 86 (20 mol%)
i-Pr2NEt (1.5 eq)
rt-80 °C, 16 h
N OSO2PhPh
CO2Et
156
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Table 5 - a.) Preparation of phosphoranes. b.) Synthesis of β-ester α,β-unsaturated ketimines.  
c.) Results table. 
To allow application of the methodology to the synthesis of 2,4,5,6-substituted 
pyridines the synthesis of the tri-substituted ketimine 189, with the additional Me substituent at 
the β-position, was attempted. Applying modified procedures from Srivastava[74] and Zhang[75] 
for the preparation of γ-aryl-β,γ-unsaturated α-ketoesters, the route began with an aldol reaction 
between benzaldehyde 185 and 2-ketobutyric acid 186 with potassium hydroxide, providing 
potassium carboxylate salt 187 in 66% yield (Scheme 37). Treatment of 187 with methanol and 
acetyl chloride gives the ketoester 186 in 42% yield. Unfortunately, condensation with 4-
toluenesulfonamide was unsuccessful and complex crude reaction mixture was obtained from 
which ketimine 189 could not be isolated. 
 
 
 
 
Keto ester Ketimine 
Entry No. R1 R2 
Yield 
(%)a 
Entry No. R1 R2 
Yield 
(%)a 
1 173 Ph Et −b 7 179 Ph Et 45c 
2 174 Ph Me 64 8 180 Ph Me −d 
3 175 4-CNC6H4 Me 59 9 181 4-CNC6H4 Me −
d 
4 176 4-CF3C6H4 Me 90 10 182 4-CF3C6H4 Me −
d 
5 177 2-Np Me 81 11 183 2-Np Me −d 
6 178 t-Bu Me 85 12 184 t-Bu Me 34c 
aIsolated yield following column chromatography. bPurchased from commercial source. cIsolated following 
recrystallisation. dObtained as a crude mixture. 
R1
O
Br
i) PPh3 (1.0 eq)
ii) aq. NaOH (2 M)
CH2Cl2
R1
O
PPh3
R2O2C
CO2R2
OH
OH
i) H5IO6 (1.0 eq)
Et2O, rt, 1 h
ii) 169  (1.5 eq)
 NaOH
CH2Cl2, rt, 2 h
168 169
170
 (1.0 eq)
R2O2C
O
R1
(1.0 eq)
TiCl4 (1.0 eq)
 Et3N (2.0 eq)
CH2Cl2, 0 °C
 16 h
H2N S
O
O
Ar
171
R2O2C
NSO2Ar
R1
172
a.) Phosphorane preparation:
b.) Ketimine preparation:
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Scheme 37 - Attempted synthesis of ketimine 189. 
2.4.2 Reactivity of β-Ester-α,β-Unsaturated Ketimines 
Investigation into the generality of the isothiourea-catalysed pyridine formation was 
initiated with variation of the ester substituents within the ketimine (Table 6). Methyl and ethyl 
esters are accommodated giving pyridines 190 and 191 in good 60% and 67% yield, 
respectively. Benzyl ester groups could also be incorporated with the corresponding pyridine 
192 obtained in moderate 50% yield over the three-step cascade. 
 
 
 
 
 
 
 
 
 
 
Table 6 - Substrate scope: variation of ester substituent. 
 The broad range of unsaturated ketimines synthesised bearing various groups at the 
C(1) position were next subjected to the previously optimised reaction conditions (Table 7). The 
2-Np substituent could be installed into the product giving pyridine 192 in excellent 69% yield. 
Electron-rich 4-MeC6H4 and 4-MeOC6H4 substituents are tolerated to provide the corresponding 
products 193 and 194 in moderate 51% and 50% yield, respectively. Further functionality could 
Ph H
O
Et
O
OH
O
Ph
O
O
OMe
K+
185
(1.0 eq)
186
(1.0 eq)
187
Ph CO2Me
O
Me
188
KOH
 (1.5 eq)
MeOH, 0 °C
16 h
AcCl (11.5 eq)
MeOH, 65 °C
16 h
H2N S
O
O
Tol
(1.0 eq)
TiCl4 (1.0 eq)
Et3N (2.0 eq)
CH2Cl2
0 °C
16 h
Ph CO2Me
NTs
Me
189
Complex crude
mixture
66% yield 42% yield
SPh
OHO
 84
 (1.0 eq)
+
CO2R1
Ph
(1.0 eq)
t-BuCOCl (1.5 eq)
i-Pr2NEt (1.5 eq)
THF, 0 °C, 10 min
then DHPB 86 (20 mol%)
i-Pr2NEt (1.5 eq)
rt-80 °C, 16 h
N OSO2ArPh
CO2R1
N OTsPh
CO2Me
190
60% yield
N OSO2PhPh
CO2Et
156
67% yield
N OTsPh
CO2Bn
191
50% yield
N
SO2Ar
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be installed onto the pyridine scaffold with 4-ClC6H4 and 2-FC6H4 substituents being accepted 
providing products 195 and 196 in good yield. Electron-deficient aryl substituents were 
compatible with this methodology giving pyridines 198-199 in good yield (51-64% yield). 
Pleasingly, the procedure was not limited to aryl groups at the C(1) position of the Michael 
acceptor. The t-Bu alkyl substituent also participates with moderate reactivity, delivering 
pyridine 200 in a 44% isolated yield. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7 - Substrate scope: variation of 2-substituent. 
Five ketimines were recalcitrant to this protocol (Table 8). In the case of 1-Np 201 and 
biphenyl 202 there was no conversion to the desired pyridine product with only starting 
materials returned, whereas the styryl ketimine provided the product 203 with a poor 30% 
conversion (as determined by 1H NMR spectroscopic analysis). Unfortunately, 203 could not be 
isolated from a complex crude mixture. The 1-Np ketimine may be too sterically demanding for 
the initial Michael addition step. The biphenyl and styryl results are particularly surprising, as it 
would be predicted that these variations in the Michael acceptors should not impart any 
significant electronic or steric demands to explain the lack of reactivity. To extend the scope 
beyond trisubstituted pyridines the α,α–disubstituted acids 2-(phenylthio)propanoic acid and 3-
SPh
OHO
 84 
(1.0 eq)
+
CO2R1
NR2
(1.0 eq)
t-BuCOCl (1.5 eq)
i-Pr2NEt (1.5 eq)
THF, 0 °C, 10 min
then DHPB 86 (20 mol%)
i-Pr2NEt (1.5 eq)
rt-80 °C, 16 h
N OTsR2
CO2R1
N OTs
CO2Et
192
69% yield
N OTs
CO2Et
193
51% yield
N OTs
CO2Bn
194
50% yield
Me MeO
N OTs
CO2Et
195
54% yield
N OTs
CO2Et
196
65% yield
N OTs
CO2Bn
197
60% yield
NCCl
F
N OTs
CO2Et
198
64% yield
N OTs
CO2Et
199
51% yield
N OTst-Bu
CO2Bn
200
44% yield
F3C O2N
Ts
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methyl-2-(phenylthio)butanoic acid were examined. Unfortunately, the intended tetrasubstituted 
pyridines 204 and 205 were not formed, with the starting materials returned.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8 - Unsuccessful 4-ester pyridine results. 
2.5 Substrate Scope: Variation of β-Trifluoromethyl-α,β-Unsaturated 
Ketimines 
2.5.1 Synthesis of β-Trifluoromethyl-α,β-Unsaturated Ketimines 
In recent decades, the inclusion of trifluoromethyl groups within drug-like molecules 
has become highly appealing due to the potential impact these substituents may have upon that 
compounds biological activity.[76] Based on this interest, further work looked to extend this 
methodology to access pyridines containing the important trifluoromethyl functional group. 
Firstly, a series of trifluoromethyl ketimine substrates were synthesised (Table 9). Following the 
procedure reported by Yamazaki, trifluoromethyl enones were synthesised via a two-step 
procedure. Treatment of 2-bromo-3,3,3-trifluoroprop-1-ene 207 with LDA at −78 °C and 
subsequent addition of arylaldehyde gave an intermediate propargyl alcohol that underwent 
isomerisation, in the presence of Et3N, to yield a mixture of (E) and (Z)-enones (≈ 80:20 E:Z 
ratio in all cases). Isolation of the (E)-enone and subsequent condensation with 4-
toluenesulfonamide in the presence of TiCl4 and Et3N gave α,β-unsaturated ketimines 214-220. 
Generally, the trifluoromethyl ketimines proved easier to isolate than the ester variants 
SPh
OHO
 
(1.0 eq)
+
CO2R2
NR3
 
(1.0 eq)
t-BuCOCl (1.5 eq)
i-Pr2NEt (1.5 eq)
THF, 0 °C, 10 min
then DHPB 86 (20 mol%)
i-Pr2NEt (1.5 eq)
rt-80 °C, 16 h
N OTsR3
CO2R2
SO2Ar
N OTs
CO2Me
201
No observable 
conversion
N OSO2Ph
CO2Me
202
No observable
conversion
N OTs
CO2Me
203
Only ≈ 30%
conversion
N OTsPh
CO2Et
204
No observable 
conversion
N OTsPh
CO2Me
205
No observable 
conversion
Me i-Pr
R1 R1
Ph
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mentioned previously with all compounds being crystalline solids that were recrystallised from 
Et2O.  
 
 
 
 
 
Table 9 - Synthesis of β-trifluoromethyl-α,β-unsaturated ketimines 
2.5.2 Reactivity of β-Trifluoromethyl-α,β-Unsaturated Ketimines 
With a selection of trifluoromethyl ketimine Michael acceptors in hand, their reactivity 
in the previously optimised one-pot pyridine cascade was assessed (Table 10). 4-BrC6H4 
substituents are well tolerated with the possibility for placing the bromo-substituent at either the 
3- or 4-position of the ring to give pyridines 221 and 222 in 60% and 52% yield, respectively. 
These examples provide a further functional handle within the molecule for potential 
derivatisation. However, the 2-BrC6H4 ketimine 214 did not show any conversion into the 
desired pyridine 223. It is likely the presence of the 2-Br substituent is too sterically demanding 
for the approach of the ammonium enolate towards the Michael acceptor. Electron-rich 
substituent 4-MeC6H4 was included in the resulting pyridine 224 obtained in good 60% isolated 
yield. The 4-FC6H4 substituent can be incorporated at the 6-position of the product giving 
pyridine 225 in a moderate 45% yield. Full consumption of the 4-FC6H4 ketimine was observed 
by 1H NMR spectroscopic analysis, implying that the ketimine may have been too unstable, 
resulting in decomposition under the reaction conditions. In the case of the 2-Np 226 and 2-
thienyl 227 examples around 60% conversion (detected by 1H NMR spectroscopic analysis) was 
CF3 Enones CF3 Ketimines 
Entry No. Ar1 
Yield 
(%)a 
Entry No. Ar1 
Yield 
(%)b 
1 207 2-BrC6H4 40 9 215 2-BrC6H4 50a 
2 208 3-BrC6H4 45 10 216 3-BrC6H4 80 
3 209 4-BrC6H4 66 11 217 4-BrC6H4 68 
4 210 4-MeC6H4 42 12 218 4-MeC6H4 70 
5 211 4-FC6H4 35 13 219 4-FC6H4 62 
6 212 2-Np 59 14 220 2-Np 61 
7 213 2-Thienyl 27 15 221 2-Thienyl 80 
8 214 2-Pyridyl −c     
aIsolated following column chromatography. bIsolated following recrystallisation. cDid not provide product. 
H Ar1
O
F3C
Br
(1.2 eq)
207
(1.2 eq)
+ F3C Ar1
O
(1.0 eq)
TiCl4 (1.0 eq)
 Et3N (2.0 eq)
CH2Cl2, 0 °C, 16 h
F3C Ar1
NSO2Ar
H2N S
O
O
Ar
i) i-Pr2NH (2.2 eq)
BuLi (2.2 eq)
THF, −78 °C, 30 min
ii) Et3N (4.0 eq)
THF, 80 °C, 16 h
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observed in both instances leading to moderate isolated yields (46% and 45%, respectively). 
These results imply low reactivity between the corresponding trifluoromethyl ketimines towards 
the intermediate ammonium enolate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10 - Scope of trifluoromethyl pyridines. 
2.6 Scale-up and Derivatisation 
With powerful methodologies available to transform aryl functional handles, the 
integration of such functional groups can allow the rapid assembly of larger, more complex 
molecules. Pyridine 190 was prepared on a large scale (26.2 mmol scale producing 5.00 g of 
product) to allow investigation into the use of the tosylate functional handle as a means for 
derivatisation (Scheme 38). 
 
 
 
 
 
 
Scheme 38 - Scaled-up synthesis of 190. 
Heteroaromatic substituent modification has become key in the construction of relevant 
complex target molecules. This trend has been driven by the advances in highly powerful cross-
coupling methods.[77] As a representative example, Skrydstrup and co-workers have shown that 
2-pyridyl tosylates can easily be coupled to olefins via Mizoroki-Heck-coupling (Scheme 
HO O
SPh
R1 N
CF3
Ts
+
84
(1.0 eq) (1.0 eq)
t-BuCOCl (1.5 eq)
i-Pr2NEt (1.5 eq)
THF, 0 °C, 10 min
then DHPB 86 (mol%)
i-Pr2NEt (1.5 eq)
rt-80 °C, 16 h
N OTsR1
CF3
N OTs
CF3
Br 221
60% yield
N OTs
CF3
222
52% yield
N OTs
CF3
223
No observable
conversion
N OTs
CF3
Me 224
60% yield
Br
Br
N OTs
CF3
F 225
45% yield
N OTs
CF3
226
46% yield
N OTs
CF3
227
45% yield
S
SPh
OHO
 84
(1.0 eq)
+
CO2Me
NPh
180
(1.0 eq)
t-BuCOCl (1.5 eq)
i-Pr2NEt (1.5 eq)
THF, 0 °C, 10 min
then DHPB 86 (20 mol%)
i-Pr2NEt (1.5 eq)
rt-80 °C, 16 h
N OTsPh
CO2Me
Ts
190
(26.2 mmol scale)
5.00 g, 50% yield
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39).[78] 2-Pyridyl tosylates 228 and N-vinyl acetamide 229 under Mizoroki-Heck-coupling 
conditions yields transformed pyridine 230 in generally good to excellent yields. 
 
 
Scheme 39 - Functionalisation of pyridine tosylates by Skrydstrup. 
Applying the procedure from Skrydstrup and co-workers a Mizoroki-Heck-coupling 
was attempted (Scheme 40).[78] Pd(dba)2 (2.5 mol%), N-methyldicyclohexylamine (dppf, 5 
mol%), N-vinylacetamide 229, pyridine 190 and Cy2NMe gave α-substituted vinyl acetamido 
pyridine 231 in excellent 79% yield with no β-substituted product observed. This 
regioselectivity is consistent with electron-rich olefins applied in the Mizoroki-Heck reaction 
under these conditions. 
 
 
 
 
 
Scheme 40 - Mizoroki-Heck reaction on pyridine 190. 
Using the procedure from Buchwald, pyridine 190 was treated under Suzuki-Miyaura 
coupling conditions using Pd(OAc)2 (5 mol%), BrettPhos (5 mol%) and K3PO4H2O in PhMe at 
110 °C overnight (Scheme 41).[79] This reaction led to no observation of intended product 233 
and returned only starting material 190 and 232 with some 232 undergoing protodeborylation to 
furan. Many of the reactions, similar to this, in the literature contain pyridines without ester 
substituents. It may be that in this case Pd coordinates to the ester and deactivates the catalyst 
towards the Suzuki-Miyaura coupling at the tosylate group. 
 
 
 
Scheme 41 - Attempted Suzuki-Miyaura coupling on pyridine 190. 
N OTs
[Pd(dba)2] (2.5 mol%)
dppf (5 mol%)
Cy2NMe (3.0 eq)
1,4-dioxane, 85 °C, 24 h N
230
H
N
O
MeN
H
O
Me
+
87% yield
228
(1.0 eq)
229
(1.0 eq)
Fe
PPh2
PPh2
dppf
N OTs
[Pd(dba)2] (2.5 mol%)
dppf (5 mol%)
Cy2NMe (3.0 eq)
1,4-dioxane, 100 °C
16 h
N
231
H
N
O
MeN
H
O
Me
+
79% yield
Ph
CO2Me
Ph
CO2Me
190
(1.0 eq)
229
(1.0 eq)
N OTsPh
190
(1.0 eq)
Pd(OAc)2 (5 mol%)
BrettPhos (5 mol%)
K3PO4•H2O (3.0 eq)
PhMe, 110 °C, 16 h NPh
233
No observable
conversion
O
+
O B(OH)2
232
(2.0 eq)
CO2MeCO2Me
i-Pr
i-Pr
i-Pr
PCy2
OMe
MeO
BrettPhos
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The tosylate substituent can also be removed from these molecules via a 
protodetosylation to give 4,6-substituted pyridine. This was accomplished with a procedure 
reported from Yoshida and co-workers (Scheme 42) using Pd(OAc)2 (5 mol%) and dppp (5 
mol%) with formic acid to give di-substituted pyridine 235 in excellent 85% yield. [80] 
 
 
 
 
 
 
Scheme 42 - Pd-catalysed protodetosylation on pyridine 190. 
An attempt to hydrolyse pyridine 190 to the corresponding 4-ester pyridone was made. 
However, reaction of 190 with tetrabutylammonium hydroxide resulted in hydrolysis of the 
ester group with no observable hydrolysis of the tosylate substituent (analysed by 1H NMR 
spectroscopic analysis). Based on the 1H NMR analysis it appeared that following hydrolysis of 
the ester to the carboxylate salt 235 the reaction did not proceed any further (Scheme 43).  
 
 
 
 
 
Scheme 43 - Attempted hydrolysis of 190 to corresponding pyridone. 
 Following the procedure by Ackermann and co-workers a Kumada cross-coupling was 
also attempted (Scheme 44).[81] Pd(dba)2 (5 mol%) Pin(O)H (10 mol%) and 4-
methoxyphenylmagnesium bromide 236 and were heated at 80 °C for 16 h. Unfortunately this 
gave no observable conversion (by 1H NMR spectroscopic analysis) to pyridine 237. As with 
the Suzuki-Miyaura reaction, the ester group may chelate to Pd and deactivate the reaction. Also 
surprising was that no addition of 236 into the ester group was observed. 
 
 
 
 
 
 
Scheme 44 - Attempted Kumada-coupling on pyridine 190. 
N OTs
Pd(OAc)2 (5 mol%)
dppp (5 mol%)
HCO2H (3.0 eq)
Et3N (5.0 eq)
DMF, 60 °C, 1 h N
234
85% yield
Ph
CO2Me
Ph
CO2Me
190
(1.0 eq)
Ph2P PPh2
dppp
N OTs
Bu4NOH (10 eq)
EtOH, rt, 15 min N
235
Ph
CO2Me
Ph
CO2
OTs
Bu4N
190
(1.0 eq)
190
(1.0 eq)
N OTs
236 (1.5 eq)
Pd(dba)2 (5 mol%)
PinP(O)H (10 mol%)
1,4-dioxane, 80 °C, 16 h NPh
CO2Me
Ph
CO2Me
OMe237
No observable
conversion
MgBrMeO
O O
P
Me
Me
Me
Me
O H
PinP(O)H
Chapter 2: One-Pot Synthesis of Functionalised Pyridines 
 48 
A nucleophilic aromatic substitution at the tosylate position using morpholine was examined 
(Scheme 45). This reaction gave a complex crude mixture of starting material 190, amide 238 
and desired product 239. Efforts to separate these constituents by column chromatography 
proved unsuccessful. 
 
 
 
 
 
 
Scheme 45 - Attempted SNAr reaction. 
Overall, derivatisation of 4-ester pyridine 190 has proven limited. This is in contrast to 
the 4-trifluoromethyl pyridine 240 that has been derivatised using various transformations 
within the Smith group (L. C. Morrill, PhD student) (Figure 20).[82] 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 - Derivatisation of 4-CF3 pyridine (L. C. Morrill, PhD student, Smith group). 
2.7 Reaction Mechanism 
It is proposed that the cascade process begins with N-acylation of DHPB 86 with in situ 
formed mixed anhydride 246 to generate the acyl ammonium intermediate 247 (Figure 21). 
Deprotonation forms the key ammonium enolate 248 that, in the presence of ketimine 249, 
undergoes Michael addition to give a second acyl ammonium species 250. This intermediate 
cyclises to provide dihydropyridinone 251 and regenerate the isothiourea catalyst. Under the 
reaction conditions, it is proposed that 251 eliminates PhSH to give to the corresponding 
N OTs
Morpholine (1.2 eq)
Et3N (2 eq)
PhMe, 120 °C, 16 h N
238
Ph
CO2Me
Ph OTs
190
(1.0 eq)
O N
O
+
N
239
Ph
CO2Me
N
O
Complex crude mixture
N OTs
240
Ph
CF3
N
CF3
Ph
241
89% yield
N
CF3
Ph
242
85% yield
N
O
N
CF3
Ph
243
76% yield
H
N Me
O
N
CF3
Ph
244
66% yield OMe
N
CF3
Ph
245
81% yield
N
Boc
OMe
N
CF3
Ph
246
74% yield
n-C6H13
Protodetosylation
Suzuki-coupling
Kumada-coupling
Heck-coupling
Fe-catalysed
sp3-sp2 coupling
SNAr
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pyridone 252 that, at elevated temperature undergoes an N- to O-sulfonyl transfer to yield 
pyridine sulfonate 253. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 - Proposed mechanism for the isothiourea-catalysed Michael addition-
lactamisation/PhSH elimination/ N- to O-sulfonyl transfer cascade. 
Given the typically high levels of anti-diastereoselectivity observed in isothiourea-
catalysed Michael addition-cyclisation processes the PhSH elimination becomes intriguing. In 
examples with ester groups installed at the C(4) position of the dihydropyridinone an E1cB 
mechanism is highly likely and would facilitate elimination of PhSH despite the anti-relative 
configuration at C(3) and C(4) (Figure 22). 
 
 
 
 
Figure 22 - E1cB mechanism for PhSH elimination. 
For the cases with C(4)CF3 substituents the mechanism for elimination is not as clear. 
Dihydropyridinone 254 was synthesised previously in the Smith group with the constitution and 
relative stereochemistry examined by X-ray crystallography (Figure 23). Although the 
conformation appears slightly puckered compared to a typical half-chair conformation, the 
stereocentres at C(3) and C(4) show the anti-configuration to place the protons anti-periplanar 
to one-another.  
N OPh
SPh E1cBelimination
N OPh
SPh
H
OEtO OEtO
Base:
N OPh
CO2Et
−PhSH
Ts Ts Ts
N
N
S
O
O
t-Bu
O
PhS
Formed in situ
O
PhS
N N
S
O
PhS
N N
S
O
PhS
N N
S
EtO2C
PhPhO2SN
N-Acylation
Deprotonation
Michael
Addition
Lactamisation
247
Acyl
Ammonium
DHPB 86
248
Ammonium
Enolate
N
N
SO2Ph
O
CO2Et
SPh
Ph
N
SO2Ph
O
CO2Et
Ph
OSO2Ph
CO2Et
Ph
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N- to O-
Sulfonyl
Transfer
no → σ*C-S interactionEtO2C Ph
NSO2Ph
t-Bu O
O
246
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252
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Figure 23 - Molecular representation and X-ray structure of dihydropyridinone (3S,4S)-254. 
Based on this crystallographic information for (3S,4S)-254, it can be suggested that the 
anti-configuration at C(3) and C(4) would therefore not place the C(4) proton and –SPh leaving 
group anti-periplanar to one another and hence not provide a σC-H to σ*C-S orbital overlap good 
enough to facilitate an E2 mechanism (Figure 24). This rationale is based upon the ground state 
energy conformations predicted for this type of molecule however, it cannot be ruled out that at 
the temperature of 80 °C a high energy conformation is present and thus allows an E2-type 
elimination. 
 
 
 
 
 
 
Figure 24 - Improbable E2 mechanism for elimination of PhSH. 
A plausible rationalisation may be a base-promoted epimerisation at C(3) leading to a 
syn-relative configuration and therefore an orbital overlap that would be satisfactory for an E2 
elimination (Figure 25). It should also be noted that oxidation of the sulfide substituent to a 
sulfoxide intermediate, under the reaction conditions, and a syn-sulfoxide elimination cannot be 
discounted. 
 
 
 
 
 
Figure 25 - Possible epimerisation at C(3) leading to an E2 elimination of the syn-
dihydropyridinone. 
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To the best of our knowledge, this is the first report to apply the N- to O-sulfonyl transfer 
as an expedient transformation. Theoretical computational studies were explored on a model 
system for the conversion of pyridone 255 into pyridine 256 (Figure 26).[83],[84] Calculation of 
the Gibbs free energy at the M06-2X/6-31+G**/ level of theory indicates a downhill in energy 
of −12.1 Kcalmol-1. Furthermore, the geometry-optimised structures of 255 and 256 show the 
conformation to change from a slightly puckered conformation in 255 to a fully planar ring 
system in 256. A main characteristic of aromaticity is the planar conformation of the cyclic 
structure (hence leading to improved side-on interaction of the contributing p-orbitals) 
therefore, in addition to the observed downhill in energy, we can imply from this computational 
experiment that there is an increase in aromatic character and the resulting product is lower in 
energy. This evidence is in line with our hypothesis that the formation of the pyridine product 
may be a thermodynamic sink in the reaction profile and hence a potential driving force for this 
cascade process. 
 
Figure 26 - N- to O-sulfonyl transfer theoretical experiment (M06-2X/6-31+G**/PCM(THF)). 
2.8 Conclusions 
In conclusion, isothiourea catalyst DHPB 86 mediates a three-step, one-pot cascade to 
produce tri-substituted pyridine sulfonates. DHPB 86 initially catalyses the Michael addition-
lactamisation between (phenylthio)acetic acid and a range of trifluoromethyl- or ester- 
containing α,β-unsaturated ketimines in the presence of pivaloyl chloride and i-Pr2NEt. The 
reaction proceeds through the elimination of PhSH to form an intermediate pyridone that, aided 
by elevated temperatures, undergoes an N- to O-sulfonyl transfer to provide pyridine tosylates 
in moderate to good yields. The N-sulfonyl group present in the ketimine was incorporated into 
the products as a synthetically valuable sulfonate group, which could be further derivatised 
through a range of methodologies. 
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Chapter 3: Three-Stage Synthesis of Tri- and Tetra-Substituted 
Pyridines 
 Having demonstrated a catalytic route to 2,4,6-substituted pyridines (Chapter 2) this 
chapter describes the exploration of further organocatalytic methods towards the synthesis of 
pyridine derivatives with the successful development of a three-stage isothiourea-mediated 
protocol. The first step consists of a DHPB 86-catalysed Michael addition-lactamisation with 
(phenylthio)acetic acids 257 and 2-N-tosyliminoacrylates 258 providing dihydropyridinones 
259. Subsequent S-oxidation-sulfoxide elimination process gives an intermediate pyridone that, 
following an N- to O-sulfonyl transfer produces the corresponding 2,3- and 2,3,5-substituted 
pyridine 6-tosylates 260 (Scheme 46).[85] 
 
 
 
 
 
 
 
 
 
Scheme 46 - Isothiourea-mediated three-stage synthesis of pyridines. 
1.1 Initial Investigation 
 Looking to expand upon the pyridine substituent classes accessible by isothiourea-
catalysis through the use of various Michael acceptors, 2-aryl-N-tosyliminoacrylate 263 was 
synthesised in 40% yield using the procedure of Tong and co-workers (Scheme 47).[86] 
 
 
 
 
Scheme 47 - Synthesis of 2-aryl-N-tosyliminoacrylates. 
 The ketimine Michael acceptor 263 was submitted to the optimum conditions developed 
in chapter 2 in an attempt to access the corresponding 2,3-pyridine 6-tosylate (Scheme 48). 
However, treatment of 263 with (phenylthio)acetic acid, i-Pr2NEt and DHPB 86 provided 
dihydropyridinone 264 in 40% yield, with no observation of either the desired pyridine 266 or 
the corresponding intermediate pyridone 265. The use of more forcing basic conditions 
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applying large excesses of either i-Pr2NEt or Et3N were also not successful with only 264 
returned. 
 
 
 
 
 
 
 
Scheme 48 - Application of 2-aryl-N-tosyliminoacrylate 263 to the isothiourea-mediated one-pot 
cascade conditions. 
 The lack of 266 formed in this initial reaction suggests that removal of the electron-
withdrawing trifluoromethyl or ester substituent from the C(4) position of the 
dihydropyridinone (as present in examples described in Chapter 2) leads to the proton at that 
position being significantly less acidic and therefore making a base-mediated elimination of 
PhSH difficult. However, it was postulated that oxidation of the sulfide to a sulfoxide, followed 
by elimination may provide access to the intended pyridone intermediate that could then be 
converted into the desired pyridine via N- to O-sulfonyl transfer (Scheme 49). 
 
 
 
 
 
Scheme 49 - Three-stage strategy towards the synthesis of functionalised pyridines. 
3.1 Process Optimisation 
3.1.1 Michael Addition-Lactamisation 
Development of this three-stage synthesis of pyridines was initiated with an 
optimisation of the Michael addition-lactamisation process (Table 11). Using CH2Cl2 as the 
reaction solvent and conducting the reaction at rt gave only 30% conversion (as determined by 
1H NMR spectroscopy) after 16 h. To improve the conversion, two equivalents of 84 were used 
leading to full consumption of 267 within 1 h and after purification an improved isolated yield 
of 70%. Alternative Lewis base catalysts were screened but with no improvement to that 
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observed with DHPB 86. Catalyst loadings of 86 can be reduced to either 10% or 5%, but result 
in lower yields of 55% and 43%, respectively. 
 
 
 
 
 
 
 
 
Entry 
84 
Equivalentsa 
Catalyst 
(mol%) 
Solventb T (°C) t (h) Yield (%)c 
1 1.0 DHPB (20) CH2Cl2 rt 16 −d 
2 2.0 DHPB (20) CH2Cl2 rt 1 70 
3 2.0 BTM (20) CH2Cl2 rt 1 65 
4 2.0 TM (20) CH2Cl2 rt 1 62 
5 2.0 DMAP (20) CH2Cl2 rt 1 58 
6 2.0 DHPB (10) CH2Cl2 rt 1 55 
7 2.0 DHPB (5) CH2Cl2 rt 1 43 
a1.5 eq of t-BuCOCl and i-Pr2NEt applied with respect to acid 84. b[0.06 M in 267]. cIsolated yield following 
column chromatography. d30% conversion by 1H NMR, product not isolated. 
Table 11 - Michael addition-lactamisation optimisation. 
3.1.2 Transformation of Dihydropyridinones into Functionalised Pyridine Tosylates 
With the Lewis base-catalysed Michael addition-lactamisation established, attention 
was next turned to the subsequent elimination step. The first attempt at an S-oxidation-sulfoxide 
elimination was conducted using the procedure from Smith and co-workers, applying m-CPBA 
as the oxidant (Scheme 50).[87] However, this reaction led to over oxidation into sulfone 269. 
Elimination of the sulfone substituent was tried using excess Et3N at an elevated temperature of 
120 °C, but with no success.  
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Scheme 50 - Initial attempt at an S-oxidation/sulfoxide-elimination protocol. 
An optimisation of the oxidation of dihydropyridinone sulfide 268 was conducted with 
m-CPBA selected as the oxidant. The major obstacle was to limit the formation of any over-
oxidised sulfone product 269 as purification of the desired pyridone or pyridine became tough 
due to co-elution of the products. It was finally established that dropwise addition of a [0.3M] 
solution of m-CPBA (1.1 eq) in CH2Cl2 to a [0.04 M] solution of 268 and Na2CO3 (excess) in 
CH2Cl2 at 0 °C was key for this method (Scheme 51). The reaction can then be warmed to rt and 
stirred for 30 min. This procedure allows complete conversion of 268 into pyridone 270 without 
any formation of the undesired sulfone 269. Simple work-up to remove the 3-chlorobenzoic 
acid by-product followed by heating in THF at 80 °C for 1 h, to promote the N- to O-sulfonyl 
transfer, provided pyridine 272 in 88% yield (62% yield over the three-steps).  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 51 - S-oxidation/sulfoxide-elimination protocol. 
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In 2013, Fukuyama and co-workers reported the use of 2-(phenylsulfinyl)acetamide 273 
and enones 274 in the DBU-mediated synthesis of pyridones 276 consisting of an in situ 
sulfoxide elimination of dihydropyridinones 275.[88] 
 
 
 
 
 
 
Scheme 52 - Reported synthesis of pyridones using 2-(phenylsulfinyl)acetamide. 
Based on this report it was proposed that the use of 2-(phenylsulfinyl)acetic acid 277 
may be used directly in the Michael addition-lactamisation system and hence eliminate the 
additional oxidation step. Unfortunately, reaction of 277 did not furnish pyridone 270 and 
instead led to a complex crude mixture. One tentative explanation could arise from a competing 
Pummerer-type rearrangement to give product 282. Following in situ formation of the mixed 
anhydride 278, a second molecule of 279 can be susceptible to sulfoxide acylation leading to 
intermediate 280. Under the basic reaction conditions, 280 can undergo an elimination to form 
thionium product 281 that, in the presence of a nucleophile such as the carboxylate anion 
eliminated in the second step, can be attacked to form Pummerer-type product 283. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 53 - a.) Attempted use of 2-(phenylsulfinyl)acetic acid 274. b.) Potential competing 
Pummerer-type rearrangement. 
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3.2 Substrate Scope: Synthesis of 2,3-Pyridine 6-Tosylates 
3.2.1 Preparation of 2-Aryl-N-Tosyliminoacrylates 
A range of 2-aryl-N-tosyliminoacrylates was synthesised to assess the scope and 
generality of this process using the protocol from Tong and co-workers (Table 12).[86] Slow-
addition of a solution of propiolate in toluene to a solution of the required aldimine in toluene at 
80 °C, in the presence of catalytic PPh3, gives the desired ketimine Michael acceptors 283-295 
in typically moderate yields. In all cases, particular care must be taken with slow adding of a 
solution of the propiolate over 3 h to minimise any dimerisation or polymerisation. The 
procedure works well for electron-neutral and electron-rich aryl aldimines, whereas aryl groups 
containing electron-withdrawing groups, ortho-substitution or alkyl aldimines proved 
recalcitrant and returned only starting materials. 
 
 
 
Entry Compound No. R1 R2 Yield (%)a 
1 283 Me Ph 40 
2 284 Me 3-MeC6H4 52 
3 285 Me 3,5-xylyl 64 
4 286 Me 4-MeC6H4 60 
5 287 Me 4-BrC6H4 42 
6 288 Me 4-ClC6H4 38 
7 289 Me 2-ClC6H4 −b 
8 290 Me 2-Np 42 
9 291 Me 2-thienyl 32c 
10 292 Me 2-MeOC6H4 −b 
11 293 Me 4-CF3C6H4 −b 
12 294 Me 4-FC6H4 −b 
13 295 Me t-Bu −b 
14 296 Bn Ph 15 
aIsolated following column chromatography. bDid not provide product. cIsolated following preparative 
HPLC 
Table 12 – Synthesis of 2-aryl-N-tosyliminoacrylates. 
3.2.2 Michael Addition-Lactamisations Applying (Phenylthio)acetic acid 84 
The next stage was to examine a selection of the prepared Michael acceptors in the 
optimised Michael addition-lactamisation conditions with (phenylthio)acetic acid 84 and 
isothiourea catalyst DHPB 86 (Table 13). The electron-neutral groups of Ph and 2-Np can be 
installed into the products to give 264 in 68% yield and 296 in 62% yield. Heteroaryl thiophene 
CO2R1 +
(1.2 eq)
R2 H
NTs
(1.0 eq)
PPh3 (20 mol%)
PhMe, 80 °C, 3 h R2 N
Ts
R1O2C
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is well tolerated and provides product 297 in 66% yield. The halogenated 4-ClC6H4 example 
298 and Bn ester example 299 were both produced with full consumption of their respective 
imines observed by 1H NMR spectroscopy. However the isolation of products proved difficult, 
leading to both 298 and 299 being obtained in 80-90% purity (as determined by 1H NMR 
spectroscopy). The contaminant could not be clearly characterised and appeared to be 
decomposition material. These dihydropyridinones were therefore carried forward in the 
sequence as their crude mixtures. 
 
 
 
 
 
 
 
 
 
 
 
 
aCarried forward as crude mixture of 80-90% purity. 
Table 13 - Subsrate scope: Isothiourea-catalysed synthesis of tri-substituted dihydropyridinones. 
3.2.3 S-Oxidation-Sulfoxide Elimination/N- to O-Sulfonyl Transfer 
 Subjecting dihydropyridinones 264-296 to the subsequent S-oxidation/sulfoxide-
elimination/N- to O-sulfonyl transfer steps proved very successful with excellent conversions 
observed into the desired tri-substituted pyridines (Table 14). Pyridine 267 displaying the Ph 6-
substituent was obtained in excellent 62% yield over the three-steps while, polyaromatic 
product 300 was produced in 54% yield overall and thienyl pyridine 301 was isolated in 59% 
yield. As dihydropyranones 295 and 296 were carried forward as crude residues the 
corresponding yields of the final pyridines were expectantly lower. Pyridine 302 containing the 
4-ClC6H4 group was produced in 56% yield and the Bn ester pyridine 303 was accessed in a 
moderate 45% overall yield.  
HO O
SPh
R1 N
R2O2C
Ts
t-BuCOCl (3.0 eq)
i-Pr2NEt (3.0 eq)
CH2Cl2, 0 °C, 10 min
then DHPB 86 (20 mol%)
i-Pr2NEt (1.0 eq)
rt, 1 h
+
N
Ts
O
R2O2C
R1
SPh
84
(2.0 eq) (1.0 eq)
N
N
S
DHPB 86
N
Ts
O
MeO2C
Ph
SPh
N
Ts
O
MeO2C SPh
N
Ts
O
MeO2C SPh
N
Ts
O
MeO2C SPh
N
Ts
O
BnO2C
Ph
SPh
264
68% yield
296
62% yield
297
66% yield
298a 299a
Cl
S
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aYield over three-steps. 
Table 14 - Substrate scope: synthesis of 2,3-substituted pyridine 6-tosylates. 
3.3 Substrate Scope: Synthesis of 2,3,5-Pyridine 6-Tosylates 
3.3.1 Initial Results 
To the point of conducting this project, the use of α,α-disubstituted carboxylic acids in 
isothiourea ammonium enolate catalysis has proven challenging. In all attempted cases within 
the Smith group to date the application of such enolate precursors led to no conversion into the 
desired products. This is assumed to be a result of higher steric demand influencing the 
deprotonation to the ammonium enolate or a lack of reactivity of the more bulky resultant 
enolate.  
 
 
 
 
 
 
Scheme 54 - Previous attempts to use α,α-disubstituted carboxylic acids. 
In 2011, Birman reported a dynamic kinetic resolution of α-(arylthio)- and α-
(alkylthio)alkanoic acids 304 using isothiourea catalyst (S)-HBTM (10 mol%) in an acylative 
process to give esters 305. This report indicated that α-substituted α-sulfide-carboxylic acids are 
able to form ammonium enolate intermediates.  
m-CPBA (1.1 eq)
Na2CO3 (excess)
CH2Cl2, 0 °C-rt, 30 minN
Ts
O
R2O2C
R1
SPh
N OTs
MeO2C
Ph N OTs
MeO2C
N OTs
MeO2C
N OTs
MeO2C
N OTs
BnO2C
Ph
266
93% yield
(62% yield)a
300
90% yield
(62% yield)a
302
(56% yield)a
N
Ts
O
R2O2C
R1 N OTs
R2O2C
R1
THF
80 °C, 1 h
303
(45% yield)a
301
90% yield
(59% yield)a
Cl
S
HO O
Ph
MeO2C O
+
O OMeO2C
Ph
R1
Ph Ph
R1
t-BuCOCl (1.5 eq)
i-Pr2NEt (1.5 eq)
CH2Cl2, 0 °C, 10 min
then (2S,3R)-HyperBTM
 53 (5 mol%)
i-Pr2NEt (2.5 eq)
−30 °C
R1 = Ph, Me, F No observableconversion
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Scheme 55 - DKR of α-(arylthio)- and α-(alkylthio)alkanoic acids using isothioureas. 
Based on the report from Birman, it was envisioned that these enolate precursors in 
combination with β-unsubstituted Michael acceptors might improve the prospect of reactivity, 
compared to the previous attempts. In this case it is assumed that the β-unsubstituted Michael 
acceptor allows for the extra steric demand imposed by the α,α-disubstituted enolate during the 
initial Michael addition step. Using the Heathcock model previously suggested for these 
systems the favoured pre-transition state assembly 306 shows higher steric congestion when 
using β-substituted Michael acceptors and an α,α-disubstituted enolate. Inputting 2-aryl-N-
tosyliminoacrylates into this model shows fewer significant interactions in favoured pre-
transition state assembly 307. Furthermore, an additional and perhaps key contributing factor is 
the presence of the sulfide. In previous systems, the groups present at the α-position have been 
either alkyl or aryl. In this case it can be suggested that the sulfide linkage may orientate the Ph 
substituent away in a more distal location from the Michael addition reaction centre.  
 
 
 
 
Figure 27 - Proposed rationale for combining β-unsubstituted Michael acceptors and α-substituted 
α-sulfide carboxylic acids. 
Pleasingly, in this case, with the application of 2-aryl-N-tosyliminoacrylates, this 
previous limitation was not apparent (Scheme 56). Dihydropyridinone was produced in 69% 
yield, under the optimum conditions used already in this protocol, from ketimine 267 and 
commercially available (phenylthio)phenyl acetic acid 308.  
 
 
 
 
 
 
SR2
R1
O
OH
i) (S)-HBTM 57 (10 mol%)
i-Pr2NEt (4.0 eq)
Bz2O (1.2 eq)
ii) Np2CHOH (1.2 eq)
d8-PhMe, rt, 24 h
SR2
R1
O
CO2CHNp2
305
11 examples
71-93% yield
84-92% ee
304
(1.0 eq)
N
N
SPh
(R)-HBTM 57
R2R
3R4
H
R2
R1
O
N N
SX
R3H
H
S
R1
O
N N
SNTs
Ph
vs
Favoured pre-TS 306 Favoured pre-TS 307
HO O
SPh
N
MeO2C
Ts
+
N
Ts
O
MeO2C SPh
Ph Ph
t-BuCOCl (3.0 eq)
i-Pr2NEt (3.0 eq)
CH2Cl2, 0 °C, 10 min
then DHPB 86 (20 mol%)
i-Pr2NEt (1.0 eq)
rt, 1 hMeO MeO
309
69% yield
308
(2.0 eq)
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(1.0 eq)
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Scheme 56 - Successful application of (phenylthio)phenyl acetic acid 308 with ketimine 267 in 
isothiourea-catalysed Michael addition-lactamisation.  
3.3.2 Preparation of α-Substituted α-Phenylthio Carboxylic Acids 
With this successful result in hand it was intended to look further into the scope of 
disubstituted acids in this system. 2-(Phenylthio)propanoic acid 311 could be synthesised using 
the procedure from Gualtieri and co-workers (Scheme 57a). Starting from bromopropanionic 
acid 310, substitution with PhSH under basic conditions in EtOH provided 311 in quantitative 
yield. Treatment of 311 under the optimum reaction conditions provided no observation of the 
desired dihydropyridinone at rt or elevated temperature of 80 °C (Scheme 57b). 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 57 - Synthesis and reactivity of 2-(Phenylthio)propanoic acid 311. 
As the sulfide substituents present on the carboxylic acid may be key for allowing this 
reaction to be successful, the use of (diphenylthio)acetic acid 313 was investigated. Synthesis of 
this originates from the procedure of Kenney and co-workers (Scheme 58a),[89] with treatment 
of (phenylsulfinyl)acetic acid 277 with glacial acetic acid at 120 °C giving 313 in 58% yield. 
Unfortunately, application of 313 in the Michael addition-lactamisation gave no conversion to 
dihydropyridinone 314 (Scheme 58b). 
 
 
 
 
 
 
 
 
HO O
SPh
Ph N
MeO2C
Ts
t-BuCOCl (3.0 eq)
i-Pr2NEt (3.0 eq)
CH2Cl2, 0 °C, 10 min
then DHPB 86 (20 mol%)
i-Pr2NEt (1.0 eq)
T (°C), 16 h
+
N
Ts
O
MeO2C
Ph
SPh
310
(2.0 eq)
263
(1.0 eq)
Me Me
T = rt, no conversion
      80 °C, no conversion
312
HO O
SPhMe
PhSH (1.0 eq)
NaOH (2.0 eq)
EtOH, 80 °C, 16 h
311
Quant.
HO O
BrMe
310
(1.0 eq)
a.) Synthesis of 2-(phenylthio)propanoic acid 311
b.) Reactivity of 2-(phenylthio)propanoic acid 311
Chapter 3: Three-Stage Synthesis of Tri- and Tetra-Substituted Pyridines 
 
 66 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 58 - Synthesis and reactivity of (diphenylthio)acetic acid 313. 
These two results imply that the presence of an aryl group at the α-position is key for 
reactivity. An explanation may be that the α-proton in the α-aryl-α-phenylthioacetic acids has a 
pKa suitable for deprotonation to the ammonium enolate with the resulting enolate possessing 
the required nucleophilicity and reactivity. 
Preparation of a range of further α-aryl-α-phenylthioacetic acids was, however, 
difficult. The first strategy was to conduct bromination and subsequent substitution with PhSH 
on the corresponding methyl esters (Scheme 59). It was envisioned that the purification of the 
ester products would be significantly easier using column chromatography compared with the 
carboxylic acids. The first step was to convert the commercially available carboxylic acids 315 
into their methyl esters 316, with quantitative yields obtained in all cases. Bromination using 
NBS and substoichiometric aq. 48% HBr, provided the bromo esters in typically good yield. 
Following this, the bromide was substituted with PhSH under basic conditions. The majority of 
problems encountered with this synthetic strategy were encountered in the final hydrolysis step. 
In all cases a complex mixture of carboxylic acid products were obtained that could not be 
separated by column chromatography (using TFA eluent additive). Analysis of the crude 
reaction by 1H NMR spectroscopy suggested that the product distribution might consist of the 
desired product 319, mandelic acid derivative 320 and methoxy-acid 321. The latter two 
products arising from potential substitution of the sulfide with H2O or the methoxide anion 
eliminated from the ester hydrolysis step. 
 
 
 
a.) Synthesis of (diphenylthio)acetic acid 313
b.) Reactivity of (diphenylthio)acetic acid 314
HO O
SPh
Ph N
MeO2C
Ts
t-BuCOCl (3.0 eq)
i-Pr2NEt (3.0 eq)
CH2Cl2, 0 °C, 10 min
then DHPB 86 (20 mol%)
i-Pr2NEt (1.0 eq)
rt, 16 h
+
N
Ts
O
MeO2C
Ph
SPh
313
(2.0 eq)
263
(1.0 eq)
PhS SPh
314
T = rt, no conversion
      80 °C, no conversion
HO O
SPhPhSAcOH (excess)
 120 °C, 16 h
313
58% yield
HO O
S
277
(2.0 eq)
Ph
O
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Scheme 59 - Initial synthetic attempts towards α-substituted (phenylthio)acetic acids. 
The next attempt looked to access bromo-acid 313 directly from 322 by forming the 
acid chloride in situ and then slow addition of bromine. The reaction was heated in 
chlorobenzene at 110 °C with the best conversion observed being 40% (as determined by 1H 
NMR spectroscopy). The nature of both starting material 322 and product 323 being carboxylic 
acids made separation difficult. As the Michael addition-lactamisation protocol applies 
carboxylic acids as the enolate precursors, a mixture of acids was not suitable to be carried 
forward. 
 
 
 
 
Scheme 60 - Attempted synthesis of 323 via an acid chloride α-bromination reaction. 
There is some precedent in the chemical literature for successfully conducting related α-
brominations on acids and esters using radical bromination approaches. A procedure was 
therefore devised that applied benzoyl peroxide as the radical initiator and NBS as the 
brominating agent under the exposure of UV-radiation (Scheme 61). After some optimisation it 
was found that freshly recrystallised NBS and freshly distilled CCl4 were necessary for full 
conversion. Although product 326 could not be fully purified (obtained as 90% pure by 1H 
NMR spectroscopy) the key feature was the full consumption of 325 was observed. The bromo-
acid 325 could then be subject to the PhSH substitution reaction giving 326. Once more this was 
obtained as a crude mixture consisting of only one carboxylic acid product. It was deemed that 
this, despite being only ≈ 80% pure by 1H NMR analysis, could be carried forward into the 
isothiourea-catalysis. 
MeO O
R1
HO O
R1
AcCl (1.5 eq)
MeOH (excess)
0-60 °C, 16 h
NBS (6.0 eq)
aq. 48% HBr (2 drops)
CHCl3, 80 °C, 16 h MeO O
R1Br
PhSH
(1.1 eq)
K2CO3
(1.1 eq)
1,4-dioxane
80 °C
2 h
MeO O
R1PhSKOH (3.0 eq)
1,4-dioxane
80 °C, 2 h
HO O
R1PhS
Complex crude mixtures
containing multiple
inseparable acids
319 318
315 316 317
R1 = 4-ClC6H4, 4-FC6H4, 4-BrC6H4, 
        3-MeC6H4, 2-Np
HO O
R1PhS
319
HO O
R1HO
320
HO O
R1MeO
321
Proposed products formed in mixture:
HO OHO O
i) SOCl2 (3.0 eq)
ClC6H5, 110 °C
ii) Br2 (1.2 eq)
110 °C, 4 h322 323
Cl Cl
Br ≈ 40% conversion: 
inseparable from 
starting material
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Scheme 61 - Devised synthetic route to carboxylic acid 326. 
At this time, bromo-acid 327 became commercially available and therefore allowed the 
synthesis of 2-(4-chlorophenyl)-2-(phenylthio)acetic acid 328 through the PhSH substitution 
reaction (Scheme 62). In this case, the equivalence of PhSH and K2CO3 were increased to give 
full conversion, with 328 isolated in 42% yield. 
 
 
 
 
 
Scheme 62 - Synthesis of carboxylic acid 328. 
3.3.3 Michael Addition-Lactamisation Applying α,α-Disubstituted (Phenylthio)acetic 
Acids 
The isothiourea-catalysed Michael addition-lactamisation process tolerates a wide range 
of 2-aryl-N-tosyliminoacrylates when applying (phenylthio)phenyl acetic acid 308 as the 
enolate precursor (Table 15). Diphenyl dihydropyridinone 329 was formed in excellent 77% 
yield. 3-Tolyl, 3,5-xylyl and 2-Np examples, 330, 331 and 335, proceeded with full 
consumption of Michael acceptor, however, the products could only be purified ≈80-90% purity 
(determined by 1H NMR spectroscopy). 4-Tolyl containing dihydropyridinone 332 was 
synthesised in good 60% isolated yield. Halogenated products 333 and 334 could be accessed in 
good 70% and 72% yield, respectively. Heteroaromatic substituents such as 2-thienyl group was 
well tolerated giving product 336 in 61% yield. Following the synthesis of α,α-disubstituted 
acids 326 and 328,  these were applied to the reaction conditions giving dihydropyridinones 337 
and 338 in 50% and 64% yields, respectively. The lower yield for 337 can be attributed to the 
use of carboxylic acid 326 as crude ≈ 80% purity. Alternative ester substituents can be 
accommodated as shown by example 339, produced in good 64% yield. 
 
PhSH (1.1 eq)
K2CO3 (2.0 eq)
1,4-dioxane
 80 °C, 16 h
HO OHO O
NBS (5.0 eq)
Benzoyl peroxide
(cat.)
CCl4, 70 °C,16 h
UV radiation324 325
F F
Br
HO O
326
F
PhS
Carried forward into catalysis
 without further purification
(≈ 80% purity)
PhSH (3.0 eq)
K2CO3 (6.0 eq)
1,4-dioxane
 80 °C, 16 h
HO O
327
Cl
Br
HO O
328
Cl
PhS
42% yield
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aCarried forward as crude mixture of 80-90% purity. 
Table 15 - Substrate scope: isothiourea-catalysed synthesis of tetra-substituted dihydropyridinones. 
3.3.4 S-Oxidation-Sulfoxide Elimination/N- to O-Sulfonyl Transfer 
The tetra-substituted dihydropyridinones were next subject to the S-oxidation-sulfoxide 
elimination/N- to O-sulfonyl transfer steps (Table 16). Highly substituted pyridines were 
produced showing excellent levels of conversion in all cases with no remaining starting 
materials or formation of any major side-products. Diphenyl pyridine 340 was achieved in 
excellent 72% yield over the three-stage protocol. With dihydropyridinones 330, 331 and 335 
being taken on for the synthesis of pyridines 342, 343 and 347 as crude mixtures, the resulting 
overall yields were only moderate (56%, 44% and 55%, respectively). Thienyl pyridine 348 was 
accessed in a good 61% overall isolated yield. Pleasingly, variation of the 5-substituent was 
accommodated into the pyridine products 349 and 350 giving yields of 64% and 45%, 
HO O
SPh
R2 N
R3O2C
Ts
t-BuCOCl (3.0 eq)
i-Pr2NEt (3.0 eq)
CH2Cl2, 0 °C, 10 min
then DHPB 86 (20 mol%)
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rt, 1 h
+
N
Ts
O
R3O2C
R2
SPh
(2.0 eq) (1.0 eq)
N
N
S
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N
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O
MeO2C
Ph
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N
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O
MeO2C SPh
N
Ts
O
MeO2C SPh
N
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O
BnO2C
Ph
SPh
MeO
329
68% yield
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69% yield
330a
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64% yield
R1 R
1
Ph Ph Ph
Me
N
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O
MeO2C SPh
N
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O
MeO2C SPh
N
Ts
O
MeO2C SPh
Me
331a 332
66% yield
333
70% yield
Ph Ph Ph
Br
Me
Me
N
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O
MeO2C SPh
N
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O
MeO2C SPh
N
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O
MeO2C SPh
334
72% yield
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Ph Ph Ph
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S
Ph
N
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O
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Ph
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50% yield
PhS
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N
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O
MeO2C
Ph
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71% yield
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respectively. Finally the 3-substituted Bn ester pyridine 351 was provided in moderate 58% 
yield. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aYield over three-steps. 
Table 16 - Substrate scope: synthesis of 2,3,5-substituted pyridine 6-tosylates. 
3.4 Scale-Up and Derivatisation 
As with the tri-substituted pyridine synthesis described in chapter 2, a key feature is the 
incorporation of the tosylate functional handle into the pyridine products. It was imagined that 
transformation of this functional group on both the tri- and tetra-substituted pyridines would 
provide access to more diverse products and substituent patterns. To accomplish this, the three-
stage pyridine protocol was scaled-up to provide large quantities of material as well as 
showcase the scalability of the process. Starting from 2.0 g (5.36 mmol) of methyl 2-((4-
N OTs
MeO2C
Ph N OTs
MeO2C
N OTs
MeO2C
N OTs
BnO2C
Ph
MeO340
93% yield
(72% yield)a
341
90% yield
(63% yield)a
342
(56% yield)a
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90% yield
(58% yield)a
Ph Ph Ph
Me
N OTs
MeO2C
N OTs
MeO2C
N OTs
MeO2C
Me343
(44% yield)a
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93% yield
(60% yield)a
345
94% yield 
(66% yield)a
Ph Ph Ph
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Me
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MeO2C
N OTs
MeO2C
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90% yield
(65% yield)a
347
(55% yield)a
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88% yield
(61% yield)a
Ph Ph Ph
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S
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(45% yield)a
F
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MeO2C
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90% yield
(64% yield)a
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methoxyphenyl)(tosylimino)methyl)acrylate 367, pyridines 272 and 341 could be synthesised in 
55% and 67%, respectively, over the three-steps of the methodology (Figure 28).  
 
 
 
 
 
 
Figure 28 - Scaled-up process for synthesis of 270 and 341. 
 The first derivatisation attempted was a Suzuki-Miyaura coupling as reported by 
Buchwald and co-workers (Scheme 63).[79] however treatment of the requisite pyridine with 
Pd(OAc)2, BrettPhos and K3PO4H2O in the presence of furanyl boronic acid 232 gave no sign 
of the intended furanyl pyridine 352. These reactions were conducted in both ambient and inert 
(Ar) atmospheres and at elevated temperatures but with no success. 
 
 
 
 
 
 
Scheme 63 - Attempted Suzuki-Miyaura coupling on pyridine 352. 
Pleasingly, the Pd-catalysed Mizoroki-Heck coupling described by Skrydstrup and co-
workers was successful (Scheme 64).[78] Reaction with either pyridine 270 or 341, Pd(dba)2, 
dppf, N-vinylacetamide 229 and Cy2NMe gave products 353 and 354 in 72% and 69% yield, 
respectively. 
 
 
 
 
 
 
 
Scheme 64 - Mizoroki-Heck reaction on pyridines 270 and 341. 
Nucleophilic aromatic substitution with morpholine also works well on both pyridine 
271 and 341, with products 356 and 357 obtained in 80% and 73% yield, respectively (Scheme 
N OTs
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MeO
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MeO2C R1
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+
229
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        Ph, 341
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65). Both this SNAr and the Mizoroki-Heck reaction provide access to functionalised 2,3,6- and 
2,3,5,6-substituted pyridines. 
 
 
 
 
 
Scheme 65 - SNAr reaction on pyridines 270 and 341. 
Finally, the tosylate group can be removed through a Pd-catalysed protodetosylation 
using HCO3H, Pd(OAc)2, dppp and Et3N in DMF at 100 °C (Scheme 66).[80] Conducting this 
transformation broadens this work into the synthesis of 2,3- and 2,3,5-substituted pyridines with 
the synthesis of 358 in 74% yield and 359 achieved in 78% yield.  
 
 
 
 
 
 
 
Scheme 66 - Protodetosylation reaction on pyridines 270 and 341. 
3.5 Conclusion 
In conclusion, thiophenyl carboxylic acids and 2-aryl-N-tosyliminoacrylates can be 
efficiently converted into functionalised tri- and tetra-subsituted pyridines. DHPB 86-mediated 
Michael addition-lactamisation initiates the synthesis to give a wide range of 
dihydropyridinones in typically good yield. These products are readily converted into the 
desired pyridine 6-tosylates through an m-CPBA mediated S-oxidation-sulfoxide elimination 
process, followed by a thermal assisted N- to O-sulfonyl transfer. These highly functionalised 
products can then be readily derivatised through the tosylate functional group to further 
elaborate the structure. Overall this procedure provides an efficient organocatalyst-mediated 
route towards the synthesis of 2,3-, 2,3,6-, 2,3,5- and 2,3,5,6-substituted pyridines. 
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Chapter 4: Application of 2-Aroyl and 2-Imino Acrylates in 
Enantioselective Isothiourea-Catalysis 
This chapter describes the application of aroyl and imino acrylate-type Michael 
acceptors for the first time in enantioselective isothiourea-catalysis giving the corresponding 
3,5,6-subsituted dihydropyranones and 2,3,5-substituted dihydropyridinones. Dihydropyranones 
362 are achieved in high enantiocontrol from homoanhydrides 360 and 2-aroylacrylates 361 
catalysed by (+)-BTM 48 (5 mol%) (Scheme 67a). Dihydropyridinones 365 are accessed in 
excellent enantiocontrol from carboxylic acids 363 and 2-N-tosyliminoacrylates 364 catalysed 
by (−)-tetramisoleHCl 47 (5 mol%)  (Scheme  67b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 67 - a.) Isothiourea-catalysed Michael addition-lactonisation using 2-aroyl acrylates. b.) 
Isothiourea-catalysed Michael addition-lactamisation using 2-N-tosyliminoacrylates. 
4.1 Introduction 
The synthesis of functionalised chiral small molecules through asymmetric catalysis 
remains a key area within synthetic methodology. Endocyclic enol dihydropyranones and 
enamine dihydropyridinones are found within bioactive compounds and as a result there has 
been many efforts towards their production.[90] Classically this can be achieved through 
uncatalysed-hetero Diels-Alder cycloaddition reactions, with more recent examples involving π-
olefin and π-alkyne cyclisations.[91] However, the state-of-the-art methods to form chiral 
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dihydropyranones and dihydropyridinones with high stereoselectivity remains 
organocatalytically generated enolate equivalents. N-Heterocyclic carbenes (NHCs) have been 
used in such a manner to form nucleophilic azolium enolate intermediates.[92] Bode and co-
workers described a pioneering example of this in 2006 (Scheme 68).[93] Treatment of α-
chloroaldehyde 366 with NHC catalyst 368 (0.5 mol%) in the presence of NEt3 generates an 
azolium enolate that can undergo a [4+2] cycloaddition with keto ester 367 to give 
dihydropyranones 369 in excellent yield and stereoselectivity. 
 
 
 
 
 
Scheme 68 - NHC-catalysed Diels-Alder reaction by Bode and co-workers. 
In 2008, Chen and co-workers reported an enamine-catalysed approach to the synthesis 
of chiral cyclic hemiaminals 373 that could then be subsequently oxidised into 
dihydropyridinones 374 (Scheme 69).[94] Reaction of aldehyde 370 and α,β-unsaturated 
ketimines 371 in the presence of prolinol-derived catalyst 372 (10 mol%) and acetic acid gives 
an inverse electron-demand Diels-Alder reaction to produce cyclic hemiaminals 373 in typically 
>80% yield and 95-99% ee and >95:5 dr. Hemiaminal 373 can then be readily oxidised with 
PCC to provide dihydropyridinones 374. 
 
 
 
 
 
 
 
Scheme 69 - Enamine-catalysed asymmetric aza-Diels-Alder reaction from Chen and co-workers. 
 As described in Chapter 1, the Smith Group have made a number of contributions to 
this area through the application of asymmetric isothiourea-generated ammonium enolate 
catalysis (Figure 29). Throughout all of the previous isothiourea work conducted in the Smith 
group, as well as the examples described in this introduction, the product substituent classes fall 
within the 3,4,6-substitution pattern. To the best of our knowledge, the chiral 3,5,6-substituted 
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dihydropyranones and dihydropyridinones have not been previously produced in 
enantioselective catalysis. 
 
 
 
 
Figure 29 - Overview of Smith Group isothiourea-catalysed Michael addition-cyclisation chemistry. 
Following the use of 2-N-tosyliminoacrylates in an isothiourea-mediated three-stage 
synthesis of functionalised pyridines, it was proposed these acrylate-derived Michael acceptors 
would provide access to chiral 3,5,6-substituted dihydropyranones and 2,3,5-substituted 
dihydropyridinones in an enantioselective isothiourea-catalysed protocol (Figure 30). 
 
 
 
 
 
Figure 30 - Enantioselective synthesis of 3,5,6-substituted dihydropyranones and 2,3,5-substituted 
dihydropyridinones. 
4.2 Michael Addition-Lactonisation 
4.2.1 Initial Results and Reaction Optimisation 
To investigate the isothiourea-catalysed Michael addition-lactonisation protocol to form 
3,5,6-substituted dihydropyranones, 2-aroylacrylate Michael acceptors were chosen as potential 
substrates. This structural class would give the desired substituent pattern, while the ester group 
should make the Michael acceptor sufficiently electron-deficient to react. The synthetic route to 
synthesise ethyl 2-benzoylacrylate started with the preparation of β-ketoester 377 using the 
reported procedure from Bretner and co-workers (Scheme 70).[95] Acetophenone 375 was 
treated with NaH in PhMe at 0 °C before a solution of diethylester 376 in PhMe was added 
dropwise. The reaction was warmed to rt over 2h before being heated at 110 °C overnight 
giving ketoester 377 in 88% yield. 
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aDetermined by 1H NMR spectroscopy. 
Scheme 70 - Synthesis of β-ketoesters. 
Next, ketoester was subject to the methenylation reaction conditions reported by 
Connell and co-workers (Scheme 71).[96] Ketoester 377, diisopropylammonium 2,2,2-
trifluoroacetate, paraformaldehyde and TFA were stirred at 60 °C overnight to give 2-
benzoylacrylate 378 in 13% yield. Following a short optimisation, it was found that conducting 
this reaction in a sealed-tube significantly improves the conversion to product, 378 in 93% 
yield. 
 
 
 
 
 
Scheme 71 – Preparation of 2-benzoylacrylate 378. 
Preliminary studies began with the optimisation of the isothiourea-catalysed Michael 
addition-lactonisation using phenylacetic acid and ethyl 2-benzoylacrylate 378. Following a 
screen of catalysts, solvents and temperatures the reaction with pivaloyl chloride, i-Pr2NEt and 
(+)-BTM (5 mol%) at −78 °C gave dihydropyranone 379 in 79% yield and 93% ee (Scheme 
72). Disappointingly, this procedure did not prove general, with the use of an alternative aryl 
acetic acid giving variable enantioselectivity. For example, when 4-bromophenyl acetic acid 
was used the corresponding dihydropyranone 380 was produced in good 80% yield but as a 
racemate.  
 
 
 
aIsolated following 
column chromatography using Biotage® Isolera™ 4. 
bDetermined by chiral HPLC. 
Scheme 72 - Initial attempts at a protocol utilising carboxylic acids. 
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It was proposed that the highly reactive 2-aroyl acrylate 378 may be prone to a 
competitive base-mediated racemic background reaction. To probe this, a control reaction in 
absence of (+)-BTM 48 was performed; forming dihydropyranone 380 in 52% yield (Scheme 
73). Therefore, this reaction process suffers from significant competition with a racemic 
background reaction between the in situ formed mixed anhydride 382 and 378 that accounts for 
the low enantioselectivities obtained. The reaction was also tried in the absence of any 
additional base (i-Pr2NEt) however in these cases only low (<10% conversion by 1H NMR 
spectroscopy) was obtained. To overcome the low enantioselectivity observed further 
optimisation was conducted using 4-bromophenyl acetic acid 381. However, despite screening a 
number of bases, temperatures and catalyst the desired product 380 was continually produced 
with no enantioselectivity. Addition of a solution of 378 (0.25 M in CH2Cl2) via syringe pump 
over 2 h gave a slight improvement, with 380 formed in 74% yield and 20% ee. 
 
 
 
 
 
 
 
 
 
 
Scheme 73 - Control reaction excluding Lewis base catalyst. 
A major breakthrough in this transformation arose from the evaluation of pre-formed 
homoanhydrides as alternative enolate precursors in place of in situ activated carboxylic acids. 
The Smith group has applied such precursors previously, with one advantage being the reduced 
levels of organic base necessary for catalysis. Reaction of homoanhydride 383, 2-aroyl acrylate 
378 and (+)-BTM 48 (5 mol%) in the presence of 1.25 eq of i-Pr2NEt gave product 380 in 88% 
yield and 88% ee. In this system, use of isothiourea catalyst (2S,3R)-HyperBTM 53 gave 380 in 
81% yield but only 46% ee while (−)-tetramisoleHCl 47 gave ent-380 in 80% yield and 78% 
ee (Table 17). Therefore, (+)-BTM 48 was chosen as the optimum catalyst and carried forward. 
Lowering the reaction temperature to −78 °C gave 380 after 1 h in 88% yield and excellent 91% 
ee. The choice of base may have an impact on the competition between the intended 
isothiourea-catalysed process and the racemic background reaction, therefore various organic 
and inorganic bases were investigated. Interestingly, the reaction with Et3N gave a dramatic 
increase in background reaction, forming 380 in 0% ee. Inorganic bases such as Cs2CO3 and 
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Na2CO3 gave product 380 in moderate to good 57% and 83% ee, respectively. Slow syringe 
pump addition of a solution of i-Pr2NEt (0.25 M in CH2Cl2) gave a reduced 70% ee and 88% 
yield after 2 h.  
 
 
 
 
 
 
Entry 
Lewis base (5 
mol%) 
T (°C) t (h) Base Yield (%)a ee (%)b 
1 48 rt 0.2 i-Pr2NEt 88 88 
2 53 rt 0.2 i-Pr2NEt 81 46 
3 47 rt 0.2 i-Pr2NEt 80 (ent) 78c 
4 48 −78 °C 1 i-Pr2NEt 88 91 
5 48 −78 °C 1 Et3N 85 0 
6 48 −78 °C 1 Cs2CO3 58 57 
7 48 −78 °C 1 Na2CO3 81 83 
8[d] 48 −78 °C 2 i-Pr2NEt 88 70 
aIsolated following column chromatography using Biotage® Isolera™ 4. bDetermined by chiral HPLC. 
c(S)-enantiomer obtained. dSyringe pump addition of 378 (0.25 M in CH2Cl2) over 2 h. 
Table 17 - Michael addition-lactonisation reaction optimisation. 
Although dihydropyranone 380 can be prepared in high yield and ee through the 
optimised reactions using homoanhydride 383, considerable care is needed when performing the 
reaction to maintain reproducible enantioselectivity. In particular, careful temperature control is 
essential. Optimisation showed that the best experimental procedure involves cooling a solution 
of homoanhydride in CH2Cl2 to −78 °C before (+)-BTM 48 was added and the reaction stirred 
for 20 min. Next, a solution of 2-aroyl acrylate in CH2Cl2 is pre-cooled to −78 °C before being 
added to the reaction mixture. Finally, i-Pr2NEt was added dropwise and the reaction stirred 
until complete by TLC analysis, with care being taken to maintain the reaction temperature at 
−78 °C. 
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4.2.2 Substrate Scope 
To assess the generality of this reaction a range of 2-aroyl acrylates was prepared in 
acceptable overall yields (Table 18). 
 
 
 
 
β-Keto esters 2-Aroyl acrylates 
Entry 
Compound 
No. 
R1 
Yield 
(%)a 
Entry Compound 
No. 
R1 
Yield 
(%)a 
1 384 4-MeOC6H4 75 7 389 4-MeOC6H4 89 
2 385 4-MeC6H4 78 8 390 4-MeC6H4 61 
3 386 2-furyl 49 9 391 2-furyl 48 
4 387 3-BrC6H4 50 10 392 3-BrC6H4 21 
5 388 2-Np 60 11 393 2-Np 50 
aIsolated following column chromatography. 
Table 18 - Synthesis of 2-aroyl acrylates. 
With the optimum conditions for applying homoanhydrides and 2-aroylacrylates in 
enantioselective isothiourea-catalysed Michael addition-lactonisation established, the substrate 
scope was first assessed with variation in the homoanhydride (Table 19). The 4-Cl substituted 
phenyl substituent was incorporated at the 3-position of dihydropyranone 395  in 85% yield and 
89% ee. 2-(4-Fluorophenyl)acetic anhydride provides product 396 in good 77% yield but 
disappointing 55% ee. Electron-rich 4-MeOC6H4 substitution, provided the corresponding 
dihydropyranone 397 in 83% yield and 91% ee. Pleasingly, the sterically demanding 2-
(naphthalen-1-yl)acetic anhydride was applied successfully with 398 formed in excellent 81% 
yield and 97% ee. However, the sterically demanding 2-tolyl group was installed at the 3-
position of 399 in good 81% yield, but with moderate 50% ee. 
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aIsolated following column chromatography using Biotage® Isolera™ 4. bDetermined by chiral HPLC. 
Table 19 - Substrate scope: variation of homoanhydride. 
The absolute configuration at the C(1) and C(2) position of 398 was confirmed by X-ray 
crystallography to be (3R). All other dihydropyranones were assigned by analogy.  
 
 
 
 
 
 
 
Figure 31 - X-ray crystal structure and molecular representation of (3R)-398. 
A number of examples proved problematic within this methodology (Table 20). 3-
Thienyl dihydropyranone 400 could be synthesised in 71% yield, but with no enantioselectivity. 
In an attempt to extend the scope beyond aryl homoanhydrides, propionic anhydride and 3-
phenylpropanoic anhydride were examined. It was predicted that these substrates would require 
a stronger base to facilitate the deprotonation of the ammonium enolate as had been discovered 
in related systems.[97] Using PS-BEMP as the reaction base unfortunately did not show any 
conversion into the corresponding dihydropyranones 401 and 402. 2-Methoxyacetic anhydride 
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was next investigated, but also gave no conversion into 403 using either i-Pr2NEt or PS-BEMP 
applied as the reaction base.  Indolyl, phenylthio, propenyl and phenylpropenyl examples 404-
407 showed full conversion into product in all cases (as determined by 1H NMR spectroscopy) 
but proved difficult to isolate due to a lack of stability towards column chromatography. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aIsolated following column chromatography using Biotage® Isolera™ 4. bDetermined by chiral HPLC. cPS-BEMP 
(1.25 eq) applied as reaction base. 
Table 20 – Substrate scope: unsuccessful dihydropyranone examples. 
Variation of the 2-aroyl acrylate Michael acceptor was next investigated (Table 21). 
Electron-rich substituents were tolerated at the 6-position giving 4-MeOC6H4 and 4-tolyl 
examples 408 and 409 in excellent 79% and 65% yield with 91% and 81% ee, respectively. 
Interestingly in the case of 409, the reaction with i-Pr2NEt gave the product in 0% ee but 
changing the reaction base to Na2CO3 provided 409 in improved 81% ee. In other instances 
where enantioselectivities were low using Na2CO3 as the base did not show any improvement. 
Three Michael acceptors, proved unsuccessful when employing phenylacetic anhydride giving 
the desired products 410, 412 and 414 in good yields but with 0% ee. Employing 4-
methoxyphenylacetic anhydride in these reactions gave the corresponding products 411, 413 
and 415 in good yield and with improved good to excellent levels of enantioselectivity.  
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aIsolated following column chromatography using Biotage® Isolera™ 4. bDetermined by chiral HPLC. cNa2CO3 
(1.25 eq) applied as reaction base. 
Table 21 - Substrate scope: variation of 2-aroyl acrylate. 
To evaluate this methodology for the synthesis of 3,6-substituted dihydropyranones, 
Michael acceptor 417 was prepared using the procedure from Iwasa and co-workers.[98] 
Treatment of 3-chloropropiophenone 416 with Et3N in CH2Cl2 at rt produces 1-phenylprop-2-
en-1-one 417 in quantitative yield (Scheme 74a). Due to the instability of 417, this was 
submitted to the optimum conditions immediately but led to complete decomposition with no 
observation of the desired product 419 (Scheme 74b).  
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Scheme 74 - Synthesis and reactivity of 1-phenylprop-2-en-1-one 417. 
4.3 Michael Addition-Lactamisation 
4.3.1 Initial Results and Reaction Optimisation 
Following the successful synthesis of dihydropyranones through an isothiourea-
catalysed Michael addition-lactonisation process, the synthesis of structurally related 2,3,5-
substituted dihydropyridinones was explored. Studies were initiated with a reaction optimisation 
applying 2-N-tosyliminoacrylate 263 and phenylacetic acid 420. Reaction of 420, pivaloyl 
chloride and i-Pr2NEt followed by addition of Michael acceptor 263 and (2S,3R)-HyperBTM 53 
(10 mol%) in CH2Cl2 at room temperature gave dihydropyridinone (ent)-421 in 60% yield and 
80% ee (Table 22). Next, a screen of isothiourea catalysts was undertaken with (+)-BTM 48 
providing (ent)-421 in 60% yield and 80% ee and (−)-tetramisoleHCl 47 gave 421 in 62% 
yield and 84% ee. With moderate enantioselectivities observed at room temperature, the 
reaction temperature was lowered to −78 °C and the catalysts 53, 47 and 48 examined. (2S,3R)-
HyperBTM 53 and (+)-BTM 48 showed slightly improved 86% and 85% ee, respectively, 
however (−)-tetramisoleHCl 47 proved optimal giving 421 in 74% yield and 91% ee. Changing 
the reaction solvent to THF gave 421 in reduced 40% yield and 86% ee. Interestingly, 
conducting the reaction in MeCN gave 421 with no enantioselectivity. Finally, the limit of the 
catalyst loading was probed with maintenance of the good yield and enantioselectivity observed 
with 5 mol% 47, but a poor 50% conversion into 47 using 2 mol%. 
 
 
 
 
 
 
 
 
 
Entry 
Catalyst 
(mol%) 
T (°C) t (h) Solvent Yield (%)a ee (%)b 
1c 53 (10) rt 16 CH2Cl2 −d −d 
2 53 (10) rt 0.5 CH2Cl2 60 (ent) 80e 
3 47 (10) rt 0.5 CH2Cl2 62 84 
4 48 (10) rt 0.5 CH2Cl2 60 (ent) 80e 
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5 53 (10) −78 16 CH2Cl2 71 (ent) 86e 
6 47 (10) −78 16 CH2Cl2 74 91 
7 48 (10) −78 16 CH2Cl2 70 (ent) 85e 
8 47 (10) −78 16 THF 40 86 
9 47 (10) −78 16 MeCN 70 0 
10 47 (5) −78 16 CH2Cl2 74 91 
11 47 (2) −78 16 CH2Cl2 −f −d 
aIsolated following column chromatography. bDetermined by chiral HPLC analysis. c Using 1.0 eq of 420 only 
58% conversion was obtained (determined by 1H NMR spectroscopy). dNot determined. e(R)-enantiomer 
obtained. e(R)-enantiomer obtained. f50% conversion (determined by 1H NMR spectroscopy). 
Table 22 – Michael addition-lactamisation reaction optimisation. 
4.3.2 Substrate Scope 
Moving onto the substrate scope, many examples gave poor conversion at −78 °C and 
so a modified system allowing the reaction to warm to room temperature over 16 h was used as 
a more general procedure. The generality was first probed with a range of acetic acids and 
Michael acceptor 263 (Table 23). Electron-rich aromatics 4-MeOC6H4 and 4-Me2NC6H4 were 
well tolerated, giving products 422 and 423 in 76% and 71% yield with excellent 95% and 94% 
ee, respectively. Electron-deficient CF3-substituted phenyl substituent was installed at the 5-
position giving 424 in 74% yield and 91% ee. Heteroaryl substituent, 2-thienyl 
dihydropyridinone 425 was achieved in 65% yield and 90% ee. 3-Tolyl acetic acid worked well 
with product 426 produced in 69% yield and 95% ee. Application of 4-bromophenylacetic acid 
gave the corresponding dihydropyridinone 427 in good 61% yield but in moderate 71% ee. This 
drop in enantioselectivity is likely due to strong competition from a base-promoted racemic 
background reaction. 4-Bromophenyl acetic anhydride was tested in hope that enhanced 
enantioselectivity would be achieved, as discovered with 2-aroyl acrylates, but this showed no 
improvements with a moderate 70% ee attained.  
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Application of 2-Aroyl and 2-Imino Acrylates in Enantioselective Isothiourea-Catalysis 
 
 87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aIsolated following column chromatography. bDetermined by chiral HPLC. 
Table 23 - Michael addition-lactamisation scope: variation of acetic acid. 
The absolute configuration at the C(5) position of 424 was confirmed by X-ray 
crystallography to be (S). All other dihydropyridinones were assigned by analogy.  
 
 
 
 
 
 
 
 
Figure 32 - X-ray crystal structure and molecular representation of (5S)-424. 
A range of 2-N-tosyliminoacrylates, prepared as in chapter 3, were next assessed in the 
scope of this enantioselective Michael addition-lactamisation. The 4-MeOC6H4 containing 
Michael acceptor 267 is tolerated giving dihydropyridinone 428 in 63% yield and excellent 98% 
ee. Methyl substituted phenyl rings 4-tolyl and 3,5-xylyl could be successfully incorporated at 
the 2-position to provide dihydropyridinones 429 and 430 in 59% and 60% yield and 90% and 
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97% ee, respectively. Finally, 2-Np ketimine 289 was applied to produce 431 in good 69% yield 
and 91% ee. 
 
 
 
 
 
 
 
 
 
aIsolated 
following column chromatography. bDetermined by chiral HPLC. 
Table 24 - Michael addition-lactamisation scope: variation of 2-N-tosyliminoacrylate. 
Given the success of the isothiourea-catalysed Michael addition-lactamisation protocol, 
some more challenging enolate precursors and Michael acceptors were investigated. 
Functionalisation of amino acids was attempted with the use of glycine and N-protected glycine 
derivatives (Table 25). Unfortunately, no conversion into desired dihydropyridinones 432-437 
was obtained (determined by 1H NMR spectroscopy). Methoxyacetic acid was probed using PS-
BEMP as the reaction base, but gave no conversion into product 436. 2-Tolyl acetic acid also 
proved unsuccessful, most likely due to the steric demand of the 2-substituted aryl acetic acid.  
 
 
 
 
 
 
 
 
 
 
 
 
 
MeO2C
R1
NTs
Ph
OH
O
+
420
(2.0 eq) (1.0 eq)
t-BuCOCl (3.0 eq)
i-Pr2NEt (3.0 eq)
CH2Cl2, 0 °C, 10 min
then (−)-Tetramisole•HCl
47 (5 mol%)
i-Pr2NEt (1.0 eq)
−78°C-rt, 16 h
NTs
O
R1
Ph
MeO2C
NTs
O
Ph
MeO2C
428
63% yielda
 98% eeb
NTs
O
MeO2C
429
59% yielda
 90% eeb
NTs
O
Ph
MeO2C
430
60% yielda
 97% eeb
NTs
O
Ph
MeO2C
431
69% yielda
 91% eeb
Ph
Me
Me
MeOMe
Chapter 4: Application of 2-Aroyl and 2-Imino Acrylates in Enantioselective Isothiourea-Catalysis 
 
 89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aPS-BEMP (1.25 eq) used as reaction base. 
Table 25 - Michael addition-lactamisation scope: unsuccessful examples. 
(Phenylthio)acetic acid 84 was previously applied to the racemic Michael addition-
lactamisation applied in the synthesis of pyridine sulfonates (Chapter 2 and 3). Interestingly, 
applying 84 in the enantioselective protocol gave racemic dihydropyridinone 264 in 65% yield 
(Scheme 75). To test if this was due to epimerisation or a competitive racemic background 
reaction, the control reaction in the absence of a Lewis base catalysis was conducted and did not 
provide any observable conversion into 264. This suggests that the C(5)−H pKa is low enough to 
undergo an epimerisation to give the racemic product. This also provides indirect evidence 
towards a feasible epimerisation mechanism of PhSH elimination discussed in Chapter 2 in the 
one-pot synthesis of pyridines. 
 
 
 
 
 
aIsolated following column chromatography. bDetermined by chiral HPLC. 
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Scheme 75 - Application of (phenylthio)acetic acid 84. 
Following the application of α,α–disubstituted acetic acids in chapter 3, a particularly 
interesting example was that of applying (phenylthio)phenyl acetic acid 308 in the 
enantioselective process. The reaction provides 329 in good 68% yield but with no 
enantioselectivity (Scheme 76). As there is no major racemic background reaction in the 
Michael addition-lactamisation protocol, the absence of enantioselectivity could be due to poor 
control over the (E)- and (Z)-enolate geometries formed in the reaction. 
 
 
 
 
 
 
 
aIsolated following column chromatography. bDetermined by chiral HPLC. 
Scheme 76 - Application of (phenylthio)phenyl acetic acid 308. 
4.4 Derivatisations 
To explore the synthetic utility of the dihydropyranones and dihydropyridinones 
produced in the enantioselective isothiourea-catalysis process developed herein, 397 and 421 
were prepared on a gram-scale and a range of derivatisations attempted. 
 
 
 
 
 
 
 
aIsolated following column chromatography. bDetermined by chiral HPLC. 
Figure 33 - Scaled-up synthesis of (3R)-397 and (5S)-421. 
4.4.1 Dihydropyranone Derivatisation 
The first dihydropyranone transformation attempted was the ring opening of (±)-397 
with either MeOH or BnNH2 in the presence of sub-stoichiometric DMAP (Scheme 77). It was 
predicted that a 50:50 mixture of diastereoisomers would be produced with no control over the 
new stereocentre at C(2). However, it was hoped that these diastereoisomers would be separable 
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and hence provide a stereodivergent process, overall. In both examples the diastereoisomers 
were not separable by column chromatography and were therefore not pursued any further. 
 
 
 
 
 
 
 
 
 
aIsolated following column chromatography.bDetermined by 1H NMR spectroscopy. 
Scheme 77 - Ring opening of (±)-397. 
An alternative ring opening using LiAlH4 was investigated (Scheme 78). Following full 
consumption of 397 a complex mixture of products was obtained (as determined by 1H NMR 
spectroscopy). From the 1H NMR analysis, it’s believed that this complex mixture consisted of 
the desired alcohol 442, ring closed lactol 443, known to form under these conditions in related 
systems,[42] with other products produced from decomposition. Efforts to isolate these products 
were unsuccessful. 
 
 
 
 
 
 
Scheme 78 - Attempted reductive ring opening of (3S)-397. 
The first attempt to utilise the olefin component of 397 was an m-CPBA epoxidation, 
with 30% conversion into epoxide 444 after 16 h was determined by 1H NMR spectroscopy 
(Scheme 79). However, product 444 underwent decomposition upon work-up or attempted 
purification. 
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aDetermined by 1H NMR spectroscopy. 
Scheme 79 - Attempted epoxidation of (3S)-397. 
Pleasingly, the Pd/C catalysed hydrogenation of 397 under one atmosphere of hydrogen 
gave pyranone 445 in 60% yield and >95:5 dr (Scheme 80).  
 
 
 
 
 
 
aIsolated following column chromatography.bDetermined by 1H NMR spectroscopy. 
Scheme 80 - Hydrogenation of 397. 
Unambiguous determination of the product enantioselectivity proved difficult, with 445 
decomposing under both chiral HPLC and GC analysis. To examine the relative configuration 
within pyranone 445, 1H NMR spectroscopy was utilised (Figure 34). Firstly, NOESY 
experiments with irradiation at the C(6) position confirmed the relative configuration to be syn 
with positive NOE signals for C(3)H and C(5)H. Coupling constant signal analysis for C(5)H 
confirms the syn-configuration at C(5) and C(6) with the ddd signal at 3.39 ppm. This analysis 
shows an axial-equatorial 3JHH coupling constant of 4.5 Hz between C(5)Hax and C(5)Heq. 
Coupling to the C(4)Hax and C(4)Heq is also observed with 3JHH coupling constants of 8.2 Hz and 
5.9 Hz, respectively.This supports a stereoselective hydrogenation with hydrogen adding to the 
Re-face opposite to that of the substituent at C(3). Given the high 87% ee observed for 397 and 
the the high >95:5 syn-diastereoselectivity observed for 445, it can be suggested that pyranone 
445 was prepared as the (2S,3R,5R)-stereoisomer. 
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Figure 34 - a.) Coupling constant analysis of C(5)H. b.) 1D gs-NOESY spectrum of 445 with 
irradiation at C(6). c.) 1H NMR (500 MHz, CDCl3) spectrum of 445. 
With (±)-445 in hand, a number of ring openings were explored. Using sub-
stoichiometric DMAP and either MeOH or benzylamine as the nucleophile, products (±)-446 
and (±)-447 were obtained in moderate to poor dr (81:19 and 60:40, respectively) (Scheme 81). 
As (±)-397 was submitted to the reactions as a single diastereoisomer this result implies that an 
epimerisation has taken place at a stereocentre under the reaction conditions. Therefore, these 
ring openings were not pursued further.  
 
 
 
 
aIsolated following column chromatography. bDetermined by 1H NMR spectroscopy. 
Scheme 81 - Attempted ring opening of (±)-397 with MeOH or BnNH2. 
A reductive ring opening with LiAlH4 provided triol (1S,2S,4R)-448 in excellent 88% 
yield from (2S,3R,5R)-445 with no loss of diastereoselectivity (Scheme 82). This compound 
proved challenging to determine the enantioselectivity, with decomposition observed in both 
chiral HPLC and GC. Nonetheless, the stereochemistry was assigned by analogy with the 
enantiomer produced in the synthesis of (3R)-397 and subsequent syn-selective hydrogenation 
to (2S,3R,5R)-445. 
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aIsolated following column chromatography. bDetermined by 1H NMR spectroscopy. 
Scheme 82 - Reductive ring opening of (2S,3R,5R)-397. 
4.4.2 Dihydropyridinone Derivatisation 
Dihydropyridinone 421 proved difficult to ring open with nucleophiles. Reaction using 
excess MeOH and substoichiometric DMAP with 421 gave no conversion with starting 
materials returned (Scheme 83). 
 
 
 
 
 
Scheme 83 - Attempted methanolic ring opening of 421. 
Dihydropyridinone 421 was treated with LiAlH4 in an attempt to produce diol 450 
(Scheme 84). Full consumption of 421 was observed but a complex mixture of products was 
obtained. Endeavours to isolate the components of the crude mixture were unsuccessful. 
 
 
 
 
 
 
Scheme 84 - Attempted reductive ring opening of 421. 
Hemiaminals derived from dihydropyridinones are useful synthetic building blocks, in 
particular for the synthesis of functionalised piperidines.[99] It was therefore intended to produce 
hemiaminal 451 from reduction of 421 using DIBAL-H, however a complex mixture of what 
was determined (by 1H NMR spectroscopy) to be mostly decomposition material was obtained 
(Scheme 85). 
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Scheme 85 - Attempted reduction of 421 into hemianminal 451. 
Applying the procedure outlined by Sakamoto and co-workers a milder Luche reduction 
with NaBH4 and CeCl37H2O was attempted, but in this case only starting materials were 
returned with no observable conversion into hemiaminal 451 (Scheme 86). 
 
 
 
 
 
 
Scheme 86 - Attempted Luche reduction of (5S)-421. 
4.5 Proposed Mechanism and Stereochemical Rationale 
Following our previous studies a proposed mechanism for the processes described in this 
chapter begins with N-acylation of isothiourea catalyst with either the homoanhydride (with 
aroyl acrylates) or in situ formed mixed anhydride (with imino acrylates) to form an acyl 
ammonium species 453 (Figure 35). Subsequent deprotonation gives the (Z)-ammonium enolate 
454, which undergoes an enantioselective Michael addition to an aroyl acrylate or imino 
acrylate. Finally, lactamisation or lactonisation provides the corresponding heterocyclic 
products 457 and releases the catalyst. 
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Figure 35 - Proposed mechanism of isothiourea-catalysed Michael addition-
lactonisation/lactamisation. 
Rationalisation of the observed enantioselectivity in the Michael addition-lactonisation 
reaction can be based upon the results and computational modelling of related systems (Figure 
36).[100] Ammonium enolate forms with a (Z)-configuration, stabilised by either an enolate 
oxygen and the C−S anti-bonding orbital (no to σ*C−S) interaction or a favourable electrostatic 
interaction.[36-37, 101] This interaction is believed to rigidify 458 with the Ph directing group from 
catalyst 48 adopting a pseudo-axial orientation and blocking one face of the ammonium enolate. 
Inputting 2-aroyl acrylate 460 into this model, the next stage is the enantiodetermining Michael 
addition that can be assigned by analogy to the Heathcock model giving 462.[102] Lactonisation 
turns over the catalyst and provides dihydropyranone (3R)-463. As the Michael addition-
lactamisation process uses (−)-TetramisoleHCl 47, the pseudoenantiomer of (+)-BTM 48, the 
stereochemical rationale is proposed to be the same but the mirror image giving (5S)-463. 
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Figure 36 - Proposed stereochemical rationale. 
4.6 Conclusions 
In conclusion, it has been shown that isothiourea-catalysed Michael addition-
lactamisation/lactonisation of either 2-aroyl acrylates or 2-imino acrylates with homoanhydrides 
or arylacetic acids, respectively, produces 3,5,6-substituted dihydropyranones and 
dihydropyridinones. Reaction yields and enantioselectivities are typically excellent in both 
protocols. Derivatisation of the products through hydrogenation and ring opening processes has 
demonstrated the use of these products as chiral building blocks. 
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Chapter 5: Michael Addition-Lactonisations using α,β-Unsaturated 
Trichloromethyl Ketones 
This chapter describes the application of α,β-unsaturated trichloromethyl ketones 465 in 
an isothiourea-catalysed Michael addition-lactonisation process to give dihydropyranones 466 
(Scheme 87). Generally, these heterocycles have been utilised with an in situ ring opening and 
substitution of the CCl3 group to provide access to chiral diesters and diamides 467 in excellent 
yield (typically 60-80%), diastereo- and enantioselectivity (80:20->95:5 dr and typically >98% 
ee).[103] 
 
 
 
 
 
 
Scheme 87 - Organocatalytic Michael addition-lactonisation using α,β-unsaturated trichloromethyl 
ketones. 
5.1 Introduction 
Enantioselective Michael addition to electron deficient alkenes is a fundamental C−C 
bond forming transformation in organic chemistry with modern day efforts directed towards 
enantioselective Michael addition reactions.[104] Consequently, this area has seen much attention 
in recent years, with numerous examples demonstrated already in this thesis. At the forefront of 
interest has remained the use of organocatalysis with the application of H-bonding catalysis,[105] 
ammonium[18, 31b] and azolium enolates[106] in combination with electron-deficient enones, enals 
and nitro olefins. Intriguingly, the activation and enantioselective Michael addition into α,β-
unsaturated esters and amides has proved challenging due to the inherent decreased reactivity of 
these substrates. 
 
 
 
 
Figure 37 - General Michael acceptor reactivity observed in asymmetric catalysis. 
To circumnavigate this problem a common strategy is the employment of activated ester 
surrogates as masked ester equivalents. Many of these examples are designed as ester/amide 
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surrogates capable of chelating chiral Lewis acid catalysts such as α,β-unsaturated N-acyl 
pyrroles,[107] N-acyl imidazoles,[108] or imides[109] (Figure 38). 
 
 
 
 
 
 
 
 
 
 
Figure 38 - Enantioselective Lewis acid-catalysed Michael addition strategies applying α,β-
unsaturated ester/amide equivalents. 
Phosphonates have also been used as ester/amide surrogates in Lewis acid-catalysed 
Michael addition reactions,[110] but more recently they have attracted interest within 
organocatalysis. Jørgensen and co-workers reported a pioneering example in 2010 using H-
bonding catalysis (Scheme 88).[111] Treatment of unsaturated phosphonate 475 with thiourea 478 
(10 mol%) and either oxazolone 476 or substituted indole 477 nucleophiles gives Michael 
addition adducts 480 and 481 in moderate to good yield and good to excellent 
enantioselectivity. In most cases the phosphonate group can be substituted in situ with a range 
of alcohols (e.g. MeOH, EtOH or BnOH) or amines (e.g. BnNH2 or morpholine) thus producing 
the corresponding esters and amides. 
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aee determined following recrystallisation. 
Scheme 88 - Application of acyl phosphonates as ester/amide surrogates in H-bonding catalysis. 
Encouraged by the application of α,β-unsaturated phosphonates in organocatalysis, in 
2014 the Smith group reported a Michael addition-lactonisation process using α,β-unsaturated 
ketophosphonates as ester/amide surrogates (Scheme 89). Reaction of arylacetic acids 482 with 
α-ketophosphonates 483 in the presence of t-BuCOCl, i-Pr2NEt and catalyst (2S,3R)-
HyperBTM 53 (10 mol%) provides phosphonate dihydropyranones 484 in moderate to good 
yield (49-83%) and excellent diastereo- and enantioselectivity (91:9->95:5 dr and 86-98% ee). 
Generally, this procedure was used in conjunction with an in situ ring opening and subsequent 
substitution of phosphate giving access to the corresponding chiral diesters and diamides 485 
with maintenance of the high levels of enantiocontrol.  
 
 
 
 
 
 
 
 
 
 
Scheme 89 - α-Ketophosphonates as ester/amide surrogates in asymmetric isothiourea-catalysis. 
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Despite the good results from this methodology, a significant limitation was the poor 
long term bench-stability of the α-ketophosphonates. To alleviate this limitation it was proposed 
that an α,β-unsaturated ester equivalent such as the trichloromethyl ketones may be more stable 
alternatives. Trichloromethyl ketones have proved to be useful synthetic building blocks with 
application as carboxylic acid, ester and amide surrogates, taking advantage of the leaving 
group ability of CCl3 in haloform-type reactions.[112] Specifically, α,β-unsaturated 
trichloromethyl ketones have been utilised in enantioselective Michael additions in a small 
number of examples. In 2009, Zhao and co-workers reported the enantioselective epoxidation of 
α,β-unsaturated trichloromethyl ketones 486 with tert-butylhydroperoxide (TBHP) catalysed by 
prolinol derivative 487 (20 mol%) (Scheme 90).[113] 
 
 
 
 
 
Scheme 90 - Application of α,β-unsaturated trichloromethyl ketones in enantioselective 
epoxidation. 
Zhao and co-workers followed this work in 2011 with an enantioselective synthesis of 
α-trichlorodihydropyrans 492 in typically good to excellent yield (>84%) and enantioselectivity 
(72-95% ee) using trichloroketone 490 and α-cyano ketones 489 catalysed by 
piperazine/thiourea catalyst 491 (Scheme 91).  
 
 
 
 
 
 
 
 
Scheme 91 - Application of α,β-unsaturated trichloromethyl ketones in enantioselective synthesis of 
α-trichlorodihydropyrans. 
More recently, Wang and co-workers have applied α,β-unsaturated trichloromethyl 
ketones 494 in enantioselective vinylogous Michael additions with γ-butyrolactams 493 
catalysed by squaramide 495 (10 mol%) to produce Michael adducts 496 in 73-93% yield, 
typically >95:5 dr and 86-99% ee (Scheme 92).  
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Scheme 92 - Application of α,β-unsaturated trichloromethyl ketones in enantioselective vinylogous 
Michael additions with γ-butyrolactams. 
Inspired by the use of α,β-unsaturated trichloromethyl ketones as ester/amide surrogates 
in enantioselective Michael additions, it was hypothesised that these compounds may be 
suitable substrates for an isothiourea-catalysed Michael addition-lactonisation protocol (Figure 
39). Furthermore, ring opening of the corresponding dihydropyranones and substitution of the 
CCl3 group would provide stereodefined diesters or diamides. Overall, this process consists of a 
similar design to that conducted previously with α,β-unsaturated ketophosphonates but with 
bench-stable substrates that can be stored for long periods of time and a wider scope of 
examples available. 
 
 
 
 
 
Figure 39 - Project design applying α,β-unsaturated trichloromethyl ketones in isothiourea-
catalysed Michael addition-lactonisation/ring opening-substitution process 
5.2 Michael Addition-Lactonisation Initial Results 
5.2.1 Synthesis of α,β-Unsaturated Trichloromethyl Ketones 
Despite the use of α,β-unsaturated trichloromethyl ketones in the chemical literature, 
the synthesis of these substrates is not trivial. Therefore, to make this methodology practical, a 
reliable synthesis of the α,β-unsaturated trichloromethyl ketones was necessary. The first 
attempted synthesis used the procedure described by Zhao and co-workers.[113] Treatment of a 
solution of cinnamaldehyde 497 and CHCl3 in DMF at 0 °C with a solution of KOH in EtOH 
and stirring at 0 °C provided some unusual results (Scheme 93). Analysis of the crude reaction 
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by 1H NMR spectroscopy appeared promising, with allylic alcohol 498 and starting material 
497 observed as the only components in a 85:15 ratio (498:497). However, following column 
chromatography 498 was isolated in a disappointing 18% yield. To examine if allylic alcohol 
498 was unstable to chromatography the product was stirred in a solution of silica gel and 
CH2Cl2. After 4 h, no decomposition of 498 was observed by 1H NMR spectroscopy with the 
full mass returned, consistent with instability to silica gel not being responsible for the poor 
yield. Characteristic of these reaction mixtures was a dark black colour consistent with either 
decomposition or polymerisation. Typically the colour change from colourless to black occurred 
following the addition of KOH in EtOH. These reaction conditions have been commonly used 
in a number of transformations, such as the Reimer-Tiemann reaction,[114] to generate the highly 
reactive dichlorocarbene intermediate 499. This can in turn lead to further side reactions and 
decomposition, with much of the polymeric material formed observable by 1H NMR 
spectroscopy. This observation is consistent with the observed clean crude 1H NMR but poor 
isolated yield. 
 
 
 
Scheme 93 - Preparation of 498 using the procedure from Zhao and co-workers. 
Next, an alternative synthesis of 498 following the procedure reported by Wang and co-
workers was investigated.[115] Reaction of cinnamaldehyde 497 with trichloroacetic acid and 
sodium trichloroacetate in DMF for 2 h gave product 498 in poor 15% conversion (as 
determined by 1H NMR spectroscopy). Heating the reaction to 50 °C led to complete 
decomposition of starting materials within 1 h. Pleasingly, conducting the reaction at 0 °C and 
slowly allowing the reaction to warm back to rt overnight provided 498 with full consumption 
of 497 and an isolated yield of 48% (Scheme 94). 
 
 
 
 
Scheme 94 - Preparation of 498 using the procedure from Wang and co-workers. 
With allylic alcohol 498 in hand, the next step was the oxidation into the corresponding 
α,β-unsaturated trichloromethyl ketone 500. The first reaction investigated was a Jones 
oxidation based on the procedure reported by Wang and co-workers (Scheme 95).[115] Addition 
of 498 to excess CrO3 and pyridine at 0 °C gave a small conversion into ketone 500 with a 
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complex crude mixture of decomposition material obtained leading to isolation of 500 in only in 
14% yield. 
 
 
 
 
Scheme 95 - Attempted Jones oxidation of 498. 
The next transformation tried was a Parikh-Doering oxidation using a modified protocol 
to that reported by Evans and co-workers (Scheme 96).[116] Treatment of allylic alcohol 498 with 
sulfur trioxide pyridine complex, pyridine and freshly distilled DMSO in CH2Cl2 gave no 
conversion into ketone 500 with only starting materials returned.  
 
 
 
 
 
Scheme 96 - Attempted Parikh-Doering oxidation of 498. 
Finally, the Swern oxidation procedure as demonstrated by Corey and co-workers 
proved successful (Scheme 97).[117] Reaction of 498 with DMSO and oxalyl chloride at −60 °C 
followed by addition of excess Et3N gave trichloromethyl ketone 500 in excellent 93% yield. 
 
 
 
 
 
Scheme 97 - Swern oxidation of 498. 
 Following the establishment of a synthetic route to synthesise α,β-unsaturated 
trichloromethyl ketones, a range was prepared by colleagues within the Smith group.[118] 
5.3 Michael addition-Lactonisation/Ring Opening Cascade 
5.3.1 Initial Results 
Based on the successful application of structurally related CF3 enones and carboxylic 
acids in isothiourea-catalysed Michael addition-lacontisation processes the optimum conditions 
from these systems were applied to CCl3 ketones.[42],[119] Reaction of phenylacetic acid 420 with 
pivaloyl chloride, i-Pr2NEt and trichloromethyl ketone 500 in the presence of (2S,3R)-
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HyperBTM 53 (5 mol%) gave anti-dihydropyranone 501 in 82% yield and 87:13 dr (Scheme 
98). Dihydropyranone 501 was unstable to storage and underwent with decomposition within a 
week even when kept below 0 °C. Moreover the lack of stability led to decomposition of 501 
when subject to either chiral HPLC or GC, making determination of the reaction 
enantioselectivity unsuccessful.  
 
 
 
 
 
aIsolated by column chromatography as 87:13 dr. bDetermined by 1H NMR spectroscopic analysis of crude mixture.  
Scheme 98 - Application of α,β-unsaturated trichloromethyl ketone 500 in Michael addition-
lactonisation. 
It was proposed that transformation of 501 into the corresponding diester via an in situ 
ring opening and substitution of the CCl3 ketone would provide products with improved 
stability. Dihydropyranone 501 was reacted with one equivalent of MeOH and 
substoichiometric DMAP at rt for 6 h giving full consumption of 501 (Scheme 99). The 1H 
NMR analysis of the crude mixture did not indicate the formation of the intended diester 503, 
however. Following purification by column chromatography the reaction product was 
determined to be pyrone 502. A possible mechanism for the formation of 502 is deprotonation 
at C(4) and elimination of Cl− to give 505. Formal tautomerisation of 505 leads to 
dichloromethyl pyrone 502.  
 
 
 
 
 
 
 
 
 
Scheme 99 - a.) Attempted ring opening of 501 with 1.0 eq MeOH and 20 mol% DMAP. b.) 
Proposed mechanism for the formation of 502. 
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An alternative protocol with an in situ ring opening using a large excess of MeOH was 
examined and pleasingly produced diester 503 in 62% yield, 87:13 dr and 99% ee with no 
observation of pyrone 502 (Scheme 100).  
 
 
 
 
aIsolated by column chromatography. bDetermined by 1H NMR spectroscopy (isolated as >95:5 dr). cDetermined by 
chiral HPLC analysis. 
Scheme 100 - Michael addition-lactonisation/in situ ring opening protocol. 
5.3.2 Substrate scope 
With a suitable Michael addition-lactonisation/in situ ring opening protocol established, 
the reaction scope was next evaluated. Firstly, a selection of acetic acids was tested with 
trichloromethyl ketone 500 (Table 26). Electron-rich carboxylic acids worked well with the 4-
MeOC6H4 substituent incorporated in 507 with 77% yield, 92:8 dr and >99% ee. The 3-MeC6H4 
substituted acetic acid was tolerated providing 508 in 65% yield, 85:15 dr and 91% ee. 
Unfortunately, the 2-MeC6H4 variant 509 gave poor conversion, most likely due to the steric 
demand of the 2-substituted aromatic substituent. Thienyl example 510 was prepared in good 
64% yield, 81:19 dr and >99% ee. Expanding the scope beyond only arylacetic acids, the 
propenyl and phenylpropenyl products 511 and 512 proved successful with 78% and 74% yield, 
85:15 and 95:5 dr and both >99% ee, respectively. Diesters 513-514 were produced by 
colleagues within the Smith group.[120] The scope could not be extended to alkyl-substituted 
acetic acids with 3-phenylpropanoic acid giving no conversion into product 515. 
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aIsolated by column chromatography as >95:5 dr. bDetermined by 1H NMR spectroscopic analysis of crude mixture. 
cDetermined by chiral HPLC analysis. 
Table 26 - Substrate scope: variation of carboxylic acid. 
A number of different trichloromethyl ketone Michael acceptors was subjected to the 
previously optimised conditions applying phenyl acetic acid 420. The diester products 516-519 
with varying groups at the C(3) positions were prepared by colleagues within the Smith group 
(Table 27). [121] 
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aIsolated by column chromatography as >95:5 dr. bDetermined by 1H NMR spectroscopic analysis of crude mixture. 
cDetermined by chiral HPLC analysis. dIsolated as mixture of diastereoisomers (80:20 dr) 
Table 27 - Substrate scope: variation in Michael acceptor conducted by colleagues within the Smith 
group. 
Lastly, different nucleophiles were investigated for the ring opening-CCl3 substitution 
by the Smith group with some interesting results (Table 28). Amines can be used to give 
stereodefined diamide 520 in 67% yield, 90:10 dr and >99% ee. Using allyl alcohol in the 
procedure successfully opens the dihydropyranone, but does not substitute the CCl3 group 
giving trichloromethyl keto ester 521 in 60% yield and comparable stereoselectivity.  
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aIsolated by column chromatography as >95:5 dr. bDetermined by 1H NMR spectroscopic analysis of crude mixture. 
cDetermined by chiral HPLC analysis.  
Table 28 - Substrate scope: alternative nucleophiles. 
Overall, it was observed in all examples that ring opening of the dihydropyranone with 
the requisite nucleophile is relatively quick (typically under 4 h) whereas substitution of the 
CCl3 proceeds much slower (typically 12 h). To take advantage of this characteristic, the 
intermediate ring opened trichloromethyl keto-amide 522 was intercepted with addition of 
excess MeOH to give γ-ester amide 423 in moderate 42% yield but with excellent >95:5 dr and 
99% ee (Scheme 101).[122] 
 
 
 
 
 
 
 
aIsolated by column chromatography as >95:5 dr. bDetermined by 1H NMR spectroscopic analysis of crude mixture. 
cDetermined by chiral HPLC analysis. 
Scheme 101 - Sequential ring opening with different nucleophiles. 
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5.4 Proposed Mechanism 
The proposed mechanism for this process starts via N-acylation of (2S,3R)-HyperBTM 53 
with in situ formed mixed anhydride 524 forming acyl ammonium 525 (Figure 40). 
Deprotonation of 525 gives the key (Z)-ammonium enolate 526, allowing either an no to σ*C–S 
interaction or favourable electrostatic stabilisation between the enolate oxygen and the sulfur 
atom of the isothiourea.[36-37, 101b] Enantioselective Michael addition to α,β-unsaturated 
trichloromethyl ketone 527 followed by lactonisation gives dihydropyranone 529 and 
regenerates the catalyst. Ring opening of dihydropyranone 529 with a nucleophile and further 
substitution of the trichloromethyl ketone gives 530. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40 - Proposed reaction mechanism. 
5.5 Conclusions 
In conclusion, a practical and reproducible synthesis of α,β-unsaturated trichloromethyl 
ketones has been developed. Application of these α,β-unsaturated trichloromethyl ketones in an 
isothiourea-catalysed Michael addition-lactonisation protocol provides anti-dihydropyranones 
that are ring opened in situ with addition of a nucleophile and subsequent substitution of CCl3 
group produces access to a range of stereodefined chiral diesters in typically excellent 
enantioselectivity. Further investigation within the Smith has discovered a sequential ring 
opening-CCl3 substitution with two different nucleophiles. 
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Chapter 6: Isothiourea-Catalysed Enantioselective Synthesis of 
Pyrrolizines 
This chapter describes an enantioselective synthesis of pyrrolizines via an isothiourea-
catalysed Michael addition-lactonisation process. An efficient and reproducible route to prepare 
a range of pyrrolo enone-acid substrates has been established. Application of pyrrolo enone-
acids in a (+)-BTM 48 (5 mol%) catalysed Michael addition-lactonisation gives 
dihydropyranone pyrrolizines 532 in situ. A range of nucleophiles have been used to undergo 
ring opening of 532 to provide pyrrolizines 533 in typically excellent yield (53%-quant. yield), 
diastereo- and enantioselectivity (>95:5 dr and 97-99% ee) (Scheme 102). 
 
 
 
 
 
Scheme 102 - Enantioselective isothiourea-catalysed synthesis of pyrrolizines. 
6.1 Introduction 
The 5,5-bicyclic pyrrolizine and pyrrolizidine structural motifs are present at the core of 
many biologically active natural products,[123] such as that of dehydroretronecine 534 (Figure 
41).[124] This natural product, along with many other derivatives, originates from metabolism of 
the pyrrolizidine alkaloids (PA’s), a natural alkaloid prevalent in plant life throughout 
nature.[125] Such PA derived molecules are known to be potent heptatoxins,[126] carcinogens,[127] 
teratogens[128] and genotoxins.[129] Compelled by such levels of biological activity, it is no 
surprise that many of these natural products have become commercial therapeutic agents with 
many more synthetic derivatives now also being developed. An early and classic example is that 
of partially reduced pyrrolizine mitomycin C 535, isolated from Streptomyces caespitosus or 
Streptomyces lavendulae this chemotherapeutic agent has been found to be a potent antitumour 
antibiotic drug with a broad scope of applications.[130] The non-steroidal anti-inflammatory drug 
(NSAID), Licofelone 536 has shown great promise in osteoarthritis treatment through a dual 
inhibition of 5-LOX/COX.[131] Additionally, another pyrrolizine based NSAID, Ketorolac 537, 
has found success as a commercial analgesic.[132] 
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Figure 41 - Biologically relevant pyrrolizines. 
 Despite the value and potential of these bicyclic compounds, methodologies that enable 
efficient access to diverse structural libraries are limited. Many syntheses have involved classic 
total synthesis approaches towards specific target molecules.[133] One of the first catalytic 
methods was reported by Cho and co-workers in 2010 with an enantioselective organocatalysed 
Michael addition-aldol reaction (Scheme 103).[134] Reaction of proline derivative 540 (20 mol%) 
with pyrroles 538 and enals 539 in the presence of benzoic acid allows the initial Michael 
addition-aldol reaction to form the bicyclic motif with reduction by NaBH4 providing the 
pyrrolizine alcohols 541 in excellent yield and stereoselectivity (>95:5 dr and 90-98% ee). 
 
 
 
Scheme 103 - Pyrrolizine synthesis via organocatalysed Michael addition-Aldol reaction. 
In recent years the state-of-the-art in pyrrolizine synthesis has involved multi-
component domino reactions with one example being the phosphine-catalysed protocol by Tong 
and co-workers (Scheme 104).[135] Reaction of pyrrolo enones 542, allenes 543, Na2CO3 and 
catalysed by PPh3 (20 mol%) gives tricyclic pyrrolizines in a proposed concerted cycloaddition 
process. This process produces the desired products in 544 in excellent yield (72-95%) and 
diastereoselectivity (>95:5 dr) but in racemic form. 
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Scheme 104 - PPh3-catalysed diastereoselective synthesis of pyrrolizines. 
A further example was reported recently but Matsuya and co-workers with a gold-
catalysed three-component domino process (Scheme 105).[136] Treatment of aldimines 545, 
maleimides 547 and alkynes 546 with catalyst (Ph3P)AuCl (10 mol%) gives pyrrolizine 
products 548 in moderate to good yield (48-68%) and excellent diastereoselectivity (>95:5 dr). 
As with the previous example, this procedure does not offer an enantioselective option and 
therefore is limited to the synthesis of racemic mixtures. 
 
 
 
 
 
Scheme 105 - Gold-catalysed diastereoselective domino synthesis of pyrrolizines. 
6.2 Previous Work 
In spite of the new advances in this area there is still a requirement for easily accessible, 
catalytic methodologies that can produce the chiral pyrrolizine derivatives with high 
enantiocontrol. As already introduced in Chapter 1, the Smith group has previously reported 
methods to synthesise fused-polycyclic compounds via enantioselective-catalysis.[41] 
Specifically, following the intramolecular isothiourea-catalysed synthesis of indanes, 
benzofurans and tetrahydrofurans, it was proposed that this methodology may provide a 
plausible route into chiral pyrrolizines 549 using pyrrolo enone-acids 550 as substrates (Figure 
42). 
 
 
 
 
 
NBnO2C •
AcO
R1
O
CN
N
H
CO2Bn
H
NC R
1
O
PPh3 (20 mol%)
Na2CO3 (1.2 eq)
PhMe, rt, 12 h
+
544
15 examples
typically 72-95% yield
typically >95:5 dr
542
(1.2 eq)
543
(1.0 eq)
R2 = CH2CO2CH2CF3
HR1
N
R2
R3
EtO2C NO
R4
O NN
O
O
R4
R1
HO
R3
CO2Et
(Ph3P)AuCl (10 mol%)
AgOTf (10 mol%.)
PhCO2H
ClCH2CH2Cl, 
65-80 °C
6 h
548
11 examples
48-68% yield, >95:5 dr
547
(2.0 eq)
546
(2.0 eq)
545
(1.0 eq)
+ +
H
H
Chapter 6: Isothiourea-Catalysed Enantioselective Synthesis of Pyrrolizines 
 119 
 
 
 
 
 
 
 
 
 
Figure 42 - Proposed enantioselective synthesis of pyrrolizines. 
Initial studies within the Smith group started the project with an investigation into the 
synthesis of the required pyrrolo enone-acid substrates (Figure 43).[137] Firstly, pyrrole 2-
carboxaldehydes 552 were purchased or prepared using a Vilsmeier-Haack formylation before 
N-alkylation with with 3-methylbromopropanoate to give 553. Subsequent ester hydrolysis to 
acid 554 followed by Horner-Wadsworth-Emmons reaction gives pyrrolo enone-acids 555. 
Although this process provided the parent phenyl containing substrate in good yield, the route 
proved problematic with alternative substrates not accessible and isolated yields not 
reproducible. 
 
 
 
 
 
 
 
 
 
 
 
Figure 43 - Initial synthetic strategy for the synthesis of pyrrolo enone-acids attempted by 
colleagues within the Smith group. 
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enone-acid 555 for 2 h with pivaloyl chloride and i-Pr2NEt followed by addition of (+)-BTM 48 
(5 mol%) and further stirring at rt for 16 h provided syn-pyrrolizine dihydropyranone 556 in 
82% yield, >95:5 dr and >99% ee (Scheme 106).  
 
 
 
 
 
Scheme 106 - Optimised Michael addition-lactonisation procedure. 
6.3 Synthesis of Pyrrolo Enone-Acid Substrates 
6.3.1 Optimisation of a Synthetic Route 
At the onset of the project, with the catalysis optimised, the first objective was to 
establish a general, reproducible synthetic route towards the required pyrrolo enone-acid 
substrates. Pleasingly, a modified strategy was devised that circumvents the problems with the 
first attempted synthetic route (Scheme 107). Pyrrole 2-carboxaldehydes 552 are treated with 
the requisite ketones and NaOH in an aldol condensation to give pyrrolo enones 557. 
Subsequent N-alkylation was achieved using methyl acrylate and substoichiometric t-BuOK to 
produce pyrrolo enone-esters 558. Finally, ester hydrolysis gives pyrrolo enone-acids 559. In 
most cases, these steps do not require column chromatography with products provided in good 
purity or purified by recrystallisation or acid-base extraction techniques. Furthermore, it was 
found that this synthetic process was efficient, practical and provided a range of variants in 
good overall yield. 
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Scheme 107 - Optimised synthetic route towards pyrrolo enone-acids. 
6.3.2 Preparation of Pyrrolo Enone-Acids 
Using this synthetic route, a range of substrates 555, 560-566 were synthesised with 
differing substituents present on the enone component using the optimised procedure described 
previously (Table 29). 
 
 
 
 
 
 
 
 
 
 
 
 
aYield over 3-steps. bFinal product obtained as a crude mixture of 70-80% purity as determined by 1H NMR 
spectroscopy. 
Table 29 - Prepared pyrrolo enone-acids 
Attempts to prepare further functionality within the enone proved difficult to obtain. 
Trifluoroacetone, 3,3-dimethylbutan-2-one and (E)-4-phenylbut-3-en-2-one gave no conversion 
in the aldol condensation with only starting materials returned (Scheme 108). Nitro containing 
pyrrolo enone 568 was synthesised however, when subject to the N-alkylation step this gave no 
conversion to product. It can be suggested that the strongly electron-withdrawing nitro 
substituent decreases the nucleophilicity of the pyrrole nitrogen and disfavours alkylation. 
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Scheme 108 - Unsuccessful examples. 
To further explore the scope of the methodology it was necessary to prepare pyrrolo 
enone-acids that contain a substituted pyrrole backbone. The preliminary attempts, conducted 
by colleagues within the Smith group, focused on the synthesis of indolyl enone-acids with the 
added benzannulation of the parent pyrrolo enone-acid (Figure 44).[138] The success of the 
synthetic route used for the synthesis of pyrrolo enone-acids, disappointingly, did not transfer to 
the synthesis of indolyl enone-acids. With only small quantities of material accessible and a 
longer, more arduous synthesis that did not prove general or reproducible, this was not pursued 
any further. Additionally, the preparation of brominated pyrroles did not prove trivial with 
brominated pyrroles, in all cases, showing poor stability to light and heat and thus made 
isolation difficult.[139]  
 
 
 
 
 
 
 
Figure 44 - Attempts at the synthesis of indolyl-based and brominated substrates by colleagues 
within the Smith group. 
Chlorinated pyrrolo substrates were next assessed as it was hoped these would offer 
improved stability. A synthetic route towards a 5-chloro substituted substrate began with an 
attempted one-pot chlorination/formylation procedure from Reynolds and co-workers (Scheme 
109).[140] This reaction gave a complex crude reaction mixture that appeared to be the result of 
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decomposition and polymerisation (determined by 1H NMR spectroscopy), as is common with 
pyrrole-containing compounds. 
 
 
 
 
 
Scheme 109 - Attempted synthesis of 5-chloro pyrrole 2-carboxaldehyde. 
Late stage chlorination was next evaluated, with treatment of pyrrolo enone-ester 571 
with N-chlorosuccinimide (NCS) providing product 572 in 25% yield with subsequent 
hydrolysis giving the desired substrate 573 in 69% yield (Scheme 110). 
 
 
 
 
 
Scheme 110 - Preparation of chloro pyrrolo enone-acid 573. 
An alternative pyrrole functionalisation via Friedel-Crafts acylation, based on the 
procedure from Su and co-workers, using benzoyl chloride and Zn(OTf)2 (10 mol%) was 
investigated on both pyrrolo enone 574 and pyrrolo enone-ester 575 (Scheme 111).[141] In both 
cases, complete decomposition was observed upon addition of Zn(OTf)2 with a dark black 
residue obtained and no pyrrolic signals present in the 1H NMR analysis of the crude mixture. 
 
 
 
 
 
 
 
 
Scheme 111 - Attempted Friedel-Crafts acylation of 574 and 575. 
Following the report from Trofimov and co-workers in 2015 on the one-pot synthesis of 
pyrroles, it was suggested that this procedure would allow the preparation of a range of 
substituted pyrroles that could then be subjected to the optimised synthetic route mentioned 
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previously (Scheme 112).[142] Reaction of ketones 576 with NH2OH•HCl, KOH and DCE gives 
substituted pyrroles 577 in typically moderate yields (11-85%). Following condensation of 
ketones 576 with NH2OH•HCl in the presence of KOH it is proposed that oxime 578 forms, 
with deprotonation and alkylation on oxygen by DCE giving intermediate 579. Subsequent 
elimination gives alkene 580 that upon heating to 120 °C promotes a [3,3]-rearrangement to 
give 582 that can then cyclise and aromatise to give pyrroles 577. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 112 - Synthesis of substituted pyrroles by Trofimov and co-workers. 
However, in our hands, this reaction proved largely unsuccessful. Reaction of a number 
of ketones did not provide any evidence for the formation of the pyrrole products with most 
reactions giving side-product 589 (Scheme 113). 
 
 
 
Scheme 113 - Attempted one-pot synthesis of substituted pyrroles. 
A number of modifications were tried to obtain conversion into the required pyrroles. 
Conducting the reaction in a sealed-tube was tried as it was postulated that evaporation of DCE 
(or acetylene resulting from double elimination of DCE) was an issue but this did not offer any 
improvements. The equivalents of DCE were increased to five in order to fully alkylate all of 
the formed oxime and hence reduce the chance of generating side-product 589. When applying 
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cyclohexanone a 13% yield of pyrrole 586 was achieved (Scheme 114). Attempts to apply other 
ketones remained unsuccessful when using this modified procedure.  
 
 
 
 
 
 
Scheme 114 - Synthesis of tetrahydro-1H-indole 586. 
With 586 in hand, it was submitted to the optimised synthesis to give enone-acid 593 
(Scheme 115). This proved generally successful however, enone-acid 593 could not be fully 
purified and was obtained at 80% purity (as determined by 1H NMR spectroscopy). 
 
 
 
 
 
 
 
 
 
 
 
aObtained as a crude mixture of 80% purity (as determined by 1H NMR). 
Scheme 115 - Synthesis of tetrahydro indolyl enone-acid 593. 
6.4 Substrate Scope 
6.4.1 Michael Addition-Lactonisation/Ring Opening Scope: Variation of Nucleophile 
Disappointingly, when assessing the substrate scope, all pyrrolizine dihydropyranones 
were found to be unstable to column chromatography or decomposed within a short time of 
isolation. Therefore, it was anticipated that an in situ ring opening of the dihydropyranone 
would provide products that were inherently more stable. A number of nucleophiles were 
examined to both find a general method for the remaining substrate scope but to also showcase 
the number of derivatives that can be prepared quickly and efficiently using this method (Table 
30). The simple procedure for conducting this ring opening involved adding an excess of 
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nucleophile with stirring at rt for a further 4-16 h. In all cases investigated, the corresponding 
products were obtained with excellent isolated yields and superb diastereo- and 
enantioselectivities. Ring opening with MeOH provided pyrrolizine 594 in 86% yield, >95:5 dr 
and >99% ee. Non-aromatic nitrogen-containing heterocycles are widespread in a number of 
commercial biologically active compounds. To show that these functional groups could be 
included into the pyrrolizine products the corresponding amines were used for the ring opening 
protocol. Pyrrolidine worked well with amide 595 produced in quantitative yield, >95:5 dr and 
>99% ee. Morpholine ring opens the intermediate dihydropyranone with 596 provided in 72% 
yield, >95:5 dr and >99% ee. The structurally related and important piperazine motif can be 
incorporated with 597 obtained in 72% yield, >95:5 dr and >99% ee. Allyl amine proved 
successful with amide 598 given in 81% yield, >95:5 and 97% ee and included the synthetically 
useful terminal alkene into the molecule. The tetrahydrothienopyridine structure is present in the 
compound Plavix®, a platelet aggregation inhibitor and one of the largest grossing 
pharmaceuticals on the market. This component could also be included into the pyrrolizine 
products with 599 produced in 60% yield, 95:5 dr and >99% ee. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aIsolated following column chromatography. bDetermined by 1H NMR spectroscopic analysis of the crude mixture. 
cDetermined by chiral HPLC analysis. 
Table 30 - Substrate scope: variation of nucleophile used for in situ ring opening. 
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Ring opening with allyl alcohol and propargyl alcohol appeared more difficult than with 
MeOH or amines. It was attempted to synthesise esters 600 and 601 as these molecules contain 
useful alkyne and alkene functional groups but even in the presence of DMAP (20 mol%) only 
trace ring opening occurred with pyrrolizine dihydropyranone returned (Table 31). 
 
 
 
 
 
 
 
 
 
Table 31 - Substrate scope: unsuccessful ring openings. 
6.4.2 Michael Addition-Lactonisation/Methanolysis Scope: Variation of Substrate 
As methanol is a cheap, readily available commodity and proved highly successful in 
the ring opening procedure it was chosen as the standard nucleophile when investigating further 
pyrrolizine substrates (Table 32). Brominated aryl units can be included with products 602 and 
603 produced in 78% and 74% yield, 99% and >99% ee, respectively and both as a single 
diastereoisomer. Heteroaromatic groups such as thiophene are tolerated with 604 accessed in 
77% yield, >95:5 dr and 98% ee. Electron-rich aromatics such as the 4-MeOC6H4 unit worked 
well in the protocol with 605 achieved in 93% yield, >95:5 dr and >99% ee. The 2-Np and more 
sterically demanding 1-Np groups can both be incorporated with 606 and 607 produced in 81% 
and 68% yield respectively, with both achieved as single diastereoisomers and enantiomer. 
Unfortunately, the inclusion of alkyl groups did not prove successful with the application of 
pyrrolo enone-acid 563 showing no observable conversion into 609 with catalyst loadings of 5 
mol% or 20 mol%. 
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aIsolated following column chromatography. bDetermined by 1H NMR spectroscopic analysis of the crude mixture. 
cDetermined by chiral HPLC analysis. 
Table 32 - Substrate scope: variation of pyrrolizine enone component. 
The absolute configuration at the C(1) and C(2) position of 602 was confirmed by X-ray 
crystallography to be (1S,2R) (Figure 45). All other dihydropyranones were assigned by 
analogy.  
 
 
 
 
 
 
 
 
Figure 45 - X-ray crystal structure and molecular representation of 603. 
Substrates 573 and 593 bearing elaborated pyrrole cores were next assessed. 
Chlorinated product 609 was isolated in 66% yield, 94:6 dr and >99% ee (Table 33). 
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Hexahydro-1H-pyrroloindole product 611 was prepared in moderate 53% yield, due to the use 
of crude substrate 593, but with excellent >95:5 dr and >99% ee. 
 
 
 
 
 
 
 
 
 
 
aIsolated following column chromatography. bDetermined by 1H NMR spectroscopic analysis of the crude mixture. 
cDetermined by chiral HPLC analysis. 
Table 33 - Substrate scope: variation of pyrrolizine core. 
6.5 Derivatisation 
To exemplify that this methodology could also be used as a basis for further synthetic 
steps, a selection of derivatisations were explored (Scheme 116). The synthesis of product 602 
using this cascade methodology gives a product with the bromine functional handle. Through 
the use of the common and powerful Suzuki-Miyaura coupling this product can be further 
elaborated to access the polyheteroaromatic pyrrolizine 611 in 60% isolated yield and with no 
loss of dr or ee.[143] 
 
 
 
 
 
 
 
 
Scheme 116 - Suzuki-Miyaura coupling. 
Furthermore, a simple chlorination of the pyrrolizine 594 core can be conducted using N-
chlorosuccinimide to access chloropyrrolizine 612 in 79% yield with the incorporation of a 
further functional handle (Scheme 117). 
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Scheme 117 - Pyrrolizine chlorination reaction. 
6.6 Computational Studies and Stereochemical Rationale 
6.6.1 Proposed Mechanism 
This process is believed to start with formation of mixed anhydride 613 in situ from the 
starting pyrrolo enone-acid, pivaloyl chloride and i-Pr2NEt. N-acylation by isothiourea catalyst 
48 gives intermediate acyl ammonium 614 that, following deprotonation, provides (Z)-
ammonium enolate 615 (Figure 46). Enantiodetermining intramolecular Michael addition gives 
pyrrolizine intermediate 616 that undergoes lactonisation to provide pyrrolizine 
dihydropyranone 617 and regenerate the catalyst. In situ ring opening of 617 with a nucleophile 
gives the syn-pyrrolizine product 618. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46 - Proposed reaction mechanism. 
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6.6.2 Computational Studies 
In collaboration with Professor Stuart Macgregor at Heriot Watt University, a 
computational study of the reaction profile and analysis of the reaction stereoselectivity was 
conducted.[144] Calculations were run with Gaussian 09 Revision D.01[145] with PCM solvent 
corrections run with Gaussian 09, Revision D.01[146] Geometry optimisations were performed 
using the M06-2X functional[147] using 6-31G** basis sets[148] on all atoms (called BS1). All 
stationary points were fully characterized via analytical frequency calculations as either minima 
(all positive eigenvalues) or transition states (one negative eigenvalue) and IRC calculations and 
subsequent geometry optimisations were used to confirm the minima linked by each transition 
state. Frequency calculations also provided a free energy in the gas-phase, computed at 298.15 
K and 1 atm. SCF energies were recomputed with the larger 6-311++G** basis set[149] (BS2) 
and incorporate a correction for CH2Cl2 solvent (CH2Cl2, PCM approach[150]). 
Firstly, the reaction pathways leading to the cis-isomer, observed as the major product of 
the reaction, and the possible trans-isomer were modelled (Figure 47a and b). The modelling for 
the cis-pathway started with the (Z)-ammonium enolate R1 proceeding via the Michael addition 
transition state TS1cis (+5.1 kcalmol−1) into cis-intermediate Intcis (−0.6 kcalmol−1). Cyclisation 
occurs through TS2cis (6.5 kcalmol−1) to provide ring-closed intermediate Int2cis (1.7 kcalmol−1). 
Elimination of the (+)-BTM catalyst gives pyrrolizine dihydropyranone product Pcis (−18.2 
kcalmol−1) with the catalyst closely associated. The reaction pathway leading to the two possible 
trans-isomers was modelled using the same reaction sequence starting from (Z)-ammonium 
enolate R1 or (E)-ammonium enolate R2 leading to the trans-products Ptrans-1 and Ptrans-2, 
respectively. The key features present in these reaction profiles are the significantly smaller 
overall barrier of the cis-pathway (6.5 kcalmol−1) compared to the trans-pathways (16.6 kcal−1 
when starting from (E)-enolate and 9.9 kcalmol−1 when starting from the (Z)-enolate). This 
suggests that the reaction proceeds under kinetic control. 
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Figure 47 - Calculated reaction pathways for formation of the a.) cis-isomer and the b.) trans-
isomers using M06-2X(BS2, DCM)//M06-2X(BS1). 
One contributing factor for the lower energy barrier of the TScis versus the TStrans-1 may 
be explained by the favourable π-stacking interaction between catalyst and the aryl substituent 
situated on the enone component (Figure 48). Modelled TScis shows these groups to be located 
in favourable conformation aiding this interaction (inter-plane angle = 5.7°). However, in 
TStrans-1 the conformation is more strained with the catalyst and phenyl substituent on the enone 
aligned in different planes (inter-plane angle = 28.1°) and hence minimising a potential π-
stacking interaction. 
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Figure 48 - Calculated transition structures for the Michael addition step leading to the cis- and 
trans-isomers. 
To rationalise the diastereo- and enantioselectivity observed in this process, the 
calculated transition state TScis can be used as a basis. Following generation of the (Z)-
ammonium enolate the intramolecular Michael addition occurs with the two protons placed in a 
syn-orientation with enone and enolate positioned pseudoequatorial (Figure 49). Reaction 
proceeds with nucleophilic attack at the Re-face of the enone leading to the formation of the 
(4aS,9aR)-enantiomer of the final pyrrolizine dihydropyranone, following lactonisation. A 
favourable stereoelectronic interaction between the sulfur of the catalyst and oxygen of the 
enolate is believed to rigidify this assembly, as described already for related isothiourea-
catalysed processes. This 1,5 oxygen to sulfur interaction appears to be present throughout all 
calculated Michael addition transition states with the enolate oxygen and catalyst sulfur 
observed to be in a syn-coplanar conformation. Moreover, this distance is found to be 0.579 Å 
shorter than the predicted van der Waals radii (3.320 Å) suggesting this interaction to be 
significant.[37] 
 
 
 
 
 
 
 
 
Figure 49 - Proposed diastereo- and enantioselectivity rationale. Molecular representation and 
calculated TS1cis (M06-2X(BS2, DCM)//M06-2X(BS1)). 
Another potential feature in TS1cis is the close proximity of the enone oxygen and the 
catalyst C(2) and C(3) protons (Figure 50). The interatomic distances of 2.191 Å (C(2)H---O) 
TS1cis (5.1 kcalmol−1) TS1trans-1 (9.9 kcalmol−1) 
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and 2.371Å (C(3)H---O) suggest that a non-classical H-bonding interaction is possible with 
potential stabilising effects. A contributing factor here may be the positioning of the C(2)H and 
C(3)H adjacent to the isothiouronium core of the catalyst. This may therefore increase the 
acidity of these C−H bonds and consequently allow them to become stronger H-bonding donors. 
Although not significantly strong individually these stabilising contacts may impart influence 
on the high selectivity for the observed stereoisomer. It should be noted that the equivalent 
contacts in the TStrans-1 structure are somewhat longer (2.720 Å and 2.648 Å) and therefore 
suggesting that this interaction is less significant in the trans-pathway compared to the cis-
pathway. 
 
 
 
 
 
 
 
 
 
 
Figure 50 - Calculated TS1cis  and TStrans-1 (M06-2X(BS2, DCM)//M06-2X(BS1)) with measured 
intramolecular O---H bond distances. 
6.7 Conclusions 
An enantioselective synthesis of pyrrolizines via an isothiourea-catalysed Michael 
addition-lactonisation process has been established. An efficient and reproducible route to 
prepare a range of pyrrolo enone-acid substrates has been was discovered with products 
obtained in good overall yield. Activation in situ of the pyrrolo enone-acids to a mixed 
anhydride using pivaloyl chloride and i-Pr2NEt is first conducted with the introduction of 
catalyst (+)-BTM 48 (5 mol%) gives pyrrolizine dihydropyranone species with a wide selection 
of amines or MeOH used to ring open these intermediates giving pyrrolizine products with 
exquisite diastereo- and enantioselectivity (>95:5 dr and 97-99% ee). Derivatisation of the 
pyrrolizine products has been demonstrated to show the utility of these compounds with no loss 
of the high dr or ee. Computational experiments indicate that the reaction for the formation of 
the observed syn-diastereoisomer to be under kinetic control with the syn-product also 
calculated to be lower in energy than either possible anti-product.  
2.371Å2.191Å
2.720Å
2.648Å
TS1cis  TStrans-1  
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Chapter 7: Application of Saccharin-Derived Substrates in 
Isothiourea-Catalysis 
This chapter describes the discovery of an enantioselective organocatalytic 
methodology for the synthesis of chiral 8,9-dihydro-7H benzo[4,5]isothiazolo[2,3-a]pyridin-7-
one 5,5-dioxides with high stereocontrol. This optimised process consists of a (2R,3S)-
HyperBTM 53 (5 mol%)-catalysed Michael addition-lactamisation using cyclic sulfonyl imines 
617 derived from saccharin and commercially available carboxylic acids 616, giving the sultam 
products 618 in typically excellent diastereo- and enantiocontrol (Scheme 118). 
 
 
 
 
 
 
 
Scheme 118 - Enantioselective isothiourea-catalysed synthesis of 8,9-dihydro-7H 
benzo[4,5]isothiazolo[2,3-a]pyridin-7-one 5,5-dioxides 
7.1 Introduction 
Saccharin (1,2-benzisothiazol-3-one 1,1-dioxide) 619 is a synthetic calorie-free additive, 
widely used as sugar substitute in many food products and has proven an important discovery in 
the fight against diabetes.[151] However, the cyclic sulfonamide core structure has also attracted 
much interest in recent decades from the medicinal chemistry community. It is now well known 
that sulfonamides, and specifically cyclic sulfonamides (sultams), are key constituents in many 
biologically active drugs such as Ampiroxicam 620,[152] a member of a large family of 
nonsteroidal anti-inflammatory agents (Figure 51). In particular, saccharin-based sultams have 
been found to be active agonists of 5-HT1A receptors and have therefore been applied as 
neuroprotectants or anxiolytics such as that of Ipsaspirone 621.[153] Current research within this 
area has led to the development of saccharin derivatives as inhibitors of carbonic anhydrase 
enzymes.[154] 
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Figure 51 - Saccharin and biologically relevant saccharin derivatives. 
With the growing medicinal interest in saccharin-derived sultams it is no wonder that a 
number of methodologies have appeared to provide efficient synthetic routes into these 
compounds. In particular, a number of enantioselective organocatalytic strategies have been 
explored to access chiral sultam products with stereocontrol. One such example was report in 
2012 from Bode and co-workers using NHC acyl azolium catalysis in an annulation process 
(Scheme 119).[155] Sulfonyl imine 622, prepared in one-step from saccharin, was treated with 
enal 623, NHC 368 (10 mol%), i-Pr2NEt and oxidant 625 giving tricylic sultams 626 in good to 
excellent yield (67-94%) and excellent enantioselectivity (81-99% ee) when monosubstituted 
enals were applied. A select few enals containing disubstitution were also tested with sultams 
627 produced as single diastereoisomers (>95:5 dr) with moderate to excellent 
enantioselectivity (60-99% ee).  
 
 
 
 
 
 
 
 
 
 
 
Scheme 119 - NHC-catalysed annulation of enals and imines via α,β-unsaturated acyl azoliums. 
Another organocatalytic approach, this time from Chen and co-workers in 2014 
investigated an aza Diels-Alder reaction using organocatalytically generated trienamines 
(Scheme 120).[156] Reaction of ketones 628, cyclic sulfonyl imine 629 and cinchona alkaloid 630 
(20 mol%) in the presence of salicylic acid generates trienamine intermediate 632 which can 
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react through the δ,ε-alkene in an inverse electron demand Diels-Alder reaction with cyclic 
sulfonyl imines 629 to give products 631 in excellent diastereo- and enantioselectivity (>95:5 dr 
and 96->99% ee). 
 
 
 
 
 
 
Scheme 120 - Enantioselective synthesis of sultams using enamine catalysis. 
In 2015, Chen and co-workers utilised iminium catalysis with an asymmetric tandem 
synthesis of saccharin-derived sultams. Reaction of sulfonyl imines 633, prepared in one-step 
from saccharin, with enals 634 in the presence of catalyst 487 (10 mol%) and DMAP (1.0 eq) 
gives hydroxy sultams 635 typically excellent diastereoselectivity (>95:5 dr) and 
enantioselectivity (83->99% ee) (Scheme 121). It is proposed that following the formation of 
iminium intermediate 637 and tautomerisation of 633 that this reaction pair can undergo a 
Michael addition step to give 638. After tautomerisation and hydrolysis of 638, the intermediate 
639 cyclises to give the observed products.  
 
 
 
 
 
 
 
Scheme 121 - Michael addition-cyclisation reaction for the synthesis of sultams using iminium 
catalysis. 
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It is evident that the synthesis of chiral sultams is of high importance in organic 
chemistry with new methodologies to prepare such molecules still required. Based upon the 
previous Smith group work in the area of enantioselective Michael addition-lactamisation 
cascades it was proposed that saccharin-derived Michael acceptors might prove suitable for 
such a process (Figure 52). Reaction with isothiourea-generated enolate equivalents would 
therefore provide access to stereodefined 8,9-dihydro-7H benzo[4,5]isothiazolo[2,3-a ]pyridin-
7-one-5,5-dioxides moieties.  
 
 
 
 
Figure 52 - Proposed project plan. 
It should be noted that during the course of this project a similar reaction process by 
Pericàs and co-workers was reported. Here the authors report a Michael addition-lactamisation 
protocol using carboxylic acids 640 as enolate precursors, Michael acceptors 641 and a polymer 
supported (+)-BTM catalyst 48 (15 mol%) (Scheme 122).[157] 
 
 
 
 
 
Scheme 122 - Related protocol reported during the undertaking of this project. 
7.2 Enantioselective Michael Addition-Lactamisation 
7.2.1 Initial Reaction Optimisation 
The cyclic sulfonyl imine was chosen as a model system that would assess the 
optimisation of the reaction and was prepared using the procedure by Chen and co-workers 
(Scheme 123).[156] The process starts with cheap and commercially available saccharin 619 with 
addition of MeMgBr and dehydration to give imine 633 in moderate yield after recrystallisation 
(45%). 633 is subjected to an aldol reaction with benzaldehyde, piperidine and acetic acid to 
provide α,β-unsaturated cyclic sulfonyl imine 617 in moderate yield (54%).  
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Scheme 123 - Synthetic route to prepare saccharin-derived Michael acceptors. 
The optimisation studies began with a isothiourea catalyst screen using the carboxylic 
acid activation protocol described previously (Table 34). Reaction conducted with (2S,3R)-
HyperBTM 53 (10 mol%) at rt gave the desired product 644 64% yield, 84:16 dr and 79% ee. 
(+)-BTM 48 (10 mol%) catalysed reaction gave 644 in slightly improved 71% yield, 85:15 dr 
and 83% ee. The optimum catalyst, however, was found to be (−)-tetramisoleHCl 47 (10 
mol%) giving tricyclic sultam 644 in 73% yield, 85:15 dr and excellent 95% ee. It was 
attempted to lower the catalyst loading to 5 mol% but this led to a reduced 56% yield isolated 
yield, 83:17 dr and 88% ee. It was observed in this case that the reaction time was longer (4 h) 
and it is likely some starting material or product began to decompose over this time, explaining 
the reduced yield. It can also be suggested that the lower stereoselectivity originates from a 
more dominant racemic background reaction in the presence of lower catalyst concentrations. 
Different solvents such as EtOAc, THF and toluene were tested with poorer results obtained 
overall and a poor solubility in toluene leading to a low conversion. 
 
 
 
 
 
 
 
Entry 
Catalyst 
(mol%) 
Solvent Yield  (%)a drb ee (%)c 
1 48 (10) CH2Cl2 64 84:16 79 (ent) 
2 53 (10) CH2Cl2 71 85:15 83 (ent) 
3 47 (10) CH2Cl2 75 86:14 95 
4 47 (5) CH2Cl2 65 85:15 95 
5 47 (2) CH2Cl2 56 86:14 88 
5 47 (10) EtOAc 65 85:15 84 
6 47 (10) THF 61 85:15 85 
7 47 (10) PhMe 16 85:15 84 
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aIsolated following column chromatography using Biotage® Isolera™ 4. bDetermined by 1H NMR 
spectroscopic analysis of crude reaction mixture. cDetermined by chiral HPLC analysis. 
Table 34 - Reaction optmisation. 
With such good results obtained for the (−)-tetramisoleHCl 47 reaction, these 
conditions were carried forward into the assessment of the substrate scope. 
7.2.2 Substrate Scope and Further Reaction Optimisation 
The first task in evaluating the reaction substrate scope was to assess a range of 
commercially available carboxylic acids using the cyclic sulfonyl imine substrate 617 (Table 
35). Through assessing the scope of carboxylic acids it was observed that many of the products 
were achieved in poor enantioselectivity. For example the reaction with 4-bromophenyl acetic 
acid gave sultam 645 in a moderate 61% ee. o-Tolyl acetic acid and (E)-4-phenylbut-3-enoic 
acid gave the corresponding products 647 and 651 in poor 50% ee. Application of 3-thiophene 
acetic acid yielded the thienyl sultam product 646 in an excellent 90% ee but in a moderate 
74:26 dr. It became apparent that the range of results was broad and in most cases selectivities 
were mediocre. Crude reaction mixtures in all examples were found to be promising (as 
determined by 1H NMR analysis) with only the desired product and a small amount of 
decomposition material observed. However, the isolated yields obtained were in a moderate to 
good range (58-72%), thus not reflecting the analysis of the crude reaction or the expected mass 
return after purification. Treatment of 644 to a solution of silica gel in EtOAc:hexane (20:80) 
and stirring for 1 h led to significant decomposition and suggests that instability to column 
chromatography is the cause of the reduced yields. 
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aIsolated by column chromatography. bDetermined by 1H NMR spectroscopic analysis of crude mixture. cDetermined 
by 1H NMR spectroscopic analysis of isolated mixture. dDetermined by chiral HPLC analysis. 
Table 35 - Substrate scope: variation of carboxylic acid using (−)-TetramisoleHCl 47 at rt. 
With the poor results obtained above it was clear that the initial optimum conditions 
were not general and that further optimisation was required. To explain the moderate 
enantioselectivity a control reaction conducted in the absence of the chiral Lewis base catalyst 
was undertaken (Scheme 124). Treatment of 4-bromophenyl acetic acid 652 with pivalolyl 
chloride, i-Pr2NEt and Michael acceptor 616 gave 24% conversion into corresponding product 
644 (as determined by 1H NMR spectroscopic analysis). Although only a small conversion, this 
evidence implies that a racemic base-mediated background reaction between the mixed 
anhydride formed in situ and 617 is possible and offers competition to that of the 
enantioselective process.  
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aDetermined by 1H NMR spectroscopic analysis of crude mixture. 
Scheme 124 - Control reaction in the absence of isothiourea catalyst. 
To minimise the competition from the racemic background reaction the reaction 
temperature was lowered to −78 °C. All of the same carboxylic acid substrates were 
investigated again as it was believed that a broader overview of the obtained results was 
necessary to assess the generality of this protocol as opposed to optimisation of a single 
substrate (Table 36). First of all, the 1H NMR spectra obtained for all crude reaction mixtures 
proved cleaner at −78 °C with only products and a small amount of decomposition material. 
This cleaner reaction mixture allowed for a greater eluent polarity to be used in the column 
chromatography purification thus minimising the exposure time of the products to silica gel and 
overall leading to improved isolated yields (61-80%). However, the simplified chromatographic 
purification made the separation of the corresponding diastereoisomers difficult. Generally, 
enantioselectivity was also improved with examples such as showing enantiomeric excesses 5-
15% higher than that observed following the rt reaction. Products 644, 646 and 650 remained in 
high selectivity although (95->99% ee); many of the sultams were accessed in what was still 
considered moderate enantiocontrol (50-86% ee). 
 
 
 
 
 
 
 
 
 
 
 
 
 
N S
O O
t-BuCOCl (1.5 eq)
i-Pr2NEt (1.5 eq)
CH2Cl2, 0 °C, 10 min
then 
i-Pr2NEt (1.0 eq)
rt, 4 h
N S
OO
O
Ph
+
OH
O
Ph
652 (1.5 eq) 617 (1.0 eq) 645
Br
Br
24% conversiona
90:10 dra
Racemic
Chapter 7: Application of Saccharin-Derived Substrates in Isothiourea-Catalysis 
 147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aIsolated by column chromatography. bDetermined by 1H NMR spectroscopic analysis of crude mixture. cDetermined 
by 1H NMR spectroscopic analysis of isolated mixture. dDetermined by chiral HPLC analysis. 
Table 36 - Substrate scope: variation of carboxylic acid using (−)-TetramisoleHCl 47 at −78 °C. 
A new catalyst screen was undertaken at the lowered reaction temperature of −78 °C 
(Table 37). (+)-BTM 48 (5 mol%) offered poorer results to that of (−)-TetramisoleHCl 47 (5 
mol%) and was therefore not pursued. Pleasingly, however, (2R,3S)-HyperBTM 53 (5 mol%) 
proved significantly more successful. Brominated sultam 645 was produced in 81% yield, 93:7 
dr and excellent 97% ee. Sultam 646 incorporating the electron rich 4-MeOC6H4 substituent was 
now achieved in 70% yield, >95:5 dr and >99% ee. Dramatic improvements in 
enantioselectivity was observed with products 647 and 648 provided in >99% and 97% ee, 
respectively. Indole containing product 651 also showed a significant increase in 
enantioselectivity with 649 prepared in 64% 80:20 dr and >99% ee. An improvement was 
recorded in the case of alkenyl example 651 but with still a moderate 71% ee obtained. Almost 
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all products showed excellent diastereoselectivities that led to the successful isolation of a 
single diastereoisomer in most cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aIsolated by column chromatography. bDetermined by 1H NMR spectroscopic analysis of crude mixture. cDetermined 
by 1H NMR spectroscopic analysis of isolated mixture. dDetermined by chiral HPLC analysis. 
Table 37 - Substrate scope: variation of carboxylic acid using (2R,3S)-HyperBTM 53 at −78 °C. 
7.3 Reaction Mechanism 
The reaction mechanism is believed to proceed similarly to that of the isothiourea-
catalysed process already described in this thesis which begins with N-acylation of isothiourea 
catalyst from in situ formed mixed anhydride 652 to form an acyl ammonium species 653 
(Figure 53). Subsequent deprotonation gives (Z)-ammonium enolate 654, which undergoes an 
enantioselective Michael addition in the presence of 617. Finally, lactamisation provides the 
corresponding sultam products 656 and releases the catalyst. 
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Figure 53 - Proposed reaction mechanism. 
Rationalisation of the observed enantioselectivity in the Michael addition-lactamisation 
reaction can be based upon the results of related systems.[42] Ammonium enolate forms with a 
(Z)-configuration, stabilised by either an enolate oxygen and the C−S anti-bonding orbital (no to 
σ*C−S) interaction or a favourable electrostatic interaction (Figure 54).[36-37, 101] This interaction is 
believed to rigidify 657 with the Ph directing group from catalyst 53 adopting a pseudo-axial 
orientation and the i-Pr group positioned pseudoequitorial, thus blocking one face of the 
ammonium enolate. Inputting cyclic sulfonyl imine 617 into this model, the next stage is the 
enantiodetermining Michael addition that can be assigned by analogy to the Heathcock model 
giving 658.[158] The adduct formed can then undergo lactamisation with substitution of the 
catalyst to provide anti-sultam (8S,9S)-659. The stereochemistry of all products was assigned by 
analogy to products produced from related isothiourea-catalysed processes. 
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Figure 54 - Proposed stereochemical rationale. 
7.4 One-Pot Michael Addition-Lactamisation/PhSH Elimination 
It was envisioned that a further application of saccharin-derived Michael acceptors was 
to that of the isothiourea-catalysed Michael addition-lactamisation/PhSH elimination protocol, 
similar to that described in Chapter 2. This methodology would therefore provide a synthetic 
route to prepare the achiral 1,2-benzoisothiazole pyridone-1,1-dioxide molecules. 
 Starting from the procedure applied in the synthesis of pyridines (Chapter 2), 
(phenylthio)acetic acid 84 was treated with pivalolyl chloride, i-Pr2NEt and Michael acceptor 
617 in the presence of DHPB 86 (20 mol%) gave desired product 660 after 4 h (Scheme 125). 
This reaction led to 660 as the only reaction product and a typically promising crude reaction 
mixture (as determined by 1H NMR analysis). Unfortunately, 660 was found to be very unstable 
to column chromatography with complete decomposition when exposed to silica gel. 
 
 
 
 
 
 
Scheme 125 - Michael addition-lactamisation/PhSH elimination protocol. 
With such a promising and efficient reaction occurring in this system it was therefore 
necessary to find an alternative purification method to access 660 successfully. As the product 
appeared to be solid, recrystallisation from Et2O was attempted, but provided 660 at an 
unsatisfactory level of purity. To simplify the system and therefore make the purification by 
recrystallisation easier an alternative strategy was attempted. Recent unpublished work in the 
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Smith group has shown that acyl imidazole reagents can act as suitable ammonium enolate 
precursors when applied in isothiourea catalysis. We proposed that using the acyl imidazoles in 
catalysis, followed by a mildly acidic work-up would remove any unreacted acyl imidazole, 
additional base and the Lewis base catalyst allowing purification by recrystallisation. Acyl 
imidazole 661 was prepared from the corresponding (phenylthio)acetic acid 84 and 
carbonyldiimazole (CDI) in quantitative yield. 661 was used immediately due to instability 
(Scheme 126). 
 
 
 
 
Scheme 126 - Synthesis of acyl imidazole 661. 
Pleasingly, the reaction of 661 with 617 in the presence of DHPB 86 (20 mol%) and i-
Pr2NEt gave full conversion into 660 with an acidic work-up and recrystallisation from Et2O 
giving the desired product in excellent 88% yield (Scheme 127). The reaction was also tried 
without the inclusion of any i-Pr2NEt as it is proposed that the imidazole eliminated during the 
reaction may act as a suitable base for the deprotonation to the enolate. In this case, conversion 
was observed however, the reaction proceeded slowly with decomposition of Michael acceptor 
617 and product 660 found after 24 h. Therefore, additional base is required to enhance the rate 
of reaction and minimise decomposition of materials. 
 
 
 
 
 
Scheme 127 - Synthesis of 660 using acyl imidazoles as enolate precursors. 
7.5 Conclusion  
An enantioselective isothiourea-catalysed Michael addition-lactamisation process 
applying cyclic sulfonyl imines derived from cheap, commercially available saccharin and 
acetic acids has been established. A range of aryl acetic acid derivatives have been assessed in 
the methodology giving sultam products with variating substituents present at the C(8) position 
in typically excellent diastereo- and enantioselectivity. Under the limitations of this project a 
full study of the reaction scope, product utility and mechanism was not completed. Future work 
will look to explore this process fully.  
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Chapter 8: Conclusions and Outlook 
This thesis has described investigations into novel, state-of-the-art methodologies for 
the synthesis of functionalised heterocycles through the use of isothiourea C1-ammonium 
enolate catalysis. 
 Firstly, the DHPB-mediated synthesis of 2,4-substitued pyridine 6-sulfonates has been 
conveyed. This methodology applies (phenylthio)acetic acid and α,β-unsaturated ketimines in a 
one-pot Michael addition-lactamisation/PhSH elimination/N- to O-sulfonyl transfer cascade 
giving the pyridine sulfonates in moderate to good yield (40-69%) (Scheme 128). This reaction 
incorporates the N-sulfonyl group from the ketimine substrate into the synthetically valuable 
sulfonate functional handle with the utility of this group being demonstrated. This procedure 
proves scalable and can be conducted in open flask and bench grade solvent conditions. 
Moreover, this report remains one of the earliest organocatalytic methods for the preparation of 
pyridine compounds in a literature area dominated by catalytic organometallic methodologies. 
 
 
 
 
 
 
 
 
 
Scheme 128 - One-pot isothiourea-mediated synthesis of pyridines.  
Following the initial report on the synthesis of pyridines, the subsequent studies focused 
on expanding the pyridine substituent classes available through isothiourea-mediated processes. 
Using (phenylthio)acetic acids and 2-N-tosyliminoacrylates a range of pyridine products were 
provided through a three-stage Michael addition-lactamisation, S-oxidation-sulfoxide 
elimination and N- to O-sulfonyl transfer protocol (Scheme 129). Overall, yields were moderate 
to good (44-72%) over the three-stage process giving 2,3- and 2,3,5-substituted pyridine 6-
tosylates. The functionalisation of the installed sulfonate group allowed access into further 
substituent patterns such as 2,3-, 2,3,5-, 2,3,6 and 2,3,5,6-substituted pyridines 
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Scheme 129 - Three-stage synthesis of pyridines. 
The 2-N-tosyliminoacrylates substrates were next applied alongside aryl acetic acids in 
an enantioselective isothiourea-catalysed methodology to give dihydropyridinones with 
typically excellent enantiocontrol (typically >90% ee) (Scheme 130). The structurally related 2-
aroyl acrylate Michael acceptors were also probed in an isothiourea-catalysed Michael addition-
cyclisation process. These substrates were discovered to possess high levels of reactivity and 
when used with carboxylic acids as the enolate precursor were found to susceptible to a racemic 
base-mediated background reaction. Optimisation studies led to the breakthrough of using 
homoanhydrides as the enolate precursor with less base required in the reaction and the desired 
dihydropyranones obtained in good to excellent enantioselectivity (up to 99% ee). The 
substituent pattern of these acrylate-based Michael acceptors had not been explored previously 
in enantioselective isothiourea-catalysed (or related) processes and thus provides a highly 
efficient route into novel classes of dihydropyridinones and dihydropyranones. 
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Scheme 130 - Application of 2-N-tosyliminoacrylates and 2-aroyl acrylates in enantioselective 
isothiourea-catalysis. 
It was also shown that an enantioselective Michael addition-lactonisation of 2-aryl and 
2-alkenylacetic acids with α,β-unsaturated trichloromethyl ketones, catalysed by (2S,3R)-
HyperBTM was shown to give dihydropyranones with subsequent ring opening and substitution 
of the CCl3 group providies a range of chiral diesters and diamides in high diastereo- and 
enantioselectivity (up to 95:5 and up to >99% ee) (Scheme 131). The use of trichloromethyl 
ketones as ester surrogates was found to offer a number of inherent advantages over the 
previously explored keto phosphonate substrates, most notably with improved bench stability 
and handling as well as a broader scope available. 
 
 
 
 
 
 
Scheme 131 - Application of α,β-unsaturated trichloromethyl ketones in isothiourea-catalysis. 
Efforts to access molecules with high importance and biological relevance led to the 
design and development of an enantioselective synthesis of chiral pyrrolizines (Scheme 132). 
Subjection of prepared pyrrolyl enone-acids to an isothiourea-catalysed Michael addition-
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lactonisation/ring opening protocol gave the corresponding pyrrolizines with outstanding 
stereoselectivity (typically >95:5 dr and >99% ee). A wide range of nucleophiles were explored 
for the ring opening and thus deliver a variety of pyrrolizine amides and esters. The synthetic 
route for the preparation of the required pyrrolyl enone-acids was optimised to enable this 
methodology be efficient and reproducible. Computational studies were also conducted and 
provide valuable insight into the origins of the high levels of syn-selectivity.  
 
 
 
 
 
 
 
Scheme 132 - Enantioselective synthesis of pyrrolizines. 
Finally, a new project aiming to investigate the application of saccharin-derived 
Michael acceptors in isothiourea-catalysis has been initiated with the synthesis of a range of 
8,9-dihydro-7H benzo[4,5]isothiazolo[2,3-a]pyridin-7-one 5,5-dioxides in good to excellent 
stereoselectivity (80:20->95:5 dr and 71->99% ee) (Scheme 133). Furthermore, these Michael 
acceptors can be utilised with 1-(1H-imidazol-1-yl)-2-(phenylthio)ethan-1-one in a Michael 
addition-lactamisation/PhSH elimination process giving access to the corresponding 1,2-
benzoisothiazole pyridone-1,1-dioxide heterocycle in a chromatography-free procedure.  
 
 
 
 
 
 
 
Scheme 133 - Application of saccharin-derived Michael acceptors in isothiourea-catalysis. 
At the beginning of this PhD in late 2012, isothioureas had only just been discovered as 
powerful organocatalysts in C1-ammonium enolate catalysis. The work outlined in this thesis 
has continued the exploration and advancement within isothiourea-generated enolate 
intermediates and through a variety of Michael addition-cyclisation processes has provided 
access to a wide range of heterocycles and functional synthetic building blocks. Most notably, 
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the first examples within this area for the preparation of aromatic heterocycles has been 
developed. It can be envisioned that such formal cycloaddition processes could be further 
expanded in the area of heterocycle synthesis through the use of unexplored substrates in not 
only formal [4+2] cycloadditions but in broader formal cycloaddition processes. Furthermore, 
such formal cycloaddition processes may not be confined to the ammonium enolate reactivity 
mode, with a number of potential heteroyclic products possible through the use of isothiourea-
generated acyl ammonium species. A defining feature of the reactions described in this thesis 
utilise a cyclisation step through a heteroatom to enable catalyst turnover. Therefore, a protocol 
that includes an external turnover mechanism has the potential to investigate a plethora of 
previously unexplored substrates. Moreover, in the general context of broadening isothiourea-
catalysis, such an external turnover feature may allow the enantioselective synthesis of acyclic 
compounds. Subsequent endeavors within this area will aim to probe these ideas and assess the 
scope and limitations of isothiourea-catalysis. 
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Chapter 9: Experimental 
9.1 General Information 
Reactions involving moisture sensitive reagents were carried out under a nitrogen 
atmosphere using standard vacuum line techniques in addition to dry solvents. All glassware 
used was flame dried and cooled under vacuum. For moisture sensitive reactions, solvents 
(THF, CH2Cl2, toluene, hexane and Et2O) were obtained anhydrous and purified by an alumina 
column (Mbraun SPS-800). Petrol is defined as petroleum ether 40-60 °C. All other solvents 
and commercial reagents were used as supplied without further purification unless stated 
otherwise. 
Room temperature (rt) refers to 20-25 °C. Temperatures of 0 °C and −78 °C were 
obtained using ice/water and CO2(s)/acetone baths respectively. Temperatures of 0 °C to -50 °C 
for overnight reactions were obtained using an immersion cooler (HAAKE EK 90). Reflux 
conditions were obtained using an oil bath equipped with a contact thermometer. Under reduced 
pressure refers to the use of a Büchi Rotavapor R-2000 rotary evaporator with a Vacubrand 
CVC2 vacuum controller or a Heidolph Laborota 4001 rotary evaporator with a vacuum 
controller.  
Analytical thin layer chromatography was performed on pre-coated aluminium plates 
(Kieselgel 60 F254 silica). Plates were visualised under UV light (254 nm) or by staining with 
either phosphomolybdic acid or KMnO4 followed by heating. Flash column chromatography 
was performed on Kieselgel 60 silica in the solvent system stated under a positive pressure of 
compressed air or on a Biotage® IsoleraTM 4, using Biotage® Snap Ultra or Biotage® KP Sil 
columns under the solvent system stated. 
1H, 13C and 19F nuclear magnetic resonance (NMR) spectra were acquired on either a 
Bruker Avance 300 (300 MHz, 1H, 75 MHz 13C, 282 MHz 19F), Bruker Avance II 400 (400 
MHz, 1H, 100 MHz 13C, 376 MHz 19F) or a Bruker Avance II 400 (500 MHz, 1H, 125 MHz 13C, 
470 MHz 19F) spectrometer at ambient temperature in the deuterated solvent stated. All 
chemical shifts are quoted in parts per million (ppm) relative to TMS = 0 as the internal 
standard for 1H and 13C NMR and relative to CFCl3 = 0 for 19F NMR. All coupling constants, J, 
are quoted in Hz. Multiplicities are indicated by: s (singlet), d (doublet), t (triplet), q (quartet), 
sept (septet), ABq (AB quartet), sept (septet), oct (octet), m (multiplet), dd (doublet of 
doublets), ddd (doublet of doublet of doublets, dt (doublet of triplets), dq (doublet of quartets) 
and td (triplet of doublets). The abbreviation Ar is used to denote aromatic, Ph to denote phenyl, 
Bn to denote benzyl, py to denote pyridyl and br to denote broad. 
Infrared spectra (νmax/cm−1) were recorded on either a Perkin-Elmer Spectrum GX FT-
IR spectrometer using either thin films on NaCl plates or KBr discs or a Shimadzu IRAffinity-1 
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using a Pike attenuated total reflectance (ATR) accessory. Only the characteristic peaks are 
quoted.  
Melting points were recorded on an Electrothermal 9100 melting point apparatus and 
are uncorrected. Decomp refers to decomposition. 
HPLC analyses were obtained on two separate machines; a Gilson HPLC consisting of 
a Gilson 305 pump, Gilson 306 pump, Gilson 811C dynamic mixer, Gilson 805 manometric 
module, Gilson 401C dilutor, Gilson 213XL sample injector and sample detection was 
performed with a Gilson 118 UV/vis detector while the temperature was assumed to be 20 °C; a 
Shimadzu HPLC consisting of a DGU-20A5 degasser, LC-20AT liquid chromatograph, SIL-
20AHT autosampler, CMB-20A communications bus module, SPD-M20A diode array detector 
and a CTO-20A column oven which allowed the temperature to be set from 25-40 °C. 
Separation was achieved using DAICEL CHIRALCEL OD-H and OJ-H columns or DAICEL 
CHIRALPAK AD-H, AS-H, IA, IB, IC and ID columns. All chiral HPLC traces were 
compared to the authentic racemic spectrum prepared in analogous fashion. 
Mass spectrometry (m/z) data were acquired by electrospray ionisation (ESI), electron 
impact (EI), atmospheric solids analysis probe (ASAP) or nanospray ionisation (NSI) either at 
the University of St Andrews or the EPSRC National Mass Spectrometry Service Centre, 
Swansea. At the University of St Andrews, low and high resolution ESI MS were carried out on 
a Micromass LCT spectrometer. At the EPSRC National Mass Spectrometry Service Centre, 
low resolution NSI MS was carried out on a Micromass Quattro II spectrometer and high 
resolution NSI MS on a Thermofisher LTQ Orbitrap XL spectrometer. 
Optical rotations were measured on a Perkin Elmer Precisely/Model-341 polarimeter 
operating at the sodium D line with a 100 mm path cell at rt. 
9.2 Experimental for Chapter 2 
9.2.1 General Experimental Procedures 
General Procedure A: Preparation of phosphoranes 
 
 
 
To a solution of requisite bromide (1.0 eq) in CH2Cl2 (0.5 M) at rt was added 
triphenylphosphine (1 eq) and the solution was allowed to stir for 4 h before being concentrated 
under reduced pressure. The residue was dissolved in CH2Cl2/H2O (40:60) and aq. NaOH (2 M) 
was added. The reaction mixture was stirred at rt for 1 h before being extracted with CH2Cl2 
(×3). The combined organic fraction were washed with brine, dried over MgSO4, filtered and 
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Br
i) PPh3 (1.0 eq)
ii) aq. NaOH (2 M)
CH2Cl2
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O
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concentrated under reduced pressure to give the crude reaction mixture. Products were purified 
by recrystallisation or column chromatography in the solvent system stated. 
 
General Procedure B: Preparation of keto esters 
 
 
 
 
 
Keto esters prepared as per literature procedure.[72] To a solution of requisite tartrate (1.0 eq) in 
Et2O (0.45 M) at rt was added periodic acid (1.0 eq) and the solution was allowed to stir for 1 h. 
The reaction mixture was filtered and the solids washed with THF. The organic fraction was 
dried over MgSO4 and filtered. The requisite phosphorane (1.5 eq) was added and the reaction 
mixture was stirred at rt for 2 h before being concentrated under reduced pressure to give the 
crude reaction mixture. Products were purified by column chromatography in the solvent 
system stated. 
 
General Procedure C: Preparation of trifluoromethyl enones 
 
 
 
 
 
Trifluoromethyl enones prepared as per the literature procedure.[159] To a solution of i-Pr2NH 
(2.2 eq) in THF at −78 °C was added n-BuLi (2.2 eq) and the solution was allowed to stir for 20 
min. A pre-cooled (−78 °C) solution of 2-bromo-3,3,3-trifluoroprop-1-ene (1.0 eq) in THF was 
added dropwise at −78 °C followed by a further 5 min of stirring. The desired aldehyde (1.2 eq) 
was added dropwise followed by stirring at −78 °C for 30 min. The reaction mixture was 
quenched by addition of aq. HCl (1 M) and allowed to warm to rt. The reaction mixture was 
extracted with EtOAc (×3) and the combined organics were dried over MgSO4, filtered and 
concentrated under reduced pressure to give the crude intermediate propargyl alcohol. The 
resulting residue was dissolved in THF before Et3N (4.0 eq) was added and the reaction mixture 
was heated at 80 °C for 16 h. Once cool the reaction mixture was quenched by addition of aq. 
HCl (1 M) and the reaction mixture was extracted with EtOAc (×3). The combined organics 
were dried over MgSO4, filtered and concentrated under reduced pressure to give the crude 
reaction mixture. Products were purified by column chromatography in the solvent system 
stated. 
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General Procedure D: Preparation of α,β-unsaturated ketimines 
 
 
 
 
 
 
To a solution of the requisite enone (1.0 eq) and requisite sulfonamide (1.0 eq) in CH2Cl2 (0.2 
M) at 0 °C was added Et3N (2.0 eq) followed by TiCl4 (1.0 eq) and the reaction mixture was 
allowed to stir at rt for 16 h. The reaction mixture was quenched by addition of H2O and 
extracted with EtOAc (×3). The combined organic extracts were dried over MgSO4, filtered and 
concentrated under reduced pressure to give the crude reaction mixture. Generally ketimines 
within the ester series proved troublesome to purify. These were judged to be >90% pure by 1H 
NMR and suitable for use in this protocol. It should be noted that these issues were not 
encountered with ketimines from the trifluoromethyl series and these were recrystallised in the 
solvent system stated.  
 
General Procedure E: One-pot pyridine synthesis 
 
 
 
 
 
To a solution of (phenylthio)acetic acid (1.0 eq) in THF (0.06 M) were added i-Pr2NEt (1.5 eq) 
and pivaloyl chloride (1.5 eq) at 0 °C. The reaction mixture was allowed to stir at 0 °C for 10 
min. The requisite Michael acceptor (1.0 eq), DHPB (20 mol%), and i-Pr2NEt (1 eq) were then 
added at rt. The reaction mixture was stirred at rt until total consumption of the Michael 
acceptor as judged by TLC analysis. The reaction mixture was then heated at 80 °C for the 
required time for complete conversion to the pyridine. The reaction mixture was subsequently 
quenched by addition of H2O and extracted with CH2Cl2 (×3). The combined organics were 
dried over MgSO4, filtered and concentrated under reduced pressure to give the crude reaction 
mixture. Products were purified by column chromatography in the solvent system stated. 
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O
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TiCl4 (1.0 eq)
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CH2Cl2, 0 °C
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rt-80 °C, 16 h
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9.2.2 Preparation of Phosphoranes 
1-Phenyl-2-(triphenylphosphoranylidene)ethanone 
 
 
 
Following general procedure A, 2-bromo-1-phenylethanone (10.0 g, 50.2 mmol) and 
triphenylphosphine (13.2 g, 50.2 mmol) in CH2Cl2 (100 mL) followed by aq. NaOH (2 M, 50 
mL, 100 mmol) in CH2Cl2 (60 mL) and H2O (90 mL) gave, after recrystallisation (EtOH:Et2O), 
phosphorane as a white solid (13.0 g, 68%); mp 174-176 °C; {lit.[160] mp 173-175 °C}; 1H NMR 
(500 MHz, CDCl3) 4.46 (1H, d, J 24.5, C(2)H), 7.38-7.39 (3H, m, ArH and ArH), 7.48-7.52 
(6H, m, ArH), 7.57-7.60 (3H, m, ArH), 7.73-7.77 (6H, m, 3 ArH), 7.99-8.01 (2 H, m, ArH). All 
data in accordance with literature.[160] 
 
4-[2-(Triphenylphosphanylidene)acetyl]benzonitrile[161] 
 
 
 
 
Following general procedure A, 2-(2-bromoacetyl)benzonitrile (5.00 g, 22.3 mmol) and 
triphenylphosphine (5.86 g, 22.3 mmol) in CH2Cl2 (50 mL) followed by aq. NaOH (2 M, 22 
mL, 100 mmol) in CH2Cl2 (30 mL) and H2O (45 mL) gave, after recrystallisation (EtOH:Et2O), 
phosphorane as a white solid (7.30 g, 81%); mp 199-201 °C;[162] 1H NMR (300 MHz, CDCl3) 
4.46 (1H, d, J 23.1, C(2)H), 7.46-7.52 (8H, m, ArH), 7.59-7.73 (9H, m, ArH), 8.02 (2H, d, J 
8.42, C(1)Ar(2,6)H). All spectroscopic data in accordance with literature.[161] 
 
1-(Naphthalene-2-yl)-2-(triphenylphosphanylidene)ethan-1-one 
 
 
 
Following general procedure A, 2-(bromoacetyl)naphthalane (6.23 g, 25.0 mmol) and 
triphenylphosphine (6.57 g, 25.0 mmol) in CH2Cl2 (50 mL) followed by NaOH (2 M, 25 mL, 
50.0 mmol) in CH2Cl2 (30 mL) and H2O (45 mL) gave, after recrystallisation (EtOAc:Petrol), 
phosphorane as a white solid (8.71 g, 66%); mp 192-194 °C; {lit.[163] mp 190-192 °C}; 1H NMR 
(300 MHz, CDCl3) 4.59 (1H, d, J 24.4, C(2)H), 7.42-7.58 (11H, m, ArH), 7.68-7.82 (9H, m, 
ArH), 8.07 (1H, dd, J 8.6, 1.7, ArH), 8.49 (1 H, s, ArH). All data in accordance with 
literature.[163] 
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9.2.3 Preparation of Keto-Esters 
Methyl (2E)-4-oxo-4-phenylbut-2-enoate[72] 
 
 
 
Following general procedure B, dimethyl tartrate (4.69 g, 26.3 mmol) and periodic acid (5.99 g, 
26.3 mmol) in Et2O (50 mL), phosphorane 662 (15.0 g, 39.4 mmol) in THF (60 mL) gave, after 
chromatographic purification (Et2O:petrol 5:95), the title compound as a light yellow oil (4.8 g, 
64%); 1H NMR (500 MHz, CDCl3) 3.82 (3H, s, OCH3), 6.87 (1H, d, J 15.6, C(2)H), 7.47-7.50 
(2H, m, Ar(3,5)H), 7.58-7.61 (1H, Ar(4)H), 7.90 (1H, d, J 15.6, C(3)H), 7.98 (2H, d, J 7.60, 
Ar(2,6)H).All data in accordance with literature.[72]  
 
Methyl (2E)-4-(4-cyanophenyl)-4-oxobut-2-enoate 
 
 
 
Following general procedure B, dimethyl tartrate (2.05 g, 11.5 mmol) and periodic acid (2.62 g, 
11.5 mmol) in Et2O (30 mL), phosphorane 663 (7.0 g, 17.3 mmol) in THF (35 mL) gave, after 
chromatographic purification (EtOAc:Petrol 30:70), the title compound as a light green solid 
(2.2 g, 59%); mp 168-170 °C; νmax (ATR)/cm−1 1629, 1668 (enone C=O), 1720 (ester C=O), 
2231 (C-N), 3086 (C-H); 1H NMR (500 MHz, CDCl3) 3.86 (3H, s, CH3), 6.94 (1H, d, J 15.5, 
C(2)H), 7.83 (2H, J 8.5, Ar(3,5)H), 7.87 (1H, d, J 15.5, C(3)H), 8.08 (2H, d, J 8.5, Ar(2,6)H); 
13C NMR (125 MHz, CDCl3) 52.6 (CH3), 117.1 (CN), 117.7 (ArC(4)), 129.2 (ArC(2,6)H), 
132.8 (ArC(3,5)), 133.6 (C(2)H), 135.3 (C(3)H), 139.5 (ArC(1)), 165.6 (C(4)), 188.2 (C(1)); 
HRMS (NSI+) C12H13N2O3+ [M+NH]+, requires 233.0921 found 233.0922 (+0.6 ppm). 
 
Methyl (2E)-4-oxo-4-[4-(trifluoromethyl)phenyl]but-2-enoate[164] 
 
 
 
Following general procedure B, dimethyl tartrate (1.06 g, 5.95 mmol) and periodic acid (1.36 g, 
5.95 mmol) in Et2O (20 mL), phosphorane 664 (4.0 g, 8.92 mmol) in THF (25 mL) gave, after 
chromatographic purification (EtOAc:Petrol 15:85), the title compound as a light yellow solid 
(2.12 g, 90%); mp 74-75 °C {lit.[164] 73.5-74.0 °C}; 1H NMR (300 MHz, CDCl3) 3.86 (3H, s, 
CH3), 6.92 (1H, d, J 15.6, C(3)H), 7.78 (2H, Ar(3)H), 7.89 (1H, d, J 15.6, C(2)H), 8.10 (2H, d, 
J 8.8, Ar(2)H). All data in accordance with literature.[164] 
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Methyl (2E)-4-(naphthalene-2-yl)-4-oxobut-2-enoate 
 
 
 
Following general procedure B, dimethyl tartrate (2.21 g, 12.4 mmol) and periodic acid (2.83 g, 
12.4 mmol) in Et2O (30 mL), phosphorane 664 (8.0 g, 18.6 mmol) in THF (35 mL) gave, after 
chromatographic purification (EtOAc:Petrol 15:85), the title compound as a light yellow solid 
(3.60 g, 81%); mp 113-115 °C; νmax (ATR)/cm-1 1624, 1666 (enone C=O), 1724 (ester C=O), 
2956, 3067 (C-H); 1H NMR (300 MHz, CDCl3) 3.88 (3H, s, OCH3), 6.97 (1H, d, J 15.5, 
C(2)H), 7.62 (2H, ddd, J 10.1, 7.8, 1.31, NpH), 7.89-8.06 (4H, m, NpH), 8.11 (1H, d, J 15.5, 
C(3)H), 8.53 (1H, s, Np(1)H); 13C NMR (125 MHz, CDCl3) 52.4 (CH3), 124.0 (NpCH), 127.1 
(NpCH), 127.9 (NpCH), 129.0 (NpCH), 129.1 (NpCH), 129.8 (NpCH), 131.2 (NpCH), 132.0 
(C(2)H), 132.4 (NpC), 134.0 (NpC), 135.9 (NpC), 136.6 (C(3)H), 166.2 (C(1)), 189.1 (C(4)). 
HRMS (NSI+) C15H13O3 [M+H]+, requires 241.0859 found 241.0860 (+0.3 ppm). 
 
Methyl (2E)-5,5-dimethyl-4-oxohex-2-enoate 
 
 
 
Following general procedure B, dimethyl tartrate (825 mg, 4.63 mmol) and periodic acid (1.06 
g, 4.63 mmol) in Et2O (20 mL), 3,3-dimethyl-1-(triphenylphosphanylidene)butan-2-one[160] (2.5 
g, 6.94 mmol) in THF (25 mL) gave, after chromatographic purification (EtOAc:Petrol 5:95), 
the title compound as a light yellow oil (1.0 g, 85%); 1H NMR (300 MHz, CDCl3) 1.13 (9H, s, 
(CH3)3), 3.74 (3H, s, CH3), 6.71 (1H, d, J 15.5, C(3)H), 7.46 (1H, d, J 15.5, C(2)H). All data in 
accordance with literature.[165] 
 
Potassium (E)-3-methyl-2-oxo-4-phenylbut-3-enoate 
 
 
 
To a solution of benzaldehyde (2.55 mL, 25.0 mmol) and 2-ketobutyric acid (2.55 g, 25.0 
mmol) in MeOH (4 mL) at 0 °C was added a solution of KOH (2.10 g, 37.5 mmol) in MeOH 
(15 mL) dropwise over 30 min. The reaction was heated to 40 °C for 1 h before being cooled 
and stirreed at 0 °C for 16 h. The precipitate was collected by filtration, washed with cold 
MeOH (×2), Et2O and dried under vacuum to provide the title compound (3.76 g, 66%); mp 312 
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°C {lit.[166] 319 °C}; 1H NMR (300 MHz, D2O) 1.94 (3H, d, J 1.3, CH3), 7.32-7.48 (6H, m, 
C(4)H and ArH). All data in accordance with literature.[166] 
 
Methyl (E)-3-methyl-2-oxo-4-phenylbut-3-enoate 
 
 
 
Acetyl chloride (13.6 mL, 190 mmol) was added to the MeOH (101 mL) at 0 °C before addition 
of 187 (3.76 g, 16.5 mmol) and reaction stirred for 30 min then warmed to rt over 2 h before 
heating at 65 °C for 16 h. The reaction was concentrated under reduced pressure with the 
resultant solid washed with H2O and extracted with CH2Cl2 (×3). The combined organics were 
washed with sat. aq. NaHCO3, H2O and brine, dried over MgSO4, filtered and concentrated 
under reduced pressure to give crude reaction mixture. Chromatographic purification 
(EtOAc:Petrol 5:95) gave the title compound  as light yellow oil (1.01 g, 30%); 1H NMR (500 
MHz, CDCl3) 2.16 (3H, s, C(3)CH3), 7.40-7.50 (6H, m, C(4)H and ArH). All data in accordance 
with literature.[167] 
9.2.4 Preparation of Trifluoromethyl Enones 
 (2E)-1-(2-Bromophenyl)-4,4,4-trifluorobut-2-en-1-one 
 
 
 
Following general procedure C, diisopropylamine (5.54 mL. 39.6 mmol) and n-BuLi (2.5 M in 
hexane, 15.8 mL, 39.6 mmol) in anhydrous THF (50 mL), 2-bromo-3,3,3-trifluoroprop-1-ene 
(1.95 mL, 18.0 mmol) and 2-bromobenzaldehyde (2.52 mL, 21.6 mmol) gave intermediate 
propargyl alcohol. Subsequent treatment of crude with Et3N (13.2 mL, 94.6 mmol) in THF (100 
mL) gave after, chromatographic purification (EtOAc:Petrol 5:95), title compound as yellow oil 
(2.0 g, 40% over 2 steps); νmax (ATR)/cm-1 763 (CF3), 1651, 1684 (C=O), 1125 (ArBr), 3063 
(ArH); 1H NMR (500 MHz, CDCl3) 6.60 (1 H, dq, J 15.8, 6.6 C(3)H), 7.18 (2 H, dq, J 15.8, 2.0, 
C(2)H)), 7.37-7.46 (3 H, m, ArH), 7.62 (1 H, m, Ar(2)H); 13C NMR (125 MHz, CDCl3) 119.8 
(ArC(2)Br) 122.5 (q, J 273.4, CF3), 127.7 (ArCH), 129.9 (ArCH), 130.3 (q, J 35.5, C(3)H), 
132.8 (ArCH), 133.8 (ArCH), 134.0 (q, J 5.5, C(2)H), 139.0 (ArC(1)), 191.4 (C(1)O); δF (470 
MHz, CDCl3);  -65.3 (CF3); HRMS (APCI+), C10H779BrF3O [M+H]+, requires 278.9627 found 
278.9627 (−0.3 ppm).  
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(2E)-1-(3-Bromophenyl)-4,4,4-trifluorobut-2-en-1-one 
 
 
 
Following general procedure C, diisopropylamine (5.54 mL. 39.6 mmol) and n-BuLi (2.5 M in 
hexane, 15.8 mL, 39.6 mmol) in THF (50 mL), 2-bromo-3,3,3-trifluoroprop-1-ene (1.95 mL, 
18.0 mmol) and 3-bromobenzaldehyde (2.52 mL, 21.6 mmol) gave intermediate alcohol. 
Subsequent treatment with Et3N (10.0 mL, 71.7 mmol) in THF (100 mL) gave, after 
chromatographic purification (EtOAc:Petrol; 5:95), the title compound as yellow solid (2.25 g, 
45% over 2 steps); mp 30-32 °C; νmax (ATR)/cm-1 1125, 1651, 1686 (C=O), 3063 (ArH);  1H 
NMR (500 MHz, CDCl3) 6.83 (1 H, dq, J 15.5, 6.7 C(3)H), 7.41 (1 H, t,  Ar(3)H), 7.48 (1 H, 
dq, J 15.5, 1.7 C(2)H), 7.75 (1 H, ddd, J 8.1, 2.1, 1.1, Ar(4)H), 7.88 (1 H, d, J 8.4, Ar(2)H), 
8.09 (1 H, s, Ar(6)H); 13C NMR (125 MHz, CDCl3) 122.3 (q, J 271.0, CF3), 123.4 (ArC(5)Br), 
127.3 (ArC(4)H), 130.4 (C(2)H), 130.5 (ArC(3)H), 131 (q, J 35.9, C(3)H), 131.7 (ArC(6)H), 
136.9 (ArC(2)H), 137.1 (ArC(1)), 186.6 (C(1)). HRMS (NSI+) C10H1079BrF3NO [M+NH4]+ 
requires 295.9892 found 295.9897 (+1.6 ppm). 
 
(E)-1-(4-Bromophenyl)-4,4,4-trifluorobut-2-en-1-one 
 
 
 
Following general procedure C, diisopropylamine (7.71 mL, 55.0 mmol) and n-BuLi (2.5 M in 
hexanes, 22.0 mL, 55.0 mmol) in THF (65 mL), 2-bromo-3,3,3-trifluoroprop-1-ene (2.65 mL, 
25.0 mmol) in THF (45 mL)  and 4-bromobenzaldehyde (5.55 g, 30.0 mmol) gave the 
intermediate alcohol. Subseqent treatment with Et3N (13.9 mL, 100 mmol) in THF (140 mL) 
gave, after chromatographic purification (Et2O:petrol 3:97), the title compound as a light yellow 
solid (4.62 g, 66% over 2 steps); mp 52-54 °C; {lit.[159] mp 51-52 °C}; 1H NMR (500 MHz, 
CDCl3) 6.86 (1H, dq, J 15.5, 6.6, C(3)H), 7.51 (1H, dq, J 15.5, 2.0, C(2)H), 7.69-7.72 (2H, m, 
Ar(3,5)H), 7.86-7.88 (2 H, m, Ar(2,6)H). All data in accordance with literature.[159] 
 
(2E)-4,4,4-Trifluoro-1-(4-methylphenyl)but-2-en-1-one 
 
 
 
Following general procedure C, diisopropylamine (8.56 mL. 61.1 mmol) and n-BuLi (2.5 M in 
hexane, 24.4 mL, 61.1 mmol) in anhydrous THF (75 mL), 2-bromo-3,3,3-trifluoroprop-1-ene 
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(3.0 mL, 27.8 mmol) and 4-tolualdehyde (3.93 mL, 33.3 mmol) gave intermediate alcohol. 
Subsequent treatment with Et3N (13.3 mL, 96 mmol) in THF (100 mL) gave, after 
chromatographic purification (EtOAc:Petrol 5:95) the title compound as yellow solid (2.85 g, 
42% over 2 steps); mp 58-60 °C {lit.[168] 56-59 °C}; 1H NMR (500 MHz, CDCl3) 2.45 (3H, s, 
ArCH3), 6.81 (1H, dq, J 15.6, 6.7 C(3)H), 7.32 (2H, d,  Ar(3,5)H), 7.53 (1 H, dq, J 15.6, 2.1 
C(2)H), 7.88 (2 H, d, J 8.30, Ar(2,6)H). All data in accordance with literature.[168] 
 
(2E)-4,4,4-Trifluoro-1-(4-fluorophenyl)but-2-en-1-one 
 
 
 
Following general procedure C, diisopropylamine (12.17 mL. 88.7 mmol) and n-BuLi (2.5 M in 
hexane, 35.5 mL, 88.7 mmol) in THF (90 mL), 2-bromo-3,3,3-trifluoroprop-1-ene (4.37 mL, 
40.3 mmol) in THF (50 mL) and 4-fluorobenzaldehyde (5.19 mL, 48.3 mmol) gave 
intermediate alcohol. Subsequent treatment with Et3N (26 mL, 187 mmol) in THF (250 mL) 
gave, after chromatographic purification (EtOAc:Petrol 5:95), the title compound as yellow 
solid (3.12 g, 35% over 2 steps); mp 78-80 °C; νmax (ATR)/cm-1 1151, 1564, 1597 (C=O), 3086 
(C-H); 1H NMR (400 MHz, CDCl3) 6.82 (1H, dq, J 15.5, 6.6 C(3)H), 7.20 (2H, t,  Ar(3,5)H), 
7.51 (1H, dq, J 15.5, C(2)H), 8.02 (2H, m, Ar(2,6)H); 13C NMR (100 MHz, CDCl3); 116.2 (d, J 
23.8, ArC(3,5)H), 122.5 (q, J 272, CF3) 130 (C(3)H), 130.3 (q, 35.6, C(2)H), 131.5 (d, J 9.92, 
ArC(2,6)H), 132 (ArC(1)), 166.4 (d, J 255.8, ArC(4)F), 186.3 (C(1)); HRMS (APCI+) 
C10H7F4O [M+H]+, requires 219.0428 found 219.0427 (−0.2 ppm).  
 
(2E)-4,4,4-Trifluoro-1-(naphthalene-2-yl)but-2-en-1-one 
 
 
 
Following general procedure C, diisopropylamine (6.58 mL. 46.9 mmol) and n-BuLi (2.5 M in 
hexane, 18.8 mL, 46.9 mmol) in anhydrous THF (100 mL), 2-bromo-3,3,3-trifluoroprop-1-ene 
(2.3 mL, 21.3 mmol) and 2-naphthaldehyde (4.0 g, 25.6 mmol) gave intermediate alcohol. 
Subsequent treatment with Et3N (11.2 mL, 80.0 mmol) in THF (75 mL) gave, after 
chromatographic purification (EtOAc:Petrol 5:95), the title compound as yellow solid (2.94 g, 
59% over 2 steps); mp 70-72 °C;[162] 1H NMR (500 MHz, CDCl3) 6.85 (1H, dq, J 15.5, 6.7 
C(3)H), 7.55-7.69 (3H, m, NpH), 7.85-8.02 (4H, m, NpH, and C(2)H), 8.40 (1H, s, Np(2)H). 
All spectrascopic data in accordance with literature.[168] 
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(2E)-4,4,4-Trifluoro-1-(thiophen-2-yl)but-2-en-1-one 
 
 
 
Following general procedure C, diisopropylamine (11.0 mL. 78.5 mmol) and n-BuLi (2.5 M in 
hexane, 31.4 mL, 78.5 mmol) in anhydrous THF (100 mL), 2-bromo-3,3,3-trifluoroprop-1-ene 
(3.2 mL, 29.8 mmol) and 2-thiophene carboxaldehyde (3.27 mL, 35.7 mmol) gave intermediate 
alcohol. Subsequent treatment or crude with Et3N (24.4 mL, 174.8 mmol) in THF (100 mL) 
gave, after chromatographic purification (EtOAc:Petrol 10:90), title compound as yellow solid 
(2.0 g, 27% over 2 steps); mp 47-49 °C;{lit.[168] 50-52 °C}; 1H NMR (500 MHz, CDCl3) 6.85 
(1H, dq, J 15.4, 6.66 C(3)H), 7.21 (1H, dd, J 4.9, 3.9,  thienyl(3)H), 7.40 (1H, dq, J 15.5, 2.0, 
C(2)H), 7.79 (1H, dd, J 5.0, 1.1, thienyl(2)H) 7.84 (1H, dd. J 3.9, 1.1, thienyl(4)H). All data in 
accordance with literature.[168] 
9.2.5 Preparation of α,β-unsaturated ketimines 
Ethyl (2E)-4-[(benzenesulfonyl)imino]-4-phenylbut-2-enoate 
 
 
 
Following general procedure D, ethyl 3-benzoylacrylate (5.5mL, 30 mmol) and 
benzenesulfonamide (4.72 g, 30 mmol) were stirred in CH2Cl2 (50mL), Et3N (8.3 mL, 60 mmol) 
and TiCl4 (3.3 mL, 30 mmol) gave, after recrystallisation (Et2O:Petrol), the title compound as 
orange solid (4.59 g, 45%): mp 54-56 °C; {lit.[169] 51-53 °C}; 1H NMR (300 MHz, CDCl3) 1.37 
(3H, t, J 7.1, CH2CH3), 4.33 (2H, q, J 7.0, CH2CH3), 6.27 (1H, d, J 16.2, C(3)H), 7.48 (1H, t, J 
7.7, ArH), 7.53-7.82 (8H, m, ArH), 8.06 (1H, d, J 7.1, ArH). All data in accordance with 
literature.[169]  
 
Methyl (2E)-4-{[(4-methylbenzene)sulfonyl]imino}-4-phenylbut-2-enoate 
 
 
 
Following general procedure D, keto ester 174 (4.70 g, 24.7 mmol) and 4-toluenesulfonamide 
(4.23 g, 24.7 mmol) in CH2Cl2 (100 mL), Et3N (6.79 mL, 49.4 mmol) and TiCl4 (2.71 mL, 24.7 
mmol) gave, after concentration under reduced pressure, crude ketimine 180 as a brown oil that 
was used crude without further purification; 1H NMR (300 MHz, CDCl3) 2.42 (3 H, s, 
F3C
O
213
S
EtO2C
NSO2Ph
Ph
154
MeO2C
NTs
Ph
180
Chapter 9: Experimental 
 
 171 
SO2ArCH3), 3.82 (3 H, s, CH3), 6.22 (1H, d, J 16.2, C(2)H), 7.24-7.57 (7H, m, ArH), 7.89 (2H, 
d, J 7.46, SO2Ar(2,6) H), 8.23 (1H, d, J 14.2, C(3)H). 
 
Methyl (2E)-4-(4-cyanophenyl)-4-{[(4-methylbenzene)sulfonyl]imino}but-2-enoate 
 
 
 
Following general procedure D, keto ester 175 (2.00 g, 9.30 mmol) and 4-toluenesulfonamide 
(1.59 g, 9.30 mmol) in CH2Cl2 (25 mL), Et3N (2.56 mL, 18.6 mmol) and TiCl4 (1.02 mL, 9.30 
mmol) gave, after concentration under reduced pressure, crude ketimine 181 as a brown oil that 
was used crude without further purification; 1H NMR (300 MHz, CDCl3) 2.48 (3H, s, 
SO2ArCH3), 3.89 (3H, s, CH3), 6.23 (1H, d, J 15.9, C(2)H), 7.38 (2H, d, J 7.92 SO2Ar(3,5)H), 
7.71-7.93 (4H, m, ArH), 8.11 (2H, d, J 8.70, SO2Ar(2,6)H), 8.29 (2H, d, J 15.6, C(3)H). 
 
Methyl (2E)-4-{[(4-methylbenzene)sulfonyl]imino}-4-[4-(trifluoromethyl)phenyl]but-2-
enoate 
 
 
 
Following general procedure D, keto ester 176 (1.57 g, 6.08 mmol) and 4-toluenesulfonamide 
(1.04 g, 6.08 mmol) in CH2Cl2 (25 mL), Et3N (1.68 mL, 12.2 mmol) and TiCl4 (0.67 mL, 6.08 
mmol) gave, after concentration under reduced pressure, crude ketimine 182 as a brown oil that 
was used crude without further purification; 1H NMR (300 MHz, CDCl3) 2.45 (3H, s, CH3), 
3.85 (3H, s, CH3), 6.21 (1H, d, J 16.1, C(2)H), 7.35 (2H, d, J 7.8, SO2Ar(3,5)H), 7.61-7.91 (6H, 
m, ArH), 8.29 (1H, d, J 16.2, C(3)H). 
 
Methyl (2E)-4-{[(4-methylbenzene)sulfonyl]imino}-4-(naphthalene-2-yl)but-enoate 
 
 
 
Following general procedure D, keto ester 177 (3.00 g, 12.5 mmol) and 4-toluenesulfonamide 
(2.15 g, 12.5 mmol) in CH2Cl2 (30 mL), Et3N (3.44 mL, 25.0 mmol) and TiCl4 (1.37 mL, 12.5 
mmol) gave, after concentration under reduced pressure, crude ketimine 183 as a brown oil that 
was used crude without further purification; 1H NMR (300 MHz, CDCl3) 2.48 (3H, s, 
SO2ArCH3), 3.87 (3H, s, CH3), 6.29 (1H, d, J 16.3, C(2)H), 7.30-7.36 (3H, m, ArH), 7.55-7.58 
(4H, m, ArH), 7.79-7.95 (5H, m, ArH and C(3)H). 
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Methyl (2E)-5,5-dimethyl-4-{[(4-methylbenzene)sulfonyl]imino}hex-2-enoate 
 
 
 
Following general procedure D, keto ester 178 (560 mg, 3.29 mmol) and 4-toluenesulfonamide 
(563 mg, 3.29 mmol) in CH2Cl2 (40 mL), Et3N (0.91 mL, 6.58 mmol) and TiCl4 (0.36 mL, 3.29 
mmol) gave, after chromatographic purification (EtOAc:Petrol 30:70), the title compound as a 
brown solid (360 mg, 34%); mp 70-72 °C; νmax (ATR)/cm-1 1310 (S=O), 1597 (C=N), 2974 (C-
H); 1H NMR (500 MHz, CDCl3) 1.17 (9H, s, (CH3)3), 2.43 (3H, s, SO2ArCH3), 6.28 (1H, d, J 
16.5, C(3)H), 7.31 (2H, d, J 8.2, SO2Ar(3,5)H), 7.55 (1H, d, J 16.5, C(2)H), 7.82 (2H, d, J 8.2, 
SO2Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 21.6 (SO2ArCH3), 27.5 ((CH3)3), 42.5 (C(CH3)3, 
52.3 (CH3O), 126.7 (C(3)H), 127.3 (SO2ArC(2,6)H), 129.4 (SO2ArC(3,5)H), 137.9 
(SO2ArC(4)), 138.7 (C(2)H), 143.8 (SO2ArC(1)), 165.0 (C(1)), 188.5 (CO2Me); HRMS 
(APCI+) C16H22NO4S [M+H]+, requires 324.1264; found 324.1267 (+0.9 ppm). 
 
N-[(2E)-1-(2-bromophenyl)-4,4,4-trifluorobut-2-en-1-ylidene]-4-methylbenzene-1-
sulfonamide 
 
 
 
Following general procedure D, and trifluoromethyl enone 207 (1.5 g, 5.37 mmol) and 4-
toluenesulfonamide (0.92 g, 5.37 mmol) in CH2Cl2 (40 mL), Et3N (1.50 mL, 10.7 mmol) and 
TiCl4 (0.59 mL, 5.37 mmol) gave, after chromatographic purification (EtOAc:Petrol 20:80), the 
title compound as yellow oil (1.16 g, 50%); νmax (ATR)/cm-1 1100 (ArBr), 1287, 1314 (SO2), 
1558 (C=N), 297.2, 3072.6 (C-H); 1H NMR (500 MHz, CDCl3) 2.41 (3H, s, SO2ArCH3), 6.00 
(1H, dq, J 16.2, 6.4, C(3)H), 6.98 (1H, d, J 16.0, C(2)H), 7.26-7.35 (4H, m, Ar(3)H, Ar(5)H and 
SO2Ar(3,5)H), 7.47 (1H, t, J 7.8, Ar(4)H), 7.61 (1H, dd, J 8.1, 2.3, Ar(6)H), 7.79 (2H, d, J 8.0, 
SO2Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 21.7 (SO2ArCH3), 119.0 (ArC(2)), 122.0 (q, J 
266.8, CF3), 127.5 (ArC(4)H), 127.6 (ArC(5)H),  127.9 (SO2ArC(2,6)H), 129.7 
(SO2ArC(3,5)H),  131.8 (ArC(3)H), 132.1 (C(3)H), 132.9 (ArC(6)H), 134.7 (SO2ArC(4)), 136.2 
(SO2ArC(1)), 137.6 (C(2)H), 144.8 (ArC(1)), 172.6 (C(1)). HRMS (NSI+) C17H1479BrF3NO2S+ 
[M+H]+, requires 431.9875 found 431.9861 (−0.1 ppm). 
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N-[(2E)-1-(3-Bromophenyl)-4,4,4-trifluoro-1-(4-methylphenyl)but-2-en-1-ylidene]benzene-
1-sulfonamide 
 
 
 
Following general procedure D, and trifluoromethyl enone 208 (1.9 g, 6.8 mmol) and 4-
toluenesulfonamide (1.16 g, 6.80 mmol) in CH2Cl2 (50 mL), Et3N (1.88 mL, 13.6 mmol) and 
TiCl4 (0.75 mL, 6.8 mmol) gave, after recrystallisation (Et2O:Petrol), the title compound as an 
orange solid (2.0 g, 80%): mp 64-66 oC; νmax (ATR)/cm-1 1100 (ArBr), 1287, 1314 (SO2), 1558 
(C=N), 297.2, 3072.6 (C-H); 1H NMR (500 MHz, CDCl3); 2.46 (3H, s, SO2ArCH3), 6.13 (1H, 
dq, J 16.3, 6.1, C(3)H), 7.30-7.37 (3H, m, Ar(5)H and SO2Ar(3,5)H), 7.60 (1H, s, Ar(4)H), 7.70 
(1H, d, J 7.8, C(2)H), 7.80-7.89 (4H, m, Ar(2)H, Ar(6)H and SO2Ar(2,6)H); 13C NMR (125 
MHz, CDCl3); 21.7 (SO2ArCH3), 122.8 (ArC(3)Br), 126.5 (SO2ArC(2,6)H), 127.6 (ArC(2)H), 
128.8 (ArC(4)H), 129.8 (ArC(5)H and SO2ArC(3,5)H), 130.3 (C(3)H), 131.2 (ArC(4)H), 136.4 
(C(2)H), 136.9 (SO2ArC(4)), 144.6 (SO2ArC(1) and ArC(1)), 171.2 (C(1)); HRMS (NSI+) 
C17H1479BrF3NO2S+ [M+H]+, requires 431.9875 found 431.9871 (−0.1 ppm). 
 
N-((E)-1-(4-Bromophenyl)-4,4,4-trifluorobut-2-en-1-ylidine)-4 methylbenzenesulfonamide 
 
 
 
Following general procedure D, trifluoromethyl enone 209 (4.62 g, 16.6 mmol) and 4-
toluenesulfonamide (2.83 g, 16.6 mmol) in CH2Cl2 (70 mL), Et3N (4.63 mL, 33.1 mmol) and 
TiCl4 (1.82 mL, 16.6 mmol) gave, after recrystallisation (Et2O:Petrol), the title compound as a 
white solid (4.62 g, 65%); mp 78-80 °C; νmax (ATR)/cm-1 1304, 1549, 1574 (S=O), 1140 (S=O), 
3103 (C-H); 1H NMR (500 MHz, CDCl3) 2.47 (3 H, s, CH3), 6.15 (1 H, dq, J 16.3, 6.1, C(3)H), 
7.38 (2 H, d, J 8.0, C(1)Ar(3,5)H), 7.62 (4 H, s, SO2ArH), 7.85-7.92 (3 H, m, C(2)H and 
C(1)Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 21.7 (CH3), 121.8 (q, J 282, CF3), 126.4 (C(3)), 
127.5 (C(1)ArC(3,5)), 129.2 (C(1)ArC(4)), 129.7 (C(1)ArC(2,6)), 131.5 (SO2ArC), 131.5 
(SO2ArC), 132.2 (C(2)), 134.3 (SO2ArC(4)), 137.1 (C(1)ArC(1)), 144.5 (SO2ArC(1)), 171.7 
(C(1)); HRMS (APCI+) C17H1479BrF3NO2S+ [M+H]+, requires 431.9875; found 431.9875 (+0.0 
ppm). 
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4-Methyl-N-[(2E)-4,4,4-trifluoro-1-(4-methylphenyl)but-2-en-1-ylidene]benzene-1-
sulfonamide 
 
 
 
Following general procedure D, trifluoromethyl enone 210 (2.0 g, 9.89 mmol) and 4-
toluenesulfonamide (1.69 g, 9.89 mmol) in CH2Cl2 (50 mL), Et3N (2.72 mL, 19.8 mmol) and 
TiCl4 (1.10 mL, 9.89 mmol) gave, after recrystallisation (Et2O:Petrol), the title compound as an 
orange solid (2.8 g, 70%): mp 106-109 °C; νmax (ATR)/cm-1 1285 (SO2), 1557 (C=N), 3261 (C-
H); 1H NMR (400 MHz, CDCl3); 2.42 (3H, s, ArCH3), 2.45 (3H, s, SO2ArCH3), 6.11 (1H, dq, J 
16.3, 6.12, C(3)H); 7.25 (2H, d, J 8.0, Ar(3)H), 7.34 (2H, d, J 8.1, SO2Ar (3,5)H), 7.62 (3H, br 
s, Ar(2,6)H), 7.75-7.95 (3H, m, C(2)H and SO2Ar (2,6)H); 13C NMR (100 MHz, CDCl3) 21.6 
(CH3), 21.7 (SO2ArCH3), 121.9 (q, J 265, CF3), 127.4 (SO2ArC(2,6)H)), 129.6 (C(3)H, 
ArC(3,5)H and SO2ArC(3,5)H), 130.3 (C(2)H), 131.9 (ArC(2,6)H), 137.6 (ArC(4) and 
SO2ArC(4)), 144.2 (ArC(1) and SO2ArC(1)), 172.2 (C(1)); HRMS (NSI+) C18H17F3NO2S 
[M+H]+, requires 368.0927 found 368.0928 (+0.4 ppm). 
 
4-Methyl-N-[(2E)-4,4,4-trifluoro-1-(4-fluorophenyl)but-2-en-1-ylidene] benzene-1-
sulfonamide 
 
 
 
Following general procedure D, trifluoromethyl enone 211 (2.6 g, 11.9 mmol) and 4-
toluenesulfonamide (2.03 g, 11.9 mmol) in CH2Cl2 (40 mL), Et3N (3.28 mL, 23.8 mmol), TiCl4 
(1.31 mL, 11.9 mmol) gave, after recrystallisation (Et2O:Petrol), the title compound as an off-
white solid (2.73 g, 62%): mp 78-80 °C; νmax (ATR)/cm-1 1303 (SO2), 1564 (C=N), 3100 (C-H); 
1H NMR (400 MHz, CDCl3) 2.45 (3 H, s, SO2ArCH3), 6.12 (1 H, dq, J 16.3, 6.1, C(3)H), 7.15 
(2 H, t, J 8.6, Ar(3,5)H), 7.36 (2 H, d, J 8.2, SO2Ar(3,5)H), 7.77-7.84 (3 H, m, Ar(2)H and 
C(2)H), 7.89 (2 H, d, J 8.6, SO2Ar(2,5)H); 13C NMR (125 MHz, CDCl3) 21.7 (SO2ArCH3), 
116.2 (d, J 22.2, ArC(3,5)H), 121.7 (q, J 270.9, CF3), 126.4 (ArC(2,6)H), 127.5 
(SO2ArC(2,6)H), 129.7 (SO2ArC(3,5)H and C(3)H), 132.8 (C(2)H), 137.2 (SO2ArC(4)), 139.3 
(ArC(1)), 144.4 (SO2ArC(1)), 165.2 (C(1)), 169.2 (d, J 519, ArC(4)F); HRMS (APCI+) 
C17H13F4NO2S [M+H]+, requires 372.0676 found 372.0677 (+0.3 ppm). 
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4-Methyl-N-[(1E)-4,4,4-trifluoro-1-(naphthalene-2-yl)but-2-en-1-ylidene]benzene-1-
sulfonamide 
 
 
 
Following general procedure D, trifluoromethyl enone 212 (2.00 g, 8.00 mmol) amd 4-
toluenesulfonamide (1.37 g, 8.00 mmol) in CH2Cl2 (50 mL), Et3N (2.20 mL, 16.0 mmol) and 
TiCl4 (0.88 mL, 8.00 mmol) gave, after recrystallisation (Et2O:Petrol), the title compound as 
yellow solid (1.97 g, 61%): mp 120-122 °C; νmax (ATR)/cm-1 1287, 1288 (SO2), 1550 (C=N), 
3067 (C-H); 1H NMR (500 MHz, CDCl3) 2.46 (3 H, s, SO2ArCH3), 6.18 (1 H, dq, J 16.3, 6.1, 
C(3)H), 7.37 (2 H, d, J 7.1, SO2Ar(3,5)H), 7.58-7.65 (2 H, m, ArH), 7.80-8.00 (7 H, m, ArH 
and  SO2Ar(2,6)H), 8.20 (C(2)H); 13C NMR (125 MHz, CDCl3) 21.7 (SO2ArCH3), 121.9 (q, J 
271, CF3), 124.9 (ArCH), 127.3 (ArCH), 127.5 (ArCH and ArCH), 127.9 (ArCH), 128.9 
(C(3)H), 129.2 (ArCH), 129.6 (SO2ArC(2,6)H), 129.7 (SO2ArC(3,5)H and ArCH), 132.3 (ArC 
and ArC), 137.5 (SO2ArC(4)), 144.3 (SO2ArC(1) and ArC(2)) 161.2 (C(1)); HRMS (NSI+) 
C21H17F3NO2S [M+H]+, requires 404.0927 found 404.0924 (−0.6 ppm). 
 
4-Methyl-N-[(2E)-4,4,4-trifluoro-1-(thiophen-2-yl)but-2-en-1-ylidene]benzene-1-
sulfonamide 
 
 
 
Following general procedure D, trifluoromethyl enone 213 (1.90 g, 6.80 mmol) and 4-
toluenesulfonamide (1.16 g, 6.80 mmol) in CH2Cl2 (50 mL), Et3N (1.88 mL, 13.6 mmol) and 
TiCl4 (0.75 mL, 6.8 mmol) gave, after recrystallisation (Et2O:Petrol), the title compound as an 
orange solid (2.0 g, 80%): mp 102-104 °C; νmax (ATR)/cm-1 1288 (S=O), 1533, 3086 (C-H); 1H 
NMR (500 MHz, CDCl3); 2.45 (3H, s, SO2ArCH3), 6.12 (1H, dq, J 16.2, 6.0, C(3)H), 7.16 (1H, 
dd, J 5.02, 3.89, C(1)Ar(4)H), 7.35 (2H, d, J 8.1, SO2ArC(3,5)H), 7.63 (1H, d, J 3.9, 
C(1)Ar(3)H), 7.70-7.75 (3H, m, C(1)Ar(5)H and C(2)H), 7.88 (2H, d, J 8.30, SO2ArC(2)H); 13C 
NMR (125 MHz, CDCl3); 21.7 (SO2ArCH3), 121.7 (q, J 270, CF3), 127.4 (SO2ArC(2,6)H), 
127.8 (C(3)H), 128.9 (C(1)ArC(4)H), 129.6 (SO2ArC(3,5)H), 131.6 (C(1)ArC(5)H), 136.6 
(C(1)ArC(3)H), 136.9 (C(2)H), 137.3 (SO2ArC(4)), 144.22 (C(1)ArC(2) and SO2ArC(1)), 165.6 
(C(1)); HRMS (NSI+) C15H13F3NO2S2 [M+H]+, requires 360.0334 found 360.0336 (0.5 ppm). 
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9.2.6 One-Pot Pyridine Synthesis 
Ethyl 2-phenyl-6-((phenylsulfonyl)oxy)isonicotinate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (101 mg, 0.6 mmol) in THF (6 mL), i-
Pr2NEt (157 µL, 0.9 mmol), pivaloyl chloride (110 µL, 0.9 mmol), ketimine 154 (206 mg, 0.6 
mmol), DHPB 86 (22 mg, 0.12 mmol), and i-Pr2NEt (101 µL, 0.6 mmol) for 4 h at rt followed 
by heating at 80 °C for 16 h gave, after chromatographic purification (EtOAc:Petrol 10:90), the 
title compound as a yellow solid (155 mg, 67%); mp 119-120 °C; νmax (ATR)/cm-1 1362, 1558 
(S=O); 1724 (C=O); 2938, 2980 (C-H); 1H NMR (400 MHz, CDCl3) 1.43 (3H, t, J 7.1, 
CH2CH3), 4.45 (2H, q, J 7.1 CH2CH3), 7.39-7.44 (3H, m, Ar(3,5)H and Ar(4)H), 7.55-7.61 (3H, 
m, SO2Ar(3,5)H and SO2Ar(4)H), 7.68-7.77 (3H, m, py(3)H, Ar(2,6)H), 8.06-8.10 (2H, m, 
SO2Ar(2,6)H), 8.21 (1H, d, J 1.06, py(5)H); 13C NMR (100 MHz, CDCl3) 14.2 (CH3), 62.3 
(CH2), 113.4 (pyC(3)), 118.2 (pyC(5)), 127.0 (py(6)ArC(4)H), 128.8 (py(6)ArC(2,6)H and 
py(6)ArC(3,5)H), 129.1 (SO2ArC(2,6)H), 130.0 (SO2ArC(3,5)H), 134.1 (SO2ArC(4)H), 136.6 
(SO2ArC(1)), 137.3 (py(6)ArC(1)), 143.0 (pyC(6)), 157.2 (pyC(4)), 157.4 (pyC(2)), 163.9 
(C(1)); HRMS (NSI+) C20H18NO5S+ [M+H]+, requires 384.0900 found 384.0899 (−0.3 ppm). 
 
Methyl 2-{[(4-methylbenzene)sulfonyl]oxy}-6-phenylpyridine-4-carboxylate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (4.41 g, 26.2 mmol) in THF (400 mL), 
i-Pr2NEt (6.85 mL, 39.3 mmol), pivaloyl chloride (4.73 mL, 39.3 mmol), ketimine 154 (9.0 mg, 
26.2 mmol), DHPB 86 (1.00 g, 5.24 mmol), and i-Pr2NEt (4.57 mL, 26.2 mmol) for 4 h at rt 
followed by heating at 80 °C for 16 h gave, after chromatographic purification (EtOAc:Petrol 
10:90), the title compound as a red solid (5.00 g, 50%); mp 118-120 °C; νmax (ATR)/cm-1 1169, 
1364 (S=O), 1557, 1730 (C=O), 2953 (Ar-H); 1H NMR (400 MHz, CDCl3) 2.47 (3H, s, 
SO2ArCH3), 3.99 (3H, s, OCH3), 7.36 (2H, d, J 8.04, SO2Ar(3,5)H), 7.40-7.43 (3H, m, 
Ar(3,5)H and Ar(4)H), 7.58 (1H, d, J 1.0, py(3)H), 7.76-7.78 (2H, m, Ar(2,6)H), 7.94 (2H, d, J 
8.3, SO2Ar(2,6)H), 8.21 (1H, d, J 1.0, py(5)H); 13C NMR (100 MHz, CDCl3) 21.8 (SO2ArCH3), 
53.1 (OCH2), 113.5 (pyC(3)), 118.1 (pyC(5)), 127.0 (py(6)ArC(2,6)H), 128.8 (SO2ArC(2,6)H), 
129.7 (SO2ArC(3,5)H),  (py(6)ArC(3,5)H), 130.1 (py(6)ArC(4)H), 134.1 (SO2ArC(4)), 136.6 
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(SO2ArC(1)), 142.5 (py(6)ArC(1)), 145.3 (pyC(6)), 157.2 (pyC(4)), 157.6 (pyC(2)), 164.5 
(C(1)); HRMS (NSI+) C20H18NO5S [M+H]+, requires 384.0900 found 384.0901 (+0.2 ppm). 
 
Benzyl 2-([(4-methylbenzene)sulfonyl]oxy)-6-phenylpyridine-4-carboxylate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (101 mg, 0.6 mmol) and i-Pr2NEt (157 
µL, 0.9 mmol) in THF (9 mL) were added pivaloyl chloride (110 µL, 0.9 mmol) DHPB 86 (22 
mg, 0.12 mmol), ketimine 154 (252 mg, 0.6 mmol) and i-Pr2NEt (110 µL, 0.6 mmol) for 4 h at 
rt followed by heating at 80 °C for 16 h gave, after chromatographic purification (Et2O:petrol 
10:90), the title compound as a white solid (166 mg, 60%); mp 64-66 °C; νmax (ATR)/cm-1 1168, 
1362 (S=O), 1734 (C=O), 3068 (Ar-H); 1H NMR (500 MHz, CDCl3) 2.49 (3H, s, SO2ArCH3), 
5.55 (2H, s, CO2CH2Ph), 7.35-7.48 (10H, m, ArH), 7.58 (1H, s,  pyC(3)H), 7.78 (2H, m, 
SO2ArC(3,5)H), 7.96 (2H, d, J 8.4, py(6)Ar(2,6)H), 8.24 (1H, m, py(5)H); 13C NMR (125 MHz, 
CDCl3); 21.8 (SO2ArCH3), 67.9 (CO2CH2Ph), 113.5 (pyC(5)H), 118.2 (pyC(3)H), 127.0 
(SO2ArC(2,6)H), 128.6 (C(1)Ar(2,6)H), 128.7-128.8  py(6)ArC(4)H, py(6)ArC(2,6)H and 
C(1)Ar(4)H), 129.7 (C(1)ArC(3,5)H), 130.1 (SO2ArC(3,5)H), 134.2 (SO2ArC(1)), 135.0 
(C(1)ArC(1)), 136.6 (SO2ArC(4)), 142.6 (py(6)ArC(1)), 145.3 (pyC(6)), 157.2 (pyC(4)), 157.6 
(pyC(2)), 163.9 (C(1)); HRMS (NSI+) C26H22NO5S [M+H]+, requires 460.1213 found 460.1200 
(−2.9 ppm). 
 
Methyl 2-{[(4-methylbenzene)sulfonyl]oxy}-6-(naphthalene-2-yl)pyridine-4-carboxylate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (427 mg, 2.54 mmol) and i-Pr2NEt (0.66 
mL, 3.81 mmol) in THF (40 mL) were added pivaloyl chloride (0.74 mL, 3.81 mmol) DHPB 86 
(97 mg, 0.51 mmol), crude ketimine 183 (1.00 g, 2.54 mmol) and i-Pr2NEt (0.44 mL, 2.54 
mmol) for 4 h at rt followed by heating at 80 °C for 16 h gave, after chromatographic 
purification (Et2O:petrol 10:90), the title compound as a green solid (760 mg, 69%); mp 142-
144 °C; νmax (ATR)/cm-1  1171 (C-O), 1369 (SO2), 1732 (C=O), 2951 (C-H) 1H NMR (400 
MHz, CDCl3) 2.49 (3H, s, SO2ArCH3), 4.02 (3H, s, CO2CH3), 7.39 (2H, d, J 8.0, SO2Ar(3,5)H), 
7.52-7.56 (2H, m, NpH), 7.61 (1H, d, J 1.0, py(5)H), 7.85-7.87 (4H, m, NpH), 7.98 (2H, d, J 
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8.4, SO2Ar(2,6)H), 8.26 (1H, s, py(3)H), 8.35 (1H, d, J 1.05, Np(1)H); 13C NMR (100 MHz, 
CDCl3) 21.8 (SO2ArCH3), 53.1 (OCH3), 113.5 (pyC(5)H), 118.4 (pyC(3)H), 124.1 (NpCH), 
126.6 (NpCH), 127.0 (NpCH), 127.2 (NpCH), 127.7 (NpCH), 128.5 (NpCH), 128.8 (NpCH), 
128.9 (SO2ArC(2,6)H), 129.8 (SO2ArC(3,5)H), 133.2 (NpC(10)), 133.9 (NpC(5)), 134.1 
(SO2ArC(1)), 134.3 (NpC(2)), 142.5 (SO2ArC(4)), 145.3 (pyC(6)), 157.2 (pyC(4)), 157.7 
(pyC(2)), 164.5 (C(1)); HRMS (NSI+) C24H20NO5S [M+H]+, requires 434.1057 found 434.1051 
(−1.3 ppm). 
 
Benzyl 2-(4-methylphenyl)-6-([(4-methylbenzene)sulfonyl]oxy)pyridine-4-carboxylate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (101 mg, 0.6 mmol) and i-Pr2NEt (157 
µL, 0.9 mmol) in THF (9 mL) were added pivaloyl chloride (110 µL, 0.9 mmol) DHPB 86 (22 
mg, 0.12 mmol), benzyl (2E)-4-(4-tolyl)-4-(tosylimino)but-2-enoate (270 mg, 0.6 mmol) and i-
Pr2NEt (110 µL, 0.6 mmol) for 4 h at rt followed by heating at 80 °C for 16 h gave, after 
chromatographic purification (Et2O:petrol 10:90), the title compound as a white solid (166 mg, 
60%); mp 127-130 °C; νmax (ATR)/cm-1  1171 (C-O), 1367 (SO2), 1722 (C=O), 3088 (Ar-H); 1H 
NMR (500 MHz, CDCl3) 2.40 (3H, s, py(6)ArCH3), 2.47 (3H, s, SO2ArCH3), 5.41 (2H, s, 
CO2CH2Ph), 7.21 (2H, d, J 8.7, py(6)Ar(3,5)H), 7.35-7.47 (7H, m, ArH), 7.55 (1H, s, py(5)H), 
7.66 (2H, d, J 7.6, SO2ArC(2,6)H), 7.94 (2H, d, J 7.6, py(6)Ar(2,6)H) 8.19 (1H, s, py(3)H); 13C 
NMR (125 MHz, CDCl3) 21.4 (ArCH3), 21.7 (SO2ArCH3), 67.9 (CO2CH2Ph), 113.0 (pyC(5)H), 
117.9 (pyC(3)H), 126.9 (SO2ArC(2,6)H), 128.5 (ArCH), 128.7 (ArCH), 128.8 
(py(6)ArC(2,6)H), 128.9 (ArCH) 129.5 (py(6)Ar(3,5)H), 129.7 (ArCH), 133.9 (SO2ArC(1)), 
134.2 (py(6)ArC(4)), 135.0 (C(1)ArC(1)), 140.4 (SO2ArC(4)), 142.4 (py(6)ArC(1)), 145.2 
(pyC(6)), 157.3 (pyC(4)), 157.4 (pyC(2)), 163.9 (C(1)); HRMS (APCI+) C27H24NO5S [M+H]+, 
requires 474.1370 found 474.1369 (−0.1 ppm).  
 
Benzyl 2-(4-methoxyphenyl)-6-([(4-methylbenzene)sulfonyl]oxy)pyridine-4-carboxylate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (101 mg, 0.6 mmol) and i-Pr2NEt (157 
µL, 0.9 mmol) in THF (9 mL) were added pivaloyl chloride (110 µL, 0.9 mmol) DHPB 86 (22 
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mg, 0.12 mmol), benzyl (2E)-4-(4-methoxyphenyl)-4-(tosylimino)but-2-enoate (270 mg, 0.6 
mmol) and i-Pr2NEt (110 µL, 0.6 mmol) for 4 h at rt followed by heating at 80 °C for 16 h gave, 
after chromatographic purification (Et2O:petrol 10:90), the title compound as an orange solid 
(150 mg, 51%); mp 129-131 °C; νmax (ATR)/cm-1 1165 (C-O), 1084, 1251 (ArOMe), 1552 
(SO2), 1726 (C=O), 2936, 2995 (Ar-H); 1H NMR (500 MHz, CDCl3) 2.46 (3H, s, OCH3), 3.86 
(3H, s, SO2ArCH3), 5.40 (2H, s, CO2CH2Ph), 6.90 (2H, d , J 8.72, py(6)Ar(3,5)H), 7.34-7.50 
(8H, m, ArH), 7.70 (2H, d, J 8.6, SO2ArC(2,6)H), 7.93 (2H, d, J 8.4, py(6)Ar(2,6)H), 8.14 (1H, 
s, pyC(3)H); 13C NMR (125 MHz, CDCl3) 21.8 (SO2ArCH3), 55.4 (OCH3), 67.9 (CH2), 112.4 
(pyC(5)H), 114.1 (pyC(3)H), 117.3 (py(6)ArC(3)H), 128.5 (SO2ArC(2)H), 128.8 
(C(1)ArC(2,6)H), 128.8  (C(1)ArC(3,5)H), 128.8 (C(1)ArC(4)H), 128.8  (py(6)ArC(2)H), 129.3 
(SO2ArC(1)), 129.7 (SO2ArC(3,5)H), 134.2 (py(6)ArC(1)), 135.0 (C(1)ArC(1)), 142.4 
(SO2ArC(4)), 145.2 (pyC(6)), 157.0 (pyC(4)), 157.5 (py(6)ArC(4)), 161.3 (pyC(2)), 164.0 
(C(1)); HRMS (APCI+) C27H24NO6S [M+H]+, requires 490.1319 found 490.1311 (−1.6 ppm). 
 
Methyl 2-(4-chlorophenyl)-6-([(4-methylbenzene)sulfonyl]oxy)pyridine-4-carboxylate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (101 mg, 0.6 mmol) and i-Pr2NEt (157 
µL, 0.9 mmol) in THF (9 mL) were added pivaloyl chloride (110 µL, 0.9 mmol) DHPB 86 (22 
mg, 0.12 mmol), methyl (2E)-4-(4-chlorophenyl)-4-(tosylimino)but-2-enoate (0.227 g, 0.6 
mmol) and i-Pr2NEt (110 µL, 0.6 mmol) for 4 h at rt followed by heating at 80 °C for 16 h gave, 
after chromatographic purification (Et2O:petrol 10:90), the title compound as a white solid (130 
mg, 54%); mp 120-122 °C; νmax (ATR)/cm-1 1086 (ArC(4)) 1171, 1181 (SO2), 1734 (C=O), 
2956, 3096 (Ar-H); 1H NMR (500 MHz, CDCl3) 2.47 (3H, s, CH3), 3.98 (3H, s, SO2ArCH3), 
7.36-7.37 (4H, m, Ar(3,5)H and SO2Ar(3,5)H), 7.57 (1H, s, py(3)H), 7.70 (2H, d, J 8.0, 
SO2Ar(2,6)H), 7.92 (2H, J 7.7, Ar(2,6)H), 8.16 (1H, s, py(5)H); 13C NMR (125 MHz, CDCl3) 
21.8 (CH3), 53.1 (SO2ArCH3), 113.7 (pyC(5)H), 117.9 (pyC(3)H), 128.3 (SO2ArC(2,6)H), 
128.8 (py(6)ArC(2,6)H), 129.0 (py(6)ArC(3,5)H), 129.7 (SO2ArC(3,5)H), 134.1 (SO2ArC(1)), 
135.1 (py(6)ArC(4)Cl), 136.3 (py(6)ArC(1)), 142.7 (SO2ArC(4)), 145.4 (pyC(6)), 155.9 
(pyC(4)), 157.6 (pyC(2)), 164.3 (C(1)); HRMS (APCI+) C20H17ClNO5S [M+H]+, requires 
418.0510 found 418.0510 (−0.1 ppm). 
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Methyl 2-(2-fluorophenyl)-6-{[(4-methylbenzene)sulfonyl]oxy}pyridine-4-carboxylate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (234 mg, 1.39 mmol) and i-Pr2NEt (360 
µL, 2.09 mmol) in THF (21 mL) were added pivaloyl chloride (260 µL, 2.09 mmol) DHPB 86 
(53 mg, 0.28 mmol), methyl (2E,4Z)-4-(2-fluorophenyl)-4-(tosylimino)but-2-enoate (500 mg, 
1.39 mmol) and i-Pr2NEt (240 mL, 1.39 mmol for 4 h at rt followed by heating at 80 °C for 16 h 
gave, after chromatographic purification (Et2O:petrol 10:90), the title compound as a yellow 
solid (375 mg, 65%); mp 86-88 °C; νmax (ATR)/cm-11368 (SO2), 1735 (C=O), 2974 (C-H); 1H 
NMR (500 MHz, CDCl3) 2.46 (3H, s, SO2ArCH3), 3.98 (3H, s, OCH3), 7.13-7.18 (2H, m, 
Ar(3)H and Ar(5)H), 7.35 (2H, d, J 8.2, SO2Ar(3,5)H), 7.37-7.42 (1H, m, Ar(4)H), 7.57-7.61 
(2H, m, py(3)H and Ar(6)H), 7.93 (2H, d, J 8.3, SO2Ar(2,6)H), 8.31 (1H, s, py(5)H); 13C NMR 
(125 MHz, CDCl3) 21.8 (SO2ArCH3), 53.1 (OCH3), 113.9 (pyC(3)H), 116.4 (d, J 23.0, 
ArC(3)H), 122.4 (d, J 12.3, pyC(5)H), 124.4 (d, J 3.42, ArC(5)H), 124.8 (d, J 10.6, ArC(1)), 
128.8 (SO2ArC(2,6)H), 129.7 (SO2ArC(3,5)H), 131.0 (d, J 1.96 (ArC(6)H), 131.6 (d, J 8.74, 
ArC(4)H), 134.0 (SO2ArC(4)), 142.4 (SO2ArC(1)), 145.4 (pyC(6)), 153.0 (pyC(4)), 157.4 
(pyC(2)), 160.7 (d, J 254, ArC(2)), 164.4 (C(1)); 19F NMR (470 MHz, CDCl3); −115.4 (ArF); 
HRMS (NSI+) C20H17FNO5S [M+H]+, requires 402.0806 found 402.0803 (−0.7 ppm). 
 
Methyl 2-(4-cyanophenyl)-6-{[(4-methylbenzene)sulfonyl]oxy}pyridine-4-carboxylate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (456 mg, 2.71 mmol) and i-Pr2NEt (0.71 
mL, 4.10 mmol) in THF (40 mL) were added pivaloyl chloride (0.5 mL, 4.10 mmol) DHPB 86 
(103 mg, 0.54 mmol), crude ketimine 181 (1.00 g, 2.71 mmol) and i-Pr2NEt (0.47 mL, 2.71 
mmol) for 4 h at rt followed by heating at 80 °C for 16 h gave, after chromatographic 
purification (Et2O:petrol 20:80), the title compound as a brown solid (664 mg, 60 %); mp 154-
156 °C; νmax (ATR)/cm-1 1165 (C-O), 1370 (SO2), 1734 (C=O), 2224 (ArCN) 1H NMR (400 
MHz, CDCl3) 2.49 (3H, s, SO2ArCH3), 4.00 (3H, s, CO2CH3), 7.38 (2H, d, J 8.56, SO2Ar(3)H), 
7.65 (1H, d, J 1.0, py(3)H), 7.71 (1H, d, J 8.0, Ar(2,6)H), 7.92 (4H, m, SO2Ar(2,6)H and 
Ar(3,5)H), 8.24 (1H, d, J 1.0, py(5)H); 13C NMR (100 MHz, CDCl3) 21.8 (SO2ArCH3), 53.3 
(OCH3), 113.6 (ArC(4)), 114.9 (pyC(3)H), 118.4 (Ar(4)CN), 118.6 (pyC(5)H), 127.5 
(ArC(2,6)H), 128.7 (SO2ArC(2,6)H), 129.8 (SO2ArC(3,5)H), 132.6 (ArC(3,5)H), 134.0 
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(SO2ArC(1)), 140.7 (SO2ArC(4)), 143.0 (ArC(1)), 145.6 (pyC(6)), 154.9 (pyC(4)), 157.8 
(pyC(2)), 164.0 (C(1)); HRMS (NSI+) C21H17N2O5S [M+H]+, requires 409.0853 found 409.848 
(−1.1 ppm). 
 
Methyl 2-{[(4-methylbenzene)sulfonyl]oxy}-6-[4-(trifluoromethyl)phenyl] pyridine-4-
carboxylate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (168 mg, 1.0 mmol) and i-Pr2NEt (260 
µL, 1.50 mmol) in THF (15 mL) were added pivaloyl chloride (180 µL, 1.50 mmol) DHPB 86 
(38 mg, 0.2 mmol), crude ketimine 182 (411 mg, 1.0 mmol) and i-Pr2NEt (170 µL, 1.0 mmol) 
for 4 h at rt followed by heating at 80 °C for 16 h gave, after chromatographic purification 
(Et2O:petrol 15:85), the title compound as a white solid (288 mg, 64%); mp 108-110 oC; νmax 
(ATR)/cm-1 1377 (SO2), 1732 (C=O), 3094 (C-H); 1H NMR (500 MHz, CDCl3) 2.48 (3H, s, 
SO2ArCH3), 4.00 (3H, s, OCH3), 7.37 (2H, d, J 8.1, SO2Ar(3,5)H), 7.63 (1H, s, py(3)H), 7.67 
(2H, d, J 8.2, Ar(2,6)H), 7.89 (2H, d, J 8.2, Ar(3,5)H), 7.93 (2H, d, J 8.3, SO2Ar (2,6)H), 8.24 
(1H, s, py(5)H);  13C NMR (125 MHz, CDCl3) 21.8 (SO2ArCH3), 53.2 (CH3), 114.5 (pyC(3)H), 
118.5 (pyC(5)H), 123.8 (q, J 272, CF3), 125.7 (ArC(3,5)H), 127.7 (ArC(2,6)H), 128.7 
(SO2ArC(2,6)H), 129.7 (SO2ArC(3,5)H), 131.8 (ArC(4)), 134.0 (SO2ArC(4)), 139.9 
(SO2ArC(1)), 142.8 (ArC(1)), 145.5 (pyC(6)), 155.5 (pyC(4)), 157.7 (pyC(2)), 164.2 (C(1)); 19F 
NMR (470 MHz, CDCl3); −62.8 (CF3); HRMS (NSI+) C21H17F3NO5S [M+H]+, requires 
452.0774 found 452.0766 (−1.8 ppm). 
 
Benzyl 2-{[(4-methylbenzene)sulfonyl]oxy}-6-(4-nitrophenyl)pyridine-4-carboxylate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (101 mg, 0.6 mmol) and i-Pr2NEt (157 
µL, 0.9 mmol) in THF (9 mL) were added pivaloyl chloride (110 µL, 0.9 mmol) DHPB 86 (22 
mg, 0.12 mmol, 20 mol%), benzyl (2E)-4-(4-nitrophenyl)-4-(tosylimino)but-2-enoate (464 mg, 
0.6 mmol) and i-Pr2NEt (110 µL, 0.6 mmol) for 4 h at rt followed by heating at 80 °C for 16 h 
gave, after chromatographic purification (Et2O:petrol 15:85), the title compound as an orange 
solid (303 mg, 51 %), sample was recrystallised (Et2O:Petrol) for analysis; mp 124-127 °C; νmax 
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(ATR)/cm-1 1165 (C-O), 1327 (SO2), 1365, 1526 (ArNO2), 1728 (C=O), 3062 (Ar-H); 1H NMR 
(500 MHz, CDCl3) 2.49 (3H, s, SO2ArCH3), 5.43 (2H, s, CO2CH2Ph), 7.36-7.47 (7H, m , ArH), 
7.67 (1H, s, py(5)H), 7.92-7.97 (4H, m, ArH), 8.25-8.27 (3H, m, ArH); 13C NMR (125 MHz, 
CDCl3) 21.8 (SO2ArCH3), 68.2 (CO2CH2Ph), 115.1 (pyC(5)H), 118.9 (pyC(3)H), 124.0 
(ArCH), 127.9 (ArCH), 128.8-128.9 (ArCH×4), 129.8 (ArCH), 134.1 (SO2ArC(1)), 134.7 
(C(1)ArC(1)), 142.4 (SO2ArC(4)), 143.1 (py(6)ArC(1)), 145.6 (py(6)ArC(4)), 148.7 (pyC(6)), 
154.5 (pyC(4)), 157.9 (pyC(2)), 163.4 (C(1)); HRMS (NSI+) C26H21N2O7S+ ([M+H]+) requires 
505.1064 found 505.1056 (−1.6 ppm). 
 
Methyl 2-tert-butyl-6-{[(4-methylbenzene)sulfonyl]oxy}pyridine-4-carboxylate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (101 mg, 0.6 mmol) and i-Pr2NEt (150 
µL, 0.9 mmol) in THF (9 mL) were added pivaloyl chloride (110 µL, 0.9 mmol) DHPB 86 
(22.8 mg, 0.12 mmol), ketimine 184 (194 mg, 0.6 mmol) and i-Pr2NEt (100 µL, 0.6 mmol for 4 
h at rt followed by heating at 80 °C for 16 h gave, after chromatographic purification 
(Et2O:petrol 15:85), the title compound as a brown solid (97 mg, 44%); mp 72-74 °C; νmax 
(ATR)/cm-1 1172, 1323 (S=O), 1371, 1730 (C=O), 2962 (C-H); 1H NMR (500 MHz, CDCl3) 
1.17 (9H, s, (CH3)3), 2.44 (3H, s, SO2ArCH3), 3.95 (3H, s, OCH3), 7.33 (2H, d, J 7.5, 
SO2Ar(3,5)H), 7.48 (1H, s, py(3)H), 7.75 (1H, s, py(5)H), 7.87 (2H, d, J 7.5, SO2Ar(2,6)H); 13C 
NMR (125 MHz, CDCl3) 21.7 (SO2ArCH3), 29.6 ((CH3)3), 37.7 (C(CH3)), 52.9 (CH3), 112.4 
(pyC(3)H), 117.4 (pyC(5)H), 128.6 (SO2ArC(2,6)H), 129.1 (SO2ArC(3,5,)H), 134.1 
(SO2ArC(4)), 141.8 (SO2ArC(1)), 145.1 (pyC(6)), 156.7 (pyC(4)), 164.8 (pyC(2)), 170.2 (C(1)); 
HRMS (NSI+) C18H22NO5S [M+H]+ requires 364.1213 found 364.1214 (+0.2 ppm). 
 
6-(4-Bromophenyl)-4-(trifluoromethyl)pyridin-2-yl 4-methylbenzene-1-sulfonate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (84.1 mg, 0.50 mmol) in THF (5 mL), i-
Pr2NEt (130 µL, 0.75 mmol), pivaloyl chloride (92.5 µL, 0.75 mmol), ketimine 217 (216 mg, 
0.5 mmol), DHPB 86 (19.0 mg, 0.1 mmol) and i-Pr2NEt (87.5 µL, 0.50 mmol) for 4 h at rt 
followed by heating at 80 °C for 16 h gave, after chromatographic purification (Et2O:petrol 
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10:90), the title compound as a white solid (146 mg, 62%); mp 134-136 °C; νmax (ATR)/cm-1 
1146 (S=O), 1306 (S=O), 1564, 1591, 1614, 3110 (C-H); 1H NMR (400 MHz, CDCl3) 2.51 (3H, 
s, CH3), 7.26 (1H, s, C(3)H), 7.40 (2H, d, J 8.6, SO2Ar(3,5)H), 7.56-7.60 (2H, m, C(6)ArH), 
7.65-7.68 (2H, m, C(6)ArH), 7.81 (1H, s, C(5)H), 7.95-7.98 (2H, m, SO2Ar(2,6)H); 13C NMR 
(100 MHz, CDCl3) 21.8 (CH3), 110.2 (q, J 3.5, (C(3)), 114.1 (q, J 3.2, C(5)),  122.0 (q, J 272, 
CF3), 125.3 (C(6)ArC(4)), 128.6 (ArC), 128.8 (ArC), 129.8 (ArC), 132.1 (ArC), 134.0 
(SO2ArC(1)), 135.1 (C(6)ArC(1)), 143.3 (q, J 34.4, C(4)), 145.7 (SO2ArC(4)), 156.7 (C(6)), 
157.5 (C(2)); 19F NMR (470 MHz, CDCl3); −64.5 (CF3); HRMS (APCI+) C19H1479BrF3NO3S 
[M+H]+, requires 471.9824; found 471.9825 (+0.1 ppm). 
 
6-(3-Bromophenyl)-4-(trifluoromethyl)pyridine-2-yl-4-methylbenzne-1-sulfonate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (101 mg, 0.6 mmol) and i-Pr2NEt (210 
µL, 1.2 mmol) in THF (9 mL) were added pivaloyl chloride (110 µL, 0.9 mmol) DHPB 86 (22 
mg, 0.12 mmol), ketimine 216 (259 mg, 0.6 mmol) and i-Pr2NEt (110 µL, 0.6 mmol) for 4 h at 
rt followed by heating at 80 °C for 16 h gave, after chromatographic purification (Et2O:petrol 
5:95), the title compound as a white solid (73 mg, 30%); mp 106-108 °C; νmax (ATR)/cm-1 1093 
(Ar-Br), 1350 (SO2), 3091 (Ar-H); 1H NMR (500 MHz, CDCl3) 2.50 (3H, s, SO2ArCH3), 7.28 
(1H, s, pyC(3)H), 7.32 (1H, t, J 7.9, ArC(3)H), 7.43 (2H, d, J 8.0, SO2Ar(3,5)H), 7.58 (1H, d, J 
8.0, ArC(2)H), 7.71 (1H, d, J 7.8, ArC(4)H), 7.77-7.83 (2H, m, Ar(5,6)H), 7.95 (2H, d, J 8.0, 
SO2Ar(2,6)H); 13C NMR (125 MHz, CDCl3); 21.9 (SO2ArCH3), 110.7 (pyC(3)H), 114.4 
(pyC(5)H), 122.0 (q, J 275, CF3), 123.3 (ArCBr), 125.4 (ArC(6)H), 128.8 (SO2ArC(2,6)H), 
130.0 (SO2ArC(3,5)H), 130.2 (ArC(4)H), 130.4 (ArC(5)H), 133.4 (ArC(2)H), 134.0 
(SO2ArC(4)), 138.2 (ArC(1)), 143.4 (pyC(4)), 145.7 (SO2ArC(1)), 156.3 (pyC(6)), 157.6 
(pyC(2)); 19F NMR (470 MHz, CDCl3); −64.6 (CF3); HRMS (NSI+) C19H1479BrF3NO3S [M+H]+, 
requires 471.9824 found 471.9819 (−1.1 ppm). 
 
6-(4-Methylphenyl)-4-(trifluoromethyl)pyridine-2-yl-4-methylbenzne-1-sulfonate 
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Following general procedure E, (phenylthio)acetic acid (67 mg, 0.4 mmol) and i-Pr2NEt (100 
µL, 0.6 mmol) in THF (6 mL) were added pivaloyl chloride (74 µL, 0.9 mmol) DHPB 86 (15.2 
mg, 0.08 mmol), ketimine 218 (147 mg, 0.4 mmol) and i-Pr2NEt (79 µL, 0.4 mmol) for 4 h at rt 
followed by heating at 80 °C for 16 h gave, after chromatographic purification (Et2O:petrol 
5:95), the title compound as a white solid (97 mg, 60%); mp 124-126 °C; νmax (ATR)/cm-1 1346, 
1368 (S=O), 3086 (Ar-H);  1H NMR (500 MHz, CDCl3) 2.44 (3H, s, ArCH3) 2.51 (3H, s, 
SO2ArCH3), 7.22 (1H, s,  pyC(3)H), 7.25 (2H, d, J 8.0, ArC(3)H), 7.40 (2H, d, J 8.6, 
SO2ArC(3)H), 7.68 (2H, d, J 8.3, SO2Ar(2)H), 7.81 (1H, s, py(5)H), 7.98 (2H, d, J 8.3, 
ArC(2)H); 13C NMR (125 MHz, CDCl3); 21.4 (ArCH3), 21.8 (SO2ArCH3), 109.3 (pyC(3)H), 
113.9 (pyC(5)H), 122.0 (q, J 274, 633, CF3), 127.0 (SO2ArC(2,6)H) 128.8 (ArC(2,6)H), 129.6 
(ArC(3,5)H), 129.7 (SO2ArC(3,5)H), 133.5 (ArC(4)), 134.1 (SO2ArC(4)), 140.9(ArC(1)), 143.0 
(SO2ArC(1)), 145.5 (pyC(6)), 157.4 (pyC(4)), 158.0 (pyC(2)); 19F NMR (470 MHz, CDCl3); 
−64.6 (CF3); HRMS (NSI+) C20H17F3NO3S [M+H]+, requires 408.0876 found 408.0874 (−0.4 
ppm). 
 
6-(4-Fluorophenyl)-4-(trifluoromethyl)pyridine-2-yl-4-methylbenzene-1-sulfonate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (101 mg, 0.6 mmol) and i-Pr2NEt (210 
µL, 1.2 mmol) in THF (9 mL) were added pivaloyl chloride (110 µL, 0.9 mmol) DHPB 86 (22 
mg, 0.12 mmol), ketimine 219 (223 mg, 0.6 mmol) and i-Pr2NEt (110 mL, 0.6 mmol) for 4 h at 
rt followed by heating at 80 °C for 16 h gave, after chromatographic purification (Et2O:petrol 
5:95), the title compound as a yellow solid (114 mg, 45%); mp 99-102 °C; νmax (ATR)/cm-1 
1170 (Ar-F), 1350 (S=O), 3094 (Ar-H); 1H NMR (400 MHz, CDCl3) 2.48 (3H, s, SO2ArCH3), 
7.11 (2H, t, J 8.6, ArC(3,5)H), 7.21 (1H, s, pyC(3)H), 7.38 (2H, d, J 7.2, SO2Ar(3,5)H), 7.74-
7.79 (3H, m, py(5)H and Ar(2,6)H), 7.95 (2H, d, J 7.2, SO2ArC(2,6)H); 13C NMR (100 MHz, 
CDCl3) 21.8 (SO2ArCH3), 109.7 (pyC(3)H), 113.9 (pyC(5)H), 115.9 (d, J 21.9, ArC(3,5)H), 
122.0 (q, J 271, CF3), 128.8 (SO2ArC(2,6)H), 129.1 (d, J 8.7, ArC(2,6)H), 129.8 
(SO2ArC(3,5)H), 132.4 (SO2ArC(4)), 134.0 (ArC(1)), 143.2 (q, J 34.9, pyC(4)), 145.6 
(SO2ArC(1)), 156.8 (pyC(6)), 157.4 (pyC(4)), 164.3 (d, J 252, ArC(4)); 19F NMR (376 MHz, 
CDCl3); −65.2 (CF3), −110.5 (ArF); HRMS (NSI+) C19H14F4NO3S [M+H]+, requires 412.0625 
found 412.0623 (−0.5 ppm). 
 
6-(Naphthalene-2-yl)-4-(trifluoromethyl)pyridine-2-yl 4-methylbenzene-1-sulfonate 
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Following general procedure E, (phenylthio)acetic acid (67 mg, 0.4 mmol) and i-Pr2NEt (100 
µL, 0.6 mmol) in THF (6 mL) were added pivaloyl chloride (74 µL, 0.6 mmol) DHPB 86 (15.2 
mg, 0.08 mmol), ketimine 220 (161 mg, 0.4 mmol) and i-Pr2NEt (79 µL, 0.4 mmol) for 4 h at rt 
followed by heating at 80 °C for 16 h gave, after chromatographic purification (Et2O:petrol 
10:90), the title compound as a yellow solid (82 mg, 46%); mp 112-114 °C; νmax (ATR)/cm-1 
1344, 1371 (S=O), 3090 (Ar-H); 1H NMR (500 MHz, CDCl3) 2.49 (3H, s, SO2ArCH3), 7.26 
(1H, s, py(3)H), 7.40 (2H, d, J 8.1, SO2Ar(3,5)H), 7.54-7.58 (2H, m, NpH), 7.83-7.90 (4H, m, 
NpH), 7.96 (1H, s, py(5)H), 7.99 (2H, d, J 8.3, SO2Ar(2,6)H), 8.24 (1H, s, Np(1)H); 13C NMR 
(125 MHz, CDCl3) 21.8 (SO2ArCH3), 109.9 (pyC(3)H), 114.5 (pyC(5)H), 122.1 (CF3), 123.9 
(NpCH), 126.8 (NpCH), 127.3(NpCH), 127.5 (NpCH), 127.8 (NpCH), 128.7 (NpCH), 128.8 
(NpCH), 128.9 (SO2ArC(2,5)H), 129.8 (SO2ArC(3,5)H), 133.2 (SO2ArC(4)), 133.5 
(SO2ArC(1)), 134.1 (NpC), 134.2 (NpC), 143.2 (q, J 34.1, pyC(4)), 145.5 (NpC(2)), 157.5 
(pyC(6)), 157.9 (pyC(2)); 19F NMR (470 MHz, CDCl3) −64.6 (CF3); HRMS (NSI+) 
C23H17F3NO3S [M+H]+, requires 444.0876 found 444.0872 (−0.8 ppm). 
 
6-(Thiophen-2-yl)-4-(trifluoromethyl)pyridine-2-yl-4-methylbenzne-1-sulfonate 
 
 
 
 
Following general procedure E, (phenylthio)acetic acid (67 mg, 0.4 mmol) and i-Pr2NEt (100 
µL, 0.4 mmol) in THF (6 mL) were added pivaloyl chloride (74 µL, 0.6 mmol) DHPB 86 (15.2 
mg, 0.08 mmol), ketimine 221 (143 mg, 0.4 mmol) and i-Pr2NEt (79 µL, 0.4 mmol) for 4 h at rt 
followed by heating at 80 °C for 16 h gave, after chromatographic purification (Et2O:petrol 
5:95), the title compound as a white solid (72 mg, 45%); mp 124-125 °C; νmax (ATR)/cm-1 1369 
(S=O), 3098 (Ar-H); 1H NMR (500 MHz, CDCl3) 2.47 (3H, s, SO2ArCH3), 7.08-7.15 (2H, m, 
py(3)H and C(1)Ar(4)H), 7.39 (2H, d, J 8.0, SO2Ar(3,5)H), 7.46 (1H, d, J 5.1, C(1)Ar(3)H), 
7.57 (1H, d, J 3.8, C(1)Ar(5)H), 7.67 (1H, s, pyC(5)H), 8.00 (2H, d, J 8.2, SO2Ar(2,6)H). 13C 
NMR (125 MHz, CDCl3) 21.8 (SO2ArCH3), 109.2 (pyC(3)H), 112.8 (pyC(5)H), 127.0 
(C(1)ArC(5)H) 127.9 (q, J 1345, 593, CF3), 128.4 (C(1)ArC(4)H) 128.9 (SO2ArC(2,6)H), 129.7 
(C(1)ArC(3)H), 129.8 (SO2ArC(3,5)H), 134.2 (SO2ArC(4)), 141.7 (C(1)ArC(1)), 143.1 
(pyC(4)), 145.6 (SO2ArC(1)), 150.5 (pyC(6)), 153.1 (pyC(4)), 157.3 (pyC(2)); 19F NMR (470 
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MHz, CDCl3) −64.8 (CF3); HRMS (NSI+) C17H13F3NO3S2 [M+H]+, requires 400.0283 found 
400.0283 (−0.1 ppm). 
9.2.7 Derivatisations 
Methyl 2-(1-acetamidoethenyl)-6-phenylpyridine-4-carboxylate 
 
 
 
 
Following the procedure of Gøgsig and co-workers.[170] A solution of 190 (115 mg, 0.3 mmol), 
N-vinylacetamide (102 mg, 1.2 mmol), N-methyldicyclohexylamine (193 µL, 0.9 mmol), DPPF 
(8.3 mg, 0.015 mmol) and [Pd(dba)2] (8.6 mg, 0.015 mmol) were stirred in 1,4-dioxane (3 mL) 
in a screw top vial at 100 °C for 16 h. Once cooled, the reaction mixture was filtered through 
celite (eluent CH2Cl2) and concentrated under reduced pressure. Chromatographic purification 
(EtOAc:Petrol 10:90) gave the title compound as a yellow solid (70 mg, 79%); mp 100-102 °C; 
νmax (ATR)/cm-1 1230, 1504, 1678 (C=O), 2949 (C-H), 3342 (N-H); 1H NMR (400 MHz, 
CDCl3) 2.26 (3H, s, CH3), 4.02 (3H, s, OCH3), 5.72 (1H, s, =CHH), 6.62 (1H, s, =CHH), 7.48-
7.57 (3H, m, Ar(3,5)H and Ar(4)H), 8.03 (2H, dd, J 8.1, 1.4, Ar(2,6)H), 8.25 (2H, m, py(3)H 
and py(5)H), 9.35 (1H, s, NH) 13C NMR (100 MHz, CDCl3) 25.1 (CH3), 53.0 (OCH3), 100 
(=CHH), 117.0 (pyC(3)H), 119 (pyC(5)H), 126.9 (py(6)ArC(2,6)H), 129.0 (py(6)ArC(4)H), 
129.8 (py(6)ArC(3,5)H), 136.7 (py(2)C=CH2), 136.9 (py(6)ArC(1)), 137.9 (pyC(4)), 139.5 
(pyC(2)), 152.8 (pyC(6)), 156.6 (C=O), 165.3 (NHC=O). HRMS (NSI+) C17H16N2O3 [M+H]+ 
requires 296.1161 found 296.1158 (+0.2 ppm). 
 
Methyl 2-phenylpyridine-4-carboxylate 
 
 
 
 
Following the procedure of Yoshida and co-workers.[80] To a solution of 190 (115 mg, 0.3 
mmol), Pd(OAc)2 (3.4 mg, 0.015 mmol, 5 mol%), DPPP (6.2 mg, 0.015 mmol, 5 mol%) and 
Et3N (0.206 mL, 1.5 mmol) in DMF (2 mL) was added formic acid (34 µL, 0.9 mmol). The 
reaction was heated in a screw top vial for 1 h at 60 °C. Once cooled, the reaction mixture was 
quenched with brine and extracted with EtOAc (×3). The combined organics were dried over 
MgSO4, filtered and concentrated under reduced pressure. Chromatographic purification 
(EtOAc:Petrol 5:95) gave the title compound as a light pink oil (54 mg, 85%); 1H NMR (400 
MHz, CDCl3) 3.98 (3 H, s, OCH3), 7.26-7.51 (3 H, m, Ar(3,5)H and Ar(4)H), 7.76 (1 H, dd, J 
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5.0, 1.5, py(3)H), 8.03-8.06 (2 H, m, Ar(2,6)H), 8.29 (1 H, s, py(5)H), 8.83 (1 H, dd, J 5.0, 0.8, 
py(2)H). All data in accordance with literature.[171] 
9.3 Experimental for Chapter 3 
9.3.1  General Experimental Procedures 
General Procedure F: Preparation of aldimines 
 
 
 
 
To a solution of requisite aldehyde (1.0 eq) and sulfonamide (1.0 eq) in toluene [0.33 M] at 120 
°C using a Dean-Stark apparatus was added BF3.OEt2 (0.016 eq). The reaction was stirred at 
120 °C until the theoretical amount of water was collected. The reaction mixture was quenched 
with aq. NaOH (2 Μ) extracted with EtOAc (×3), dried over MgSO4 and concentrated under 
reduced pressure to give crude reaction mixture. Products were purified by recrystallisation. 
 
General Procedure G: Preparation of 2-aryl-N-tosyliminoacrylates 
 
 
 
To a solution of requisite aldimine (1.0 eq) and triphenylphosphine (0.2 eq) in toluene [0.07 M 
in aldimine] at 80 °C was added a solution of requisite propiolate (1.2 eq) in toluene [0.24 M in 
propiolate] over 3 h. The reaction was concentrated under reduced pressure to give crude 
reaction mixture. Products were purified by column chromatography in the solvent system 
stated.  
 
General Procedure H: Isothiourea-catalyzed Michael addition/lactamisation 
 
 
To a solution of requisite acid (2.0 eq) in CH2Cl2 [0.06 M in imine] were added i-Pr2NEt (3.0 
eq) and pivaloyl chloride (3.0 eq) at 0 °C. The reaction mixture was allowed to stir at 0 °C for 5 
min. The requisite ketimine (1.0 eq), DHPB 86 (0.2 eq) and i-Pr2NEt (1.0 eq) were added. The 
reaction mixture was stirred at rt until total consumption of ketimine as judged by TLC analysis. 
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The reaction mixture was quenched with aq. HCl (1 M), extracted with EtOAc (×3), dried over 
MgSO4 and concentrated under reduced pressure to give crude reaction mixture. Products were 
purified by column chromatography in the solvent system stated. 
 
General Procedure I: Oxidation-sulfoxide elimination/N- to O-sulfonyl transfer 
 
 
 
To a solution of dihydropyridinone in CH2Cl2 [0.04 M in dihydropyridinone] and Na2CO3 (39 
eq) at 0 oC was added a solution of m-CPBA (1.1 eq) in CH2Cl2 [0.3 M in m-CPBA]. The 
reaction was warmed to rt and stirred for 30 min until total consumption of dihydropyridinone 
as judged by LC/MS or TLC analysis. The reaction mixture was quenched with sat. aq. 
NaHCO3, extracted with EtOAc (×3), dried over MgSO4 and concentrated under reduced 
pressure to give crude intermediate pyridone. The residue was dissolved in THF and heated to 
80 °C until total consumption of intermediate pyridone as judged by LC/MS or TLC analysis.  
9.3.2 Preparation of Aldimines 
N-(4-Methoxybenzylidene)-4-methylbenzenesulfonamide 
 
 
 
Following general procedure F, benzaldehyde (2.54 mL, 25 mmol), p-toluenesulfonamide (4.28 
g, 25.0 mmol) and BF3.OEt2 (37 µL, 0.4 mmol) in toluene (76 mL) for 2 h at 120 °C gave, after 
recrystallisation (EtOAc:isohexane), the title compound as a white solid (5.0 g, 77%): mp 128-
130 °C {lit. 128-129 °C}; 1H NMR (400 MHz, CDCl3) 2.44 (3H, s, SO2ArCH3), 3.91 (3H, s, 
ArOCH3), 6.99 (2H, d, J 8.7, Ar(3,5)H), 7.35 (2H, d, J 8.1, SO2Ar(3,5)H), 7.88-7.91 (4H, m, 
Ar(2,6)H and SO2Ar(2,6)H), 8.97 (1H, s, C(1)H). All data in accordance with literature.[74] 
 
N-Benzylidene-4-methylbenzenesulfonamide 
 
 
 
Following general procedure F, benzaldehyde (2.54 mL, 25 mmol), p-toluenesulfonamide (4.28 
g, 25.0 mmol) and BF3.OEt2 (37 µL, 0.4 mmol) in toluene (76 mL) for 2 h at 120 °C gave, after 
recrystallization (EtOAc:isohexane), the title compound as a white solid (5.00 g, 77%): mp 110-
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112 °C {lit. 111-112 °C}; 1H NMR (400 MHz, CDCl3) 2.44 (3H, s, SO2ArCH3), 7.35 (2H, d, J 
8.1, SO2Ar(3,5)H), 7.49 (2H, t, J 7.7, Ar(3,5)H), 7.62 (1H, t, J 7.5, Ar(4)H), 7.91 (4H, m, 
Ar(2,6)H and SO2Ar(2,6)H), 9.03 (1H, s, C(1)H). All data in accordance with literature.[74] 
 
4-Methyl-N-(3-methylbenzylidene)benzenesulfonamide 
 
 
 
Following general procedure F, 3-tolualdehyde (2.94 mL, 25.0 mmol), p-toluenesulfonamide 
(4.28 g, 25.0 mmol) and BF3.OEt2 (37 µL) in toluene (76 mL) for 2 h at 120 °C gave, after 
recrystallisation (EtOAc:isohexane), the title compound as a white solid (5.15 g, 80%); mp 89-
90 °C {lit. 88-89 °C} 1H NMR (400 MHz, CDCl3) 2.40 (3H, s, SO2ArCH3), 2.45 (3H, s, 
ArCH3), 7.31-7.44 (4H, m, SO2Ar(3,5)H) and Ar(5)H and Ar(4)H), 7.71 (1H, d, J 7.3, Ar(6)H), 
7.77 (1H, Ar(2)H), 7.90 (2H, d, J 7.9, SO2Ar(2,6)H), 9.01 (1H, s, C(1)H). All data in 
accordance with literature.[172] 
 
N-(3,5-Dimethylbenzylidene)-4-methylbenzenesulfonamide 
 
 
 
 
Following general procedure F, 3,5-dimethylbenzaldehyde (3.0 mL, 22.4 mmol), p-
toluenesulfonamide (3.84 g, 22.4 mmol) and BF3.OEt2 (33 µL) in toluene (68 mL) for 2 h at 120 
°C gave, after recrystallisation (EtOAc:isohexane), the title compound as a white solid (5.15 g, 
80%): mp 101-103 °C 1H NMR (400 MHz, CDCl3) 2.35 (6H, s, Ar(3)CH3 and Ar(5)CH3), 2.43 
(3H, s, SO2ArCH3), 7.24 (1H, s, Ar(4)H), 7.34 (2H, d, J 7.8, SO2Ar(3,5)H), 7.54 (2H, s, 
Ar(2,6)H), 7.88 (2H, d, J 8.3, SO2Ar(2,6)H), 8.96 (1H, s, C(1)H). All data in accordance with 
literature.[173] 
 
4-Methyl-N-(4-methylbenzylidene)benzenesulfonamide 
 
 
 
Following general procedure F, p-tolualdehyde (2.94 mL, 25 mmol), p-toluenesulfonamide 
(4.28 g, 25 mmol) and BF3.OEt2 (37 µL, 0.4 mmol) in toluene (76 mL) for 2 h at 120 °C gave, 
after recrystallisation (EtOAc:isohexane), the title compound as a white solid (5.80 g, 85%): mp 
112-114 °C {lit. 114-116 °C}; 1H NMR (400 MHz, CDCl3) 2.43-2.44 (6H, m, SO2ArCH3 and 
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ArCH3), 7.29 (2H, d, J 8.0, Ar(3,5)H), 7.34 (2H, d, J 8.1, SO2Ar(3,5)H), 7.82 (2H, d, J 8.2, 
Ar(2,6)H), 7.88 (2H, d, J 8.3, SO2Ar(2,6)H), 8.99 (1H, s, C(1)H). All data in accordance with 
literature.[174] 
 
N-(4-Bromobenzylidene)-4-methylbenzenesulfonamide 
 
 
 
Following general procedure F, 4-bromobenzaldehyde (3.00 g, 16.2 mmol), p-
toluenesulfonamide (2.77 g, 16.2 mmol) and BF3.OEt2 (24 µL) in toluene (50 mL) for 2 h at 120 
°C gave, after recrystallisation (EtOAc:isohexane), the title compound as a white solid (4.90 g, 
90%); mp 188-189 °C {lit. 190 °C}; 1H NMR (400 MHz, CDCl3) 2.44 (3H, s, SO2ArCH3), 7.35 
(2H, d, J 8.5, SO2Ar(3,5)H), 7.63 (2H, d, J 8.5, Ar(3,5)H), 7.78 (2H, d, J 8.5, SO2Ar(2,6)H), 
7.88 (2H, d, J 8.3, Ar(2,6)H), 8.98 (1H, s, C(1)H). All data in accordance with literature.[175] 
 
N-(4-Chlorobenzylidene)-4-methylbenzenesulfonamide 
 
 
 
Following general procedure F, 4-chlorobenzaldehyde (3.00 g, 21.3 mmol), p-
toluenesulfonamide (3.65 g, 21.3 mmol) and BF3.OEt2 (31 µL) in toluene (65 mL) for 2 h at 120 
°C gave, after recrystallisation (EtOAc:isohexane), the title compound as a white solid (5.26 g, 
84%); mp 175-177 °C {lit. 175-176 °C}; 1H NMR (400 MHz, CDCl3) 2.44 (3H, s, SO2ArCH3), 
7.36 (2H, d, J 7.8, SO2Ar(3,5)H), 7.47 (2H, d, J 8.3, Ar(3,5)H), 7.86-7.90 (4H, m, SO2Ar(2,6)H 
and Ar(2,6)H), 9.00 (1H, s, C(1)H). All data in accordance with literature.[74] 
 
4-Methyl-N-(naphthalen-2-ylmethylene)benzenesulfonamide 
 
 
 
Following general procedure F, 2-naphthaldehyde (3.00 g, 19.2 mmol), p-toluenesulfonamide 
(3.29 g, 19.2 mmol) and BF3.OEt2 (28 µL, 0.31 mmol) in toluene (58 mL) for 2 h at 120 °C 
gave, after recrystallisation (EtOAc:isohexane), the title compound as a white solid (5.23 g, 
88%); mp 116-117 °C {lit. 114-116 °C}; 1H NMR (400 MHz, CDCl3) 2.43 (3H, s, SO2ArCH3), 
7.37 (2H, J 8.4, ArH), 7.57 (1H, t, J 7.1, ArH), 7.62 (1H, t, J 7.1), 7.87 (2H, d, J 8.8, ArH), 
7.91-7.99 (3H, m, ArH), 8.01 (1H, dd, J 8.4, 1.3, ArH), 8.32 (1H, s, ArH), 9.17 (1H, s, C(1)H). 
A|ll data in accordance with literature.[176] 
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4-Methyl-N-(thiophen-2-ylmethylene)benzenesulfonamide 
 
 
 
Following general procedure F, 2-thiophene carboxaldehyde (2.50 mL, 26.7 mmol), p-
toluenesulfonamide (4.57 g, 26.7 mmol) and BF3.OEt2 (39 µL, 0.43 mmol) in toluene (81 mL) 
for 2 h at 120 °C gave, after recrystallisation (EtOAc:isohexane), the title compound as a white 
solid (4.46 g, 63%); mp 99-100 °C {lit.[175] 98 °C}; 1H NMR (400 MHz, CDCl3) 2.43 (3H, s, 
SO2ArCH3), 7.21 (1H, t, J 4.4, Ar(4)H), 7.34 (2H, d, J 7.9, SO2Ar(3,5)H), 7.78 (2H, m, Ar(2)H 
and Ar(5)H), 7.87 (2H, d, J 8.3, SO2Ar(2,6)H), 9.11 (1H, s, C(1)H). All data in accordance with 
literature.[175] 
9.3.3 Preparation of 2-Aryl(tosylimino) acrylates 
Methyl 2-((4-methoxyphenyl)(tosylimino)methyl)acrylate 
 
 
 
 
Following general procedure G, aldimine 665 (1.00 g, 3.48 mmol), triphenylphosphine (184 mg, 
0.70 mmol) in toluene (50 mL) and methyl propiolate (0.37 mL, 4.18 mmol) in toluene (20 mL) 
for 3 h at 80 °C gave, after column chromatography (EtOAc:isohexane 5:95) the title compound 
as yellow oil (910 mg, 70%); 1H NMR (400 MHz, CDCl3) 2.43 (3H, s, SO2ArCH3), 3.78 (3H, s, 
ArOCH3), 3.85 (3H, s, CO2CH3), 5.87 (1H, s, =CHH), 6.80 (1H, s, =CHH), 6.88 (2H, d, J 9.0, 
Ar(3,5)H), 7.32 (2H, d, J 8.0, SO2Ar(3,5)H), 7.82-7.88 (4H, m, SO2Ar(2,6)H and Ar(2,6)H). All 
data in accordance with literature.[86] 
 
Methyl 2-(phenyl(tosylimino)methyl)acrylate 
 
 
 
 
Following general procedure G, aldimine 666 (1.0 g, 3.89 mmol), triphenylphosphine (204 mg, 
0.78 mmol) in toluene (58 mL) and methyl propiolate (0.42 mL, 4.7 mmol) in toluene (20 mL) 
for 3 h at 80 °C gave, after column chromatography (EtOAc:isohexane 5:95), the title 
compound as a colourless oil (534 mg, 40%); 1H NMR (400 MHz, CDCl3) 2.47 (3H, s, 
SO2ArCH3), 3.81 (3H, s, CO2CH3), 5.96 (1H, s, =CHH), 6.86 (1H, s, =CHH), 7.37 (2H, d, J 
8.1, SO2Ar(3,5)H), 7.44 (2H, t, J 7.9, Ar(3,5)H), 7.59 (1H, t, J 7.4, Ar(4)H), 7.88-7.93 (4H, m, 
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Ar(2,6)H and SO2Ar(2,6)H). All data in accordance with literature.[86] 
 
Methyl 2-(m-tolyl(tosylimino)methyl)acrylate 
 
 
 
 
Following general procedure G, aldimine 667 (1.50 g, 5.53 mmol), triphenylphosphine (290 mg, 
1.11 mmol) in toluene (91 mL) and methyl propiolate (0.59 mL, 6.64 mmol) in toluene (20 mL) 
for 3 h at 80 °C gave, after column chromatography (EtOAc:isohexane 25:75) the title 
compound as white solid (1.03 mg, 52%); mp 90-91 °C; νmax (ATR)/cm-1 1147 (S=O), 1433 (C-
O), 1566 (C=N), 1732 (C=O), 2951 (C-H); 1H NMR (400 MHz, CDCl3) 2.36 (3H, s, ArCH3), 
2.44 (3H, s, SO2ArCH3), 3.78 (3H, s, CO2CH3), 5.90 (1H, s, =CHH), 6.82 (1H, s, =CHH), 7.27-
7.37 (4H, m, Ar(4)H and Ar(5)H) and SO2Ar(3,5)H), 7.64 (1H, br. d, J 7.8, Ar(6)H), 7.68 (1H, 
br. s, Ar(2)H), 7.89 (2H, d, J 8.3, SO2Ar(2,6)H); 13C NMR (100 MHz, CDCl3) 21.5 (ArCH3), 
21.8 (SO2ArCH3), 52.7 (CO2CH3), 127.4 (ArC(6)), 127.8 (SO2ArC(2,6)H), 128.7 (ArC(5)H), 
129.6 (SO2ArC(3,5)H), 130.2 (ArC(2)H), 130.6 (=CHH), 135.0 (ArC(4)H), 135.7 (SO2ArC(4)), 
137.3 (C(2)), 137.7 (ArC(1)), 138.7 (ArC(3)), 144.0 (SO2ArC(1), 163.7 (C(1)), 174.0 (CO2Me); 
HRMS (NSI+) C19H19NO4S ([M+H]+) requires 358.1113 found 358.1103 (−1.3 ppm). 
 
Methyl 2-((3,5-dimethylphenyl)(tosylimino)methyl)acrylate 
 
 
 
 
Following general procedure G, aldimine 668 (1.00 g, 3.51 mmol), triphenylphosphine (184 mg, 
0.70 mmol) in toluene (50 mL) and methyl propiolate (0.37 mL, 4.21 mmol) in toluene (20 mL) 
for 3 h at 80 °C gave, after column chromatography (EtOAc:isohexane 5:95) the title compound 
as yellow oil (833 mg, 64%); νmax (ATR)/cm-1 1149 (S=O), 1312 (C-O), 1551 (C=N), 1728 
(C=O), 2924, 3020 (C-H); 1H NMR (400 MHz, CDCl3) 2.31 (6H, s, Ar(3)CH3 and Ar(5)CH3), 
2.46 (3H, s, SO2ArCH3), 3.78 (3H, s, CO2CH3), 5.87 (1H, s, =CHH), 6.81 (1H, s, =CHH), 7.19 
(1H, br. s, Ar(4)H), 7.34 (2H, d, J 7.8, SO2Ar(3,5)H), 7.46 (2H, br. s, Ar(2,6)H), 7.88 (2H, d, J 
8.3, SO2Ar(2,6)H); 13C NMR (100 MHz, CDCl3) 21.3 (Ar(3)CH3 and Ar(5)CH3), 21.8 
(SO2ArCH3), 52.7 (CO2CH3), 127.7 (ArC(2,6)H), 127.8 (SO2ArC(2,6)H), 129.6 
(SO2ArC(3,5,)H), 130.4 (=CHH), 135.8 (C(2)), 136.0 (ArC(4)H), 137.4 (ArC(1)), 137.8 
(SO2ArC(4)), 138.5 (ArC(3) and ArC(5)), 144.0 (SO2ArC(1)), 163.8 (C(1)), 174.3 (CO2Me); 
HRMS (NSI+) C20H22NO4S ([M+H]+) requires 372.1264 found 372.1257 (−2.0 ppm). 
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Methyl 2-(4-tolyl(tosylimino)methyl)acrylate 
 
 
 
 
Following general procedure G, aldimine 669 (1.00 g, 3.69 mmol), triphenylphosphine (194 mg, 
0.74 mmol) in toluene (54 mL) and methyl propiolate (0.39 mL, 4.43 mmol) in toluene (20 mL) 
for 3 h at 80 °C gave, after column chromatography (EtOAc:isohexane 5:95) the title compound 
as yellow oil (791 mg, 60%); 1H NMR (400 MHz, CDCl3) 2.39, (3H, s, ArCH3), 2.44 (3H, s, 
SO2ArCH3), 3.78 (3H, s, ArCH3), 3.77 (3H, s, CO2CH3), 5.89 (1H, s, =CHH), 6.81 (1H, s, 
=CHH), 7.20 (2H, d, J 8.1, Ar(3,5)H), 7.33 (2H, d, J 7.9, SO2Ar(3,5)H), 7.76 (2H, d, J 8.3, 
Ar(2,6)H), 7.88 (2H, d, J 8.30, SO2Ar(2,6)H). All data in accordance with literature.[86] 
 
Methyl 2-((4-bromophenyl)(tosylimino)methyl)acrylate 
 
 
 
 
Following general procedure G, aldimine 670 (1.50 g, 4.44 mmol), triphenylphosphine (233 mg, 
0.89 mmol) in toluene (69 mL) and methyl propiolate (0.47 mL, 5.32 mmol) in toluene (20 mL) 
for 3 h at 80 °C gave, after column chromatography (EtOAc:isohexane 5:95) the title compound 
as colourless oil (788 mg, 42%); 1H NMR (400 MHz, CDCl3), 2.44 (3H, s, SO2Ar(CH3)), 3.78 
(3H, s, CO2CH3), 5.93 (1H, s, =CHH), 6.82 (1H, s, =CHH), 7.32 (2H, d, J 8.0, Ar(3,5)H), 7.52 
(2H, d, J 8.2, SO2Ar(3,5)H), 7.70 (2H, d, J 8.4, SO2Ar(2,6)H), 7.86 (2H, d, J 8.2 Ar(2,6)H). All 
data in accordance with literature.[86] 
 
Methyl 2-((4-chlorophenyl)(tosylimino)methyl)acrylate 
 
 
 
 
Following general procedure G, aldimine 671 (1.00 g, 3.42 mmol), triphenylphosphine (179 mg, 
0.68 mmol) in toluene (48 mL) and methyl propiolate (0.37 mL, 4.11 mmol) in toluene (20 mL) 
for 3 h at 80 °C gave, after column chromatography (EtOAc:isohexane 5:95, Rf = 0.20) the title 
compound as yellow oil (491 mg, 38%); 1H NMR (400 MHz, CDCl3), 2.46 (3H, s, 
SO2Ar(CH3)), 3.79 (3H, s, CO2CH3), 5.93 (1H, s, =CHH), 6.78 (1H, s, =CHH), 7.34 (2H, d, J 
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7.9, Ar(3,5)H), 7.38 (2H, d, J 8.2, SO2Ar(3,5)H), 7.79 (2H, d, J 8.6, SO2Ar(2,6)H), 7.88 (2H, d, 
J 8.3 Ar(2,6)H). All data in accordance with literature.[86] 
 
Methyl 2-(naphthalen-2-yl(tosylimino)methyl)acrylate 
 
 
 
 
Following general procedure G, aldimine 672 (1.50 g, 4.85 mmol), triphenylphosphine (254 mg, 
0.97 mmol) in toluene (79 mL) and methyl propiolate (0.52 mL, 5.82 mmol) in toluene (20 mL) 
for 3 h at 80 °C gave, after column chromatography (EtOAc:isohexane 5:95) the title compound 
as white solid (788 mg, 42%); mp 128-131 °C νmax (ATR)/cm-1 1149 (S=O), 1304  (C-O), 1551 
(C=N), 1736 (C=O), 2947, 3055 (C-H); 1H NMR (400 MHz, CDCl3) 2.45 (3H, s, SO2Ar(CH3)), 
3.79 (3H, s, CO2CH3), 5.99 (1H, s, =CHH), 6.92 (1H, s, =CHH), 7.36 (2H, d, J 8.1, 
SO2Ar(3,5)H), 7.53 (1H, ddd, J 8.2, 6.9, 1.3, ArH), 7.60 (1H, ddd, J 8.2, 6.8, 1.4, ArH), 7.82-
7.90 (3H, m, ArH and ArH and ArH), 7.94 (2H, d, J 8.3, SO2Ar(2,6)H), 8.03 (1H, dd, J 8.8, 1.9, 
ArH), 8.27 (1H, s, ArH); 13C NMR (100 MHz, CDCl3) 21.7 (SO2ArCH3), 52.8 (CO2CH3), 124.4 
(ArCH), 127.1 (ArCH), 127.7 (SO2ArC(2,6)H), 127.9 (ArCH), 128.7 (ArCH), 129.2 (ArCH), 
129.6 (SO2ArC(3,5)H), 129.8 (ArCH), 130.9 (=CHH), 132.4 (ArC), 133.1 (ArCH), 136.0 
(ArC), 137.2 (ArC), 137.8 (SO2ArC(4)), 144.1 (SO2ArC(1)), 163.7 (C(1)), 173.6 (CO2Me); 
HRMS (NSI+) C22H20NO4S ([M+H]+) requires 394.1108 found 394.1105 (−0.6 ppm). 
 
Methyl 2-(thiophen-2-yl(tosylimino)methyl)acrylate 
 
 
 
 
Following general procedure G, aldimine 673 (1.50 g, 5.65 mmol), triphenylphosphine (296 mg, 
1.13 mmol) in toluene (93 mL) and methyl propiolate (0.60 mL, 6.78 mmol) in toluene (20 mL) 
for 3 h at 80 °C gave, after preparative HPLC (MeCN:H2O with 10 mM ammonium acetate), the 
title compound as yellow oil (631 mg, 32%); νmax (ATR)/cm-1 1146 (S=O), 1323  (C-O), 1545 
(C=N), 1743 (C=O), 2949, 3065 (C-H); 1H NMR (400 MHz, CDCl3) 2.41 (3H, s, SO2ArCH3), 
3.79 (3H, s, CO2CH3), 5.92 (1H, s, =CHH), 6.77 (1H, s, =CHH), 7.09 (1H, dd, J 5.0, 3.9, 
Ar(4)H), 7.30 (2H, d, J 8.3, SO2Ar(3,5)H), 7.55 (1H, dd, J 3.9, 1.2, Ar(3)H), 7.69 (1H, dd, J 
4.9, 1.2, Ar(5)H), 7.84 (2H, d, J 8.3, SO2Ar(2,6)H); 13C NMR (100 MHz, CDCl3) 21.7 
(SO2ArCH3), 52.7 (CO2CH3), 127.6 (SO2ArC(2,6)H), 128.8 (ArC(4)H), 129.6 (SO2ArC(3,5)H), 
130.3 (=CHH), 136.6 (ArC(5)H), 136.6 (ArC(3)H), 137.1 (ArC(2)), 137.6 (C(2)), 142.8 
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(SO2ArC(4)), 144.0 (SO2ArC(1)), 163.4 (C(1)), 167.0 (CO2Me); HRMS (NSI+) C16H16NO4S2 
([M+H]+) requires 350.0515 found 350.0518 (+0.8 ppm). 
 
Benzyl 2-(phenyl(tosylimino)methyl)acrylate 
 
 
 
 
Following general procedure G, aldimine 666 (5.00 g, 19.3 mmol), triphenylphosphine (1.01 
mg, 3.86 mmol) in toluene (603 mL) and benzyl propiolate (3.72 g, 23.2 mmol) in toluene (40 
mL) for 3 h at 80 °C gave, after column chromatography (EtOAc:isohexane 15:85) the title 
compound as colourless oil (1.21 g, 15%); 1H NMR (400 MHz, CDCl3), 2.43 (3H, s, 
SO2ArCH3), 5.26 (2H, s, CO2CH2Ph), 5.99 (1H, s, =CHH), 6.88 (1H, s, =CHH), 7.23-7.30 (3H, 
m, ), 7.38-7.42 (6H, m, ), 7.44 (1H, t, J 7.6, ), 7.86 (4H, d, J 6.8, ) All data in accordance with 
literature.[86] 
9.3.4 Preparation of α,α-Disubstituted Acetic Acids 
2-(4-Chlorophenyl)-2-(phenylthio)acetic acid 
 
 
 
 
To a solution of 2-Bromo-2-(4-chlorophenyl)acetic acid (1.50 g, 6.01 mmol) and K2CO3 (4.99 
g, 36.1 mmol) in 1,4-dioxane (20 mL) was added thiophenol (1.84 mL, 18.0 mmol) and reaction 
stirred at 80 °C for 16 h. Reaction diluted with H2O (50 mL) and extracted with EtOAc (×3). 
The aqueous layers were combined and acidified with aq. HCl (6 M) and extracted with EtOAc 
(×3), combined organics were dried over MgSO4 and concentrated under reduced pressure. 
Crude product gave, following recrystallisation (Et2O:hexane), the title compound as brown 
solid (709 mg, 42%): mp 91-93 °C {lit. 92.5-93.5 °C}; 1H NMR (500 MHz, CDCl3) 4.75 (1H, s, 
C(2)H), 7.17-7.20 (5H, m, ArH), 7.26-7.28 (4H, m, ArH), 11.0 (1H, br. s, CO2H). All data in 
accordance with literature.[177] 
 
2-Bromo-2-(4-fluorophenyl)acetic acid 
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To a solution of 4-fluorophenylacetic acid (3.00 g, 19.5 mmol) in CCl4 at 70 °C, was added 
NBS (6.94 g, 93.0 mmol) and benzoyl peroxide (25 mg, 0.08 mmol) and reaction stirred for 16 
h under UV irradiation. Reaction mixture concentrated under reduced pressure and carried 
forward without further purification: 1H NMR (400 MHz, CDCl3) 5.35 (1H, s, C(2)H), 7.04-
7.08 (2H, m, Ar(3,6)H), 7.54-7.57 (2H, m, Ar(2,6)H), 11.5 (1H, s, CO2H). 
 
2-(4-Fluorophenyl)-2-(phenylthio)acetic acid 
 
 
 
 
To a solution of 2-bromo-2-(4-fluorophenyl)acetic acid 325 (1.55 g, 6.64 mmol) and K2CO3 
(1.84 g, 13.3 mmol) in 1,4-dioxane (22 mL) was added thiophenol (0.745 mL, 7.30 mmol) and 
reaction stirred at 80 °C for 16 h. Reaction diluted with H2O (50 mL) and extracted with EtOAc 
(×3). The aqueous layers were combined and acidified with aq. HCl (6 M) and extracted with 
EtOAc (×3), combined organics were dried over MgSO4 and concentrated under reduced 
pressure to give residue of 80-90% purity which was carried forward without further 
purification: 1H NMR (500 MHz, CDCl3) 4.90 (1H, s, C(2)H), 7.03-7.07 (2H, m, 
C(2)Ar(3,5)H), 7.31-7.36 (3H, m, SAr(3,5)H and SAr(4)H), 7.51-7.54 (4H, m, C(2)Ar(2,6)H 
and SAr(2,6)H),  10.7 (1H, br. s, CO2H). 
9.3.5 Isothiourea-Catalysed Michael Addition/Lactamisation 
Methyl 2-(4-methoxyphenyl)-6-oxo-5-(phenylthio)-1-tosyl-1,4,5,6-tetrahydropyridine-3-
carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)acetic acid (252 mg, 1.5 mmol) and i-Pr2NEt (0.39 
mL, 2.25 mmol) were added pivaloyl chloride (0.28 mL, 2.25 mmol), DHPB 86 (29 mg, 0.15 
mmol), ketimine 267 (280 mg, 0.75 mmol) and i-Pr2NEt (0.13 mL, 0.75 mmol) for 1 h at rt 
gave, after chromatographic purification (EtOAc:isohexane 10:90) the title compound as 
colourless oil (267 mg, 68%); νmax (ATR)/cm-1 1147 (S=O), 1340 (C-O), 1718 (C=O), 3004 (C-
H); 1H NMR (400 MHz, CDCl3) 2.41 (3H, s, SO2ArCH3), 2.94 (1H, dd, J 15.8, 5.8, C(4)HH), 
3.08 (1H, dd, J 15.8, 4.2, C(4)HH), 3.56 (3H, s, CO2CH3), 3.84 (3H, s, ArOCH3), 3.93 (1H, dd, 
J 5.7, 4.1, C(5)H), 6.80 (2H, d, J 8.8, C(2)Ar(3,5)H), 7.14-7.18 (4H, m, SAr(3,5)H and 
SO2Ar(3,5)H), 7.29-7.32 (3H, m, SAr(4)H and SAr(2,6)H), 7.46-7.52 (4H, m, SO2Ar(2,6)H and 
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C(2)Ar(2,6)H); 13C NMR (100 MHz, CDCl3) 21.8 (SO2ArCH3), 29.1 (C(4)HH), 51.2 (C(5)H), 
52.1 (CO2CH3), 55.4 (ArOCH3), 113.0 (C(2)ArC(3,5)H), 118.6 (C(3)), 126.3 (C(2)ArC(1)), 
128.6 (SArC(4)H), 128.9 (SO2ArC(2,6)H), 129.2 (SArC(2,6)H), 129.4 (SO2ArC(3,5)H), 130.9 
(SArC(3,5)H), 132.4 (SArC(1)), 133.2 (C(2)ArC(2,6)H), 136.3 (SO2ArC(4)), 145.2 (SO2Ar(1)), 
145.5 (C(2)), 160.3 (C(2)ArC(4)), 166.6 (CO2Me), 169.8 (C(6)); HRMS (NSI+) C27H26NO6S2 
([M+H]+) requires 524.1196 found 524.1191 (−1.0 ppm). 
 
Methyl 6-oxo-2-phenyl-5-(phenylthio)-1-tosyl-1,4,5,6-tetrahydropyridine-3-carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)acetic acid (101 mg, 0.6 mmol) and i-Pr2NEt (0.16 
mL, 0.9 mmol) were added pivaloyl chloride (0.11 mL, 0.9 mmol), DHPB 86 (11 mg, 0.06 
mmol), ketimine 263 (103 mg, 0.3 mmol) and i-Pr2NEt (53 µL, 0.75 mmol) for 1 h at rt gave, 
after chromatographic purification (EtOAc:isohexane 5:95) and recrystallisation 
(Et2O:isohexane), the title compound as white solid (101 mg, 68%); mp 138-140 °C νmax 
(ATR)/cm-1 1141 (S=O), 1366 (C-O), 1713 (C=O), 3055 (C-H); 1H NMR (400 MHz, CDCl3) 
2.40 (3H, s, SO2ArCH3), 2.96 (1H, dd, J 15.9, 5.6 C(4)HH), 3.12 (1H, dd, J 15.9, 4.2 C(4)HH), 
3.53 (3H, s, CO2CH3), 3.96 (1H, dd, J 5.6, 4.2, C(5)H), 7.15 (2H, d, J 8.3, SO2Ar(3,5)H), 7.21-
7.23 (2H, m, SAr(3,5)H), 7.28-7.32 (5H, m, SAr(4)H and SAr(2,6)H and Ar(3,5)H), 7.35-7.40 
(1H, m, Ar(4)H), 7.43-7.51 (4H, m, SO2Ar(2,6)H and Ar(2,6)H); 13C NMR (100 MHz, CDCl3) 
21.8 (SO2ArCH3), 29.1 (C(4)HH), 51.0 (C(5)H), 52.1 (CO2CH3), 119.3 (C(3)), 127.5 
(SArC(4)H), 128.6 (SArC(3,5)H), 128.9 (SO2ArC(2,6)H), 129.1 (ArC(4)H), 129.3 
(SO2ArC(3,5)H), 129.4 (ArC(3,5)H), 129.5 (SArC(2,6)H), 132.3 (SArC(1)), 133.2 (ArC(2,6)H), 
133.9 (SO2ArC(4)), 136.1 (ArC(1)), 145.2 (SO2ArC(1)), 145.3 (C(2)), 166.4 (CO2Me), 169.7 
(C(6)); HRMS (NSI+) C26H24NO5S2 ([M+H]+) requires 494.1090 found 494.1084 (−1.3 ppm). 
 
Methyl 2-(naphthalen-2-yl)-6-oxo-5-(phenylthio)-1-tosyl-1,4,5,6-tetrahydropyridine-3-
carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)acetic acid (101 mg, 0.6 mmol) and i-Pr2NEt (0.16 
mL, 0.9 mmol) were added pivaloyl chloride (0.11 mL, 0.9 mmol), DHPB 86 (11 mg, 0.06 
mmol), ketimine 290 (118 mg, 0.3 mmol) and i-Pr2NEt (53 µL, 0.75 mmol) for 4 h at rt gave, 
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after chromatographic purification (EtOAc:isohexane 5:95) and recrystallisation 
(Et2O:isohexane), the title compound as white solid (101 mg, 62%): 117-118 °C; νmax 
(ATR)/cm-1 1089 (S=O), 1368 (C-O), 1715 (C=O), 2949, 3048 (C-H);  δH (400 MHz, CDCl3) 
2.30 (3H, s, SO2ArCH3), 3.03 (1H, dd, J 15.8, 5.7, C(4)HH), 3.19 (1|H, dd, J 15.8, 4.2, 
C(4)HH), 3.50 (3H, s, CO2CH3), 4.04 (1H, dd, J 5.6, 4.2, C(5)H), 6.90 (2H, d, J 8.1, 
SO2Ar(3,5)H), 7.29-7.34 (5H, m, ArH), 7.38 (1H, br. s, ArH), 7.42-7.47 (2H, m, ArH), 7.52-
7.55 (4H, m, ArH), 7.79 (1H, d, J 8.6, SO2Ar(2,6)H), 7.84-7.87 (1H, m, ArH); δC (100 MHz, 
CDCl3) 21.7 (SO2ArCH3), 29.2 (C(4)HH), 51.2 (C(5)H), 52.1 (CO2CH3), 119.2 (C(3)), 126.2 
(ArCH), 126.8 (SO2Ar(2,6)H), 127.0 (ArCH), 127.9 (ArCH), 128.0 (ArCH), 128.0 (ArCH), 
128.5 (ArCH), 128.6 (ArCH), 128.7 (ArCH), 129.1 (ArCH), 129.4 (ArCH), 131.3 (ArC), 132.3 
(ArC), 132.4 (ArC), 133.2 (ArCH), 133.4 (ArC), 136.1 (ArC), 145.1 (SO2ArC(1)), 145.7 (C(2)), 
166.3 (CO2Me), 169.8 (C(6)); HRMS (NSI+) C30H26NO5S2 ([M+H]+) requires 544.1247 found 
544.1245 (−0.4 ppm). 
 
(Phenylthio)-1-tosyl-1,4,5,6-tetrahydropyridine-3-carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)acetic acid (101 mg, 0.6 mmol) and i-Pr2NEt (0.16 
mL, 0.9 mmol) were added pivaloyl chloride (0.11 mL, 0.9 mmol), DHPB 86 (11 mg, 0.06 
mmol), ketimine 288 (113 mg, 0.3 mmol) and i-Pr2NEt (53 µL, 0.75 mmol) for 1 h at rt gave, 
after chromatographic purification (EtOAc:isohexane 5:95) the title compound as 90% pure 
brown oil which was carried forward without further purification: 1H NMR (400 MHz, CDCl3) 
2.42 (3H, s, SO2ArCH3), 2.97 (1H, dd, J 15.9, 5.4 C(4)HH), 3.10 (1H, dd, J 15.9, 4.2 C(4)HH), 
3.56 (3H, s, CO2CH3), 3.95 (1H, t, J 4.7, C(5)H), 7.15-7.20 (4H, m, SO2(3,5)H and SAr(3,5)H), 
7.24-7.31 (5H, m, Ar(2,6)H and SAr(2,6)H and SAr(4)H), 7.46-7.50 (4h, m, SO2Ar(2,6)H and 
Ar(3,5)H). 
 
Methyl 6-oxo-5-(phenylthio)-2-(thiophen-2-yl)-1-tosyl-1,4,5,6-tetrahydropyridine-3-
carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)acetic acid (101 mg, 0.6 mmol) and i-Pr2NEt (0.16 
mL, 0.9 mmol) were added pivaloyl chloride (0.11 mL, 0.9 mmol), DHPB 86 (11 mg, 0.06 
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mmol), ketimine 291 (105 mg, 0.3 mmol) and i-Pr2NEt (53 µL, 0.75 mmol) for 1 h at rt gave, 
after chromatographic purification (EtOAc:isohexane 5:95) and recrystallisation 
(Et2O:isohexane), the title compound as yellow oil (99 mg, 66%); νmax (ATR)/cm-1 1149 (S=O), 
1310 (C-O), 1712 (C=O), 2877, 2955 (C-H); 1H NMR (400 MHz, CDCl3) 2.42 (3H, s, 
SO2ArCH3), 2.92 (1H, dd, J 15.9, 6.1, C(4)HH), 3.05 (1H, dd, J 15.9, 4.2, C(4)HH), 3.63 (3H, s, 
CO2CH3), 3.93 (1H, dd, J 6.0, 4.3, C(5)H), 6.98 (1H, dd, J 4.9, 3.7, C(2)Ar(4)H), 7.08-7.09 
(1H, m, C(2)Ar(3)H), 7.20 (2H, d, J 8.2, SO2Ar(3,5)H), 7.26-7.31 (3H, m, C(5)Ar(4)H and 
C(5)Ar(3,5)H), 7.40 (1H, d, J 5.0, C(2)Ar(5)H), 7.46-7.49 (2H, m, C(5)Ar(2,6)H), 7.61 (2H, J 
8.3, SO2Ar(2,6)H); 13C NMR (100 MHz, CDCl3) 21.9 (SO2ArCH3), 29.4 (C(4)HH), 50.9 
(C(5)H), 52.4 (CO2CH3), 121.4 (C(3)), 126.3 (C(5)ArC(4)H), 128.0 (C(2)ArC(3)H), 128.7 
(C(2)ArC(4)H), 128.9 (C(5)ArC(3,5)H), 129.4 (SO2ArC(3,5)H), 129.4 (C(5)ArC(2,6)H), 130.6 
(C(2)ArC(5)H), 132.0 (C(5)ArC(1)), 133.5 (SO2ArC(2,6)H), 134.6 (SO2ArC(4)), 136.2 
(C(2)ArC(2)), 138.3 (SO2ArC(1)), 145.3 (C(2)), 166.2 (CO2Me), 169.3 (C(6)); HRMS (NSI+) 
C24H22NO5S3 ([M+H]+) requires 500.0655 found 500.0648 (−1.3 ppm).  
 
Benzyl 6-oxo-2-phenyl-5-(phenylthio)-1-tosyl-1,4,5,6-tetrahydropyridine-3-carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)acetic acid (101 mg, 0.6 mmol) and i-Pr2NEt (0.16 
mL, 0.9 mmol) were added pivaloyl chloride (0.11 mL, 0.9 mmol), DHPB 86 (11 mg, 0.06 
mmol), ketimine 263 (126 mg, 0.3 mmol) and i-Pr2NEt (53 µL, 0.75 mmol) for 1 h at rt gave, 
after chromatographic purification (EtOAc:Petrol 15:85), the title compound as 90% pure 
brown oil which was carried forward without further purification: 1H NMR (500 MHz, CDCl3) 
2.40 (3H, s, SO2ArCH3), 2.98 (1H, dd, J 15.7, 5.8, C(4)HH), 3.12 (1H, dd, J 15.7, 4.2, C(4)HH), 
3.97 (1H, t, J 4.9, C(5)H), 7.02-7.03 (2H, m, ArH), 7.14 (2H, d, J 8.2, ArH), 7.19-7.23 (4H, m, 
ArH), 7.26-7.47 (11H, m, ArH). 
 
Methyl 2-(4-methoxyphenyl)-6-oxo-5-phenyl-5-(phenylthio)-1-tosyl-1,4,5,6-
tetrahydropyridine-3-carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)phenyl acetic acid (147 mg, 0.6 mmol) and i-
Pr2NEt (0.16 mL, 0.9 mmol) were added pivaloyl chloride (0.11 mL, 0.9 mmol), DHPB 86 (15 
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mg, 0.08 mmol), ketimine 267 (112 mg, 0.3 mmol) and i-Pr2NEt (53 µL, 0.3 mmol) for 1 h at rt 
gave, after chromatographic purification (EtOAc:isohexane 10:90), the title compound as 
yellow oil (124 mg, 68%): νmax (ATR)/cm-1 1090 (S=O), 1321 (C-O), 1721 (C=O), 2889, 2999 
(C-H); 1H NMR (400 MHz, CDCl3) 2.44 (3H, s, SO2ArCH3), 3.06 (1H, d, J 15.6, C(4)HH), 3.44 
(3H, s, CO2CH3), 3.50 (1H, d, J 15.6, C(4)HH), 3.78 (3H, s, ArOCH3), 6.68 (2H, J 8.9, 
C(2)Ar(3,5)H), 6.88 (2H, d, J 8.4, ArH), 7.18 (2H, d, J 8.1, SO2Ar(3,5)H), 7.21-7.28 (5H, m, 
ArH), 7.31-7.36 (3H, m, ArH), 7.39-7.40 (2H, m, ArH), 7.54 (2H, d, J 8.4, SO2Ar(2,6)H); δC 
(100 MHz, CDCl3) 21.9 (SO2ArCH3), 34.8 (C(4)HH), 51.9 (CO2CH3), 55.3 (ArOCH3), 63.3 
(C(5)), 112.7 (C(2)ArC(3,5)H), 118.6 (C(3)), 125.9 (C(2)ArC(1)), 127.2 (ArCH), 128.7 
(ArCH), 128.8 (SO2ArC(2,6)H), 128.9 (ArCH), 129.1 (ArCH), 129.2 (ArCH), 129.6 (ArCH), 
130.4 (ArCH), 130.8 (ArCH), 135.6 (ArC), 136.3 (ArC), 136.5 (ArCH), 145.1 (C(6)), 145.2 
(SO2ArC(1)), 160.1 (C(2)ArC(4)), 166.0 (CO2Me), 170.8 (C(6)); HRMS (NSI+) C27H26NO6S2 
([M+H]+) requires 524.1196 found 524.1191 (−1.0 ppm). 
 
Methyl 6-oxo-2,5-diphenyl-5-(phenylthio)-1-tosyl-1,4,5,6-tetrahydropyridine-3-
carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)phenyl acetic acid (195 mg, 0.8 mmol) and i-
Pr2NEt (0.21 mL, 1.2 mmol) were added pivaloyl chloride (0.15 mL, 1.2 mmol) in CH2Cl2 (7 
mL), DHPB 86 (15 mg, 0.08 mmol), ketimine 263 (137 mg, 0.4 mmol) and i-Pr2NEt (70 µL, 0.4 
mmol) for 1 h at rt gave, after chromatographic purification (EtOAc:isohexane 10:90) and 
recrystallisation (Et2O:isohexane), the title compound as white solid (174 mg, 77%): mp 152-
154 °C; νmax (ATR)/cm-1 1048 (S=O), 1320 (C-O), 1719 (C=O), 2897, 3021 (C-H); 1H NMR 
(400 MHz, CDCl3) 2.43 (3H, s, SO2ArCH3), 3.09 (1H, d, J 15.7, C(4)HH), 3.40 (3H, s, 
CO2CH3), 3.51 (1H, d, J 15.7, C(4)HH), 6.93 (2H, d, J 7.2, ArH), 7.13-7.17 (4H, m, ArH), 7.21-
7.30 (6H, m, ArH), 7.32-7.37 (3H, m, ArH), 7.40-7.42 (2H, m, ArH), 7.47 (2H, d, J 8.4, 
SO2Ar(2,6)H); 13C NMR (100 MHz, CDCl3) 21.9 (SO2ArCH3), 34.8 (C(4)HH), 51.9 (CO2CH3), 
63.2 (C(5)), 119.4 (C(3)), 127.2 (ArCH), 127.3 (ArCH), 128.7 (ArC), 128.8 (ArCH), 128.9 
(ArCH), 129.0 (ArCH), 129.1 (SO2ArC(2,6)H), 129.2 (ArCH), 129.5 (ArCH), 129.7 (ArCH), 
130.5 (SO2ArC(4)), 133.7 (ArC), 135.6 (ArC)), 136.2 (ArC), 136.6 (ArCH), 145.0 (C(2)), 145.1 
(SO2ArC(1)), 165.9 (CO2Me), 170.8 (C(6)); HRMS (NSI+) C33H29NO5S2 ([M+H]+) requires 
584.1560 found 584.1561 (+0.2 ppm). 
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Methyl 6-oxo-5-phenyl-5-(phenylthio)-2-(3-tolyl)-1-tosyl-1,4,5,6-tetrahydropyridine-3-
carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)phenyl acetic acid (403 mg, 1.65 mmol) and i-
Pr2NEt (0.0.43 mL, 2.46 mmol) were added pivaloyl chloride (0.30 mL, 2.46 mmol), DHPB 86 
(31 mg, 0.16 mmol), ketimine 284 (294 mg, 0.82 mmol) and i-Pr2NEt (0.14 mL, 0.82 mmol) for 
1 h at rt gave, after chromatographic purification (EtOAc:isohexane 5:95), the title compound as 
80% pure brown oil which was carried forward without further purification: (154 mg, 66%); 1H 
NMR (400 MHz, CDCl3) 2.12 (3H, s, C(2)ArCH3) 2.43 (3H, s, SO2ArCH3), 3.11 (1H, d, J 15.6, 
C(4)HH), 3.42 (3H, s, CO2CH3), 3.51 (1H, d, J 15.7, C(4)HH), 6.55 (1H, s, C(2)Ar(2)H), 6.87 
(1H, d, J 6.4, C(2)Ar(4)H), 7.08-7.10 (2H, m, ArH), 7.17 (2H, d, J 8.2, SO2Ar(3,5)H), 7.24-7.48 
(10H, m, ArH), 7.50 (2H, d, J 8.3, SO2Ar(2,6)H).  
 
Methyl 2-(3,5-dimethylphenyl)-6-oxo-5-phenyl-5-(phenylthio)-1-tosyl-1,4,5,6-
tetrahydropyridine-3-carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)phenyl acetic acid (293 mg, 1.2 mmol) and i-
Pr2NEt (0.31 mL, 1.8 mmol) were added pivaloyl chloride (0.22 mL, 1.8 mmol), DHPB 86 (23 
mg, 0.12 mmol), ketimine 285 (223 mg, 0.6 mmol) and i-Pr2NEt (0.11 mL, 0.6 mmol) for 1 h at 
rt gave, after chromatographic purification (EtOAc:isohexane 5:95), the title compound as 80% 
pure brown oil which was carried forward without further purification: 1H NMR (400 MHz, 
CDCl3) 2.15 (6H, s, C(2)Ar(3)CH3 and C(2)Ar(5)CH3), 2.46 (3H, s, SO2ArCH3), 3.12 (1H, d, J 
15.6, C(4)HH), 3.44 (3H, s, CO2CH3), 3.49 (1H, d, J 15.6, C(4)HH), 6.52 (2H, s, ArH), 6.91 
(1H, s, ArH), 7.20 (2H, d, J 8.0, ArH), 7.23-7.32 (5H, m, ArH), 7.34-7.41 (5H, ArH), 7.53 (2H, 
d, J 8.4, SO2Ar(2,6)H). 
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Methyl 6-oxo-5-phenyl-5-(phenylthio)-2-(4-tolyl)-1-tosyl-1,4,5,6-tetrahydropyridine-3-
carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)phenyl acetic acid (195 mg, 0.8 mmol) and i-
Pr2NEt (0.21 mL, 1.2 mmol) were added pivaloyl chloride (0.15 mL, 1.2 mmol), DHPB 86 (15 
mg, 0.08 mmol), ketimine 286 (143 mg, 0.4 mmol) and i-Pr2NEt (70 µL, 0.4 mmol) for 1 h at rt 
gave, after chromatographic purification (EtOAc:isohexane 5:95) and recrystallisation 
(Et2O:isohexane), the title compound as white solid (154 mg, 66%): mp  142-144 °C; νmax 
(ATR)/cm-1 1142 (S=O), 1342 (C-O), 1705 (C=O), 2924, 3032 (C-H); 1H NMR (400 MHz, 
CDCl3) 2.32 (3H, s, C(2)ArCH3), 2.45 (3H, s, SO2ArCH3), 3.06 (1H, d, J 15.7, C(4)HH), 3.43 
(3H, s, CO2CH3), 3.49 (1H, d, J 15.6, C(4)HH), 6.84 (2H, ArH), 6.97 (2H, d, J 7.9, ArH), 7.16 
(2H, d, J 8.1, SO2Ar(3,5)H), 7.22-7.26 (5H, m, ArH), 7.31-7.36 (3H, m, ArH), 7.38-7.40 (2H, 
m, ArH), 7.52 (2H, d, J 8.3, SO2Ar(2,6)H); 13C NMR (100 MHz, CDCl3) 21.6 C(2)ArCH3), 
21.90 (SO2ArCH3), 34.8 (C(4)HH), 51.9 (CO2CH3), 63.2 (C(5)), 118.9 (C(3)), 127.2 (ArCH), 
128.0 (SO2ArC(3,5)H), 128.7 (ArCH), 128.8 (ArCH), 128.9 (ArCH), 129.2 (ArCH), 129.3 
(ArCH), 129.6 (ArC), 130.5 (ArC), 135.6 (SO2ArC(4)), 136.3 (ArC), 136.5 (ArC), 139.0 (ArC), 
145.1 (SO2ArC(1)), 145.4 (C(2)), 166.0 (CO2CH3), 170.8 (C(6)); HRMS (NSI+) C33H29NO5S2 
([M+H]+) requires 584.1565 found 584.1540 (−1.1 ppm). 
 
Methyl 2-(4-bromophenyl)-6-oxo-5-phenyl-5-(phenylthio)-1-tosyl-1,4,5,6-
tetrahydropyridine-3-carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)phenyl acetic acid (147 mg, 0.6 mmol) and i-
Pr2NEt (0.16 mL, 0.9 mmol) were added pivaloyl chloride (0.11 mL, 0.9 mmol), DHPB 86 (11 
mg, 0.06 mmol), ketimine 287 (127 mg, 0.3 mmol) and i-Pr2NEt (53 µL, 0.3 mmol) for 1 h at rt 
gave, after chromatographic purification (EtOAc:isohexane 5:95) and recrystallisation 
(Et2O:isohexane), the title compound as white solid (136 mg, 70%): mp 157-158 °C; νmax 
(ATR)/cm-1 1150 (S=O), 1377 (C-O), 1695 (C=O), 2951, 3065 (C-H); 1H NMR (400 MHz, 
CDCl3) 2.46 (3H, s, SO2ArCH3), 3.06 (1H, d, J 15.8, C(4)HH), 3.45 (3H, s, CO2CH3), 3.51 (1H, 
d, J 15.8, C(4)HH), 6.79 (2H, d, J 8.2, ArH), 7.19-7.25 (5H, m, ArH), 7.27-7.29 (4H, m, ArH), 
7.32-7.35 (3H, m, ArH), 7.37-7.39 (2H, m, ArH), 7.52 (2H, d, J 8.4, SO2Ar(2,6)H); 13C NMR 
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(100 MHz, CDCl3) 21.9 (SO2ArCH3), 34.6 (C(4)HH), 52.1 (CO2CH3), 63.0 (C(5)), 119.9 
(C(3)), 123.3 (C(2)ArC(4)), 127.2 (ArCH), 128.8 (ArCH), 128.9 (ArCH), 129.0 
(SO2ArC(2,6)H), 129.8 (ArCH), 130.3 (ArCH), 130.5 (ArCH), 131.1 (ArCH), 132.7 (ArC), 
135.4 (ArC), 136.1 (ArC), 136.5 (ArCH), 144.0 (SO2ArC(1)), 145.4 (C(2)), 165.6 (CO2Me), 
170.5 (C(6)); HRMS (NSI+) C32H2779BrNO5S2 ([M+H]+) requires 648.0509 found 648.0509 
(+0.1 ppm). 
 
Methyl 2-(4-chlorophenyl)-6-oxo-5-phenyl-5-(phenylthio)-1-tosyl-1,4,5,6-
tetrahydropyridine-3-carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)phenyl acetic acid (391 mg, 1.6 mmol) and i-
Pr2NEt (0.42 mL, 2.4 mmol) were added pivaloyl chloride (0.30 mL, 2.4 mmol), DHPB 86 (30 
mg, 0.12 mmol), ketimine 288 (302 mg, 0.8 mmol) and i-Pr2NEt (0.14 mL, 0.8 mmol) for 1 h at 
rt gave, after chromatographic purification (EtOAc:isohexane 5:95) and recrystallisation 
(Et2O:isohexane), the title compound as white solid (576 mg, 72%); mp 110-112 °C; νmax 
(ATR)/cm-1 1080 (S=O), 1343 (C-O), 1705 (C=O), 2901, 2986 (C-H); 1H NMR (400 MHz, 
CDCl3) 2.46 (3H, s, SO2ArCH3), 3.06 (1H, d, J 15.8, C(4)HH), 3.44 (3H, s, CO2CH3), 3.51 (1H, 
d, J 15.8, C(4)HH), 6.86 (2H, d, J 8.1, ArH), 7.13 (2H, d, J 8.7, ArH), 7.19-7.27 (7H, m, ArH), 
7.31-7.39 (4H, m, ArH), 7.53 (2H, d, J 8.4, SO2Ar(2,6)H); 13C NMR (100 MHz, CDCl3) 21.9 
(SO2ArCH3), 34.7 (C(4)HH), 52.1 (CO2CH3), 63.0 (C(5)), 119.9 (C(3)), 127.16 (ArCH), 127.6 
(ArCH), 128.8 (ArCH), 128.9 (ArCH), 129.0 (SO2ArC(2,6)H) 129.0 (ArCH), 129.4 (ArCH), 
129.7 (ArCH), 130.4 (Ar), 130.8 (ArCH), 132.2 (C(2)ArC(1)), 135.0 (C(5)ArC(4)), 135.5 
(SO2ArC(4)), 136.1 (SArC(1)), 136.5 (ArCH), 144.0 (C(2)), 145.4 (SO2ArC(1)), 165.6 
(CO2Me), 170.5 (C(6)); HRMS (NSI+) C32H2735ClNO6S2 ([M+H]+) requires 604.1014 found 
604.1013 (−0.1 ppm). 
 
Methyl 2-(naphthalen-2-yl)-6-oxo-5-phenyl-5-(phenylthio)-1-tosyl-1,4,5,6-
tetrahydropyridine-3-carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)phenyl acetic acid (147 mg, 0.6 mmol) and i-
Pr2NEt (0.16 mL, 0.9 mmol) were added pivaloyl chloride (0.11 mL, 0.9 mmol), DHPB 86 (11 
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mg, 0.06 mmol), ketimine 290 (118 mg, 0.3 mmol) and i-Pr2NEt (53 µL, 0.3 mmol) for 1 h at rt 
gave, after chromatographic purification (EtOAc:isohexane 5:95), the title compound as 80% 
pure brown oil which was carried forward without further purification; 1H NMR (400 MHz, 
CDCl3) 2.33 (3H, s, SO2ArCH3), 3.16 (1H, d, J 15.6, C(4)HH), 3.37 (3H, s, CO2CH3), 3.57 (1H, 
d, J 15.6, C(4)HH), 6.91 (2H, d, J 8.2, ArH), 7.04 (1H, br. s, ArH), 7.23-7.49 (16H, m, ArH), 
7.69 (1H, d, J 8.6, ArH), 7.79 (1H, d, J 8.0, ArH). 
 
Methyl 6-oxo-5-phenyl-5-(phenylthio)-2-(thiophen-2-yl)-1-tosyl-1,4,5,6-
tetrahydropyridine-3-carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)phenyl acetic acid (147 mg, 0.6 mmol) and i-
Pr2NEt (0.16 mL, 0.9 mmol) were added pivaloyl chloride (0.11 mL, 0.9 mmol), DHPB 86 (11 
mg, 0.06 mmol), ketimine 291 (105 mg, 0.3 mmol) and i-Pr2NEt (53 µL, 0.3 mmol) for 1 h at rt 
gave, after chromatographic purification (EtOAc:isohexane 5:95) and recrystallisation 
(Et2O:isohexane), the title compound as white solid (119 mg, 69%): mp 134-136 °C; νmax 
(ATR)/cm-1 1087 (S=O), 1335 (C-O), 1697 (C=O), 2947, 3078 (C-H); 1H NMR (400 MHz, 
CDCl3) 2.44 (3H, s, SO2ArCH3), 3.04 (1H, d, J 15.8, C(4)HH), 3.47 (1H, d, J 15.8, C(4)HH), 
3.49 (3H, s, CO2CH3), 6.87 (2H, d, J 3.2, ArH), 7.20-7.29 (9H, m, ArH), 7.31-7.35 (2H, m, 
ArH), 7.40 (2H, d, J 8.1, SO2Ar(2,6)H); 13C NMR (100 MHz, CDCl3) 21.9 (SO2CH3), 35.5 
(C(4)HH), 52.2 (CO2CH3), 62.4 (C(3)), 122.0 (C(5)), 126.1 (ArCH), 127.3 (ArCH), 127.8 
(ArCH), 128.7 (ArCH), 128.8 (ArCH), 128.9 (SO2ArC(2,6)H), 129.0 (ArCH), 129.3 (ArCH), 
129.7 (ArC), 130.4 (ArC), 130.7 (ArCH), 134.3 (ArC), 135.6 (ArC), 136.3 (ArC), 136.6 (ArC), 
138.0 (ArC), 145.2 (SO2C(1)), 165.6 (CO2CH3), 170.4 (C(6)); HRMS (NSI+) C30H26NO5S3 
([M+H]+) requires 576.0968 found 576.0961 (−1.1 ppm). 
 
Methyl 5-(4-fluorophenyl)-6-oxo-2-phenyl-5-(phenylthio)-1-tosyl-1,4,5,6-
tetrahydropyridine-3-carboxylate 
 
 
 
 
Following general procedure H, 2-(4-fluorophenyl)-2-(phenylthio)acetic acid (456 mg, 1.74 
mmol) and i-Pr2NEt (0.455 mL, 2.61 mmol) were added pivaloyl chloride (0.322 mL, 2.61 
mmol), DHPB 86 (22 mg, 0.12 mmol), ketimine 263 (200 mg, 0.58 mmol) and i-Pr2NEt (101 
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µL, 0.58 mmol) for 1 h at rt gave, after chromatographic purification (EtOAc: Petrol 10:90), the 
title compound as white solid (170 mg, 50%): mp 122-125 °C; νmax (ATR)/cm-1 1144 (S=O), 
1371 (C-O), 1697 (C=O), 2951, 3063 (C-H); 1H NMR (500 MHz, CDCl3) 2.43 (3H, s, 
SO2ArCH3), 3.09 (1H, d, J 15.7, C(4)HH), 3.41 (3H, s, CO2CH3), 3.46 (1H, d, J 15.6, C(4)HH), 
6.93-6.98 (4H, m, ArH), 7.15-7.18 (4H, m, ArH), 7.22-7.25 (2H, m, ArH), 7.28-7.31 (1H, m, 
ArH), 7.33-7.38 (5H, m, ArH), 7.45 (2H, d, J 8.3, SO2Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 
21.9 (SO2ArCH3), 34.8 (C(4)HH), 52.0 (CO2CH3), 62.6 (C(5)), 115.8 (d, J 21.5, 
C(5)ArC(3,5)H), 119.1 (C(3)), 127.3 (ArCH), 129.0 (ArCH), 129.0 (ArCH), 129.1 (ArCH), 
129.2 (ArCH), 129.3 (ArCH), 129.5 (ArCH), 129.9 (ArCH), 130.2 (ArC), 131.6 (d, J 3.4, 
C(5)ArC(1)), 133.5 (ArC), 136.0 (ArC), 136.5 (SO2ArC(2,6)H), 145.2 (ArC), 145.2 (ArC), 
162.2 (d, J 249.2, C(5)ArC(4)), 165.9 (C(6)), 170.6 (CO2Me); HRMS (NSI+) C32H26FNO5S2Na 
([M+Na]+) requires 610.1129 found 610.1118 (−1.7 ppm). 
 
Methyl 5-(4-chlorophenyl)-6-oxo-2-phenyl-5-(phenylthio)-1-tosyl-1,4,5,6-
tetrahydropyridine-3-carboxylate 
 
 
 
 
Following general procedure H, 2-(4-chlorophenyl)-2-(phenylthio)acetic acid (167 mg, 0.6 
mmol) and i-Pr2NEt (0.16 mL, 0.9 mmol) were added pivaloyl chloride (0.11 mL, 0.9 mmol), 
DHPB 86 (11 mg, 0.06 mmol), ketimine 263 (105 mg, 0.3 mmol) and i-Pr2NEt (53 µL, 0.3 
mmol) for 30 min at rt gave, after chromatographic purification (EtOAc:Petrol 12:88) the title 
compound as colourless oil (128 mg, 71%): νmax (ATR)/cm-1 1150 (S=O), 1312 (C-O), 1722 
(C=O), 2977, 3054 (C-H); 1H NMR (500 MHz, CDCl3) 2.45 (3H, s, SO2ArCH3), 3.12 (1H, d, J 
15.7, C(4)HH), 3.44-3.49 (4H, m, CO2CH3 and C(4)HH), 6.97 (2H, d, J 7.44, ArH), 7.17-7.22 
(4H, m, ArH), 7.25-7.28 (4H, m, ArH), 7.31-7.40 (6H, m, ArH), 7.47 (2H, d, J 8.3, 
SO2Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 21.9 (SO2ArCH3), 34.7 (C(4)HH), 52.0 (CO2CH3), 
62.6 (C(5)), 119.0 (C(3)), 127.3 (ArCH), 128.7 (ArCH), 129.0 (ArCH), 129.0 (ArCH), 129.0 
(ArCH), 129.3 (ArCH), 129.5 (ArCH), 129.9 (ArCH), 130.0 (ArCH), 133.0 (ArC), 133.4 (ArC), 
134.4 (ArC), 134.6 (ArC), 135.9 (ArC), 136.5 (SO2ArC(2,6)H), 145.2 (ArC), 145.3 (ArC), 
165.8 (C(6)), 170.4 (CO2Me); HRMS (NSI+) C32H2735ClNO5S2 ([M+H]+) requires 604.1014 
found 604.1013 (−0.1 ppm). 
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Benzyl 6-oxo-2,5-diphenyl-5-(phenylthio)-1-tosyl-1,4,5,6-tetrahydropyridine-3-carboxylate 
 
 
 
 
Following general procedure H, (phenylthio)phenyl acetic acid (147 mg, 0.6 mmol) and i-
Pr2NEt (157 µL, 0.9 mmol) were added pivaloyl chloride (111 µL, 0.9 mmol) in CH2Cl2 (5 mL), 
DHPB 86 (11 mg, 0.06 mmol), ketimine 263 (126 mg, 0.3 mmol) and i-Pr2NEt (53 µL, 0.3 
mmol) for 1 h at rt gave, after chromatographic purification (EtOAc:Petrol 12.5:87.5) and 
recrystallisation (Et2O), the title compound as white solid (124 mg, 64%): mp 180-181 °C; νmax 
(ATR)/cm-1 1153 (S=O), 1728 (C=O), 2953, 3030 (C-H); 1H NMR (400 MHz, CDCl3) 2.43 
(3H, s, SO2ArCH3), 3.10 (1H, d, J 15.6, C(4)HH), 3.50 (1H, d, J 15.6, C(4)HH), 4.83 (2H, d, J 
2.8, CO2CH2Ph), 6.86-6.93 (4H, m, ArH), 7.06 (2H, t, J 7.8, ArH), 7.14-7.28 (12H, m, ArH), 
7.32-7.35 (1H, m, ArH), 7.39-7.40 (2H, m, ArH), 7.46 (2H, d, J 8.3, ArH); 13C NMR (100 
MHz, CDCl3) 21.9 (SO2ArCH3), 34.7 (C(4)HH), 63.2 (C(5)), 66.7 (CO2CH2Ph), 119.6 (C(3)), 
127.1 (ArCH), 127.3 (ArCH), 128.3 (ArCH), 128.4 (ArCH), 128.5 (ArCH), 128.6 (ArCH), 
128.8 (ArCH), 128.9 (ArCH), 128.9 (ArCH), 129.1 (ArCH), 129.2 (ArCH), 129.5 (ArCH), 
129.7 (ArCH), 130.5 (ArC), 133.6 (ArC), 135.2 (ArC), 135.4 (ArC), 136.2 (ArC), 136.7 
(ArCH), 145.1 (ArC), 145.2 (ArC), 165.3 (C(6)), 170.8 (CO2Bn); HRMS (NSI+) C38H35N2O5S2 
([M+NH4]+), found 663.1983, requires 663.1982 (+0.2 ppm). 
9.3.6 Oxidation-Sulfoxide Elimination/N- to O-Sulfonyl Transfer 
Methyl 2-(4-methoxyphenyl)-6-(tosyloxy)nicotinate 
 
 
 
Following general procedure I, dihydropyridinone 268 (151 mg, 0.29 mmol) and Na2CO3 
(1.19g, 11.3 mmol) in CH2Cl2 (6 mL), were added m-CPBA (71 mg, 0.32 mmol) in CH2Cl2 (3 
mL) for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) 
for 1 h gave, after recrystallisation (Et2O:isohexane), the title compound as white solid (105 mg, 
88%): mp 105-107 °C; νmax (ATR)/cm-1 1172 (S=O), 1373 (C-O), 1713 (C=O), 2947, 2986 (C-
H); 1H NMR (400 MHz, CDCl3) 2.45 (3H, s, SO2ArCH3), 3.73 (3H, s, CO2CH3), 3.86 (3H, s, 
ArOCH3), 6.89 (2H, d, J 8.8, C(2)Ar(3,5)H), 7.04 (1H, d, J 8.3, C(5)H), 7.27-7.32 (4H, m, 
C(2)Ar(2,6)H and SO2Ar(3,5)H), 7.92 (2H, d, J 8.4, SO2Ar(2,6)H), 8.09 (1H, d, J 8.3, C(4)H); 
13C NMR (100 MHz, CDCl3) 21.9 (SO2ArCH3), 52.7 (CO2CH3), 55.5 (ArOCH3), 112.2 
(C(5)H), 113.6 (C(2)ArC(3,5)H), 124.9 (C(3)), 129.2 (SO2ArC(2,6)H), 129.7 (C(2)ArC(2,6)H), 
130.5 (SO2ArC(3,5)H), 130.7 (C(2)ArC(1)), 134.1 (SO2ArC(4)), 142.5 (C(4)H), 145.5 
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(SO2ArC(1)), 157.4 (C(2)), 157.7 (C(2)ArC(4)), 160.8 (C(6)), 168.1 (CO2CH3); HRMS (NSI+) 
C21H20NO6S ([M+H]+) requires 414.1006 found 414.1001 (−2.1 ppm).  
 
Methyl 2-phenyl-6-(tosyloxy)nicotinate 
 
 
 
Following general procedure I, dihydropyridinone 264 (50 mg, 0.1 mmol) and Na2CO3 (413 mg, 
3.9 mmol) in CH2Cl2 (3 mL), were added m-CPBA (25 mg, 0.11 mmol) in CH2Cl2 (2 mL) for 
30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) for 1 h 
gave, after recrystallisation (Et2O:isohexane), the title compound as colourless oil (36 mg, 
93%); νmax (ATR)/cm-1 1172 (S=O), 1373 (C-O), 1728 (C=O), 2954, 3051 (C-H);  1H NMR 
(400 MHz, CDCl3) 2.44 (3H, s, SO2ArCH3), 3.70 (3H, s, CO2CH3), 7.10 (1H, d, J 8.3 C(5)H), 
7.29-7.33 (4H, m, C(2)Ar(3,5)H and SO2Ar(3,5)H), 7.36-7.44 (3H, m, C(2)Ar(2,6)H and 
C(2)Ar(4)H), 7.91 (2H, d, J 8.3, SO2Ar(2,6)H), 8.15 (1H, d, J 8.3, C(4)H); 13C NMR (100 MHz, 
CDCl3) 21.9 (SO2ArCH3), 52.6 (CO2CH3), 112.9 (C(5)H), 125.4 (C(3)), 128.1 
(C(2)ArC(2,6)H), 128.9 (SO2ArC(3,5)H), 129.2 (SO2ArC(2,6)H), 129.4 (C(2)ArC(4)H), 129.7 
(C(2)ArC(3,5)H), 134.0 (SO2ArC(3,5)H), 138.3 (C(2)ArC(1)), 142.5 (C(4)H), 145.5 
(SO2ArC(1)), 157.5 (C(2)), 158.3 (C(6)), 167.7 (CO2CH3); HRMS (NSI+) C20H18NO5S1 
([M+H]+) requires 384.0900 found 384.0892 (−2.1 ppm). 
 
Methyl 2-(naphthalen-2-yl)-6-(tosyloxy)nicotinate 
 
 
 
 
Following general procedure I, dihydropyridinone 296 (50 mg, 0.1 mmol) and Na2CO3 (413 mg, 
0.39 mmol) in CH2Cl2 (3 mL), were added m-CPBA (25 mg, 0.11 mmol) in CH2Cl2 (2 mL) for 
30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) for 1 h 
gave, after column chromatography (EtOAc:isohexane 10:90), the title compound as colourless 
oil (36 mg, 90%): νmax (ATR)/cm-1 1172 (S=O), 1371 (C-O), 1732 (C=O), 2955, 3053 (C-H);  
1H NMR (300 MHz, CDCl3) 2.44 (3H, s, SO2ArCH3), 3.67 (3H, s, CO2CH3), 7.14 (1H, d, J 8.3, 
C(5)H), 7.29 (2H, d, J 8.6, SO2Ar(3,5)H), 7.42 (1H, dd, J 8.6, 1.8, C(2)ArH), 7.50-7.57 (2H, m, 
C(2)ArH), 7.81-7.89 (4H, m, C(2)ArH), 7.94 (2H, d, J 8.4, SO2Ar(2,6)H), 8.20 (1H, d, J 8.3, 
C(4)H); 13C NMR (100 MHz, CDCl3) 21.9 (SO2CH3), 52.7 (CO2CH3), 113.0 (C(5)H), 125.5 
(C(3)), 126.3 (C(2)ArH), 126.5 (C(2)ArH), 127.1 (C(2)ArH), 127.6 (C(2)ArH), 127.9 
(C(2)ArH), 127.7 (C(2)ArH), 127.9 (C(2)ArH), 128.7 (C(2)ArH), 128.8 (C(2)ArH), 129.2 
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(SO2Ar(2,6)H), 129.7 (SO2Ar(3,6)H), 133.0 (C(2)ArC(10)), 133.6 (C(2)ArC(5)), 134.1 
(SO2Ar(4)), 135.7 (C(2)ArC(2)), 142.6 (C(4)H), 145.5 (SO2ArC(1)), 157.7 (C(2)), 158.1 (C(6)), 
167.8 (CO2Me); HRMS (NSI+) C24H20NO5S1 ([M+H]+) requires 434.1057 found 434.1051 (−1.3 
ppm). 
 
Methyl 2-(thiophen-2-yl)-6-(tosyloxy)nicotinate 
 
 
 
Following general procedure I, dihydropyridinone 297 (50 mg, 0.10 mmol) and Na2CO3 (413 
mg, 0.39 mmol) in CH2Cl2 (3 mL), were added m-CPBA (25 mg, 0.11 mmol) in CH2Cl2 (2 mL) 
for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) for 1 h 
gave, after recrystallisation (Et2O:isohexane), the title compound as white solid (35 mg, 90%); 
mp 46-48 °C; νmax (ATR)/cm-1 1176 (S=O), 1365 (C-O), 1736 (C=O), 2899, 2964 (C-H); 1H 
NMR (400 MHz, CDCl3) 2.45 (3H, s, SO2ArCH3), 3.87 (3H, s, CO2CH3), 7.01 (1H, d, J 8.3, 
C(5)H), 7.04 (1H, dd, J 5.1, 3.8, C(2)Ar(4)H), 7.32 (1H, dd, J 3.8, 1.0, C(2)Ar(3)H), 7.35 (2H, 
d, J 8.1, SO2Ar(3,5)H), 7.44 (1H, dd, J 5.1, 1.0, C(2)Ar(5)H), 7.96-7.99 (3H, m, C(4)H and 
SO2Ar(2,6)H); 13C NMR (100 MHz, CDCl3) 21.9 (SO2CH3), 53.0 (CO2CH3), 112.8 (C(5)H), 
124.1 (C(3)), 127.8 (C(2)ArC(4)H), 128.9 (C(2)ArC(3)H), 129.0 (SO2ArC(2,6)H), 129.6 
(C(2)ArC(5)H), 129.9 (SO2Ar(3,5)H), 133.9 (SO2Ar(4)), 141.0 (C(2)ArC(2)), 142.1 (C(4)H), 
145.5 (SO2ArC(1)), 150.2 (C(2)), 157.0 (C(6)), 167.9 (CO2Me); HRMS (NSI+) C24H22NO5S3+ 
([M+H]+) requires 500.0660 found 500.0623 (−1.0 ppm). 
 
Methyl 2-(4-chlorophenyl)-6-(tosyloxy)nicotinate 
 
 
 
Following general procedure I, crude dihydropyridinone 298 (118 mg, 0.22 mmol) and Na2CO3 
(922 mg, 8.70 mmol) in CH2Cl2 (4 mL), were added m-CPBA (56 mg, 0.25 mmol) in CH2Cl2 (3 
mL) for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) 
for 1 h gave, after recrystallisation (Et2O:isohexane), the title compound as white solid (68 mg, 
54% over 2 steps): mp 117-119 °C; νmax (ATR)/cm-1 1172 (S=O), 1373 (C-O), 1728 (C=O), 
2854, 2924 (C-H); 1H NMR (400 MHz, CDCl3) 2.45 (3H, s, SO2ArCH3), 3.73 (3H, s, CO2CH3), 
7.11 (1H, d, J 8.4, C(5)H), 7.25-7.31 (4H, m, SO2Ar(3,5)H and C(2)Ar(3,5)H), 7.36 (2H, d, J 
8.5, C(2)Ar(2,6)H), 7.90 (2H, d, J 8.3, SO2Ar(2,6)H), 8.17 (1H, d, J 8.4, C(4)H); δC (100 MHz, 
CDCl3) 22.2 (SO2ArCH3), 53.1 (CO2CH3), 113.5 (C(5)H), 125.4 (C(3)), 128.7 
(C(2)ArC(2,6)H), 129.5 (SO2ArC(2,6)H), 130.0 (C(2)ArC(3,5)H), 130.7 (SO2ArC(3,5)H), 
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134.3 (SO2ArC(4)), 136.0 (C(2)ArC(4)), 137.3 (C(2)ArC(1)), 143.1 (C(4)H), 146.0 
(SO2ArC(1)), 157.5 (C(2)), 158.0 (C(6)), 167.6 (CO2Me); HRMS (NSI+) C20H1735ClNO5S1 
([M+H]+) requires 418.0510 found 418.0502 (−2.0 ppm). 
 
Benzyl 2-phenyl-6-(tosyloxy)nicotinate 
 
 
 
Following general procedure I, dihydropyridinone 299 (91 mg, 0.16 mmol) and Na2CO3 (661 
mg, 6.24 mmol) in CH2Cl2 (3 mL), were added m-CPBA (39 mg, 0.18 mmol) in CH2Cl2 (2 mL) 
for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (5 mL) for 1 h 
gave, after column chromatography (EtOAc:isohexane), the title compound as colourless oil (62 
mg, 45% over 2 steps): νmax (ATR)/cm-1 1170 (S=O), 1373 (C-O), 1721 (C=O), 3032, 3062 (C-
H); 1H NMR (400 MHz, CDCl3) 2.44 (3H, s, SO2ArCH3), 5.13 (2H, s, CH2), 7.02-7.05 (2H, 
ArH), 7.10 (1H, d, J 8.4, C(5)H), 7.28-7.34 (9H, m, ArH), 7.37 (1H, m, ArH), 7.91 (2H, d, J 
8.4, SO2Ar(2,6)H), 8.16 (1H, d, J 8.4, C(4)H); 13C NMR (100 MHz, CDCl3) 21.9 (SO3ArCH3), 
67.7 (CH2), 112.9 (C(5)H), 125.5 (C(3)), 128.1 (ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.6 
(ArCH), 129.0 (ArCH), 129.2 (ArCH), 129.3 (ArCH), 129.7 (ArCH), 134.0 (ArC), 134.8 (ArC), 
138.3 (ArC), 142.5 (ArC), 145.5 (SO2ArC(1)), 157.5 (C(2)), 158.4 (C(6)), 167.1 (CO2Bn); 
HRMS (NSI+) C25H20NO5S ([M+H]+) requires 446.1062 found 446.1061 (−0.4 ppm). 
 
Methyl 2-(4-methoxyphenyl)-5-phenyl-6-(tosyloxy)nicotinate 
 
 
 
 
Following general procedure I, dihydropyridinone 309 (151 mg, 0.29 mmol) and Na2CO3 
(1.19g, 11.3 mmol) in CH2Cl2 (6 mL), were added m-CPBA (71 mg, 0.32 mmol) in CH2Cl2 (3 
mL) for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) 
for 1 h gave, after recrystallisation (Et2O:isohexane), the title compound as white solid (105 mg, 
88%); mp 148-151 °C; νmax (ATR)/cm-1 1170 (S=O), 1323(C-O), 1719 (C=O), 3010, 3026 (C-
H); 1H NMR (400 MHz, CDCl3) 2.45 (3H, s, SO2ArCH3) 2.43 (3H, s, SO2ArCH3), 3.76 (3H, s, 
CO2CH3), 3.89 (3H, s, ArOCH3), 6.92 (2H, d, J 8.8, C(2)Ar(3,5)H), 7.23 (2H, d, J 8.8, 
C(5)Ar(2,6)H), 7.37 (2H, d, J 8.09, SO2Ar(3,5)H),, 7.40-7.48 (3H, m, C(5)Ar(3,5)H and 
C(5)Ar(4)H), 7.54-7.57 (2H, m, C(2)Ar(2,6)H), 7.85 (2H, d, J 8.4, SO2Ar(2,6)H), 8.13 C(4)H); 
13C NMR (125 MHz, CDCl3) 21.8 (SO2ArCH3), 52.7 (CO2CH3), 55.5 (ArOCH3), 113.5 
(C(2)ArC(3,5)H), 125.0 (C(3)), 125.6 (C(5)), 128.7 (C(5)ArC(4)H), 128.8 (C(5)ArC(3,5)H), 
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129.0 (SO2ArC(2,6)H), 129.3 (C(2)ArC(2,6)H), 129.5 (C(5)ArC(2,6)H), 130.3 (C(5)ArC(1)), 
130.6 (SO2ArC(3,5)H), 133.8 (C(5)ArC(1)), 134.8 (SO2ArC(4)), 142.8 (C(4)H), 145.1 
(SO2ArC(1)), 154.3 (C(2)), 155.7 (C(2)ArC(4)), 160.7 (C(6)), 169.1 (CO2Me); HRMS (NSI+) 
C27H23NO6S+ ([M+H]+) requires 490.1319 found 490.1316 (−0.6 ppm). 
 
Methyl 2,5-diphenyl-6-(tosyloxy)nicotinate 
 
 
 
Following general procedure I, dihydropyridinone 329 (147 mg, 0.25 mmol) and Na2CO3 
(1.03g, 9.75 mmol) in CH2Cl2 (6 mL), were added m-CPBA (47 mg, 0.275 mmol) in CH2Cl2 (2 
mL) for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) 
for 1 h gave, after recrystallisation (Et2O:isohexane), the title compound as white solid (110 mg, 
90%); mp 161-163 °C; νmax (ATR)/cm-1 1165 (S=O), 1366 (C-O), 1728 (C=O), 2947, 3055 (C-
H); 1H NMR (400 MHz, CDCl3) 2.42 (3H, s, SO2ArCH3), 3.72 (3H, s, CO2CH3), 7.21 (2H, d, J 
8.1, ArCH), 7.39-7.50 (8H, m, ArCH), 7.55-7.59 (2H, m, ArCH), 7.85 (2H, d, J 8.3, 
SO2Ar(2,6)H), 8.18 (C(4)H); 13C NMR (100 MHz, CDCl3) 21.8 (SO2ArCH3), 52.6 (CO2CH3), 
125.5 (C(3)), 126.3 (C(5)), 128.0 (ArCH), 128.8 (ArCH), 128.8 (ArCH), 128.8 (ArCH), 129.0 
(SO2ArC(2,6)H), 129.2 (ArCH), 129.3 (ArCH), 129.3 (ArCH), 129.4 (ArCH), 129.5 (ArCH), 
133.7 (ArC), 134.8 (ArC), 138.0 (ArC), 142.8 (C(4)), 145.1 (ArC), 154.5 (C(2)), 156.2 (C(6)), 
167.7 (CO2Me); HRMS (NSI+) C26H21NO5S ([M+H]+) requires 460.1213 found 460.1214 (−2.0 
ppm). 
 
Methyl 5-phenyl-2-(m-tolyl)-6-(tosyloxy)nicotinate 
 
 
 
 
Following general procedure I, crude dihydropyridinone 330 (314 mg, 0.54 mmol) and Na2CO3 
(2.24 g, 21.1 mmol) in CH2Cl2 (12 mL), were added m-CPBA (132 mg, 0.59 mmol) in CH2Cl2 
(6 mL) for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 
mL) for 1 h gave, after recrystallisation (Et2O:isohexane), the title compound as white solid 
(217 mg, 56% over 2 steps): mp 144-145 °C; νmax (ATR)/cm-1 1167 (S=O), 1369 (C-O), 1727 
(C=O), 2920, 3051 (C-H); 1H NMR (400 MHz, CDCl3) 2.41 (3H, s, SO2Ar(3,5)H), 2.43 (3H, s, 
C(2)ArCH3), 3.72 (3H, s, CO2CH3), 7.17-7.30 (6H, m, C(2)Ar(2)H and C(2)Ar(4)H and 
C(2)Ar(5)H and C(2)Ar(6)H and SO2Ar(3,5)H), 7.41-7.50 (3H, m, C(5)Ar(3,5)H and 
C(5)Ar(4)H), 7.56-7.59 (2H, m, C(5)Ar(2,6)H), 7.85 (2H, d, J 8.4, SO2Ar(2,6)H), 8.16 (1H, s, 
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C(4)H); 13C NMR (100 MHz, CDCl3) 21.6 (SO2ArCH3), 21.9 (C(2)ArCH3), 52.7 (CO2CH3), 
125.7 (ArC), 126.2 (C(2)ArC(4)H), 126.4 (ArC), 127.9 (C(2)ArC(6)H), 128.8 (C(5)ArC(3,5)H), 
129.2 (SO2ArC(2,6)H), 129.3 (C(5)ArC(2,6)H), 129.5 (SO2ArC(3,5)H), 129.6 (C(2)Ar(5)H), 
130.2 (C(2)Ar(2)H), 133.8 (ArC), 134.9 (ArC), 137.7 (ArC), 137.9 (ArC), 142.7 (C(4)H), 145.0 
(SO2ArC(1)), 154.5 (C(2)), 156.3 (C(6)), 167.9 (CO2Me); HRMS (NSI+) C27H24NO5S ([M+H]+) 
requires 474.1370 found 474.1359 (−2.3 ppm). 
 
Methyl 2-(3,5-dimethylphenyl)-5-phenyl-6-(tosyloxy)nicotinate 
 
 
 
 
Following general procedure I, crude dihydropyridinone 331 (179 mg, 0.3 mmol) and Na2CO3 
(1.36 g, 12.8 mmol) in CH2Cl2 (6 mL), were added m-CPBA (74 mg, 0.33 mmol) in CH2Cl2 (4 
mL) for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) 
for 1 h gave, after recrystallisation (Et2O:isohexane), the title compound as white solid (129 mg, 
44% over 2 steps): mp 135-137 °C; νmax (ATR)/cm-1 1163 (S=O), 1356 (C-O), 1727 (C=O), 
2952, 3015 (C-H); 1H NMR (400 MHz, CDCl3) 2.37 (6H, s, C(2)Ar(3)CH3 and C(2)Ar(5)CH3), 
2.45 (3H, s, SO2Ar(CH3), 3.74 (3H, s, CO2CH3), 7.00 (2H, s, C(2)Ar(2,6)H), 7.08 (1H, s, 
C(2)Ar(4)H), 7.26 (2H, m, SO2Ar(3,5)H), 7.44-7.51 (3H, m, ArH), 7.58-7.60 (2H, m, 
C(5)Ar(2,6)H), 7.87 (2H, d, J 8.3, SO2Ar(2,6)H), 8.15 (1H, s, C(4)H); 13C NMR (100 MHz, 
CDCl3) 21.5 (C(2)ArCH3), 21.5 (C(2)ArCH3), 21.9 (SO2ArCH3), 52.6 (CO2CH3), 125.8 (ArC), 
126.4 (ArC), 126.8 (C(2)ArC(2,6)H), 128.8 (C(5)ArC(4)H), 128.8 (C(5)ArC(3,5)H), 129.1 
(SO2ArC(2,6)H), 129.3 (C(5)ArC(2,6)H), 129.5 (SO2ArC(3,5)H), 131.1 (C(2)ArC(4)H), 133.8 
(ArC), 135.0 (ArC), 137.5 (ArC), 137.8 (ArC), 142.6 (C(4)H), 144.9 (SO2ArC(1)), 154.4 
(C(2)), 156.4 (C(6)), 168.1 (CO2Me); HRMS (NSI+) C19H20NO4S ([M+H]+) requires 358.1108 
found 358.1103 (−1.3 ppm). 
 
Methyl 5-phenyl-2-(p-tolyl)-6-(tosyloxy)nicotinate 
 
 
 
 
Following general procedure I, dihydropyridinone 332 (108 mg, 0.19 mmol) and Na2CO3 (785 
mg, 7.41 mmol) in CH2Cl2 (4 mL), were added m-CPBA (47 mg, 0.21 mmol) in CH2Cl2 (2 mL) 
for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) for 1 h 
gave, after recrystallisation (Et2O:isohexane), the title compound as white solid (84 mg, 93%): 
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mp 152-155 °C; νmax (ATR)/cm-1 1175 (S=O), 1373 (C-O), 1711 (C=O), 2949, 3046 (C-H); 1H 
NMR (400 MHz, CDCl3) 2.43 (6H, d, J 2.1, SO2ArCH3 and C(2)ArCH3), 3.74 (3H, s, CO2CH3), 
7.19-7.24 (4H, m, SO2Ar(3,5)H and C(2)Ar(3,5)H), 7.30 (2H, d, J 8.1, C(2)Ar(2,6)H), 7.42-
7.49 (3H, m, C(5)Ar(3,5)H) and C(5)Ar(4)H), 7.55-7.57 (2H, m, C(5)Ar(2,6)H), 7.85 (2H, d, J 
8.3, SO2Ar(2,6)H), 8.15 (1H, s, C(4)H); 13C NMR (100 MHz, CDCl3) 21.6 (C(2)ArCH3), 21.9 
(SO2ArCH3), 52.7 (CO2CH3), 125.4 (ArC), 126.0 (ArC), 128.7 (ArCH), 128.8 (ArCH), 128.8 
(ArCH), 129.1 (ArCH), 129.2 (ArCH), 129.3 (ArCH), 129.5 (ArCH), 133.8 (ArC), 134.9 (ArC), 
135.1 (ArC), 139.5 (ArC), 142.8 (C(4)H), 145.1 (SO2ArC(1)), 154.5 (C(2)), 156.2 (C(6)), 168.0 
(CO2Me); HRMS (NSI+) C27H24NO5S ([M+H]+) requires 474.1370 found 474.1370 (+0.1 ppm). 
 
Methyl 2-(4-bromophenyl)-5-phenyl-6-(tosyloxy)nicotinate 
 
 
 
 
Following general procedure I, dihydropyridinone 333 (50 mg, 0.08 mmol) and Na2CO3 (318 
mg, 3.00 mmol) in CH2Cl2 (3 mL), were added m-CPBA (19 mg, 0.11 mmol) in CH2Cl2 (2 mL) 
for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) for 1 h 
gave, after recrystallisation (Et2O), the title compound as white solid (39 mg, 94%); mp 160-161 
°C ; νmax (ATR)/cm-1 1165 (S=O), 1366 (C-O), 1744 (C=O), 2955, 3055 (C-H); 1H NMR (400 
MHz, CDCl3) 2.44 (3H, SO2ArCH3), 3.75 (3H, s, CO2CH3), 7.23 (2H, d, J 8.1, C(2)Ar(3,5)H), 
7.28 (2H, d, J 8.5, SO2Ar(3,5)H), 7.42-7.49 (3H, m, C(5)Ar(3,5)H and C(5)Ar(4)H), 7.53-7.57 
(4H, m, C(5)Ar(2,6)H and C(2)Ar(2,6)H), 7.82 (2H, d, J 8.3, SO2Ar(2,6)H), 8.20 (C(4)H); 13C 
NMR (100 MHz, CDCl3) 21.9 (SO2ArCH3), 52.8 (CO2CH3), 124.0 (ArC), 125.2 (ArC), 126.7 
(ArC), 128.9 (C(5)ArC(3,5)H), 128.9 (C(5)ArC(4)H), 129.1 (SO2ArC(2,6)H), 129.3 
(C(2)ArC(2,6)H), 129.5 (C(2)ArC(3,5)H), 130.8 (SO2ArC(3,5)H), 131.3 (C(5)ArC(2,6)H), 
133.5 (ArC), 134.8 (ArC), 136.9 (ArC), 143.1 (C(4)H), 145.3 (SO2ArC(1)), 154.6 (C(2)), 155.2 
(C(6)), 167.3 (CO2Me); HRMS (NSI+) C26H2179BrNO5S ([M+H]+) requires 538.0318 found 
538.0311 (−1.4 ppm). 
 
Methyl 2-(4-chlorophenyl)-5-phenyl-6-(tosyloxy)nicotinate 
 
 
 
 
Following general procedure I, crude dihydropyridinone 334 (179 mg, 0.3 mmol) and Na2CO3 
(1.36 g, 12.8 mmol) in CH2Cl2 (6 mL), were added m-CPBA (74 mg, 0.33 mmol) in CH2Cl2 (4 
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mL) for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) 
for 1 h gave, after recrystallisation (Et2O:isohexane), the title compound as white solid (129 mg, 
44% over 2 steps): mp 145-147; °C νmax (ATR)/cm-1 1161 (S=O), 1377 (C-O), 1726 (C=O), 
2951 (C-H); 1H NMR (400 MHz, CDCl3) 2.44 (3H, s, SO2ArCH3), 3.75 (3H, s, CO2CH3), 7.23 
(2H, d, J 8.1, SO2Ar(3,5)H), 7.33-7.40 (4H, m, C(2)Ar(3,5)H and C(2)Ar(2,6)H), 7.43-7.49 
(3H, m, C(5)Ar(3,5)H and C(5)Ar(4)H), 7.55-7.57 (2H, m, C(5)ArC(2,6)H), 7.82 (2H, d, J 8.3, 
SO2Ar(2,6)H), 8.20 (1H, C(4)H); 1H NMR (100 MHz, CDCl3) 21.9 (SO2ArCH3), 52.8 
(CO2CH3), 125.2 (ArC), 126.7 (ArC), 128.3 (C(2)ArC(2,6)H), 128.9 (C(5)ArC(3,5)H), 128.9 
(C(5)ArC(4)H), 129.1 (SO2ArC(2,6)H), 129.3 (C(5)ArC(2,6)H), 129.5 (SO2ArC(3,5)H), 130.5 
(C(2)ArC(3,5)H), 133.5 (ArC), 134.8 (ArC), 135.6 (ArC), 136.5 (ArC), 143.1 (C(4)H), 145.3 
(SO2ArC(1)), 154.6 (C(2)), 155.1 (C(6)), 167.3 (CO2Me); HRMS (NSI+) C26H2135ClNO5S 
([M+H]+) requires 494.0823 found 494.0818 (−1.1 ppm). 
 
Methyl 2-(naphthalen-2-yl)-5-phenyl-6-(tosyloxy)nicotinate 
 
 
 
 
Following general procedure I, dihydropyridinone 335 (121 mg, 0.20 mmol) and Na2CO3 (980 
mg, 9.24 mmol) in CH2Cl2 (5 mL), were added m-CPBA (58 mg, 0.26 mmol) in CH2Cl2 (3 mL) 
for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) for 1 h 
gave, after column chromatography (EtOAc:isohexane, 5:95), the title compound as white solid 
(35 mg, 90%): mp 149-151 °C; νmax (ATR)/cm-1 1175 (S=O), 1371 (C-O), 1732 (C=O), 3049, 
3065 (C-H); 1H NMR (300 MHz, CDCl3) 2.41 (3H, s, SO2ArCH3), 3.70 (3H, s, CO2CH3), 7.20 
(2H, d, J 8.2, SO2Ar(3,5)H), 7.42-7.62 (8H, m, ArH), 7.86-7.92 (6H, m, ArH), 8.23 (1H, s, 
C(4)H); δC (100 MHz, CDCl3) 21.8 (SO2ArCH3), 52.7 (CO2CH3), 125.7 (C(3)), 126.4 (ArCH), 
126.5 (ArCH), 126.5 (ArCH), 127.1 (ArCH), 127.5 (ArCH), 127.9 (ArCH), 128.7 (ArCH), 
128.9 (ArCH), 128.9 (ArCH), 128.9 (ArCH), 129.2 (ArCH), 129.4 (ArCH), 129.5 (ArCH), 
133.1 (ArC), 133.7 (ArC), 133.7 (ArC), 135.0 (ArC), 135.4 (ArC), 143.0 (C(4)H), 145.1 (ArC), 
154.7 (ArC), 156.1 (C(6)), 167.8 (CO2Me); HRMS (NSI+) C30H24NO5S+ ([M+H]+) requires 
510.1370 found 510.1362 (−1.5 ppm). 
 
Methyl 5-phenyl-2-(thiophen-2-yl)-6-(tosyloxy)nicotinate 
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Following general procedure I, dihydropyridinone 336 (50 mg, 0.09 mmol) and Na2CO3 (372 
mg, 3.51 mmol) in CH2Cl2 (3 mL), were added m-CPBA (22 mg, 0.10 mmol) in CH2Cl2 (2 mL) 
for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) for 1 h 
gave, after recrystallisation (Et2O:isohexane), the title compound as white solid (37 mg, 88%): 
mp 122-123 °C; νmax (ATR)/cm-1 1167 (S=O), 1373 (C-O), 1732 (C=O), 2949, 3117 (C-H); 1H 
NMR (400 MHz, CDCl3) 2.45 (3H, s, SO2ArCH3), 3.90 (3H, s, CO2CH3), 7.08 (1H, t, J 4.2, 
C(1)Ar(4)H), 7.31 (2H, d, J 7.8, SO2Ar(3,5)H), 7.37-7.47 (5H, m, C(5)Ar(4)H) and 
C(5)Ar(3,5)H and C(1)Ar(3)H and C(1)Ar(5)H), 7.56 (2H, d, J 7.3, C(5)Ar(2,6)H), 7.93 (2H, d, 
J 7.8 SO2Ar(2,6)H), 8.04 (1H, s, C(3)H); 13C NMR (100 MHz, CDCl3) 21.9 (SO2ArCH3), 53.0 
(CO2CH3), 124.3 (ArC), 126.2 (ArC), 127.8 (C(1)ArC(4)H), 128.8 (SO2ArC(2,6)H), 128.8 
(C(1)ArC(3)H) 128.9 (C(1)ArC(5)H), 129.0 (C(5)ArC(4)H), 129.3 (C(5)ArC(3,5)H), 129.5 
(C(5)ArC(2,6)H), 129.7 (SO2ArC(3,5)H), 133.7 (ArC), 134.6 (ArC), 140.8 (ArC), 142.4 
(C(4)H), 145.2 (SO2ArC(1)), 148.4 (C(2)), 153.9 (C(6)), 167.8 (CO2Me); HRMS (NSI+) 
C24H20NO5S2 ([M+H]+) requires 466.0777 found 466.0772 (−1.2 ppm). 
 
Methyl 5-(4-fluorophenyl)-2-phenyl-6-(tosyloxy)nicotinate 
 
 
 
 
Following general procedure I, dihydropyridinone 337 (105 mg, 0.179 mmol) and Na2CO3 (737 
mg, 6.98 mmol) in CH2Cl2 (3 mL), were added m-CPBA (44 mg, 0.20 mmol) in CH2Cl2 (3 mL) 
for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) for 1 h 
gave, after recrystallisation (Et2O), the title compound as white solid (80 mg, 90%): mp 188-190 
°C; νmax (ATR)/cm-1 1171 (S=O), 1371 (C-O), 1721 (C=O), 3055 (C-H); 1H NMR (500 MHz, 
CDCl3) 2.43 (3H, s, SO2ArCH3), 3.72 (3H, s, CO2CH3), 7.14-7.19 (2H, m, C(5)Ar(3,5)H), 7.23 
(2H, d, J 8.1, SO2Ar(3,5)H), 7.38-7.45 (5H, m, C(2)Ar(3,5)H and C(2)Ar(4)H and 
C(2)Ar(2,6)H), 7.53-7.57 (2H, m, C(5)Ar(2,6)H), 7.85 (2H, d, J 8.3, SO2Ar(2,6)H), 8.15 (1H, s, 
C(4)H); 13C NMR (125 MHz, CDCl3) 21.9 (SO2ArCH3), 52.7 (CO2CH3), 116.0 (d, J 21.7, 
C(5)ArC(3,5)H), 125.4 (C(3)), 125.5 (C(5)), 128.1 (C(2)ArC(3,5)H), 129.1 (SO2ArC(2,6)H), 
129.2 (C(2)ArC(2,6)H), 129.4 (C(2)ArC(4)H), 129.5 (SO2ArC(3,5)H), 129.7 (d, J 3.3, 
C(5)ArC(1)), 131.2 (d, J 8.4, C(5)ArC(2,6)H), 134.7 (ArC), 137.9 (ArC), 142.7 (C(4)), 145.3 
(SO2ArC(1)), 154.4 (C(2)), 156.4 (C(6)), 163.1 (d, J 249.0, C(5)ArC(4)), 167.7 (CO2Me); 19F 
NMR (376 MHz, CDCl3) 112.6 (C(5)ArF). HRMS (NSI+) C26H21FNO5S ([M+H]+) requires 
478.1119 found 478.1114 (−1.0 ppm). 
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Methyl 5-(4-chlorophenyl)-2-phenyl-6-(tosyloxy)nicotinate 
 
 
 
 
Following general procedure I, dihydropyridinone 338 (110 mg, 0.18 mmol) and Na2CO3 (636 
mg, 6.00 mmol) in CH2Cl2 (3 mL), were added m-CPBA (45 mg, 0.20 mmol) in CH2Cl2 (3 mL) 
for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) for 1 h 
gave, after recrystallisation (Et2O), the title compound as white solid (80 mg, 90%): mp 194-196 
°C; νmax (ATR)/cm-1 1176 (S=O), 1435 (C-O), 1697 (C=O), 2789 (C-H); 1H NMR (500 MHz, 
CDCl3) 2.43 (3H, s, SO2ArCH3), 3.72 (3H, s, CO2CH3), 7.22 (2H, d, J 8.2, SO2Ar(3,5)H), 7.39-
7.51 (9H, m, ArH), 7.84 (2H, d, J 8.2, SO2Ar(2,6)H), 8.15 (1H, s, C(4)H); 13C NMR (125 MHz, 
CDCl3) 21.9 (SO2ArCH3), 52.7 (CO2CH3), 125.2 (C(3)), 125.6 (C(5)), 128.1 (ArCH), 129.1 
(SO2ArC(2,6)H), 129.1 (ArCH), 129.1 (ArCH), 129.5 (ArCH), 129.5 (SO2ArC(3,5)H), 130.6 
(ArCH), 132.1 (ArC), 134.6 (ArC), 135.1 (ArC), 137.8 (ArC), 142.6 (ArC), 145.3 (SO2ArC(1)), 
154.4 (C(2)), 156.6 (C(6)), 167. 6 (CO2Me); HRMS (NSI+) C26H2135ClNO5S ([M+H]+) requires 
494.0823 found 494.0812 (−2.3 ppm). 
 
Benzyl 2,5-diphenyl-6-(tosyloxy)nicotinate 
 
 
 
Following general procedure I, dihydropyridinone 339 (64 mg, 0.099 mmol) and Na2CO3 (409 
mg, 3.86 mmol) in CH2Cl2 (3 mL), were added m-CPBA (25 mg, 0.109 mmol) in CH2Cl2 (2 
mL) for 30 min to give intermediate pyridone. Crude mixture heated at 80 °C in THF (10 mL) 
for 1 h gave, after recrystallisation (Et2O:isohexane), the title compound as white solid (48 mg, 
90%); mp 122-124 °C; νmax (ATR)/cm-1 1166 (S=O), 1368 (C-O), 1724 (C=O), 3032, 3063 (C-
H);  1H NMR (500 MHz, CDCl3) 2.44 (3H, s, SO2ArCH3), 5.18 (2H, s, CO2CH2Ph), 7.06-7.08 
(2H, m, ArH), 7.23 (2H, d, J 8.1, ArH), 7.30-7.51 (11H, m, ArH), 7.57-7.59 (2H, m, ArH), 7.86 
(2H, d, J 8.3, SO2Ar(2,6)H), 8.20 (1H, s, C(4)H); 13C NMR (125 MHz, CDCl3) 21.9 
(SO2ArCH3), 67.7 (CO2CH2Ph), 125.7 (C(3)), 126.3 (C(5)), 128.1 (ArCH), 128.5 (ArCH), 
128.5 (ArCH), 128.6 (ArCH), 128.8 (ArCH), 128.8 (ArCH), 129.1 (ArCH), 129.2 (ArCH), 
129.3 (ArCH), 129.3 (ArCH), 129.5 (ArCH), 133.7 (ArC), 134.7 (ArC), 134.8 (ArC), 138.0 
(ArC), 142.7 (C(4)H), 145.1 (SO2ArC(1)), 154.5 (C(2)), 156.2 (C(6)), 167.2 (CO2Bn); HRMS 
(NSI+) C32H26NO5S ([M+H]+) requires 536.1526 found 536.1519 (−1.3 ppm). 
N OTsPh
MeO2C
350
Cl
N OTsPh
BnO2C Ph
351
Chapter 9: Experimental 
 
 216 
9.3.7 Derivatisations 
Methyl 6-(1-acetamidovinyl)-2-(4-methoxyphenyl)nicotinate 
 
 
 
 
Following the procedure of Gøgsig and co-workers[170] A solution of 270 (100 mg, 0.24 mmol), 
N-vinylacetamide (61 mg, 0.72 mmol), N-methyldicyclohexylamine (206 µL, 0.96 mmol), 
DPPF (7 mg, 0.012 mmol) and [Pd(dba)2] (7 mg, 0.012 mmol) were stirred in 1,4-dioxane (2 
mL) in a screw top vial at 100 °C for 16 h. Once cooled, the reaction was filtered through celite 
(eluent CH2Cl2) and concentrated under reduced pressure. Chromatographic purification 
(EtOAc:Petrol 25:75) gave the title compound as yellow oil (56 mg, 72%); νmax (ATR)/cm-1 
1253, 1429, 1728 (C=O), 2839, 2951 (C-H), 3327 (N-H); 1H NMR (500 MHz, CDCl3) 2.18 
(3H, s, CH3), 3.75 (3H, s, CO2CH3), 3.88 (3H, s, ArOCH3), 5.65 (1H, s, =CHH), 6.61 (1H, s, 
=CHH), 7.00 (2H, d, J 8.8, C(2)Ar(3,5)H), 7.52 (2H, d, J 8.8, C(2)Ar(2,6)H), 7.72 (1H, d, J 8.3, 
C(5)H), 8.10 (1H, d, J 8.30, C(4)H), 9.27 (1H, br. s, NH); 13C NMR (125 MHz, CDCl3) 25.2 
(CH3), 52.6 (CO2CH3), 55.5 (ArOCH3), 101.3 (=CHH), 113.8 (C(2)ArC(3,5)H), 116.3 (C(5)H), 
125.6 (C(3)), 130.2 (C(2)ArC(2,6)H), 132.1 (C(2)ArC(1)), 137.0 (C=CHH), 139.3 (C(4)H), 
153.3 (C(2)), 156.8 (C(6)), 160.6 (C(2)ArC(4)), 168.4 (NHCOMe), 169.3 (CO2Me); HRMS 
(NSI+) C18H19N2O4 ([M+H]+) requires 327.1339 found 327.1342 (+0.8 ppm). 
 
Methyl 6-(1-acetamidovinyl)-2-(4-methoxyphenyl)-5-phenylnicotinate 
 
 
 
 
Following the procedure of Gøgsig and co-workers[170] A solution of 341 (100 mg, 0.20 mmol), 
N-vinylacetamide (68 mg, 0.80 mmol), N-methyldicyclohexylamine (171 µL, 0.80 mmol), 
DPPF (6 mg, 0.010 mmol) and [Pd(dba)2] (6 mg, 0.010 mmol) were stirred in 1,4-dioxane (2 
mL) in a screw top vial at 100 °C for 16 h. Once cooled, the reaction was filtered through celite 
(eluent CH2Cl2) and concentrated under reduced pressure. Chromatographic purification 
(EtOAc:Petrol 30:70) gave the title compound as yellow oil (55 mg, 69%); νmax (ATR)/cm-1 
1246, 1425, 1717 (C=O), 2837, 2949 (C-H), 3296 (N-H); 1H NMR (400 MHz, CDCl3) 2.07 
(3H, s, CH3), 3.76 (3H, s, CO2CH3), 3.89 (3H, s, ArOCH3), 4.84 (1H, s, =CHH), 6.27 (1H, s, 
=CHH), 7.01 (2H, d, J 8.9), 7.36-7.46 (4H, m, C(5)Ar(2,6)H, C(5)Ar(3,5)H and C(5)Ar(4)H), 
7.58 (2H, d, J 8.9, C(2)ArC(2,6)H), 8.03 (1H, s, C(4)H), 8.55 (1H, br. s, NH); 13C NMR (100 
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MHz, CDCl3) 25.1 (CH3), 52.6 (CO2CH3), 55.5 (ArOCH3), 108.1 (=CHH), 113.9 
(C(2)ArC(3,5)H), 125.1 (C(3)), 128.2 (C(5)ArC(4)H), 128.8 (C(5)ArC(3,5)H), 129.1 
(C(5)ArC(2,6)H), 130.3 (C(2)ArC(2,6)H), 131.7 (C(2)ArC(1)), 133.5 (C(5)), 136.7 
(C(5)ArC(1)), 139.0 (C=CHH), 141.9 (C(4)H), 152.4 (C(2)), 155.4 (C(6)), 160.6 (C(2)ArC(4)), 
168.2 (NHCOMe), 169.2 (CO2Me); HRMS (NSI+) C24H23N2O4 ([M+H]+) requires 403.1652 
found 403.1655 (+0.7 ppm). 
 
Methyl 2-(4-methoxyphenyl)-6-morpholinonicotinate 
 
 
 
 
Following the procedure by Volochnyuk et al.[178] A solution of 341 (100 mg, 0.24 mmol), 
morpholine (0.207 mL, 2.4 mmol), Et3N (67 µL, 0.48 mmol) were stirred in toluene (2 mL) in a 
screw top vial at 120 °C for 16 h. Once cooled, the reaction was concentrated under reduced 
pressure. Chromatographic purification (EtOAc:Petrol 25:75) gave the title compound as 
colourless oil (62 mg, 80%); νmax (ATR)/cm-1 1111, 1225, 1587, 1722, 2883, 2949 (C-H) 1H 
NMR (500 MHz, CDCl3) 3.65-3.68 (7H, m, CO2CH3 and 2×OCH2), 3.79-3.81 (4H, m, 
2×NCH2), 3.85 (3H, s, ArOCH3), 6.52 (1H, d, J 8.9, C(5)H), 6.93 (2H, d, J 8.7, C(2)Ar(3,5)H), 
7.48 (2H, d, J 8.7, C(2)Ar(2,6)H), 8.00 (1H, d, J 8.9, C(4)H); 13C NMR (125 MHz, CDCl3) 45.0 
(OCH2), 51.8 (CO2CH3), 55.4 (ArOCH3), 66.8 (NCH2), 103.3 (C(5)H), 113.2 (C(2)ArC(3,5)H), 
114.6 (C(3)), 130.3 (C(2)ArC(2,6)H), 133.6 (C(2)ArC(1)), 140.7 (C(5)H), 159.0 (C(2)), 159.1 
(C(6)), 160.0 (C(2)ArC(4)), 168.5 (CO2Me); HRMS (NSI+) C18H21N2O4+ ([M+H]+) requires 
329.1496 found 329.1497 (+0.4 ppm). 
 
Methyl 2-(4-methoxyphenyl)-6-morpholino-5-phenylnicotinate 
 
 
 
 
Following the procedure by Volochnyuk et al.[178] A solution of 341 (100 mg, 0.24 mmol), 
morpholine (172 µL, 2.00 mmol), Et3N (56 µL, 0.40 mmol) were stirred in toluene (2 mL) in a 
screw top vial at 120 °C for 16 h. Once cooled, the reaction was concentrated under reduced 
pressure. Chromatographic purification (EtOAc:Petrol 15:85) gave the title compound as 
colourless oil (59 mg, 73%); νmax (ATR)/cm-1 1107, 1230, 1624, 1722, 2882, 2951 (C-H); 1H 
NMR (500 MHz, CDCl3) 3.27-3.29 (4H, m, OCH2), 3.61-3.64 (4H, m, NCH2), 3.71 (3H, s, 
CO2CH3), 3.87 (3H, s, ArOCH3), 6.96 (2H, d, J 8.8, C(2)Ar(3,5)H), 7.31-7.35 (1H, m, 
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C(5)Ar(4)H), 7.41-7.45 (2H, m, C(5)Ar(3,5)H), 7.56-7.59 (4H, m, C(5)Ar(2,6)H and 
C(2)Ar(2,6)H), 7.95 (1H, s, C(4)H));  13C NMR (125 MHz, CDCl3) 48.8 (OCH2), 52.0 
(CO2CH3), 55.4 (ArOCH3), 66.7 (NCH3), 113.4 (C(2)ArC(3,5)H), 117.6 (C(3)), 122.3 
(C(2)ArC(1)), 127.7 (C(5)ArC(2,6)H), 127.7 (C(5)ArC(5)H), 129.1 (C(5)C(3,5)H), 130.5 
(C(2)ArC(2,6)H), 132.8 (C(5)), 139.4 (C(5)ArC(1)), 142.6 (C(4)H), 156.2 (C(2)), 158.9 
(C(2)ArC(4)), 160.3 (C(6)), 168.8 (CO2Me); HRMS (NSI+) C24H25N2O4 ([M+H]+) requires 
405.1809 found 405.1801 (−1.9 ppm). 
 
Methyl 2-(4-methoxyphenyl)nicotinate 
 
 
 
Following the procedure from Yoshida et al.[80] To a solution of 270 (50 mg, 0.12 mmol), 
Pd(OAc)2 (1.3 mg, 0.006 mmol), DPPP (2.5 mg, 0.006 mmol), and Et3N (84 µL, 0.6 mmol), in 
DMF (1 mL) was added formic acid (14 µL, 0.36 mmol). The reaction was heated in a screw 
top vial for 16 h at 100 °C. Once cooled, the reaction mixture was quenched with brine and 
extracted with EtOAc (×3). The combined organics were dried over MgSO4, filtered and 
concentrated under reduced pressure. Chromatographic purification (EtOAc:Petrol 15:85) gave 
the title compound as colourless oil (23 mg, 78%); νmax (ATR)/cm-1 1253, 1429 (C-O), 1728 
(C=O), 2837, 2951 (C-H); 1H NMR (500 MHz, CDCl3) 3.73 (3H, s, CO2CH3), 3.85 (3H, s, 
ArOCH3), 6.96 (2H, d, J 8.8, C(2)Ar(3,5)H), 7.28, (1H, dd, J 7.8, 4.8, C(5)H), 7.51 (2H, d, J 
8.8, C(2)Ar(2,6)H), 8.05 (1H, dd, J 7.8, 1.8, C(4)H), 8.74 (1H, dd, J 4.8, 1.8, C(6)H); 13C NMR 
(125 MHz, CDCl3) 52.5 (CO2CH3), 55.4 (ArOCH3), 113.8 (C(2)ArC(3,5)H), 121.1 (C(5)H), 
126.7 (C(3)), 130.1 (C(2)ArC(2,6)H), 132.5 (C(2)ArC(1)), 138.0 (C(4)H), 151.4 (C(6)H), 158.3 
(C(2)), 160.3 (C(2)ArC(4)), 169.1 (CO2Me); HRMS (NSI+) C14H14NO3 ([M+H]+) requires 
244.0968 found 244.0967 (−0.5 ppm). 
 
Methyl 2-(4-methoxyphenyl)-5-phenylnicotinate 
 
 
 
 
Following the procedure from Yoshida et al.[80] To a solution of 341 (100 mg, 0.2 mmol), 
Pd(OAc)2 (2 mg, 0.01 mmol), DPPP (4 mg, 0.01 mmol), and Et3N (140 µL, 1.0 mmol), in DMF 
(1.3 mL) was added formic acid (23 µL, 0.6 mmol). The reaction was heated in a screw top vial 
for 16 h at 100 °C. Once cooled, the reaction mixture was quenched with brine and extracted 
with EtOAc (×3). The combined organics were dried over MgSO4, filtered and concentrated 
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under reduced pressure. Chromatographic purification (EtOAc:Petrol 5:95) gave the title 
compound as white solid (47 mg, 73%); mp 142-145 °C; νmax (ATR)/cm-1 1246, 1435 (C-O), 
1709 (C=O), 2835, 2945, 3001 (C-H); 1H NMR (500 MHz, CDCl3) 3.77 (3H, s, CO2CH3), 3.87 
(3H, s, ArOCH3), 6.99 (2H, d, J 8.6, C(2)Ar(3,5)H), 7.42-7.45 (1H, m, C(5)Ar(4)H), 7.51 (2H, 
t, J 7.6, C(2)Ar(2,6)H), 7.57 (2H, d, J 8.6, C(5)Ar(3,5)H), 7.65 (2H, d, J 7.4, C(5)Ar(2,6)H), 
8.25 (1H, d, J 2.2, C(4)H), 8.97 (1H, d, J 2.2, C(6)H); 13C NMR (125 MHz, CDCl3) 52.6 
(CO2CH3), 55.5 (ArOCH3), 113.9 (C(2)ArC(3,5)H), 126.6 (C(3)), 127.2 (C(5)ArC(2,6)H), 
128.6 (C(5)ArC(4)H), 129.4 (C(5)ArC(3,5)H), 130.1 (C(2)ArC(2,6)H), 132.1 (C(2)ArC(1)), 
134.2 (C(5)), 136.2 (C(4)H), 136.7 (C(5)ArC(1)), 149.6 (C(6)H), 156.8 (C(2)), 160.4 
(C(2)ArC(4)), 169.1 (CO2Me); HRMS (NSI+) C20H18NO3 ([M+H]+) requires 320.1286 found 
320.1290 (−0.6 ppm). 
9.4 Experimental for Chapter 4 
9.4.1  General Experimental Procedures 
General Procedure J: Preparation of Homoanhydrides 
 
 
To a solution of requisite carboxylic acid (1.0 eq) in toluene (0.37 M) at rt was added DCC (0.55 
eq) and the reaction stirred for 15 min. The reaction was filtered through Celite (eluent toluene) 
and concentrated under reduced pressure to give crude reaction mixture. Products were purified 
by recrystallisation if required. 
 
General Procedure K: Preparation of keto esters 
 
 
 
Following the literature procedure of Bretner and co-workers,[95] to a solution of ketone in 
toluene (0.42 M in ketone) at 0 °C was added NaH (60% w/w in mineral oil, 4.0 eq) and reaction 
warmed to rt and stirred for 2 h. Reaction mixture was added dropwise to a solution of diethyl 
carbonate (5.0 eq) in toluene [6.3 M in carbonate] and reaction stirred at reflux for 24 h. Once 
cooled the reaction mixture was quenched slowly with H2O, acidified with HCl (2 M in H2O) 
and extracted with EtOAc (×3). The combined organic fractions were dried over MgSO4, 
filtered and concentrated under reduced pressure. Products were purified by column 
chromatography in the solvent system reported. 
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General Procedure L: Preparation of ethyl aroylacrylates 
 
 
 
 
 
 
Keto ester (1.0 eq), diisopropylammonium 2,2,2-trifluoroacetate (1.0 eq), paraformaldehyde (4 
eq) and TFA (0.1 eq) were added to THF (0.67 M in keto ester) in a sealable reaction tube. The 
reaction mixture was sealed and heated at reflux for 24 h. Once cooled the reaction mixture was 
diluted with H2O and extracted with EtOAc (×3). The combined organic fractions were dried 
over MgSO4, filtered and concentrated under reduced pressure. Products were purified by 
column chromatography in the solvent system reported. 
 
General Procedure M: Isothiourea-catalysed Michael addition-lactonisation 
 
 
 
 
 
To a solution of requisite homoanhydride (1.25 eq) in CH2Cl2 (0.31 M) at −78 °C was added 
Lewis base catalyst (5 mol%) and reaction stirred for 20 min. A solution of Michael acceptor 
(1.0 eq) in CH2Cl2 (0.25 M), pre-cooled to −78 °C, is added followed by a solution of i-Pr2NEt 
(1.25 eq) in CH2Cl2 (0.31 M), also pre-cooled to −78 °C, and reaction stirred until complete by 
TLC analysis. The reaction was quenched with aq. HCl (1 M), extracted with CH2Cl2 (×3), dried 
over MgSO4 and concentrated under reduced pressure to give crude residue. Products were 
purified by Biotage® IsoleraTM 4 in the solvent system reported. 
 
General Procedure N: Isothiourea-catalysed Michael addition-lactamisation 
 
 
 
 
 
To a solution of requisite carboxylic acid (2.0 eq) in CH2Cl2 (0.1 M in carboxylic acid) at 0 °C 
was added i-Pr2NEt (3.0 eq) and pivaloyl chloride (3.0 eq). The reaction was left to stir for 10 
min before being cooled to −78 °C at which point Lewis base catalyst (5 mol%) and Michael 
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acceptor (1.0 eq) and i-Pr2NEt (1.0 eq) were added and reaction was warmed to room 
temperature over 16 h. The reaction was quenched with HCl (1 M in H2O), extracted with 
CH2Cl2 (×3), dried over MgSO4 and concentrated under reduced pressure to give crude residue. 
Products were purified by column chromatography in the solvent system reported.  
9.4.2 Preparation of Homoanhydrides 
2-(4-Bromophenyl)acetic anhydride 
 
 
 
Following general procedure J, 4-bromophenylacetic acid (1.00 g, 4.65 mmol) and DCC (528 
mg, 2.56 mmol) in toluene (20 mL) gave crude reaction mixture. Recrystallisation (Et2O) gave 
title compound as white solid (0.97 g, 97%); mp 75-77 °C; {lit.[2] mp 76-78 °C}; 1H NMR (300 
MHz, CDCl3) 3.61 (4H, s, CH2), 6.98–7.03 (4H, m, Ar(3,5)H), 7.36–7.41 (4H, m, Ar(2,6)H). 
All data are in accordance with the literature.[2] 
 
2-Phenylacetic anhydride 
 
 
 
Following general procedure J, phenylacetic acid (1.00 g, 7.34 mmol) and DCC (757 mg, 3.67 
mmol) in toluene (20 mL) gave crude reaction mixture. Recrystallisation (Et2O) gave title 
compound as white solid (1.70 g, 91%); mp 70-72 °C; {lit.[179] mp 72-72.5 °C}; 1H NMR (500 
MHz, CDCl3) 3.76 (4H, s, CH2), 7.23–7.25 (4H, m, Ar(3,5)H), 7.32–7.38 (6H, m, Ar(4)H and 
Ar(2,6)H). All data are in accordance with the literature.[179] 
 
2-(4-Methoxyphenyl)acetic anhydride 
 
 
 
 
Following general procedure J, 4-methoxyphenylacetic acid (1.00 g, 6.00 mmol) and DCC (681 
mg, 3.30 mmol) in toluene (25 mL) gave crude reaction mixture. Recrystallisation (Et2O) gave 
title compound as white solid (1.70 g, 90%); mp 61-62 °C; {lit.[179] mp 60-62 °C}; 1H NMR 
(500 MHz, CDCl3) 3.66 (4H, s, CH2), 3.80 (4H, s, CH2), 6.83–6.86 (4H, m, Ar(3,5)H), 7.10–
7.13 (4H, m, Ar(2,6)H). All data are in accordance with the literature.[179] 
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2-(4-Chlorophenyl)acetic anhydride 
 
 
 
Following general procedure J, 4-chlorophenylacetic acid (1.00 g, 5.90 mmol) and DCC (669 
mg, 3.25 mmol) in toluene (50 mL) gave crude reaction mixture. Recrystallisation (Et2O) gave 
title compound as white solid (0.94 g, 98%); mp 62-64 °C; {lit.[179] mp 62-64 °C}; 1H NMR 
(500 MHz, CDCl3) 3.70 (4H, s, CH2), 7.13 (4H, d, J 8.5, Ar(3,5)H), 7.28-7.31 (4H, m, 
Ar(2,6)H). All data are in accordance with the literature.[179] 
 
2-(4-Fluorophenyl)acetic anhydride 
 
 
 
Following general procedure J, 4-chlorophenylacetic acid (1.00 g, 6.49 mmol) and DCC (737 
mg, 3.57 mmol) in toluene (20 mL) gave crude reaction mixture. Recrystallisation (Et2O) gave 
title compound as white solid (1.46 g, 77%); mp 34-36 oC; {lit.[179] mp 36-38 oC}; 1H NMR (400 
MHz, CDCl3) δH: 3.70 (4H, s, CH2), 6.99-7.05 (4H, m, Ar(3,5)H), 7.16-7.19 (4H, m, Ar(2,6)H). 
Spectroscopic data are in accordance with the literature.[179] 
 
2-(Naphthalen-1-yl)acetic anhydride 
 
 
 
Following general procedure J, 1-naphthylacetic acid (2.00 g, 10.8 mmol) and DCC (1.23 g, 
5.94 mmol) in toluene (50 mL) gave crude reaction mixture. Recrystallisation (Et2O) gave title 
compound as white solid (2.26 g, 59%); mp 34-36 °C; {lit.[180] mp 36-38 °C}; 1H NMR (400 
MHz, CDCl3) 4.30 (4H, C(2)H), 7.23 (2H, d, J 6.9, Ar(1)H), 7.33-7.36 (2H, m, Ar(8)H), 7.47-
7.50 (6H, m, ArH), 7.79-7.82 (4H, m, ArH), 7.86-7.87 (2H, m, ArH). All data are in accordance 
with the literature.[180] 
 
2-(2-Tolyl)acetic anhydride 
 
 
 
Following general procedure J, 2-tolylphenylacetic acid (2.00 g, 16.6 mmol) and DCC (1.88 
mg, 9.13 mmol) in toluene (70 mL) gave crude reaction mixture as yellow oil that was used 
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immediately without further purification. 1H NMR (400 MHz, CDCl3) 2.74 (6H, s, ArCH3), 
3.72 (4H, s, C(2)H), 7.09-7.21 (8H, m, ArH). Compound was 679 used immediately without 
further purification or analysis due to instability. 
 
(E)-Pent-3-enoic anhydride 
 
 
 
Following general procedure J, 3-pentenoic acid (1.13 g, 11.1 mmol) and DCC (1.17 g, 5.67 
mmol) in toluene (33 mL) gave title compound as pale yellow oil (2.00 g, 99%); 1H NMR (400 
MHz, CDCl3) 1.69-1.73 (6H, m, CH3), 3.11-3.20 (4H, m, C(2)H2), 5.42-5.57 (2H, m, C(4)H), 
5.57-5.70 (2H, m, C(3)H). Spectroscopic data are in accordance with the literature.[181] 
 
2-Methoxyacetic anhydride 
 
 
 
Following general procedure J, 4-chlorophenylacetic acid (1.00 g, 11.1 mmol) and DCC (1.26 
g, 6.11 mmol) in toluene (46 mL) gave crude reaction mixture as colourless oil that was used 
immediately without further purification. 1H NMR (400 MHz, CDCl3) 3.48 (6H, s, OCH3), 4.18 
(4H, s, C(2)H2). Due to instability this compound was used immediately without further 
characterisation. 
 
3-Phenylpropanoic anhydride 
 
 
 
Following general procedure J, 3-phenylpropanoic acid (1.00 g, 6.66 mmol) and DCC (756 mg, 
3.66 mmol) in toluene (28 mL) gave title compound as pale yellow oil (2.00 g, 99%); 1H NMR 
(400 MHz, CDCl3) 2.74 (4H, t, J 8.0, C(2)H2), 2.96 (4H, t, J 8.0, C(3)H2), 7.17-7.33 (10H, m, 
ArH). All data are in accordance with the literature.[182] 
 
2-(Phenylthio)acetic anhydride 
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Following general procedure J, (phenylthio)acetic acid (2.00 g, 11.9 mmol) and DCC (1.35 g, 
6.54 mmol) in toluene (50 mL) gave title compound as pale yellow oil (3.79 g, 99%); 1H NMR 
(400 MHz, CDCl3) 3.75 (4H, s, C(2)H2), 7.23-7.35 (6H, m, ArH), 7.38-7.40 (4H, m, ArH). Due 
to instability this compound was used immediately without further characterisation. 
9.4.3 Preparation of Keto Esters 
Ethyl 3-(4-methoxyphenyl)-3-oxopropanoate 
 
 
 
Following general procedure K, 4-methoxyacetophenone (5.00 g, 33.3 mmol) in toluene (79 
mL), NaH (3.19 g, 133 mmol), diethyl carbonate (20 mL, 166 mmol) in toluene (25 mL) gave 
crude product. Column chromatography (10:90 EtOAc:hexane) gave the title compound as a 
yellow oil as a (5.55 g, 75%, 2.5:1 keto:enol tautomeric mixture); 1H NMR (500 MHz, CDCl3) 
1.26 (3H, t, J 7.1, keto CO2CH2CH3), 1.33 (1.2H, t, J 7.1, enol CO2CH2CH3), 3.85 (1.2H, s, enol 
ArOCH3), 3.88 (3H, s, keto ArOCH3), 3.94 (2H, s, keto C(2)H), 4.17-4.29 (2.8H, m, keto 
CO2CH2CH3 and enol CO2CH2CH3), 5.58 (0.4H, s, enol C(2)H), 6.91-6.96 (2.8H, m, keto 
Ar(3,5)H and enol Ar(3,5)H), 7.74 (0.8H, d, J 7.7, enol Ar(2,6)H), 7.93 (2H, d, J 9.0, keto 
Ar(2,6)H), 12.6 (0.4H, s, enol OH). All data in accordance with literature.[183] 
 
Ethyl 3-oxo-3-(p-tolyl)propanoate 
 
 
 
Following general procedure K, 4-methylacetophenone (2.97 mL, 22.4 mmol) in toluene (53 
mL), NaH (3.58 g, 89.6 mmol), diethyl carbonate (13.6 mL, 112 mmol) in toluene (18 mL) gave 
crude product. Column chromatography (7.5:92.5 EtOAc:hexane) gave the title compound as a 
yellow oil as a (6.02 g, 78%); 1H NMR (500 MHz, CDCl3) 1.27 (3H, t, J 7.1, CO2CH2CH3), 
2.42 (ArCH3), 3.96 (2H, s, C(2)H), 4.21 (2H, q, J 7.2, CO2CH2CH3), 7.28 (2H, d, J 8.0, 
Ar(3,5)H), 7.85 (2H, d, J 8.3, Ar(2,6)H). All data in accordance with literature.[183] 
 
Ethyl 3-(furan-2-yl)-3-oxopropanoate 
 
 
 
To a solution of 2-acetylfuran (3.00 g, 27.2 mmol) in diethyl carbonate (54.4 mL) was added 
NaH (2.72 g, 68.0 m mmol) and the reaction stirred at rt for 1 h. Reaction was then heated to 90 
O
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°C and stirred for further 2 h. The reaction was cooled and quenched with H2O, acidified to pH 
5 and extracted with EtOAc (×3). Combined organics were washed with brine, dried over 
MgSO4 and concentrated under reduced pressure to give crude mixture. Column 
chromatography (EtOAc:hexane 10:90) gave the title compound as a brown oil as a (2.43 g, 
49%, 2:1 keto:enol tautomeric mixture); 1H NMR (500 MHz, CDCl3) 1H NMR 1.25 (3H, t, J 
7.1, CO2CH2CH3), 3.84 (2H, s, C(2)H2), 4.20 (2H, q, J 7.1, CO2CH2CH3), 6.57 (1H, dd, J 3.6, 
1.6, Ar(4)H), 7.27 (1H, d, J 3.59, Ar(3)H), 7.61 (1H, s, Ar(5)H). All data in accordance with 
literature.[184] 
 
Ethyl 3-(3-bromophenyl)-3-oxopropanoate 
 
 
 
Following general procedure K, 4-bromoacetophenone (3.00 g, 15.1 mmol) in toluene (36 mL), 
NaH (1.45 g, 60.4 mmol), diethyl carbonate (9.16 mL, 75.5 mmol) in toluene (12 mL) gave 
crude product. Column chromatography (7.5:92.5 EtOAc:hexane,) gave the title compound as a 
yellow oil as a (2.05 g, 50%, 2:1 keto:enol tautomeric mixture); 1H NMR (500 MHz, CDCl3) 
1.24-1.36 (4.5H, t, J 7.1, keto CO2CH2CH3  enol CO2CH2CH3), 3.96 (2H, s, keto C(2)H), 4.18-
4.28 (3H, m, keto CO2CH2CH3 and enol CO2CH2CH3), 5.65 (0.5H, s, enol C(2)H), 7.29-7.40 
(1.5H, m, keto Ar(5)H and enol Ar(5)H), 7.58 (0.5H, ddd, J 8.0, 2.0, 1.0, enol Ar(4)H), 7.67-
7.74 (1.5H, m, keto Ar(4)H and enol Ar(6)H), 7.86 (1H, dt, J 7.8, 1.3, keto Ar(6)H), 7.92 (0.5H, 
t, J 1.8, enol Ar(2)H), 8.08 (1H, t, J 1.8, keto C(2)H), 12.5 (0.5H, s, enol OH). All data in 
accordance with literature.[185] 
 
Ethyl 3-(naphthalen-2-yl)-3-oxopropanoate 
 
 
 
Following general procedure K, 4-acetylnaphthalene (3.00 g, 17.6 mmol) in toluene (42 mL), 
NaH (2.82 g, 70.4 mmol), diethyl carbonate (10.7 mL, 88.1 mmol) in toluene (14 mL) gave 
crude product. Column chromatography (EtOAc:hexane 10:90) gave the title compound as a 
yellow oil as a (2.56 g, 60%, 4:1 keto:enol tautomeric mixture); 1H NMR (500 MHz, CDCl3) 
1.27 (3H, t, J 7.1, keto CO2CH2CH3), 4.13 (2H, s, keto C(2)H2), 4.24 (2H, q, J 7.1, keto 
CO2CH2CH3), 7.56-7.59 (1H, td, J 7.6, 7.0, 1.2, keto ArH), 7.61-7.64 (1H, m, keto ArH), 7.88-
7.92 (2H, m, keto ArH ), 7.98 (1H, d, J 8.1, keto ArH), 8.02 (1H, dd, J 8.6, 1.8, keto ArH), 8.46 
(1H, s, keto ArH). All data in accordance with literature.[184] 
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9.4.4 Preparation of Aroyl Acrylates 
Diisopropylammonium 2,2,2-trifluoroacetate 
 
 
 
Following literature procedure,[96] to a solution of DIPA (14.1 mL, 100 mmol) in Et2O (100 mL) 
at 0 °C was added TFA (7.70 mL, 100 mmol) dropwise and the reaction mixture was stirred for 
5 min at 0 °C. The reaction mixture was filtered and the resulting solid was washed with cold 
Et2O and dried under reduced pressure to give the title compound (18.4 g, 86%) as a white 
solid; mp 120-122 °C {Lit.[96] mp 122-123 °C}; 1H NMR (500 MHz, CDCl3) 1.31 (12H, d, J 
6.7, 4 CH3), 3.35 (2H, septet, J 6.7, 2 CH), 8.92 (2H, s, NH2). All data in accordance with 
literature.[96] 
 
Ethyl 2-benzoylacrylate 
 
 
 
Following general procedure L, ethyl benzoylacetate (1.73 mL, 10.0 mmol), 
diisopropylammonium 2,2,2-trifluoroacetate (2.15 g, 10.0 mmol), paraformaldehyde (1.20 g, 40 
mmol) and TFA (77 µL, 1.00 mmol) in THF (60 mL) gave crude product. Column 
chromatography (10:90 Petrol:EtOAc) to give the title compound (1.80 g, 89%) as a pale yellow 
oil: 1H NMR (500 MHz, CDCl3) 1.19 (3H, t, J 7.1, CH3), 4.22 (2H, q, J 7.1, CH2CH3), 6.07 
(1H, d, J 0.8, =CHH), 6.70 (1H, d, J 0.8, =CHH), 7.47 (2H, t, J 7.8, ArC(3,5)H), 7.56-7.65 (1H, 
m, ArC(4)H), 7.86 (2H, d, J 8.1, ArC(2,6)H). All data in accordance with literature.[186] 
 
Ethyl 2-(4-methoxybenzoyl)acrylate 
 
 
 
Following general procedure L, ethyl 3-(4-methoxyphenyl)-3-oxopropanoate 384 (2.00 mL, 
9.43 mmol), diisopropylammonium 2,2,2-trifluoroacetate (2.03 g, 9.43 mmol), 
paraformaldehyde (1.13 g, 37.7 mmol) and TFA (74 µL, 0.94 mmol) in THF (60 mL) gave 
crude product. Column chromatography (10:90 Petrol:EtOAc) to give the title compound (1.80 
g, 89%) as a yellow oil: 1H NMR (500 MHz, CDCl3) 1.22 (3H, t, J 7.1, CH3), 3.88 (3H, s, 
ArOCH3), 4.23 (2H, q, J 7.1, CH2CH3), 6.00 (1H, d, J 0.7, =CHH), 6.66 (1H, d, J 0.7, =CHH), 
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6.94 (2H, d, J 9.0, ArC(3,5)H), 7.86 (2H, d, J 9.0, ArC(2,6)H). All data in accordance with 
literature.[186] 
 
Ethyl 2-(4-methylbenzoyl)acrylate 
 
 
 
 
Following general procedure L, ethyl 3-(4-tolyl)-3-oxopropanoate 385 (2.0 g, 9.69 mmol), 
diisopropylammonium 2,2,2-trifluoroacetate (2.08 g, 9.69 mmol), paraformaldehyde (1.17 g, 
38.8 mmol) and TFA (75µL, 0.97 mmol) in THF (60 mL) gave crude product. Column 
chromatography (10:90 Petrol:EtOAc) to give the title compound (1.23 g, 61%) as a yellow oil; 
1H NMR (500 MHz, CDCl3) 1.21 (3H, t, J 7.1, CO2CH2CH3), 4.13 (2H, q, J 7.2, 6.03 (1H, d, J 
0.7, =CHH), 6.68 (1H, d, J 0.7, =CHH), 7.26 (2H, d, J 8.2, Ar(3,5)H), 7.77 (2H, d, J 8.2, 
Ar(2,6)H). All data in accordance with literature.[186] 
 
Ethyl 2-(furan-2-carbonyl)acrylate 
 
 
 
Following general procedure L, ethyl 3-(furan-2-yl)-3-oxopropanoate 386 (1.50 g, 8.23 mmol), 
diisopropylammonium 2,2,2-trifluoroacetate (1.77 g, 8.23 mmol), paraformaldehyde (987 mg, 
32.9 mmol) and TFA (92 µL, 0.82 mmol) in THF (60 mL) gave crude product. Column 
chromatography (15:85 Petrol:EtOAc) to give the title compound (766 g, 48%) as a yellow oil: 
1H NMR (400 MHz, CDCl3) 1.26 (3H, t, J 7.1, CO2CH2CH3), 4.27 (2H, q, J 7.1, CO2CH2CH3), 
6.21 (1H, d, J 0.7, =CHH), 6.57 (1H, dd, J 3.6, 1.7, Ar(4)H), 6.66 (1H, d, J 0.7, =CHH), 7.20 
(1H, dd, J 3.6, 0.8, Ar(3)H), 7.65 (1H, dd, J 1.7, 0.8, Ar(5)H). All data in accordance with 
literature.[186] 
 
Ethyl 2-(3-bromobenzoyl)acrylate 
 
 
 
Following general procedure L, ethyl 3-(3-bromophenyl)-3-oxopropanoate 387 (2.05 g, 7.56 
mmol), diisopropylammonium 2,2,2-trifluoroacetate (1.63 g, 7.56 mmol), paraformaldehyde 
(906 mg, 30.2 mmol) and TFA (57 µL, 0.76 mmol) in THF (60 mL) gave crude product. 
Column chromatography (10:90 Petrol:EtOAc) to give the title compound (447 mg, 21%) as a 
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yellow oil: 1H NMR (500 MHz, CDCl3) 1.21 (3H, t, J 7.1, CH3), 4.24 (2H, q, J 7.1, CH2CH3), 
6.10 (1H, s, =CHH), 6.72 (1H, d, J 0.7, =CHH), 7.35 (1H, t, J 7.9, Ar(5)H), 7.72 (1H, ddd, J 
8.0, 1.9, 1.0, Ar(5)H), 7.76 (1H, dt, J 7.8, 1.3, Ar(2)H), 7.99 (1H, t, J 1.8, Ar(2)H). All data in 
accordance with literature.[186] 
 
Ethyl 2-(2-naphthoyl)acrylate 
 
 
 
Following general procedure L, ethyl 3-(naphthalen-2-yl)-3-oxopropanoate 388 (2.00 g, 8.30 
mmol), diisopropylammonium 2,2,2-trifluoroacetate (1.78 g, 8.30 mmol), paraformaldehyde 
(997 mg, 33.2 mmol) and TFA (64 µL, 0.83 mmol) in THF (60 mL) gave crude product. 
Column chromatography (10:90 Petrol:EtOAc) to give the title compound (1.01 g, 50%) as a 
yellow oil: 1H NMR (500 MHz, CDCl3) 1.19 (3H, t, J 7.1, CH3), 4.24 (2H, q, J 7.1, CH2CH3), 
6.13 (1H, d, J 0.6, =CHH), 6.78 (1H, d, J 0.6, =CHH), 7.56 (1H, ddd, J 8.1, 6.9, 1.2, ArH), 7.63 
(1H, ddd, J 8.2, 6.2, 1.3, ArH), 7.89-8.00 (4H, m, ArH), 8.33 (1H, s, ArH). All data in 
accordance with literature.[186] 
 
1-phenylprop-2-en-1-one 
 
 
 
To a solution of 3-chloro-1-phenylpropan-1-one (1.00 g, 5.93 mmol) in CHCl3 (13 mL) was 
added Et3N (2.07 mL, 14.8 mmol) and reaction stirred at rt for 16 h. Reaction quenched with aq. 
HCl (1 M), extracted with CH2Cl2, washed with sat. aq. NaHCO3 and brine then dried over 
MgSO4 and concentrated under reduced pressure to give the title compound as a yellow oil (781 
mg, 99%); 1H NMR (300 MHz, CDCl3) 5.94 (1H, dd, J 1.7, 10.5, C(3)HaHb), 6.45 (1H, dd, J 
1.8, 17.1, C(3)HaHb), 7.17 (1H, dd, J 10.4, 17.1, C(2)H), 7.46-7.52 (2H, m, Ar(3,6)H), 7.55-7.61 
(1H, m, Ar(4)H), 7.94-7.97 (2H, m, Ar(2,6)H). All data in accordance with literature.[98] 
9.4.5 Enantioselective Isothiourea-Catalysed Michael Addition Lactonisation 
Ethyl (R)-2-oxo-3,6-diphenyl-3,4-dihydro-2H-pyran-5-carboxylate 
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Following general procedure M, homoanhydride 675 (155 mg, 0.61 mmol) in CH2Cl2 (2 mL), 
(+)-BTM (5 mg, 0.024 mmol), ethyl 2-benzoylacrylate 378 (100 mg, 0.49 mmol) in CH2Cl2 (2 
mL) and i-Pr2NEt (106 µL, 0.61 mmol) in CH2Cl2 (2 mL) at −78 °C gave crude product.  
Purification by Biotage® IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (100:0 1 CV, 100:0 
to 70:30 10 CV, 70:30 3 CV)] gave the title compound (44 mg, 69%) as a white solid. mp 120-
122 °C; νmax (ATR)/cm−1 3057, 2980 (C-H), 1769 (C=O dihydropyranone), 1692 (C=O Ester); 
1H NMR (500 MHz, CDCl3) 1.00 (3H, t, J 7.1, CO2CH2CH3), 3.05-3.23 (2H, m, C(4)HH and 
C(4)HH), 3.99 (1H, dd, J 10.9, 7.0, C(3)H), 4.04 (2H, q, J 7.1, CO2CH2CH3), 7.29-7.48 (10H, 
m, ArCH); 13C NMR (125 MHz, CDCl3) 13.8 (CH3), 29.2 (C(4)), 44.4 (C(3)), 61.1 (CH2CH3), 
108.8 (C(5)), 128.0 (ArC), 128.1 (ArC), 128.1 (ArC), 128.8 (ArC), 129.1 (ArC), 130.1 (ArC), 
133.1 (C(6)ArC(1)), 135.8 (C(3)ArC(1)), 158.6 (ArC(6)), 166.4 (CO2Et), 168.2 (C(2)); HRMS 
(NSI+) C20H19O4 [M+H]+, found 323.1275, requires 323.1278 (−0.9 ppm). 
 
Ethyl (R)-3-(4-methoxyphenyl)-2-oxo-6-phenyl-3,4-dihydro-2H-pyran-5-carboxylate 
 
 
 
 
 
Following general procedure M, homoanhydride 676 (198 mg, 0.61 mmol) in CH2Cl2 (2 mL), 
(+)-BTM (5 mg, 0.024 mmol), ethyl 2-benzoylacrylate 378 (100 mg, 0.49 mmol) in CH2Cl2 (2 
mL) and i-Pr2NEt (106 µL, 0.61 mmol) in CH2Cl2 (2 mL) at −78 °C gave crude product. 
Purification by Biotage® IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (100:0 1 CV, 100:0 
to 70:30 10 CV, 70:30 3 CV)] gave the title compound (143 mg, 83%) as a white solid. mp 113-
115 °C; 
€ 
α[ ]D
20  −32.0 (c 0.1 CH2Cl2); Chiral HPLC analysis, Chiralpak AD-H (80:20 
hexane:IPA, flow rate 1 mLmin−1, 254 nm, 30 °C) tS (3S): 33.7 min, tR (3R): 37.5 min; 91% ee; 
νmax (ATR) 3001, 2837 (C-H), 1775 (C=O dihydropyranone), 1717 (C=O Ester); 1H NMR (400 
MHz, CDCl3) 1.00 (3H, t, J 7.1, CO2CH2CH3), 3.11-3.18 (2H, m, C(4)HH and C(4)HH), 3.82 
(3H, s, ArOCH3), 3.94 (1H, dd, J 10.7, 7.0, C(3)H), 4.04 (2H, q, J 7.1, CO2CH2CH3), 6.93 (2H, 
d, J 8.8, C(3)Ar(3,5)H), 7.25 (2H, d, J 8.7, C(3)Ar(2,6)H), 7.36-7.45 (5H, m, C(6)Ar(3,5)H and 
C(6)Ar(2,6)H and C(6)Ar(4)H); 13C NMR (100 MHz, CDCl3) 13.8 (CO2CH2CH3), 29.3 
(C(4)HH), 43.6 (C(3)H), 55.5 (ArOCH3), 61.1 (CO2CH2CH3), 108.8 (C(5)), 114.5 
(C(3)ArC(3,5)H), 127.8 (C(6)ArC(4)H), 128.0 (C(6)ArC(2,6)H), 128.8 (C(6)ArC(3,5)H), 129.2 
(C(3)ArC(2,6)H), 130.1 (C(6)ArC(1)), 133.1 (C(3)ArC(1)), 158.6 (C(6)), 159.4 
(C(3)ArC(4)OMe), 166.5 (CO2Et), 168.5 (C(2)); HRMS (NSI+) C21H20O5Na [M+Na]+, found 
375.1208, requires 375.1203 (+1.3 ppm). 
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Ethyl (R)-3-(4-bromophenyl)-2-oxo-6-phenyl-3,4-dihydro-2H-pyran-5-carboxylate 
 
 
 
 
 
Following general procedure M, homoanhydride 383 (80 mg, 0.30 mmol) in CH2Cl2 (2 mL), 
(+)-BTM (3 mg, 0.012 mmol) ethyl 2-benzoylacrylate 378 (50 mg, 0.24 mmol) in CH2Cl2 (2 
mL) and i-Pr2NEt (52 µL, 0.30 mmol) in CH2Cl2 (2 mL) at −78 °C gave crude product. 
Purification by Biotage® IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (100:0 1 CV, 100:0 
to 70:30 10 CV, 70:30 3 CV)] gave the title compound (44 mg, 69%) as a white solid. mp 176-
177 °C; 
€ 
α[ ]D
20  −42.0 (c 0.1 CH2Cl2); Chiral HPLC analysis, Chiralpak AD-H (80:20 
hexane:IPA, flow rate 1 mLmin-1, 254 nm, 30 °C) tR(R): 13.6 min, tR(S): 15.5 min, 90% ee; νmax 
(ATR) 2984, 2905 (C-H), 1769 (C=O dihydropyranone), 1694 (C=O Ester); 1H NMR (400 
MHz, CDCl3) 0.99 (3H, t, J 7.1, CO2CH2CH3), 3.06 (1H, dd, J 17.2, 11.4, C(4)HH), 3.16 (1H, 
dd, J 17.2, 6.8, C(4)HH), 3.94 (1H, dd, J 11.3, 6.8, C(3)H), 4.04 (2H, q, J 7.1, CO2CH2CH3), 
7.20 (2H, d, J C(3)Ar(2,6)H), 7.37-7.45 (5H, m, C(6)Ar(3,5)H and C(6)Ar(2,6)H and 
C(6)Ar(4)H), 7.53 (2H, d, J 8.4, C(3)Ar(3,5)H); 13C NMR (100 MHz, CDCl3) 13.8 
(CO2CH2CH3), 29.1 (C(4)HH), 43.9 (ArOCH3), 61.2 (CO2CH2CH3), 108.7 (C(5)), 122.3 
(C(3)ArC(4)), 128.1 (C(6)ArC(2,6)H), 128.8 (C(6)ArC(3,5)H), 129.9 (C(3)ArC (3,5)H), 130.3 
(C(6)ArC(4)H), 132.2 (C(3)ArC(2,6)H), 132.9 (C(6)ArC(1)), 134.8 (C(3)ArC(1)), 158.7 (C(6)), 
166.3 (CO2Et), 167.7 (C(2)); HRMS (NSI+) C20H17BrO4Na [M+Na]+, found 423.0198, requires 
423.0202 (−1.0 ppm). 
 
Ethyl (R)-3-(4-chlorophenyl)-2-oxo-6-phenyl-3,4-dihydro-2H-pyran-5-carboxylate 
 
 
 
 
 
Following general procedure M, homoanhydride 677 (197 mg, 0.61 mmol) in CH2Cl2 (2 mL), 
(+)-BTM (5 mg, 0.024 mmol), ethyl 2-benzoylacrylate 378 (100 mg, 0.49 mmol) in CH2Cl2 (2 
mL) and i-Pr2NEt (106 µL) in CH2Cl2 (2 mL) at −78 °C gave crude product. Purification by 
Biotage® IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (100:0 1 CV, 100:0 to 70:30 10 CV, 
70:30 3 CV)] gave the title compound (148 mg, 85%) as a white solid. mp 168-170 °C; 
€ 
α[ ]D
20 
−21.0 (c 0.1 CH2Cl2); Chiral HPLC analysis, Chiralpak AD-H (95:5 hexane:IPA, flow rate 1 
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mLmin-1, 220 nm, 30 °C) tR(R): 29.9 min, tR(S): 34.3 min, 88% ee; νmax (ATR) 2980 (C-H), 
1752 (C=O dihydropyranone), 1697 (C=O Ester); 1H NMR (500 MHz, CDCl3) 1.00 (3H, t, J 
7.1, CO2CH2CH3), 3.07 (1H, dd, J 17.2, 11.4, C(4)HH), 3.16 (1H, dd, J 17.2, 6.8, C(4)HH), 
3.96 (1H, dd, J 11.3, 6.8, C(3)H), 4.04 (2H, q, J 7.1, CO2CH2CH3), 7.27 (2H, d, J 6.9, 
C(3)Ar(3,5)H), 7.37-7.45 (7H, m, C(6)Ar(3,5)H and C(3)Ar(2,6)H and C(6)Ar(4)H and 
C(6)Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 13.8 (CO2CH2CH3), 29.2 (C(4)HH), 43.8 (C(3)H), 
61.2 (CO2CH2CH3), 108.7 (C(5)), 128.1 (C(6)ArC(2,6)H), 128.8 (C(6)ArC(3,5)H), 129.3 
(C(3)ArC(3,5)H), 129.6 (C(6)ArC(4)H), 130.3 (C(3)ArC(2,6)), 132.9 (C(3)ArC(4)), 134.2 
(C(3)ArC(1)), 134.2 (C(6)ArC(1)), 158.7 (C(6)), 166.3 (CO2Et), 167.9 (C(2)); HRMS (APCI+) 
C20H18Cl35O4 [M+H]+, found 357.0888, requires 357.0888 (0.0 ppm). 
 
Ethyl (R)-3-(4-fluorophenyl)-2-oxo-6-phenyl-3,4-dihydro-2H-pyran-5-carboxylate 
 
 
 
 
 
Following general procedure M, homoanhydride 678 (177 mg, 0.61 mmol), (+)-BTM (5 mg, 
0.025 mmol) and i-Pr2NEt (206 µL) at −78 °C gave crude product. Purification by Biotage® 
IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (100:0 1 CV, 100:0 to 70:30 10 CV, 70:30 3 
CV)] the title compound (128 mg, 77%) as a white solid. mp 120-122 °C; 
€ 
α[ ]D
20 −11.0 (c 0.1 
CH2Cl2);  Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane:IPA, flow rate 1 mLmin-1, 211 
nm, 30 °C) tR(R): 9.1 min, tR(S): 12.5 min, 49% ee; νmax (ATR)/cm−1 2986 (C-H), 1771 (C=O 
dihydropyranone), 1694 (C=O Ester); 1H NMR (500 MHz, CDCl3) 1.00 (3H, t, J 7.1, 
CO2CH2CH3), 3.07 (1H, dd, J 17.2, 11.4, C(4)HH), 3.16 (1H, dd, J 17.2, 6.8, C(4)HH), 3.97 
(1H, dd, J 11.4, 6.8, C(3)H), 4.04 (2H, q, J 7.1, CO2CH2CH3), 7.10 (2H, t, J 8.6, C(3)Ar(3,5)H), 
7.30 (2H, dd, J 8.5, 5.3, C(3)Ar(2,6)H), 7.37-7.45 (5H, m, C(6)Ar(3,5)H and C(6)Ar(2,6)H and 
C(6)Ar(4)H); 13C NMR (100 MHz, CDCl3) 13.8 (CO2CH2CH3), 29.3 (C(4)HH), 43.7 
(ArOCH3), 61.2 (CO2CH2CH3), 108.8 (C(5)), 116.1 (d, J 21.7, C(3)ArC(3,5)H), 128.1 
(C(6)ArC(2,6)H), 128.8 (C(6)ArC(3,5)H), 129.9 (d, J 8.2, C(3)ArC(2,6)H), 130.2 
(C(6)ArC(4)H), 131.6 (C(3)ArC(1)), 133.0 (C(6)ArC(1)), 158.6 (C(6)), 162.5 (d, J 247, 
C(3)ArC(4)F), 166.4 (CO2Et), 168.1 (C(2)); 19F NMR (282 MHz, CDCl3) −114.0 (ArF); HRMS 
(NSI+) C20H17FO4Na [M+Na]+, found 363.1002, requires 363.1003 (−0.3 ppm).  
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Ethyl (R)-3-(naphthalen-1-yl)-2-oxo-6-phenyl-3,4-dihydro-2H-pyran-5-carboxylate 
 
 
 
 
 
Following general procedure M, homoanhydride 679 (216 mg, 0.61 mmol) in CH2Cl2 (2 mL), 
(+)-BTM (5 mg, 0.024 mmol), ethyl 2-benzoylacrylate 278 (100 mg, 0.49 mmol) in CH2Cl2 (2 
mL) and i-Pr2NEt (106 µL, 0.61 mmol) in CH2Cl2 (2 mL) at −78 °C gave crude product. 
Purification by Biotage® IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (100:0 1 CV, 100:0 
to 80:20 10 CV, 80:20 3 CV)]  gave the title compound (147 mg, 81%) as a white solid. mp 
124-126 °C; 
€ 
α[ ]D
20  +6.0 (c 0.1 CH2Cl2); Chiral HPLC analysis, Chiralpak OD-H (80:20 
hexane:IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR(S): 18.2 min, tR(R): 26.3 min, 97% ee; νmax 
(ATR) 3052, 2990 (C-H), 1759 (C=O dihydropyranone), 1705 (C=O Ester); 1H NMR (500 
MHz, CDCl3) 0.99 (3H, t, J 7.1, CO2CH2CH3), 3.25-3.34 (2H, m, C(4)HH and C(4)HH), 4.03 
(2H, q, J 7.1, CO2CH2CH3), 4.73 (1H, dd, J 10.3, 8.1, C(3)H), 7.41-7.59 (9H, m, ArH), 7.86-
7.88 (1H, m, ArH), 7.92 (1H, d, J 8.0, ArH), 7.96 (1H, d, J 8.4, ArH); 13C NMR (125 MHz, 
CDCl3) 13.8 (CO2CH2CH3), 29.2 (C(4)HH), 41.1 (C(3)H), 61.2 (CO2CH2CH3), 109.0 (C(5)), 
123.0 (ArCH), 125.5 (ArCH), 125.7 (ArCH), 126.1 (ArCH), 126.8 (ArCH), 128.1 (ArCH), 
128.9 (ArCH), 129.1 (ArCH), 129.4 (ArCH), 130.2 (ArCH), 131.2 (ArC), 132.1 (ArC), 133.1 
(ArC), 134.2 (ArC), 158.6 (C(6)), 166.4 (CO2Et), 168.0 (C(2)); HRMS (APCI+) C24H21O4 
[M+H]+, found 373.1437, requires 373.1434 (+0.7 ppm). 
 
Ethyl (R)-2-oxo-6-phenyl-3-(o-tolyl)-3,4-dihydro-2H-pyran-5-carboxylate 
 
 
 
 
 
Following general procedure M, homoanhydride 680 (178 mg, 0.61 mmol) in CH2Cl2 (2 mL), 
(+)-BTM (5 mg, 0.024 mmol), ethyl 2-benzoylacrylate 278 (100 mg, 0.49 mmol) in CH2Cl2 (2 
mL) and i-Pr2NEt (106 µL, 0.61 mmol) in CH2Cl2 (2 mL) at −78 °C gave crude product. 
Purification by Biotage® IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (100:0 1 CV, 100:0 
to 80:20 10 CV, 80:20 3 CV)] gave the title compound (134 mg, 81%) as a white solid. mp 100-
102 °C; 
€ 
α[ ]D
20 −10.0 (c 0.1 CH2Cl2); Chiral HPLC analysis, Chiralpak OJ-H (70:30 hexane:IPA, 
flow rate 1 mLmin-1, 220 nm, 30 °C) tR(S): 15.1 min, tR(R): 24.4 min, 50% ee; νmax (ATR) 2978 
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(C-H), 1767 (C=O dihydropyranone), 1694 (C=O Ester); 1H NMR (500 MHz, CDCl3) 1.01 (3H, 
t, J 7.1, CO2CH2CH3), 3.06 (1H, dd, J 16.9, 12.6, C(4)HH), 3.13 (1H, dd, J 17.2, 7.3, C(4)HH), 
4.04 (2H, q, J 7.1, CO2CH2CH3), 4.14 (1H, dd, J 12.5, 7.3, C(3)H), 7.25-7.26 (4H, m, 
C(3)Ar(3)H and C(3)Ar(4)H and C(3)Ar(5)H and C(3)Ar(6)H), 7.39-7.50 (5H, m, 
C(6)Ar(3,5)H and C(6)Ar(2,6)H and C(6)Ar(4)H); 13C NMR (125 MHz, CDCl3) 13.8 
(CO2CH2CH3), 19.9 (ArCH3), 28.9 (C(4)HH), 41.3 (C(3)H), 61.2 (CO2CH2CH3), 109.1 (C(5)), 
126.8 (C(3)ArC(5)H), 127.5 (C(3)ArC(6)H), 128.1 (C(6)ArC(3,5)H), 128.1 (C(3)ArC(4)H), 
128.9 (C(6)ArC(2,6)H), 130.2 (C(6)ArC(4)H), 131.1 (C(3)ArC(3)H), 133.1 (C(3)ArC(1)), 
134.6 (C(6)ArC(1)), 136.5 (C(3)ArC(2)), 158.7 (C(6)), 166.4 (CO2Et), 168.0 (C(2)); HRMS 
(APCI+) C21H21O4 [M+H]+, found 337.1435, requires 337.1434 (+0.2 ppm). 
 
Ethyl (R)-6-(4-methoxyphenyl)-2-oxo-3-phenyl-3,4-dihydro-2H-pyran-5-carboxylate 
 
 
 
 
 
Following general procedure M, homoanhydride 675 (140 mg, 0.53 mmol) in CH2Cl2 (2 mL), 
(+)-BTM (5 mg, 0.024 mmol) ethyl 2-(4-methoxybenzoyl)acrylate 389 (100 mg, 0.43 mmol) in 
CH2Cl2 (2 mL) and i-Pr2NEt (93 µL, 0.53 mmol) in CH2Cl2 (2 mL) at −78 °C gave crude 
product. Purification by Biotage® IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (100:0 1 
CV, 100:0 to 70:30 10 CV, 70:30 3 CV)] gave the title compound (116 mg, 77%) as a white 
solid. mp 96-98 °C; 
€ 
α[ ]D
20 −63.0 (c 0.1 CH2Cl2); Chiral HPLC analysis, Chiralpak AD-H (80:20 
hexane:IPA, flow rate 1 mLmin-1, 254 nm, 30 °C) tR(S): 12.1 min, tR(R): 16.0 min, 91% ee; νmax 
(ATR) 2978, 2968 (C-H), 1773 (C=O dihydropyranone), 1713 (C=O Ester); 1H NMR (500 
MHz, CDCl3) 1.08 (3H, t, J 7.1, CO2CH2CH3), 3.06-3.19 (2H, m, C(4)HH and C(4)HH), 3.84 
(3H, s, ArOCH3), 3.96 (1H, dd, J 11.1, 6.9, C(3)H), 4.08 (2H, q, J 7.1, CO2CH2CH3), 6.90 (2H, 
d, J 8.8, C(6)Ar(3,5)H), 7.31-7.35 (3H, m, C(3)Ar(3,5)H and C(3)Ar(4)H), 7.39-7.42 (4H, m, 
C(3)Ar(2,6)H and C(6)Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 14.0 (CO2CH2CH3), 29.5 
(C(4)HH), 44.5 (ArOCH3), 55.5 (C(3)H), 61.1 (CO2CH2CH3), 107.8 (C(5)), 113.4 
(C(6)ArC(3,5)H), 125.2 (C(6)ArC(1)), 128.1 (C(3)ArC(4)H), 128.2 (C(3)ArC(3,5)H), 129.1 
(C(6)ArC(2,6)H), 130.6 (C(3)ArC(2,6)H), 136.0 (C(3)ArC(1)), 158.5 (C(6)), 161.2 
(C(6)ArC(4)), 166.6 (CO2Et), 168.5 (C(2)); HRMS (NSI+) C21H20O5Na [M+Na]+, found 
375.1208, requires 375.1203 (+1.3 ppm).  
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Ethyl (R)-2-oxo-3-phenyl-6-(p-tolyl)-3,4-dihydro-2H-pyran-5-carboxylate 
 
 
 
 
Following general procedure M, homoanhydride 675 (153 mg, 0.58 mmol) in CH2Cl2 (2 mL), 
(+)-BTM (5 mg, 0.023 mmol) ethyl 2-(4-methylbenzoyl)acrylate 390 (100 mg, 0.46 mmol)  in 
CH2Cl2 (2 mL) and Na2CO3 (61 mg, 0.58 mmol) in CH2Cl2 (2 mL) at −78 °C gave crude 
product. Purification by Biotage® IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (100:0 1 
CV, 100:0 to 70:30 10 CV, 70:30 3 CV)] gave the title compound (101 mg, 69%) as a white 
solid. mp 72-74 °C; 
€ 
α[ ]D
20 −36.0 (c 0.1 CH2Cl2); Chiral HPLC analysis, Chiralpak AD-H (90:10 
hexane:IPA, flow rate 1 mLmin-1, 220 nm, 30 °C) tR(S): 15.3 min, tR(R): 18.8 min, 84% ee; νmax 
(ATR) 2998, 2986 (C-H), 1755 (C=O dihydropyranone), 1717 (C=O Ester); 1H NMR (400 
MHz, CDCl3) 1.05 (3H, t, J 7.1, CO2CH2CH3), 2.39 (3H, s, ArCH3),  3.06-3.19 (2H, m, C(4)HH 
and C(4)HH), 3.97 (1H, dd, J 10.8, 7.1, C(3)H), 4.06 (2H, q, J 7.1, CO2CH2CH3), 7.18-7.20 
(2H, m, C(6)Ar(3,5)H), 7.30-7.36 (5H, m, C(3)Ar(3,5)H and C(3)Ar(4)H and C(6)Ar(2,6)H), 
7.38-7.42 (2H, m, C(6)Ar(2,6)H); 13C NMR (100 MHz, CDCl3) 13.9 (CO2CH2CH3), 21.6 
(ArCH3) 29.4 (C(4)HH), 44.4 (ArOCH3), 61.1 (CO2CH2CH3), 108.3 (C(5)), 128.1 
(C(3)ArC(4)H), 128.2 (C(6)ArC(3,5)H), 128.7 (C(3)ArC(3,5)H), 128.8 (C(6)ArC(2,6)H), 129.1 
(C(3)ArC(2,6)H), 135.9 (C(6)ArC(1)), 140.4 (C(3)ArC(1)), 158.8 (C(6)), 166.5 (CO2Et), 168.3 
(C(2)); HRMS (NSI+) C21H21O4 [M+H]+, found 337.1437, requires 337.1434 (+0.8 ppm). 
 
Ethyl (R)-6-(furan-2-yl)-3-(4-methoxyphenyl)-2-oxo-3,4-dihydro-2H-pyran-5-carboxylate 
 
 
 
 
 
Following general procedure M, homoanhydride 676 (208 mg, 0.64 mmol) in CH2Cl2 (2 mL), 
(+)-BTM (5 mg, 0.024 mmol) ethyl 2-(furan-2-carbonyl)acrylate 391 (100 mg, 0.51 mmol) in 
CH2Cl2 (2 mL) and i-Pr2NEt (111 µL, 0.64 mmol) in CH2Cl2 (2 mL) at −78 °C gave crude 
product. Purification by Biotage® IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (100:0 1 
CV, 100:0 to 70:30 10 CV, 70:30 3 CV)] gave the title compound (107 mg, 61%) as a white 
solid. mp 92-94 °C; 
€ 
α[ ]D
20 −34.0 (c 0.1 CH2Cl2); Chiral HPLC analysis, Chiralpak OD-H (90:10 
hexane:IPA, flow rate 1 mLmin-1, 254 nm, 30 °C) tR(R): 17.6 min, tS(S): 21.4 min, 99% ee; νmax 
(ATR) 2980, 2941 (C-H), 1778 (C=O dihydropyranone), 1713 (C=O Ester); 1H NMR (400 
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MHz, CDCl3) 1.25 (3H, t, J 7.1, CO2CH2CH3), 3.01-3.13 (2H, m, C(4)HH and C(4)HH), 3.81 
(3H, s, ArOCH3), 3.90 (1H, dd, J 10.5, 7.6, C(3)H), 4.24 (2H, q, J 7.1, CO2CH2CH3), 6.49 (1H, 
dd, J 3.5, 1.8, C(6)Ar(4)H), 6.89-6.93 (3H, m, C(6)Ar(3)H and C(3)Ar(3,5)H), 7.22 (2H, d, J 
8.6, C(3)Ar(2,6)H), 7.48 (1H, dd, C(6)Ar(5)H); 13C NMR (100 MHz, CDCl3) 14.3 
(CO2CH2CH3), 29.8 (C(4)HH), 43.7 (C(3)H), 55.5 (ArOCH3), 61.5 (CO2CH2CH3), 108.0 
(C(5)), 111.7 (C(6)ArC(4)H), 113.6 (C(6)ArC(3)H), 114.5 (C(3)ArC(3,5)H), 127.7 
(C(3)ArC(1)), 129.3 (C(3)ArC(2,6)H), 144.2 (C(6)ArC(5)H) 145.5 (C(3)ArC(4)), 146.2 (C(6)), 
149.6 (C(6)ArC(2)) 159.4 (C(3)ArC(4)), 166.4 (CO2Et), 168.1 (C(2)); HRMS (NSI+) 
C19H18O6Na [M+Na]+, found 365.1003, requires 365.0996 (+2.0 ppm). 
 
Ethyl (R)-6-(3-bromophenyl)-3-(4-methoxyphenyl)-2-oxo-3,4-dihydro-2H-pyran-5-
carboxylate 
 
 
 
 
 
Following general procedure M, homoanhydride 676 (243 mg, 0.44 mmol) in CH2Cl2 (2 mL), 
(+)-BTM (5 mg, 0.024 mmol), ethyl 2-(3-bromobenzoyl)acrylate 392 (100 mg 0.35 mmol) in 
CH2Cl2 (2 mL) and i-Pr2NEt (77 µL, 0.44 mmol) in CH2Cl2 (2 mL) at −78 °C gave crude 
product. Purification by Biotage® IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (100:0 1 
CV, 100:0 to 70:30 10 CV, 70:30 3 CV)] gave the title compound (92 mg, 61%) as a white 
solid. mp 96-98 °C; 
€ 
α[ ]D
20 −33.0 (c 0.1 CH2Cl2); Chiral HPLC analysis, Chiralpak OD-H (90:10 
hexane:IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR(R): 18.4 min, tR(S): 26.2 min, 68% ee; νmax 
(ATR) 2982, 2902 (C-H), 1773 (C=O dihydropyranone), 1697 (C=O Ester); 1H NMR (400 
MHz, CDCl3) 1.04 (3H, t, J 7.1, CO2CH2CH3), 3.04-3.18 (2H, m, C(4)HH and C(4)HH), 3.82 
(3H, s, ArOCH3), 3.93 (1H, dd, J 10.8, 7.0, C(3)H), 4.06 (2H, q, J 7.1, CO2CH2CH3), 6.94 (2H, 
d, J 8.8, C(3)Ar(3,5)H), 7.21-7.28 (3H, m, C(6)Ar(5)H) and C(3)Ar(2,6)H), 7.36 (1H, dt, 7.8, 
1.3, C(6)Ar(4)H), 7.54-7.58 (2H, m, C(6)Ar(2)H and C(6)Ar(6)H); 13C NMR (100 MHz, 
CDCl3) 13.8 (CO2CH2CH3), 29.2 (C(4)HH), 43.5 (C(3)H), 55.5 (ArOCH3), 61.3 (CO2CH2CH3), 
109.7 (C(5)), 114.6 (C(3)ArC(3,5)H), 121.9 (C(6)ArC(3)), 127.5 (C(6)ArC(4)H), 129.2 
(C(3)ArC(2,6)H), 129.2 (C(3)ArC(1)), 129.6 (C(6)ArC(5)H), 131.9 (C(6)ArC(5)H), 133.1 
(C(6)ArC(2)H), 135.0 (C(6)ArC(1)), 156.8 (C(6)), 159.5 (C(3)ArC(4)), 166.0 (CO2Et), 168.2 
(C(2)); HRMS (NSI+) C21H19Br79O5Na [M+Na]+, found 453.0301, requires 453.0308 (−1.6 
ppm). 
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Ethyl (R)-3-(4-methoxyphenyl)-6-(naphthalen-2-yl)-2-oxo-3,4-dihydro-2H-pyran-5-
carboxylate 
 
 
 
 
 
Following general procedure M, homoanhydride 676 (140 mg, 0.53 mmol) in CH2Cl2 (2 mL), 
(+)-BTM (5 mg, 0.024 mmol), ethyl 2-(2-naphthoyl)acrylate 393 (100 mg, 0.39 mmol) in 
CH2Cl2 (2 mL) and i-Pr2NEt (93 µL, 0.53 mmol) in CH2Cl2 (2 mL) at −78 °C gave crude 
product. Purification by Biotage® IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (100:0 1 
CV, 100:0 to 70:30 10 CV, 70:30 3 CV)] gave the title compound (116 mg, 77%) as a white 
solid. mp 88-90 °C; 
€ 
α[ ]D
20 −8.0 (c 0.1 CH2Cl2); Chiral HPLC analysis, Chiralpak OD-H (90:10 
hexane:IPA, flow rate 1 mLmin-1, 220 nm, 30 °C) tR(S): 24.1 min, tR(R): 28.2 min, 86% ee; νmax 
(ATR) 2980, 2902 (C-H), 1771 (C=O dihydropyranone), 1695 (C=O Ester); 1H NMR (500 
MHz, CDCl3) 0.94 (3H, t, 7.1, CO2CH2CH3), 3.10-3.23 (2H, m, C(4)HH and C(4)HH), 3.82 
(3H, s, ArOCH3), 3.97-4.06 (3H, m, C(3)H and CO2CH2CH3), 6.95 (2H, d, J 8.7, 
C(3)Ar(3,5)H), 7.28 (2H, d, J 8.7, C(3)Ar(2,6)H), 7.49-7.54 (3H, m, ArH), 7.83-7.86 (3H, m, 
ArH), 7.99 (1H, s, ArH); 13C NMR (125 MHz, CDCl3) 13.8 (CO2CH2CH3), 29.5 (C(4)HH), 
43.7 (C(3)H), 55.5 (ArOCH3), 61.2 (CO2CH2CH3), 109.1 (C(5)), 114.5 (C(3)ArC(3,5)H), 126.0 
(C(6)ArCH), 126.6 (C(6)ArCH), 127.4 (C(6)ArCH), 127.5 (C(6)ArCH), 127.8 (C(3)ArC(1)), 
127.8 (C(6)ArCH), 128.7 (C(6)ArCH), 128.9 (C(6)ArCH), 129.2 (C(3)ArC(2,6)H), 130.3 
(C(6)ArC), 132.6 (C(6)ArC), 134.0 (C(6)ArC(2)), 158.3 (C(6)), 159.4 (C(3)ArC(4)), 166.6 
(CO2Et), 168.6 (C(2)); HRMS (NSI+) C25H22O5Na [M+Na]+, found 425.1355, requires 425.1359 
(−1.0 ppm). 
9.4.6 Derivatisation of Dihydropyranone 397 
Ethyl (2S,3R,5R)-5-(4-methoxyphenyl)-6-oxo-2-phenyltetrahydro-2H-pyran-3-carboxylate 
 
 
 
 
 
To a solution of 397 (150 mg, 0.43 mmol) in EtOAc (11 mL) was added 10% Pd/C (46 mg, 
0.043 mmol), a balloon of hydrogen was appended and the reaction stirred at rt for 24 h. 
Reaction mixture was filtered through celite and concentrated under reduced pressure to give 
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crude reaction product. Purification by Biotage® IsoleraTM 4 [SNAP 25 g, 75 mL−1, 
hexane:EtOAc (100:0 1 CV, 100:0 to 70:30 10 CV, 70:30 3 CV)] (hexane:EtOAc 85:15) gave 
the title compound gave title compound (91 mg, 60% yield) as white solid. mp 128-130 °C; 
€ 
α[ ]D
20 −51.0 (c 0.1 CH2Cl2); νmax (ATR) 2984, 2979 (C-H), 1769 (C=O dihydropyranone), 1690 
(C=O Ester); 1H NMR (300 MHz, CDCl3) 0.98 (3H, t, J 7.15, CO2CH2CH3), 2.37-2.60 (2H, m, 
C(4)HH and C(4)HH), 3.39 (1H, ddd, J 8.2, 6.0, 4.5, C(3)H), 3.82 (3H, s, ArOCH3) 3.84-4.01 
(3H, m, C(5)H and CO2CH2CH3), 5.81 (1H, d, J 4.4, C(2)H), 6.93 (2H, d, J 8.8, C(5)Ar(3,5)H), 
7.26-7.30 (2H, m, C(5)Ar(2,6)H), 7.33-7.40 (5H, m, C(2)Ar(3,5)H and C(2)Ar(4)H and 
C(2)Ar(2,6)H); 13C NMR (75 MHz, CDCl3) 13.90 (CO2CHCH3), 29.6 (C(4)HH), 44.6 (C(5)H), 
45.7 (C(3)H), 55.5 (ArOCH3), 61.2 (CO2CH2CH3), 78.7 (C(2)H), 114.4 (C(5)ArC(3,5)H), 125.9 
(C(2)ArC(3,5)H), 128.6 (C(2)ArC(2,6)H), 128.6 (C(2)ArC(4)H), 129.5 (C(5)ArC(1)), 129.9 
(C(5)ArC(2,6)H), 136.4 (C(2)ArC(1)), 159.2 (C(5)ArC(4)), 171. 3 (C(6)), 172.4 (CO2Et); 
HRMS (NSI+) C21H22O5Na [M+Na]+, found 377.1355, requires 377.1359 (−1.2 ppm). 
 
(1S,2S,4R)-2-(hydroxymethyl)-4-(4-methoxyphenyl)-1-phenylpentane-1,5-diol 
 
 
 
 
 
To a solution of 445 (42 mg, 0.13 mmol) in anhydrous THF (2 mL), under an N2 atmosphere, at 
0 °C was added dropwise LiAH4 (195 µL, 0.39 mmol, 2 M in THF). The reaction was stirred for 
10 min then quenched with aq. HCl (0.1 M). The reaction mixture was extracted with EtOAc 
(×3) and combined organics dried over MgSO4, filtered and concentrated under reduced 
pressure to give crude reaction product. Purification by Biotage® IsoleraTM 4 [SNAP 10 g, 25 
mL−1, hexane:EtOAc (100:0 1 CV, 100:0 to 90:10 10 CV, 90:10 3 CV)] gave the title 
compound (36 mg, 88% yield) as colourless oil. 
€ 
α[ ]D
20 −42.0 (c 0.1 CH2Cl2); νmax (ATR); 3301 
(OH), 2909 (C-H) 1H NMR (500 MHz, CDCl3) 1.59-1.65 (2H, m, C(3)H2), 2.32 (1H, tt, J 10.4, 
4.4, C(2)H), 2.77 (1H, br. s. OH), 2.82-2.87 (1H, m, C(4)H), 3.41-3.43 (2H, m, C(2)C(1’)H2), 
3.65-3.68 (3H, m, C(5)H2 and OH), 3.80 (3H, s, ArOCH3), 4.25 (1H, br. s, OH), 4.94-4.96 (1H, 
C(1)H), 6.89 (2H, d, J 8.7, C(4)Ar(3,5)H), 7.12 (2H, d, J 8.7, C(4)Ar(2,6)H), 7.20-7.26 (3H, m, 
C(1)Ar(3,5)H and C(1)Ar(4)H), 7.30-7.33 (2H, C(1)Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 
31.0 (C(3)H2), 43.4 (C(2)H), 45.1 (C(4)H), 55.4 (ArOCH3), 65.1 (C(2)C(1’)H2), 68.0 (C(5)H2), 
76.1 (C(1)H), 114.4 (C(4)ArC(3,5)H), 125.9 (C(1)ArC(4)H), 127.4 (C(1)ArC(3,5)H), 128.5 
(C(1)ArC(2,6)H), 129.0 (C(4)ArC(2,6)H), 133.4 (C(4)ArC(1)), 143.4 (C(1)ArC(1)), 158.7 
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(C(4)ArC(4)); HRMS (CI+) C19H26NO3 [M+NH4]+, found 334.2011, requires 334.2013 (−0.6 
ppm). 
9.4.7 Enantioselective Isothiourea-Catalysed Michael addition-Lactamisation 
Methyl (S)-6-oxo-2,5-diphenyl-1-tosyl-1,4,5,6-tetrahydropyridine-3-carboxylate 
 
 
 
 
Following general procedure N, phenylacetic acid (37 mg, 0.27 mmol), i-Pr2NEt (70 µL, 0.40 
mmol) and pivaloyl chloride (49 µL, 0.40 mmol) in CH2Cl2 (3 mL), (−)-tetramisoleHCl 47 (3 
mg, 0.013 mmol), ketimine 263 (50 mg, 0.13 mmol) and i-Pr2NEt (23 µL, 0.13 mmol) were 
warmed from −78 °C to rt over 16 h to give crude product. Column chromatography (12:88 
EtOAc:Petrol) gave the title compound (44 mg, 72%) as a white solid. mp 172-174 °C; 
€ 
α[ ]D
20 
−23.3 (c 0.15 CH2Cl2); Chiral HPLC analysis, Chiralpak AD-H (80:20 hexane:IPA, flow rate 1 
mLmin-1, 211 nm, 30 °C) tR(S): 15.8 min, tR(R): 23.0 min, 91% ee; νmax (ATR) 3028, 2955 (C-
H), 1711 (C=O dihydropyridone), 1701 (C=O Ester); 1H NMR (500 MHz, CDCl3) 2.40 (3H, s, 
ArCH3), 3.01 (1H, dd, J 15.2, 5.0, C(4)HH), 3.14 (1H, dd, J 15.2, 11.5, C(4)HH), 3.52 (3H, s, 
CO2CH3), 3.83 (1H, dd, J 11.4, 5.0, C(5)H), 7.14-7.20 (6H, m, ArCH), 7.26-7.40 (6H, m, 
ArCH), 7.47 (2H, d, J 8.0, ArCH); 13C NMR (125 MHz, CDCl3) 21.8 (ArCH3), 30.3 (C(4)), 
51.3 (C(5)), 52.0 (CO2CH3), 120.7 (C(3)), 127.6 (ArC), 128.0 (ArC), 128.2 (ArC), 129.0 (ArC), 
129.0 (ArC), 129.1 (ArC), 129.2 (ArC), 129.6 (ArC), 133.9 (4ry ArC), 136.1 (ArC), 136.8 
(ArC), 145.1 (ArC), 145.3 (ArC), 166.6 (CO2CH3), 173.4 (C(6)); HRMS (NSI+) C26H24NO5S 
[M+H]+, found 462.1369, requires 462.1370 (−0.2 ppm). 
 
Methyl (S)-5-(4-methoxyphenyl)-6-oxo-2-phenyl-1-tosyl-1,4,5,6-tetrahydropyridine-3-
carboxylate 
 
 
 
 
 
Following general procedure N, 4-methoxyphenylacetic acid (45 mg, 0.27 mmol), i-Pr2NEt (70 
µL, 0.40 mmol), pivaloyl chloride (49 µL, 0.40 mmol) in CH2Cl2 (3 mL), (−)-tetramisoleHCl 
47 (3 mg, 0.013 mmol), ketimine 263 (50 mg, 0.13 mmol) and i-Pr2NEt (23 µL, 0.13 mmol) 
were warmed from −78 °C to rt over 16 h to give crude product. Column chromatography 
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(15:75 EtOAc:Petrol) to give the title compound (50 mg, 76%) as a colourless oil; 
€ 
α[ ]D
20 −31.6 
(c 0.25 CH2Cl2); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane:IPA, flow rate 1 
mLmin-1, 211 nm, 30 °C) tR(S): 12.7 min, tR(R): 25.4 min, 95% ee; νmax (ATR) 2951, 2918 (C-
H), 1719 (C=O dihydropyridone), 1699 (C=O Ester); 1H NMR (500 MHz, CDCl3) 2.39 (3H, s, 
SO2ArCH3), 2.98 (1H, dd, J 15.2, 5.0 C(4)HH), 3.10 (1H, dd, J 15.2, 11.6 C(4)HH), 3.52 (3H, s, 
CO2CH3), 3.76-3.79 (4H, m, C(5)H and ArOCH3), 6.87 (2H, d, J 8.7, C(5)Ar(3,5)H), 7.09 (2H, 
d, J 8.7, SO2Ar(3,5)H), 7.14 (2H, d, J 8.1, C(2)Ar(3,5)H), 7.18-7.19 (2H, m, C(2)Ar(2,6)H), 
7.28 (2H, d, J 7.8, C(5)Ar(2,6)H), 7.37 (1H, t, J 7.41, C(2)Ar(4)H), 7.46 (2H, d, J 8.4, 
SO2Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 21.8 (SO2ArCH3), 30.4 (C(4)HH), 50.6 (C(5)H), 
52.1 (CO2CH3), 55.4 (ArOCH3), 114.4 (C(5)ArC(3,5)H), 120.8 (C(3)), 127.6 (C(5)ArC(2,6)H), 
128.9 (C(5)ArC(1)), 129.1 (SO2ArC(2,6)H), 129.1 (C(2)ArC(3,5)H), 129.2 (C(2)ArC(4)H), 
129.3 (SO2ArC(3,5)H), 129.6 (C(2)ArC(2,6)H), 133.9 (C(2)ArC(1)), 136.2 (SO2ArC(4)), 145.1 
(C(2)), 145.2 (SO2ArC(1)), 159.2 (C(5)ArC(4)), 166.7 (CO2Me), 173.7 (C(6)); HRMS (NSI+) 
C26H24NO6S [M+H]+, found 492.1466, requires 492.1475 (−1.9 ppm). 
 
Methyl (S)-5-(4-(dimethylamino)phenyl)-6-oxo-2-phenyl-1-tosyl-1,4,5,6-
tetrahydropyridine-3-carboxylate 
 
 
 
 
 
Following general procedure N, 4-(dimethylamino)phenyl acetic acid (104 mg, 0.58 mmol), i-
Pr2NEt (152 µL, 0.87 mmol), pivaloyl chloride (107 µL, 0.87 mmol) in CH2Cl2 (5 mL), (−)-
tetramisole (4 mg, 0.015 mmol), ketimine 263 (100 mg, 0.29 mmol) and i-Pr2NEt (51 µL, 0.29 
mmol) were warmed −78 °C to rt over 16 h to give crude product. Column chromatography 
(12:88 EtOAc:Petrol) to give the title compound (100 mg, 68%) as a white solid; mp 164-166 
°C : 
€ 
α[ ]D
20 −27.1 (c 0.25 CH2Cl2); Chiral HPLC analysis, Chiralpak AD-H (80:20 hexane:IPA, 
flow rate 1 mLmin-1, 254 nm, 30 °C) tR(S): 23.4 min, tR(R): 26.2 min, 94% ee; νmax (ATR) 2883 
(C-H), 1722(C=O dihydropyridinone), 1690 (C=O Ester) 1155 (C-O ester); 1H NMR (400 
MHz, CDCl3) 2.39 (3H, s, SO2ArCH3), 2.93-3.00 (7H, m, ArN(CH3)2 and C(4)HH), 3.10 (1H, 
dd, J 15.2, 11.3, C(4)HH), 3.52 (3H, s, CO2CH3), 3.73 (1H, dd, J 11.1, 5.0, C(5)H), 6.68 (2H, d, 
J 8.6, C(5)Ar(3,5)H), 7.03 (2H, J 8.59, SO2Ar(3,5)H), 7.13 (2H, d, J 8.2, C(2)Ar(3,5)H), 7.19 
(2H, d, J 7.3, C(5)Ar(2,6)H), 7.26-7.29 (2H, m, C(2)Ar(3,5)H), 7.37 (1H, t, J 7.32, 
C(2)Ar(4)H), 7.47 (2H, d, J 8.3, SO2Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 21.8 (SO2ArCH3), 
30.3 (C(4)HH), 40.7 (ArN(CH3)2), 50.5 (C(5)H), 52.0 (CO2CH3), 112.9 (C(5)ArC(3,5)H), 120.9 
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(C(3)), 124.3 (C(5)ArC(1)), 127.6 (C(2)ArC(3,5)H), 128.8 (SO2ArC(3,5)H), 129.0 
(C(2)ArC(4)H), 129.1 (C(2)ArC(3,5)H), 129.1 (SO2ArC(2,6)H), 129.5 (C(5)ArC(2,6)H), 134.1 
(SO2ArC(4)), 136.3 (C(2)C(1)), 145.0 (C(2)), 145.1 (SO2ArC(1)), 150.2 (C(5)ArC(4)NMe2), 
166.8 (CO2Me), 174.0 (C(6)); HRMS (NSI+) C28H29N2O5S [M+H]+, found 505.1780, requires 
505.1792 (−2.3 ppm). 
 
Methyl (S)-6-oxo-2-phenyl-1-tosyl-5-(4-(trifluoromethyl)phenyl)-1,4,5,6-
tetrahydropyridine-3-carboxylate 
 
 
 
 
 
Following general procedure N, phenylacetic acid (45 mg, 0.27 mmol), i-Pr2NEt (70 µL, 0.40 
mmol), pivaloyl chloride (49 µL, 0.40 mmol) in CH2Cl2 (3 mL), (−)-tetramisoleHCl 47 (3 mg, 
0.013 mmol), ketimine 263 (50 mg, 0.13 mmol) and i-Pr2NEt (23 µL, 0.13 mmol) were warmed 
from −78 °C to rt over 16 h to give crude product. Column chromatography (15:75 
EtOAc:Petrol) to give the title compound (50 mg, 76%) as a white solid: mp 138-140 °C; 
€ 
α[ ]D
20 
−66.0 (c 0.10 CH2Cl2); Chiral HPLC analysis, Chiralpak AD-H (80:20 hexane:IPA, flow rate 1 
mLmin-1, 211 nm, 30 °C) tR(R): 17.2 min, tR(S): 21.5 min, 97% ee; νmax (ATR) 2957, 2930 (C-
H), 1730 (C=O dihydropyridone), 1721 (C=O Ester); 1H NMR (500 MHz, CDCl3) 2.40 (3H, s, 
SO2ArCH3), 3.02 (1H, dd, J 15.2, 5.0 C(4)HH), 3.14 (1H, dd, J 15.1, 12.1 C(4)HH), 3.53 (3H, s, 
CO2CH3), 3.89 (1H, dd, J 11.9, 4.9, C(5)H), 7.15 (2H, d, J 8.2, SO2Ar(3,5)H), 7.19 (2H, d, J 
7.4, C(5)Ar(2,6)H), 7.26-7.32 (4H, m, C(2)Ar(3,5)H and C(2)Ar(2,6)H), 7.39 (1H, t, J 7.4, 
C(2)Ar(4)H), 7.45 (2H, d, J 8.3, SO2Ar(2,6)H), 7.61 (2H, d, J 8.0, C(5)Ar(3,5)H); 13C NMR 
(100 MHz, CDCl3) 21.8 (SO2ArCH3), 30.2 (C(4)HH), 51.2 (C(5)H), 52.1 (CO2CH3), 120.5 
(C(3)), 124.0 (q, 1JCF 271, ArCF3), 125.9 (q, 3JCF 2.75, C(5)ArC(3,5)H), 127.7 (C(2)ArC(3,5)H), 
128.8 (C(2)ArC(2,6)H), 129.1 (SO2ArC(2,6)H), 129.2 (C(5)ArC(2,6)H), 129.3 (C(2)ArC(4)H), 
129.6 (SO2ArC(3,5)H), 130.3 (q, 2JCF 32.3, C(5)ArC(4)), 133.7 (C(2)ArC(1)), 136.0 
(SO2ArC(4)), 140.8 (C(5)ArC(1)), 145.4 (C(2)), 145.6 (SO2ArC(1)), 166.4 (CO2Me), 172.7 
(C(6)); 19F NMR (470 MHz) −62.8 (ArCF3); HRMS (NSI+) C27H23NO5F3S [M+H]+, found 
530.1235, requires 530.1244 (−1.6 ppm). 
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Methyl (S)-6-oxo-2-phenyl-5-(thiophen-3-yl)-1-tosyl-1,4,5,6-tetrahydropyridine-3-
carboxylate 
 
 
 
 
 
Following general procedure N, 3-thiophene acetic acid (57 mg, 0.40 mmol), i-Pr2NEt (105 µL, 
0.60 mmol), pivaloyl chloride (74 µL, 0.60 mmol) in CH2Cl2 (5 mL), (−)-tetramisoleHCl 47 (3 
mg, 0.013 mmol), ketimine 263 (75 mg, 0.20 mmol) and i-Pr2NEt (35 µL, 0.20 mmol) were 
warmed −78 °C to rt over 16 h to give crude product. Column chromatography (10:90 
EtOAc:Petrol) to give the title compound (61 mg, 65%) as a white solid: mp 159-152 °C; 
€ 
α[ ]D
20 
−28.0 (c 0.1 CH2Cl2); Chiral HPLC analysis, Chiralpak IB (92.5:7.5 hexane:IPA, flow rate 1.5 
mLmin-1, 220 nm, 30 °C) tR(S): 13.9 min, tR(R): 15.8 min, 91% ee;  νmax (ATR) 3096, 2957 (C-
H), 1720 (C=O dihydropyridone), 1699 (C=O Ester) 1150 (C-O); 1H NMR (400 MHz, CDCl3) 
2.39 (3H, s, SO2ArCH3), 3.05-3.16 (2H, m, C(4)HH and C(4)HH), 3.52 (3H, s, CO2CH3), 4.00 
(1H, dd, J 8.6, 5.6, C(5)H), 6.98 (1H, dd, J 5.0, 1.3, C(5)Ar(4)H), 7.12-7.15 (5H, m, 
SO2Ar(3,5)H and C(2)Ar(3,5)H and C(5)Ar(2)H), 7.24-7.27 (2H, m, C(2)Ar(2,6)H), 7.30 (1H, 
dd, J C(5)Ar(5)H), 7.36 (1H, tt, J 6.8, 1.2, C(2)Ar(4)H), 7.45 (2H, d, J 8.4, SO2Ar(2,6)H); 13C 
NMR (125 MHz, CDCl3) 21.8 (SO2ArCH3), 29.3 (C(4)HH), 46.6 (C(5)H), 52.1 (CO2CH3), 
120.1 (C(3)), 122.8 (C(5)ArC(2)H), 126.6 (C(5)ArC(5)H), 127.1 (C(5)ArC(4)H), 127.6 
(C(2)ArC(2,6)H), 129.0 (SO2ArC(2,6)H), 129.1 (C(2)ArC(4)H), 129.2 (SO2ArC(3,5)H), 129.6 
(C(2)ArC(3,5)H), 133.9 (SO2ArC(4)), 136.1 (C(2)ArC(1)), 136.2 (C(5)C(3)), 145.2 (C(2)), 
145.2 (SO2ArC(1)), 166.7 (CO2Me), 172.4 (C(6)); HRMS (NSI+) C24H21NO5S2Na [M+Na]+, 
found 490.0739, requires 490.0753 (−2.9 ppm). 
 
Methyl (S)-6-oxo-2-phenyl-5-(m-tolyl)-1-tosyl-1,4,5,6-tetrahydropyridine-3-carboxylate 
 
 
 
 
 
Following general procedure N, m-tolylacetic acid (40 mg, 0.27 mmol), i-Pr2NEt (70 µL, 0.40 
mmol), pivaloyl chloride (49 µL, 0.40 mmol), in CH2Cl2 (3 mL), (−)-tetramisoleHCl 47 (3 mg, 
0.013 mmol), ketimine 263 (50 mg, 0.13 mmol) and i-Pr2NEt (23 µL, 0.13 mmol) were warmed 
−78 °C to rt over 16 h to give crude product. Column chromatography (12.5:87.5 EtOAc:Petrol) 
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to give the title compound (44 mg, 69%) as a colourless oil; 
€ 
α[ ]D
20 −32.1 (c 0.10 CH2Cl2); 
Chiral HPLC analysis, Chiralpak AD-H (80:20 hexane:IPA, flow rate 1 mLmin-1, 211 nm, 30 
°C) tR(S): 14.7 min, tR(R): 28.7 min, 95% ee; νmax (ATR) 2953 (C-H), 1717 (C=O 
dihydropyridinone), 1703 (C=O Ester); 1H NMR (500 MHz, CDCl3) 2.32 (3H, s, C(5)ArCH3), 
2.40 (3H, s, SO2ArCH3), 2.98 (1H, dd, J 15.2, 5.0 C(4)HH), 3.12 (1H, dd, J 15.2, 11.8 C(4)HH), 
3.52 (3H, s, CO2CH3), 3.78 (1H, dd, J 11.7, 5.0, C(5)H), 6.93-6.97 (2H, m, C(5)Ar(2)H and 
C(5)Ar(4)H),  7.10 (1H, d, J 7.6, C(5)Ar(6)H), 7.16 (2H, d, J 8.2, SO2Ar(3,5)H), 7.20-7.24 (3H, 
m, C(5)Ar(5)H and C(2)Ar(3,5)H), 7.27-7.30 (2H, m, C(2)Ar(2,6)H), 7.38 (1H, t, J 7.4, 
C(2)Ar(4)H), 7.50 (2H, d, J 8.4, SO2Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 21.7 
(C(5)ArCH3), 21.8 (SO2ArCH3), 30.4 (C(4)HH), 51.3 (C(5)H), 52.0 (CO2CH3), 120.7 (C(3)), 
125.3 (C(5)ArC(2)H), 127.6 (C(2)ArC(2,6)H), 128.8 (C(5)ArC(4)H), 128.9 (C(5)ArC(6)H), 
128.9 (C(5)ArC(5)H), 129.1 (SO2ArC(2,6)H), 129.1 (C(2)ArC(4)H), 129.2 (SO2ArC(3,5)H), 
129.5 (C(2)ArC(3,5)H), 134.0 (C(5)ArC(3)), 136.2 (SO2ArC(4)), 136.8 (C(2)ArC(1)), 138.6 
(C(5)ArC(1)), 145.1 (C(2)), 145.3 (SO2ArC(1)), 166.7 (CO2Me), 173.5 (C(6)); HRMS (NSI+) 
C27H26NO5S [M+H]+, found 476.1517, requires 476.1526 (−1.9 ppm). 
 
Methyl (S)-5-(4-bromophenyl)-6-oxo-2-phenyl-1-tosyl-1,4,5,6-tetrahydropyridine-3-
carboxylate 
 
 
 
 
 
Following general procedure N, 4-bromophenylacetic acid (86 mg, 0.40 mmol), i-Pr2NEt (105 
µL, 0.60 mmol), pivaloyl chloride (74 µL, 0.60 mmol) in CH2Cl2 (5 mL), (−)-tetramisoleHCl 
47 (3 mg, 0.013 mmol), ketimine 263 (75 mg, 0.20 mmol) and i-Pr2NEt (35 µL, 0.20 mmol) 
were warmed −78 °C to rt over 16 h to give crude product. Column chromatography (10:90 
EtOAc:Petrol) to give the title compound (44 mg, 69%) as a white solid: mp 136-138 °C; 
€ 
α[ ]D
20 
−12.0 (c 0.1 CH2Cl2); Chiral HPLC analysis, Chiralpak AD-H (80:20 hexane:IPA, flow rate 1 
mLmin-1, 254 nm, 30 °C) tR(R): 23.3 min, tR(S): 28.3 min, 72% ee; νmax (ATR) 2949 (C-H), 
1730 (C=O dihydropyridinone), 1730 (C=O Ester) 1138 (C-O ester); 1H NMR (500 MHz, 
CDCl3) 2.40 (3H, s, SO2ArCH3), 2.99 (1H, dd, J 15.2, 5.1 C(4)HH), 3.09 (1H, dd, J 15.2, 11.7 
C(4)HH), 3.52 (3H, s, CO2CH3), 3.78 (1H, dd, J 11.7, 5.1, C(5)H), 7.05 (2H, d, J 8.4, 
C(5)Ar(2,5)H), 7.15 (2H, d, J 8.2, SO2Ar(3,5)H), 7.18 (2H, d, J 7.2, C(2)Ar(3,5)H), 7.29 (2H, 
d, J 7.9, C(2)Ar(2,6)H), 7.38 (1H, t, J 7.5, C(2)Ar(4)H), 7.44-7.48 (4H, m, SO2Ar(2,6)H and 
C(5)Ar(3,5)H); 13C NMR (125 MHz, CDCl3) 21.8 (SO2ArCH3), 30.1 (C(4)HH), 50.9 (C(5)H), 
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52.1 (CO2CH3), 120.5 (C(3)), 122.1 (C(5)ArC(4)Br), 127.6 (C(2)ArC(2,6)H), 129.1 
(SO2ArC(2,6)H), 129.2 (SO2ArC(3,5)H), 129.2 (C(2)ArC(4)H), 129.6 (C(2)ArC(3,5)H), 130.0 
(C(5)ArC(3,5)H), 132.2 (C(5)ArC(3,5)H), 133.7 (SO2ArC(4)), 135.8 (C(2)ArC(1)), 136.0 
(C(5)ArC(1)), 145.3 (C(2)), 145.4 (SO2ArC(1)), 166.5 (CO2Me), 172.9 (C(6)); HRMS (NSI+) 
C26H22Br79O5SNa [M+Na]+, found 562.0283, requires 562.0294 (−2.0 ppm). 
 
Methyl (S)-2-(4-methoxyphenyl)-6-oxo-5-phenyl-1-tosyl-1,4,5,6-tetrahydropyridine-3-
carboxylate 
 
 
 
 
Following general procedure N, phenylacetic acid (74 mg, 0.54 mmol), i-Pr2NEt (141 µL, 0.81 
mmol), pivaloyl chloride (100 µL, 0.81 mmol) in CH2Cl2 (5 mL), (−)-tetramisoleHCl 47 (3 
mg, 0.014 mmol), ketimine 267 (100 mg, 0.27 mmol) and i-Pr2NEt (47 µL, 0.27 mmol) were 
warmed −78 °C to rt over 16 h to give crude product. Column chromatography (12.5:87.5 
EtOAc:Petrol) to give the title compound (44 mg, 69%) as a colourless oil: 
€ 
α[ ]D
20 −16.0 (c 0.25 
CH2Cl2); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane:IPA, flow rate 1 mLmin-1, 254 
nm, 30 °C) tR(S): 15.5 min, tR(R): 25.8 min, 98% ee; νmax (ATR) 3001 (C-H), 1727 (C=O 
dihydropyridone), 1705 (C=O Ester); 1H NMR (500 MHz, CDCl3) δH: 2.40 (3H, s, SO2ArCH3), 
2.99 (1H, dd, J 15.2, 5.0 C(4)HH), 3.10 (1H, dd, J 15.2, 11.6 C(4)HH), 3.55 (3H, s, CO2CH3), 
3.80 (1H, dd, J 11.5, 5.0, C(5)H), 3.85 (3H, s, ArOCH3), 6.80 (2H, d, J 8.8, C(2)Ar(3,5)H), 
7.12-7.18 (6H, m, SO2Ar(3,5)H, C(5)Ar(3,5)H and C(5)Ar(2,6)H), 7.28-7.34 (3H, m, 
C(2)Ar(2,6)H and C(5)Ar(4)H), 7.54 (2H, d, J 8.4, SO2Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 
δC: 21.8 (SO2ArCH3), 30.4 (C(4)HH), 51.6 (C(5)H), 52.1 (CO2CH3), 55.4 (ArOCH3), 113.1 
(C(2)ArC(3,5)), 119.9 (C(3)), 126.3 (C(2)ArC(1)), 128.0 (C(5)ArC(4)H), 128.3 
(C(5)ArC(3,5)H), 129.0 (SO2ArC(2,6)H), 129.1 (C(5)ArC(2,6)H), 129.2 (C(2)ArC(2,6)H), 
131.0 (SO2ArC(3,5)H), 136.4 (SO2ArC(4)), 137.0 (C(5)ArC(1)), 145.1 (C(2)), 145.5 
(SO2ArC(1)), 160.3 (C(2)ArC(4)), 166.8 (CO2Me), 173.5 (C(6)); HRMS (NSI+) C27H26NO6S 
[M+H]+, found 492.1467, requires 492.1475 (−1.7 ppm). 
 
Methyl (S)-6-oxo-5-phenyl-2-(p-tolyl)-1-tosyl-1,4,5,6-tetrahydropyridine-3-carboxylate 
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Following general procedure N, phenylacetic acid (76 mg, 0.56 mmol), i-Pr2NEt (146 µL, 0.84 
mmol), pivaloyl chloride (103 µL, 0.84 mmol) in CH2Cl2 (5 mL), (−)-tetramisoleHCl 47 (3 
mg, 0.014 mmol), methyl 2-((4-methylphenyl)(tosylimino)methyl)acrylate 286 (100 mg, 0.28 
mmol) and i-Pr2NEt (49 µL, 0.28 mmol) were warmed −78 °C to rt over 16 h to give crude 
product. Column chromatography (15:85 EtOAc:Petrol) to give the title compound (79 mg, 
59%) as a white solid: mp 134-136 °C; 
€ 
α[ ]D
20 −14.8 (c 0.25 CH2Cl2); Chiral HPLC analysis, 
Chiralpak AD-H (80:20 hexane:IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR(R): 13.3 min, 
tR(S): 25.6 min, 90% ee; νmax (ATR) 3032, 2953 (C-H), 1738 (C=O dihydropyridinone), 1717 
(C=O Ester); 1H NMR (500 MHz, CDCl3) 2.56 (3H, s, SO2ArCH3), 2.57 (3H, s, C(2)ArCH3), 
3.15 (1H, dd, J 15.2, 5.0 C(4)HH), 3.27 (1H, dd, J 15.2, 11.6 C(4)HH), 3.71 (3H, s, CO2CH3), 
3.97 (1H, dd, J 11.5, 5.0, C(5)H), 7.26-7.33 (6H, m, SO2Ar(3,5)H and C(2)Ar(3,5)H), 7.42-7.51 
(5H, m, C(5)Ar(3,5)H and C(5)Ar(2,6)H and C(5)Ar(5)H), 7.68 (2H, d, J 8.4, SO2Ar(2,6)H); 
13C NMR (125 MHz, CDCl3) 21.7 (C(2)ArCH3), 21.8 (SO2ArCH3), 30.4 (C(4)HH), 51.4 
(C(5)H), 52.1 (CO2CH3), 120.2 (C(3)), 128.0 (C(5)ArC(4)H), 128.3 (C(2)ArC(3,5)H), 128.4 
(SO2ArC(3,5)H), 129.0 (C(5)ArC(3,5)H), 129.1 (SO2ArC(2,6)H), 129.2 (C(2)ArC(2,6)H), 
129.4 (C(5)ArC(2,6)H), 131.1 (C(2)ArC(1)), 136.3 (SO2ArC(4)), 136.9 (C(2)ArC(4)), 139.2 
(C(5)ArC(1)), 145.1 (C(2)), 145.6 (SO2ArC(1)), 166.7 (CO2Me), 173.4 (C(6)); HRMS (NSI+) 
C27H25NO5SNa [M+Na]+, found 498.1338, requires 498.1346 (−1.5 ppm). 
 
Methyl (S)-2-(3,5-dimethylphenyl)-6-oxo-5-phenyl-1-tosyl-1,4,5,6-tetrahydropyridine-3-
carboxylate 
 
 
 
 
 
Following general procedure N, phenylacetic acid (74 mg, 0.54 mmol), i-Pr2NEt (141 µL, 0.81 
mmol), pivaloyl chloride (100 µL, 0.81 mmol) in CH2Cl2 (5 mL), (−)-tetramisoleHCl 47 (3 
mg, 0.014 mmol), ketimine 285 (100 mg, 0.27 mmol) and i-Pr2NEt (47 µL, 0.27 mmol) were 
warmed −78 °C to rt over 16 h to give crude product. Column chromatography (10:90 
EtOAc:Petrol) to give the title compound (44 mg, 69%) as a white solid: mp 182-184 °C; 
€ 
α[ ]D
20 
−15.0 (c 0.1 CH2Cl2); Chiral HPLC analysis, Chiralpak AD-H (90:10 hexane:IPA, flow rate 1 
mLmin-1, 211 nm, 30 °C) tR(R): 11.8 min, tR(S): 17.6 min, 97% ee; νmax (ATR) 2950 (C-H), 
1730 (C=O dihydropyridone), 1700 (C=O Ester) 1150 (C-O ester); 1H NMR (400 MHz, CDCl3) 
2.22 (6H, s, C(2)Ar(3,5)CH3) 2.40 (3H, s, SO2ArCH3), 2.96 (1H, dd, J 15.2, 5.1 C(4)HH), 3.12 
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(1H, dd, J 15.2, 11.9 C(4)HH), 3.54 (3H, s, CO2CH3), 3.80 (1H, dd, J 11.9, 5.0, C(5)H), 6.74 
(2H, br. s, C(2)Ar(2,6)H), 6.98 (1H, br. s, C(2)Ar(4)H), 7.14-7.20 (4H, m, SO2Ar(3,5)H and 
C(5)Ar(3,5)H), 7.28-7.37 (3H, m, C(2)Ar(2,6)H and C(5)Ar(4)H), 7.50 (2H, d, J 8.4, 
SO2Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 21.3 (C(2)Ar(3,5)CH3), 21.8 (SO2ArCH3), 30.7 
(C(4)HH), 51.7 (C(5)H), 52.0 (CO2CH3), 120.4 (C(3)), 127.3 (C(2)ArC(2,6)H), 128.0 
(C(5)ArC(3,5)H), 128.4 (SO2ArC(3,5)H), 129.0 (C(5)ArC(4)H), 129.1 (C(5)ArC(2,6)H), 129.1 
(SO2ArC(2,6)H), 130.9 (C(2)ArC(4)H), 133.4 (SO2ArC(4)), 136.3 (C(5)ArC(1)), 137.0 
(C(2)ArC(1)), 137.1 (C(2)ArC(3,5)), 145.0 (C(2)), 145.4 (SO2ArC(1)), 166.9 (CO2Me), 173.7 
(C(6)); HRMS (NSI+) C28H26NO5SNa [M+Na]+, found 512.1488, requires 512.1502 (−2.8 ppm). 
 
Methyl (S)-2-(naphthalen-2-yl)-6-oxo-5-phenyl-1-tosyl-1,4,5,6-tetrahydropyridine-3-
carboxylate 
 
 
 
 
 
Following general procedure N, phenylacetic acid (68 mg, 0.50 mmol), i-Pr2NEt (131 µL, 0.75 
mmol), pivaloyl chloride (93 µL, 0.75 mmol) in CH2Cl2 (5 mL), (−)-tetramisoleHCl 47 (3 mg, 
0.014 mmol), ketimine 290 (100 mg, 0.25 mmol) and i-Pr2NEt (44 µL, 0.25 mmol) were 
warmed −78 °C to rt over 16 h to give crude product. Column chromatography (15:85 
EtOAc:Petrol) to give the title compound (88 mg, 69%) as a white solid: mp 157-159 °C; 
€ 
α[ ]D
20 
+46.0 (c 0.25 CH2Cl2); Chiral HPLC analysis, Chiralpak AD-H (80:20 hexane:IPA, flow rate 1 
mLmin-1, 254 nm, 30 °C) tR(R): 15.3 min, tR(S): 23.7 min, 91% ee; νmax (ATR) 3037, 2952 (C-
H), 1735 (C=O dihydropyridone), 1718 (C=O Ester);  1H NMR (400 MHz, CDCl3) δH: 2.31 
(3H, s, SO2ArCH3), 3.08 (1H, dd, J 15.2, 5.1 C(4)HH), 3.20 (1H, dd, J 15.2, 11.6 C(4)HH), 3.50 
(3H, s, CO2CH3), 3.89 (1H, dd, J 11.5, 5.1, C(5)H), 6.91 (2H, d, J 8.1, ArH), 7.22-7.26 (2H, m, 
ArH), 7.29-7.38 (6H, m, ArH), 7.44-7.55 (4H, m, ArH), 7.80 (1H, d, J 8.5, ArH). 7.86 (1H, d, J 
8.0, ArH); 13C NMR (125 MHz, CDCl3) δC: 21.7 (SO2ArCH3), 30.5 (C(4)HH), 51.6 (C(5)H), 
52.1 (CO2CH3), 120.7 (C(3)), 126.3 (ArCH), 127.0 (ArCH), 127.0 (ArCH), 127.9 (ArCH), 
127.9 (ArCH), 128.1 (ArCH), 128.1 (ArCH), 128.3 (ArCH), 128.4 (ArC), 128.9 (ArCH), 129.1 
(ArCH), 131.4 (ArC), 132.4 (ArC), 133.4 (ArC), 136.2 (ArC), 137.0 (ArC), 145.1 (C(2)), 145.7 
(SO2ArC(1)), 166.5 (CO2Me), 173.5 (C(2)); HRMS (NSI+) C30H25NO5SNa [M+Na]+, found 
534.1339, requires 534.1346 (−1.2 ppm). 
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9.4.8 X-Ray Structure Determination 
Crystal data for 378: C24H20O4, M = 372.42, colourless prism, orthorhombic space group P21/c; 
a = 79008(4) Å, b = 9.1343(5) Å, c = 25.7027(16) Å, α = β = γ = 90°, V = 1854.92(18) Å3, Z = 
4, Dc = 1.333 g cm−3, flack parameter = 0.11(4), R = 0.0302, RW = 0.0.0759 for 3354 data with 
I> 2σ(I) and 255 parameters. Data were recorded at 93 K on Rigaku XtaLAB P100 
diffractometer using multi-layer mirror monochromated Cu-Kσ radiation and the structures 
were solved by direct methods and refined using full-matrix least square analysis. 
 
Crystal data for 424: C27H22F3NO5S, M = 529.52, colourless prism, orthorhombic space group 
P21/c; a = 10.1761(10) Å, b = 14.7964(15) Å, c = 16.1403(17) Å, α = β = γ = 90°, V = 
2430.2(4) Å3, Z = 4, Dc = 1.447 g cm−3, flack parameter = 0.016(4) R = 0.0287, RW = 0.0759 for 
4413 data with I> 2σ(I) and 336 parameters. Data were recorded at 93 K on Rigaku XtaLAB 
P100 diffractometer using multi-layer mirror monochromated Cu-Kσ radiation and the 
structures were solved by direct methods and refined using full-matrix least square analysis. 
9.5 Experimental for Chapter 5 
9.5.1  General Experimental Procedures 
General Procedure O: Preparation of trichloromethyl carbinols 
 
 
 
 
Following a literature procedure,[115] trichloroacetic acid (1.5 eq) and sodium trichloroacetate 
(1.5 eq) were added to a solution of the appropriate aldehyde (1.0 eq) in DMF at 0 °C. The 
reaction mixture was stirred in the ice/water bath and allowed to warm slowly to rt over 16 h 
before being diluted with water and extracted with EtOAc (×3). The combined organic fraction 
was washed with water (×3), sat. aq. NaHCO3, dried over MgSO4, filtered and concentrated 
under reduced pressure to give the crude product, which was purified by column 
chromatography in the solvent system stated. 
 
General Procedure P: Preparation of α,β-unsaturated trichloromethyl ketones 
 
 
 
 R1
OH
CCl3 R1
O
CCl3
i) DMSO (8.0 eq)
(COCl)2 (4.0 eq)
CH2Cl2
 −60 °C, 15 min 
ii) Et3N (20.0 eq)
rt, 30 min
R1
O
H R1
OH
CCl3
i) Cl3CCO2H (1.5 eq)
Cl3CCO2Na (1.5 eq)
DMF, 0 °C-rt
16 h
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Following a literature procedure,[117] a solution of DMSO (8.0 eq) in CH2Cl2 was added 
dropwise to a solution of oxalyl chloride (4.0 eq) in CH2Cl2  at −60 °C followed by stirring for 2 
min at −60 °C. A solution of the appropriate alcohol (1.0 eq) in CH2Cl2 was added dropwise 
followed by stirring for 15 min at −60 °C. Et3N (20 eq) was added dropwise and the reaction 
mixture was stirred and allowed to warm to rt. The reaction mixture was quenched with aq. HCl 
(2 M) and extracted with CH2Cl2 (×3). The combined organic fraction was dried over MgSO4, 
filtered and concentrated under reduced pressure to give the crude product, which was purified 
by column chromatography in the solvent system stated. 
 
General procedure Q: Intermolecular Michael addition-lactonisation followed by in situ ring 
opening 
 
 
 
 
 
 
 
To a solution of requisite carboxylic acid (1.5 eq) in CH2Cl2 (0.1 M in trichloromethyl ketone) 
were added i-Pr2NEt (2.25 eq) and pivaloyl chloride (2.25 eq) and the reaction mixture was 
stirred for 5 min before cooling to −78 °C. (2S,3R)-HyperBTM 53 (5 mol%), the requisite α,β-
unsaturated trichloromethyl ketone (1 eq) and i-Pr2NEt (1.5 eq) were added in succession and 
the reaction mixture was stirred at −78 °C for 16 h. The appropriate nucleophile (excess) and 
DMAP (20 mol%) were added and the reaction mixture was stirred at rt for 16 h. The reaction 
mixture was diluted with CH2Cl2 and washed with aq. HCl (1 M) and brine. The organic layer 
was dried over MgSO4, filtered and concentrated under reduced pressure to give the crude 
product, which was purified by column chromatography in the solvent system stated. 
9.5.2 Preparation of Trichloromethyl Carbinols 
(E)-1,1,1-Trichloro-4-phenylbut-3-en-2-ol  
 
 
 
Following general procedure O, cinnamaldehyde (5.03 mL, 40.0 mmol), DMF (30 mL), 
trichloroacetic acid (9.80 g, 60.0 mmol) and sodium trichloroacetate (11.1 g, 60.0 mmol) gave, 
after column chromatography (Et2O:Petrol 20:80), the title compound as an orange oil (4.78 g, 
48%); 1H NMR (400 MHz, CDCl3) 2.92 (1H, d, J 5.6, OH), 4.75-4.80 (1H, m, C(2)H), 6.37 
t-BuCOCl (2.25 eq)
i-Pr2NEt (2.25 eq)
CH2Cl2, rt, 5 min
then 
(2S,3R)-HyperBTM 
53 (5 mol%)
i-Pr2NEt (1.5 eq)
−78 °C, 16 h
O
O
CCl3
R1
R2
NuH (excess)
DMAP (20 mol%)
CH2Cl2, rt, 16 h CONu
CONuR1
R2
R2
O
CCl3
R1
OH
O
(1.5 eq)
(1.0 eq)
+
Ph
OH
CCl3
498
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(1H, dd, J 15.9, 6.1, C(3)H), 6.91 (1H, d, J 15.9, C(4)H), 7.28-7.39 (3H, m, ArC(3,5)H and 
ArC(4)H), 7.43-7.47 (2H, m, ArC(2,6)H). All spectroscopic data in accordance with the 
literature.[186] 
9.5.3 Preparation of α,β-Unsaturated Trichloromethyl Ketones 
(E)-1,1,1-Trichloro-4-phenylbut-3-en-2-one 
 
 
 
Following general procedure P, oxalyl chloride (6.43 mL, 76.0 mmol) in CH2Cl2 (300 mL), 
DMSO (10.8 mL, 152 mmol) in CH2Cl2 (35 mL), trichloromethyl carbinol 498 (4.78 g, 19.0 
mmol) in CH2Cl2 (20 mL) and Et3N (53.0 mL, 380 mmol) gave, after column chromatography 
(Et2O:Petrol 5:95), the title compound (4.41 g, 93%) as a yellow solid; mp 56–58 °C; νmax 
(ATR) 3059, 3030 (C–H), 1707 (C=O); 1H NMR (500 MHz, CDCl3) 7.35 (1H, d, J 15.7, 
C(3)H), 7.43-7.49 (3H, m, ArC(3,5)H and ArC(4)H), 7.65-7.66 (2H, m, ArC(2,6)H), 8.01 (1H, 
d, J 15.7, C(4)H); 13C NMR (125 MHz, CDCl3) 96.6 (C(1)), 115.9 (C(3)), 129.1 (ArC), 129.3 
(ArC), 131.9 (ArC(4)), 133.9 (ArC(1)), 149.8 (C(4)), 180.2 (C(2)); HRMS (APCI+) C10H835Cl3O 
[M+H]+, found 248.9634, requires 248.9635 (−0.5 ppm). 
9.5.4 Enantioselective Isothiourea-Catalysed Michael Addition-Lactonisation/Ring 
Opening 
(3R,4R)-3,4-diphenyl-6-(trichloromethyl)-3,4-dihydro-2H-pyran-2-one 
 
 
 
 
Phenyl acetic acid (164 mg, 1.2 mmol), i-Pr2NEt (312 µL, 1.8 mmol), pivaloyl chloride (222 
µL, 1.8 mmol), in CH2Cl2 (8 mL), (2S,3R)-HyperBTM 53  (12 mg, 0.04 mmol), trichloromethyl 
ketone 500 (200 mg, 0.8 mmol), i-Pr2NEt (208 µL, 1.2 mmol) gave crude product (87:13 dr 
anti:syn). Column chromatography (92.5:7.5 Petrol:EtOAc) gave title compound (244 mg, 
82%) as a white solid (89:11 anti:syn): mp 86-88 °C; νmax (ATR) 1003, 1119, 1454, 1773, 2031, 
3063; 
€ 
α[ ]D
20 −98.6 (c 0.5 CHCl3); Data for major anti diastereoisomer: 1H NMR (500 MHz, 
CDCl3) 3.97-4.01 (1H, m, C(4)H), 4.05-4.07 (1H, m, C(3)H), 6.37 (1H, d, J 4.1, C(5)H), 7.09 
(2H, d, J 6.7, ArH), 7.16 (2H, d, J 6.4, ArH), 7.27-7.35 (6H, m, ArH); 1C NMR (125 MHz, 
CDCl3) δC 45.2 (C(3)H), 52.6 (C(4)H), 90.1 (CCl3), 107.8 (C(5)H), 127.5 (ArCH), 128.1 
(ArCH), 128.2 (ArCH), 128.3 (ArCH), 129.0 (ArCH), 129.3 (ArCH), 135.4 (ArC), 139.4 (ArC), 
149.0 (ArC), 166.4 (C(2)); Data for minor syn diastereomer; 1H NMR (500 MHz, CDCl3) δH 
Ph
O
CCl3
500
O
O
CCl3Ph
Ph
501
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3.73 (1H, br. s, C(4)H), 4.28 (1H, d, J 7.0, C(3)H), 6.54 (1H, d, J 6.0, C(5)H), 6.76 (2H, d, J 
6.8, ArH), 6.81 (2H, d, J 6.9, ArH), 7.27-7.35 (6H, m, ArH); 13C NMR (125 MHz, CDCl3)  44.6 
(C(3)H), 50.9 (C(4)H), 91.2 (CCl3), 108.6 (C(5)H), 127.2 (ArCH), 128.0 (ArCH), 128.4 
(ArCH), 128.7 (ArCH), 128.9 (ArCH), 128.9 (ArC), 129.6 (ArC), 129.8 (ArCH), 149.7 (ArC), 
166.1 (C(2)); HRMS (NSI+) C18H1335Cl3O2Na [M+Na]+, found 388.9880, requires 388.9873 
(+1.7 ppm). HPLC or GC analysis was not possible in our hands due to the instability of 501, ee 
was determined through derivatisation to corresponding diester 507. 
 
6-(Dichloromethyl)-3,4-diphenyl-2H-pyran-2-one 
 
 
 
 
To a solution of dihydropyranone 501 (81 mg, 0.22 mmol) and DMAP (5 mg, 0.04 mmol) in 
CH2Cl2 (2 mL) at rt was added a solution of MeOH in CH2Cl2 (2.4 mL) and reaction stirred for 
6 h. Column chromatography (85:15 Petrol: EtOAc) gave the title compound (47 mg, 65%) as a 
white solid; mp 196-197 °C; νmax (ATR) 1348, 1647, 1709, 3001, 3030, 3090; 1H NMR (500 
MHz) 6.40 (1H, s, CHCl2), 6.73 (1H, s, C(5)H), 7.10-7.12 (2H, m, ArH), 7.16 (2H, m, ArH), 
7.23-7.30 (6H, m, ArH); 13C NMR (125 MHz) 65.2 (CHCl2), 107.2 (C(5)H), 126.2 (C(3)), 
128.3 (ArCH), 128.4 (ArCH), 128.7 (ArCH), 128.8 (ArCH), 129.3 (ArCH), 130.8 (ArCH), 
133.1 (ArC(4)), 136.8 (C(3)ArC(1)), 151.2 (C(4)ArC(1)), 155.2 (C(2)), 161.2 (C(6)); HRMS 
(NSI+) C18H1335Cl2O2 [M+H]+, found 331.0296, requires 331.0287 (+2.7 ppm). 
 
Dimethyl (2R,3R)-2-(4-methoxyphenyl)-3-phenylpentanedioate 
 
 
 
 
Following general procedure Q, 4-methoxyphenylacetic acid (99.7 mg, 0.60 mmol), i-Pr2NEt 
(156 µL, 0.90 mmol), pivaloyl chloride (111 µL, 0.90 mmol) in CH2Cl2 (4 mL), (2S,3R)-
HyperBTM 53 (6 mg, 0.02 mmol), trichloromethyl ketone 500 (100 mg, 0.40 mmol), i-Pr2NEt 
(104 µL, 0.60 mmol), MeOH (4 mL) and DMAP (10 mg, 0.08 mmol) gave the crude product 
(92:8 dr). Column chromatography (Et2O:Petrol 25:75) gave the title compound (105 mg, 77%) 
as a white solid (>95:5 dr); mp 96-98 °C; {Lit.[187] mp 99-101 °C}; 
€ 
α[ ]D
20 −126.8 (c 0.5 CHCl3); 
{Lit.[187] 
€ 
α[ ]D
20  −135.1 (c 0.2 CHCl3) for >99% ee (2R,3R) stereoisomer}; Chiral HPLC 
analysis, Chiralpak AD-H (95:5 hexane:IPA, flow rate 1 mL min−1, 211 nm, 30 °C) tR (2S,3S): 
CO2Me
CO2Me
Ph
MeO
507
O
O
CHCl2Ph
Ph
502
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16.7 min, tR (2R,3R): 22.9 min, >99% ee; 1H NMR (400 MHz, CDCl3) 2.73-2.82 (2H, m, 
C(4)HH and C(4)HH), 3.51 (3H, s, C(5)O2CH3), 3.69 (3H, s, CH3), 3.70 (3H, s, CH3), 3.78-3.83 
(2H, m, C(2)H and C(3)H), 6.64-6.68 (2H, m, C(2)ArC(3,5)H), 6.99-7.14 (7H, m, ArCH). All 
data in accordance with literature.[187] 
 
Dimethyl (2R,3R)-3-phenyl-2-(3-tolyl)pentanedioate 
 
 
 
 
Following general procedure Q, m-tolylacetic acid (90 mg, 0.6 mmol), i-Pr2NEt (156 µL, 0.90 
mmol, pivalolyl chloride (111 µL 0.90 mmol), in CH2Cl2 (4 mL), (2S,3R)-HyperBTM 53 (6 
mg, 0.02 mmol), trichloromethyl ketone 500 (100 mg, 0.40 mmol), i-Pr2NEt (104 µL, 0.60 
mmol) and MeOH (5 mL) gave the crude product (92:8 dr). Column chromatography 
(EtOAc:Petrol 10:90) gave the title compound (79 mg, 60%) as a white solid (>95:5 dr); mp 
72–74 °C {Lit.[187] 73-75 °C}; 
€ 
α[ ]D
20 −135.0 (c 0.1 CHCl3); {Lit.[187] 
€ 
α[ ]D
20−127.4 (c 0.1 CHCl3) 
for 99% ee (2R,3R) stereoisomer}; Chiral HPLC analysis, Chiralpak AD-H (95:5 hexane:IPA, 
flow rate 1 mL min−1, 211 nm, 30 °C) tR (2S,3S): 8.7 min, tR (2R,3R): 10.4 min, 99% ee; 1H 
NMR (500 MHz, CDCl3) 2.21 (3H, s, ArCH3), 2.79-2.84 (2H, m, C(4)HH and C(4)HH), 3.51 
(3H, s, C(5)O2CH3), 3.68 (3H, s, C(1)O2CH3), 3.80–3.88 (2H, m, C(2)H and C(3)H), 6.90-6.92 
(2H, m, ArH), 6.94 (1H, br. s, C(2)Ar(2)H), 7.00-7.07 (4H, m, ArH), 7.10-7.13 (2H, m, ArH). 
All data in accordance with literature.[187] 
 
Dimethyl (2R,3R)-3-phenyl-2-(thiophen-3-yl)pentanedioate 
 
 
 
 
Following general procedure Q, 3-thiophene acetic acid (85 mg, 0.6 mmol), i-Pr2NEt (156 µL, 
0.90 mmol, pivalolyl chloride (111 µL 0.90 mmol), in CH2Cl2 (4 mL), (2S,3R)-HyperBTM 53 
(6 mg, 0.02 mmol), trichloromethyl ketone 500 (99.8 mg, 0.40 mmol), i-Pr2NEt (104 µL, 0.60 
mmol) and MeOH (5 mL) gave the crude product (81:19 dr). Column chromatography 
(EtOAc:Petrol 10:90) gave the title compound (81 mg, 64%) as a white solid (>98:2 dr); mp 61-
64 °C {Lit.[187] 60-64 °C}; 
€ 
α[ ]D
20 −72.0 (c 0.5 CHCl3); {Lit.[187] −69.0 (c 0.5 CHCl3) for 97% ee 
(2R,3R) stereoisomer}; Chiral HPLC analysis, Chiralpak AD-H (95:5 hexane:IPA, flow rate 1 
mL min−1, 211 nm, 30 °C) tR (2R,3R): 16.9 min, tR (2S,3S): 18.3 min, >99% ee; 1H NMR (500 
CO2Me
CO2Me
Ph
Me
508
CO2Me
CO2Me
Ph
S
510
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MHz, CDCl3) 2.75-2.83 (2H, m, C(4)HH and C(4)HH), 3.52 (3H, s, C(5)O2CH3), 3.71 (3H, s, 
C(1)O2CH3), 3.77-3.82 (1H, m, C(3)H), 4.00 (1H, d, J 10.2, C(2)H), 6.85 (1H, dd, J 1.1, 5.0, 
C(2)ArH), 6.91 (1H, dd, J 1.0, 2.9, C(2)ArH), 7.00-7.02 (2H, m, C(3)ArH), 7.09-7.12 (2H, m, 
ArH), 7.14-7.17 (2H, m, ArH). All data in accordance with literature.[187] 
 
Dimethyl (2S,3R)-3-phenyl-2-((E)-prop-1-en-1-yl)pentanedioate 
 
 
 
Following general procedure Q, 3-pentenoic acid (61 µL, 0.6 mmol), i-Pr2NEt (156 µL, 0.90 
mmol, pivalolyl chloride (111 µL 0.90 mmol), in CH2Cl2 (4 mL), (2S,3R)-HyperBTM 53 (6 mg, 
0.02 mmol), trichloromethyl ketone 500 (100 mg, 0.40 mmol), i-Pr2NEt (104 µL, 0.60 mmol) 
and MeOH (5 mL) gave the crude product (85:15 dr). Column chromatography (EtOAc:Petrol 
10:90) gave the title compound (86 mg, 78%) as a colourless oil (>95:5 dr) 
€ 
α[ ]D
20−67.3 (c 0.5 
CHCl3); {Lit.[187] 
€ 
α[ ]D
20 −69.0 (c 0.5 CHCl3) for >99% ee (2S,3R) stereoisomer}; Chiral HPLC 
analysis, Chiralpak OD-H (97:3 hexane:IPA, flow rate 1 mL min−1, 220 nm, 30 °C) tR (2R,3S): 
9.82 min, tR (2S,3R): 15.5 min, >99% ee; 1H NMR (500 MHz, CDCl3) 1.55 (3H, dd, J 1.3, 6.3, 
C(2)C(3′)H), 2.69 (2H, d, J 7.6, C(4)H), 3.27 (1H, d, J 8.7, C(3)H), 3.52-3.62 (4H, m, C(2)H 
and C(5)O2CH3), 3.67 (C(1)O2CH3), 5.22-5.44 (2H, m, C(2)C(1′)H and C(2)C(2′)H), 7.09-7.12 
(2H, m, C(3)ArH), 7.18-7.29 (3H, m, C(3)ArH). All data in accordance with literature.[187] 
 
Dimethyl (2S,3R)-3-phenyl-2-((E)-3-phenylprop-1-en-1-yl)-pentanedioate  
 
 
 
Following general procedure Q, (E)-5-phenylpent-3-enoic acid (106 mg, 0.60 mmol), i-Pr2NEt 
(156 µL, 0.90 mmol), pivaloyl chloride (111 µL, 0.90 mmol) in CH2Cl2 (4 mL), (2S,3R)-
HyperBTM 53 (6 mg, 0.02 mmol), trichloromethyl ketone 500 (100 mg, 0.40 mmol), i-Pr2NEt 
(104 µL, 0.60 mmol), MeOH (4 mL) and DMAP (10 mg, 0.08 mmol) gave the crude product 
(95:5 dr). Column chromatography (80:20 Petrol:Et2O) gave the title compound (105 mg, 74%) 
as a colourless oil (>95:5 dr). 
€ 
α[ ]D
20 −6.7 (c 1.0 CHCl3); {Lit.[187] 
€ 
α[ ]D
20 −6.9 (c 1.0 CHCl3) for 
>99% ee (2S,3R) stereoisomer}; Chiral HPLC analysis, Chiralcel OJ-H (99:1 hexane:IPA, flow 
rate 1 mL min−1, 211 nm, 40 °C) tR (2S,3R): 44.0 min, tR (2R,3S): 48.4 min, 99% ee; 1H NMR 
(400 MHz, CDCl3) 2.69 (2H, d, J 7.5, C(4)HH and C(4)HH), 3.20 (2H, d, J 6.3, C(2)C(3′)HH 
and C(2)C(3′)HH), 3.33 (1H, t, J 9.3, C(2)H), 3.53 (3H, s, C(5)O2CH3), 3.57-3.63 (1H, m, 
C(3)H), 3.71 (3H, s, C(1)O2CH3), 5.34 (1H, ddt, J 15.3, 9.3, 1.3, C(2)C(1′)H), 5.42-5.53 (1H, 
CO2Me
CO2Me
Ph
Me
511
CO2Me
CO2Me
Ph
Bn
512
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m, C(2)C(2′)H), 6.75-6.79 (2H, m, ArCH), 7.11-7.32 (8H, m, ArCH). All data in accordance 
with literature.[187] 
9.6 Experimental for Chapter 6 
9.6.1  General Experimental Procedures 
General procedure R: Preparation of Pyrrole 2-Carboxaldehydes 
 
 
 
 
 
Following literature procedure,[188] POCl3 (1.1 eq) was added dropwise to DMF (1.1 eq) and the 
reaction was stirred for 15 min at rt. DCE (2.2 M in DMF) was added and the mixture cooled to 
0 °C. A solution of requisite pyrrole (1.0 eq) in DCE (2.0 M in pyrrole) was added dropwise and 
the reaction was heated to 85 °C for 15 min before cooling to rt. A solution of aq. NaOAc (9.0 
M, 9.0 eq) was added and the biphasic mixture stirred at 100 °C for 15 min. The reaction was 
cooled to rt and the phases separated. The aqueous phase was extracted with Et2O (×3). The 
combined organics were washed with NaHCO3, dried over MgSO4 and concentrated under 
reduced pressure to provide the desired pyrrole 2-carboxaldehyde. 
 
General Procedure S: Preparation of Pyrrolyl Enones 
 
 
 
 
 
To an aqueous solution of NaOH (10% w/v in H2O, 2.0 eq) was added dropwise to a solution of 
pyrrole-2-carboxaldehyde (1.0 eq) and the requisite ketone (1.0 eq) in ethanol (2.5 M in ketone). 
The reaction was stirred at rt for 16 h then acidified to pH 3 with aqueous HCl (2 M in H2O). 
The resultant precipitate was filtered, washed with cold ethanol to provide the desired enone 
product. Products were purified as described. 
 
 
 
 
 
N
H
i) POCl3 (1.1 eq)
DMF (1.1 eq)
DCE, 85 °C, 30 min
ii) NaOAc (9.0 eq)
H2O, 100 °C, 15 min
N
H
H
O
R1 R1
N
H
H
O
(1.0 eq)
aq. NaOH
EtOH, rt, 16 h
Me R1
O
N
H O
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R1 R1
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General Procedure T: N-Alkylation of Pyrrolyl Enones 
 
 
 
 
 
To a solution of pyrrole enone (1.0 eq) in methyl acrylate (0.2 M in pyrrolyl enone) was added 
potassium tert-butoxide (1-10 mol%) and the reaction stirred at 70 °C for 16 h. The reaction 
was concentrated under reduced pressure, diluted with EtOAc, washed with brine (×3), dried 
over MgSO4 and concentrated under reduced pressure to provide the crude product. Products 
were isolated by column chromatography in the solvent system stated.  
 
General Procedure U: Hydrolysis of Pyrrolyl Enone-Esters 
 
 
 
 
To a solution of pyrrolyl enone ester (1.0 eq) in H2O/ethanol (1:1) was added LiOH.H2O (4.0 
eq) and reaction stirred at rt for 4 h. The reaction was then basified to pH 8 with aqueous aq. 
NaOH (2 M) and washed with Et2O (×3). The aqueous layer was carefully acidified to pH 3 
(caution: acidifying beyond pH 3 can lead to decomposition of product) with aq. HCl (2 M) and 
extracted with EtOAc (×3). Combined organic layers were washed with brine, dried over 
MgSO4 and concentrated under reduced pressure to provide enone-acid products. 
 
General Procedure V: Michael Addition-Lactonisation in situ Ring Opening 
 
 
 
 
To a solution of pyrrolyl enone-acid (1.0 eq) in CH2Cl2 (0.1 M) was added pivaloyl chloride (3.0 
eq) and i-Pr2NEt (3.0 eq) at 0 °C and the reaction was allowed to warm to rt over 2 h. (+)-BTM 
48 (5 mol%) and i-Pr2NEt (1.5 eq) was added and reaction stirred at rt overnight. The requisite 
nucleophile was then added and the reaction stirred until complete by TLC analysis. Reaction 
was quenched with aq. HCl (1 M) and extracted with CH2Cl2 (×3). Combined organic layers 
were dried over MgSO4 and concentrated in vacuo to provide crude products. Products were 
isolated by column chromatography in the solvent system stated. 
(excess)
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9.6.2 Synthesis of Pyrrole Aldehydes 
1H-Pyrrole 2-carboxaldehyde 
 
 
 
Following general procedure R, POCl3 (2.0 mL, 21.5 mmol), DMF (1.7 mL, 21.5 mmol) and 
DCE (10 mL), pyrrole (1.4 mL, 20.2 mmol) in DCE (10 mL) and NaOAc (15 g, 182.9 mmol) in 
H2O (20 mL) gave the title compound as a red oil (1.83 g, 96%); 1H NMR (500 MHz, d6-
DMSO) 6.33 (1H, m, pyrrolyl(4)H), 7.01 (1H, m, pyrrolyl(3)H), 7.18 (1H, m, pyrrolyl(5)H), 
9.49 (1H, s, CHO), 11.13 (1H, br. s, NH). All data in accordance with literature.[189] 
 
4,5,6,7-Tetrahydro-1H-indole 
 
 
 
Following the literature procedure,[142] NH2OH.HCl (3.54 g, 50.9 mmol), cyclohexanone (5.28 
mL, 50.9 mmol) and KOH (2.86 g, 50.9 mmol) were stirred in DMSO (42 mL) at 70 °C for 30 
min. The temperature was increased to 120 °C and further KOH (7.15 g, 127.4 mmol) was 
added before the slow addition of a solution of DCE (20.5 mL, 259.5 mmol) in DMSO (65 mL) 
via syringe pump over 4 h. The reaction was cooled and added to aq. NH4Cl (100 mL, 10% in 
H2O) and extracted with Et2O (3×30 mL). The combined organics were washed with aq. KOH 
(1 M) then dried over MgSO4 and concentrated under reduced pressure to give the crude 
product. Purification by column chromatography provided the title compound as pink solid 
(2.19 g, 35%); mp 50-51 °C {Lit.[142] 51-52 °C}; 1H NMR (500 MHz, CDCl3) 1.74-1.87 (4H, m, 
C(5)H2 and C(6)H2), 2.57 (4H, dt, J 5.8, 20.2, C(4)H2 and C(7)H2), 6.00 (1H, br. s, C(3)H), 6.64 
(1H, t, J 2.6, C(2)H), 7.70 (1H, NH). All data in accordance with literature.[142] 
 
4,5,6,7-tetrahydro-1H-indole-2-carbaldehyde 
 
 
 
 
Following general procedure R, POCl3 (1.85 mL, 19.9 mmol), DMF (1.54 mL, 19.9 mmol) and 
DCE (9 mL), 4,5,6,7-tetrahydro-1H-indole 586 (1.4 mL, 20.2 mmol) in DCE (9 mL) and 
NaOAc (13.3 g, 162.3 mmol) in H2O (18 mL) gave the title compound as a brown oil (2.21 g, 
82%); 1H NMR (500 MHz, CDCl3) 1.71-1.83 (4H, m, C(5)H2 and C(6)H2), 2.51 (2H, t, J 6.1, 
586
N
H
590
N
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H
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(C(4)H2), 2.67 (2H, t, J 6.2, C(7)H2), 6.73 (1H, s, C(3)H), 9.17 (1H, s, CHO), 10.5 (1H, br. s, 
NH). All data in accordance with literature.[190] 
9.6.3 Synthesis of Pyrrolyl Enones 
(E)-1-phenyl-3-(1H-pyrrol-2-yl)prop-2-en-1-one 
 
 
 
Following general procedure S, pyrrole carboxaldehyde (5.00 g, 52.6 mmol), aq. NaOH (5 mL, 
10% w/v in H2O) and acetophenone (6.14 mL, 52.6 mmol) in EtOH (21 mL) gave the title 
compound as a yellow solid (7.05 g, 68%); mp 135-137 °C; {lit.[190] 136-137 °C}; 1H NMR 
(500 MHz, CDCl3) 6.34 (1H, s, pyrrolyl(4)H), 6.72 (1H, s, pyrrolyl(3)H), 7.00 (1H, s, 
pyrrolyl(5)H), 7.20 (1H, d, J 15.5, C(2)H), 7.47 (2H, m, C(1)Ar(3,5)H), 7.33 (1H, m, 
C(1)Ar(4)H), 7.78 (1H, d, J 15.5, C(3)H), 7.98 (2H, d, J 7.3, C(1)Ar(2,6)H). All data in 
accordance with literature.[191] 
 
(E)-1-(Naphthalen-2-yl)-3-(1H-pyrrol-2-yl)prop-2-en-1-one 
 
 
 
 
Following general procedure S, pyrrole carboxaldehyde (3.00 g, 31.5 mmol), aq. NaOH (3 mL, 
10% w/v in H2O) and 2-acetylnaphthalene (5.36 g, 31.5 mmol) in EtOH (20 mL) gave the title 
compound as a yellow solid (5.92 g, 76%); mp 158-160 °C; νmax (ATR)/cm−1 820, 974, 1541 (C-
O), 3284 (C-H); 1H NMR (400 MHz, CDCl3) 6.36 (1H, dd, J 1.1, 2.5, pyrrolyl(4)H), 6.75-6.76 
(1H, m, pyrrolyl(3)H), 7.02 (1H, td, 1.4, 2.7, pyrrolyl(5)H), 7.30 (1H, d, J 15.5, C(2)H), 7.57 
(2H, dddd, J 1.4, 6.9, 8.1, 19.5, ArH), 7.80 (1H, d, J 15.5, C(3)H), 7.88-7.97 (3H, m, ArH), 8.07 
(1H, dd, J 1.8, 8.6, ArH), 8.49 (1H, s, ArH), 8.91 (1H, br. s, NH); 13C NMR (100 MHz) 111.7 
(pyrrolylC(4)H), 115.6 (pyrrolylC(3)H), 116.0 (C(2)H), 123.2 (pyrrolylC(5)H), 124.7 (ArCH), 
126.9 (ArCH), 128.0 (ArCH), 128.3 (ArCH), 128.6 (ArCH), 129.5 (pyrrolylC(2)), 129.6 
(ArCH), 129.6 (ArCH), 132.7 (ArC), 134.5 (ArC), 135.5 (ArC), 136.1 (C(3)H), 190.2 (C(1)); 
HRMS (NSI+), C17H14NO2 [M+H]+, requires 248.1068, found 248.1070 (−0.8 ppm). 
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(E)-1-(Naphthalen-1-yl)-3-(1H-pyrrol-2-yl)prop-2-en-1-one 
 
 
 
 
Following general procedure S, pyrrole carboxaldehyde (2.00 g, 21.0 mmol), aq. NaOH (2 mL, 
10% w/v in H2O) and 1-acetylnaphthalene (6.14 mL, 52.6 mmol) in EtOH (8.4 mL) gave the 
title compound as a yellow oil (1.06 g, 20%); 1H NMR (300 MHz, CDCl3) 6.30-6.33 (1H, m, 
pyrrolyl(4)H), 6.62 (1H, br. s, pyrrolyl(3)H), 6.89 (1H, d, J 15.9, C(2)H), 6.98 (1H, br. s, 
pyrrolyl(5)H), 7.45 (1H, d, J 16.0, C(3)H), 7.50-7.56 (3H, m, ArH), 7.69 (1H, dd, J 1.2, 7.1, 
ArH), 7.88-7.92 (1H, m, ArH), 7.96-7.99 (1H, m, ArH), 8.23-8.26 (1H, m, ArH), 8.84 (1H, br. 
s, NH); 13C NMR (100 MHz) 111.7 (pyrrolylC(4)H), 116.4 (pyrrolylC(3)H), 121.0 (C(2)H), 
124.2 (pyrrolylC(5)H), 124.8 (ArCH), 125.8 (ArCH), 126.5 (ArCH), 126.6 (ArCH), 127.3 
(ArCH), 128.5 (ArCH), 129.0 (pyrrolylC(2)), 130.6 (ArC), 131.1 (ArCH), 133.9 (ArC), 136.9 
(C(3)H), 137.7 (ArC), 196.7 (C(1)); HRMS (NSI+), C17H14NO [M+H]+, requires 248.1070, 
found 248.1071 (+0.4 ppm). 
 
(E)-1-(4-methoxyphenyl)-3-(1H-pyrrol-2-yl)prop-2-en-1-one 
 
 
 
 
Following general procedure S, pyrrole carboxaldehyde (1.50 g, 15.8 mmol), aq. NaOH (1.5 
mL, 10% w/v in H2O) and 4’-methoxyacetophenone (2.37 g, 15.8 mmol) in EtOH (6.3 mL) 
gave the title compound as a yellow solid (2.30 g, 64%); mp 164-166 °C; νmax (ATR)/cm−1 1134, 
1539 (C-O), 3224 (C-H); 1H NMR (500 MHz, CDCl3) 3.88 (3H, s, C(1)ArOCH3), 6.33 (1H, br. 
s, pyrrolyl(4)H), 6.71 (1H, s, pyrrolyl(3)H), 6.95-6.98 (3H, m, C(1)Ar(3,5)H and pyrrolyl(5)H), 
7.16 (1H, d, J 15.5, C(2)H), 7.74 (1H, d, J 15.5, C(3)H), 8.00 (2H, d, J 8.8, C(1)Ar(2,6)H), 8.85 
(1H, s, NH); 13C NMR (125 MHz) 55.6 (C(1)ArOCH3), 111.6 (pyrrolylC(4)H), 113.9 
(C(1)ArC(3,5)H), 114.9 (pyrrolylC(3)H), 115.7 (C(2)H), 122.9 (pyrrolylC(5)H), 129.5 
(pyrrolylC(2)), 130.7 (C(1)ArC(2,6)H), 131.6 (C(1)ArC(1)), 133.8 (C(3)H), 163.3 
(C(1)ArC(4)), 188.7 (C(1)); HRMS (APCI+), C14H13NO2 [M+H]+, requires 226.0863, found 
226.0862 (−0.2 ppm). 
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(E)-1-(4-bromophenyl)-3-(1H-pyrrol-2-yl)prop-2-en-1-one 
 
 
 
 
Following general procedure S, pyrrole carboxaldehyde (3.00 g, 31.5 mmol), aq. NaOH (3 mL, 
10% w/v in H2O) and 4’-bromoacetophenone (6.27 g, 31.5 mmol) in EtOH (13 mL) gave the 
title compound as a yellow solid (5.48 g, 63%); mp 182-184 °C; νmax (ATR)/cm−1 975, 1330, 
1539 (C-O), 3307 (C-H);1H NMR (500 MHz, d6-DMSO) 6.35 (1H, dt, J 2.3, 3.6, pyrrolyl(4)H), 
6.75 (1H, br. s, pyrrolyl(3)H), 7.17 (1H, br. s, pyrrolyl(5)H), 7.53 (1H, d, J 15.4, C(2)H), 7.61 
(1H, d, J 15.5, C(3)H), 7.79 (2H, d, J 8.7, C(1)Ar(3,5)H), 7.96 (2H, d, J 8.6, C(1)Ar(2,6)H), 
11.74 (1H, s, NH); 13C NMR (125 MHz d6-DMSO) 110.8 (pyrrolylC(4)H), 114.1 (C(2)H), 
116.8 (pyrrolylC(3)H), 124.6 (pyrrolylC(5)H), 126.6 (pyrrolylC(2)), 129.1 (C(1)ArC(4)), 129.9 
(C(1)ArC(3,5)H), 131.8 (C(1)ArC(2,6)H), 134.7 (C(1)ArC(1)), 137.3 (C(3)H), 187.3 (C(1)); 
HRMS (APCI+), C13H10BrNO [M+H]+, requires 277.9998, found 277.9999 (+0.2 ppm). 
 
(E)-1-(3-bromophenyl)-3-(1H-pyrrol-2-yl)prop-2-en-1-one 
 
 
 
 
Following general procedure S, pyrrole carboxaldehyde (3.00 g, 31.5 mmol), aq. NaOH (3 mL, 
10% w/v in H2O) and 3’-bromoacetophenone (4.16 mL, 31.5 mmol) in EtOH (13 mL) gave the 
title compound as a crude mixture of E/Z isomers (85:15) (5.48 g, 63%). Data for (E)-isomer; 
1H NMR (500 MHz, d6-DMSO) 6.21 (1H, m, pyrrolyl(4)H), 6.75 (1H, br. s, pyrrolyl(3)H), 7.16 
(1H, br. s, pyrrolyl(5)H), 7.49-7.54 (2H, m, Ar(5)H and C(2)H), 7.61 (1H, d, J 15.3, C(3)H), 
7.81-7.82 (1H, m, Ar(6)H), 7.99-8.00 (1H, m, Ar(4)H), 8.14-8.15 (1H, m, Ar(2)H), 11.7 (1H, s, 
NH). Due to instability this compound was used immediately without further characterisation. 
 
(E)-3-(1H-pyrrol-2-yl)-1-(thiophen-2-yl)prop-2-en-1-one 
 
 
 
 
Following general procedure S, pyrrole carboxaldehyde (3.00 g, 31.5 mmol), aq. NaOH (3 mL, 
10% w/v in H2O) and 2-acetylthiophene (3.40 mL, 31.5 mmol) in EtOH (13 mL) gave the title 
compound as a yellow solid (4.55 g, 71%); mp 131-132 °C {Lit.[192] 130 °C}; 1H NMR (500 
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MHz, CDCl3) 6.34-6.35 (1H, m, pyrrolyl(4)H), 6.73 (1H, s, pyrrolyl(3)H), 7.00-7.03 (2H, m, 
C(2)H and pyrrolyl(5)H), 7.16 (1H, dd, J 3.8, 4.9, C(1)Ar(3)H), 7.64 (1H, dd, J 1.0, 4.9, 
C(1)Ar(3)H), 7.76 (1H, d, J 15.4, C(3)H), 7.81 (1H, dd, J 1.1, 3.8, C(1)Ar(5)H). All data in 
accordance with literature.[192] 
 
 (E)-4-(1H-Pyrrol-2-yl)but-3-en-2-one 
 
 
 
Following the procedure from Chimni and Mahajan,[192] to a solution of pyrrole aldehyde (3.00 
g, 31.5 mmol) and acetone (23.2 mL, 315.0 mmol) in H2O (157.5 mL) was added pyrrolidine 
(0.77 mL, 9.45 mmol) and the reaction stirred at rt for 16 h. The reaction was quenched with 
HCl (1M in H2O), extracted with CH2Cl2 (×3), dried over MgSO4 and concentrated under 
reduced pressure to the title compound as a yellow solid (2.97 g, 70%); mp 115-117 °C {Lit.[193] 
117-120 °C}; 1H NMR (300 MHz, CDCl3) 2.33 (3H, s, C(1)H3), 6.30-6.36 (2H, m, C(3)H and 
pyrrolyl(4)H), 6.60-6.62 (1H, m, pyrrolyl(3)H), 6.98-6.99 (1H, m, pyrrolyl(5)H), 7.41 (1H, d, J 
16.2, C(4)H), 8.94 (1H, br. s, NH). All data in accordance with literature.[194] 
 
(E)-1-Phenyl-3-(4,5,6,7-tetrahydro-1H-indol-2-yl)prop-2-en-1-one 
 
 
 
Following general procedure S, 4,5,6,7-tetrahydro-1H-indole-2-carbaldehyde 590 (2.21 g, 14.6 
mmol), aq. NaOH (3 mL, 10% w/v in H2O) and acetophenone (1.70 mL, 14.6 mmol) in EtOH 
(10 mL) gave crude product. The reaction mixture was neutralised to pH 7 with aq. HCl (1 M) 
and extracted with EtOAc (×3), dried over MgSO4 and concentrated under reduced pressure. 
Purification by column chromatography (EtOAc:hexane 7.5:92.5) gave the title compound as a 
brown oil (1.26 g, 34%); 1H NMR (500 MHz, CDCl3) 1.69-1.87 (4H, m, C(3)C(5)H2 and 
C(3)C(6)H2), 2.52 (2H, t, J 6.0, (C(3)C(4)H2), 2.64 (2H, t, J 6.1, C(3)C(7)H2), 6.47 (1H, br. s, 
C(3)C(3)H), 7.01 (1H, d, J 15.4, C(3)H), 7.43-7.48 (2H, m, C(1)Ar(3,5)H), 7.50-7.58 (1H, m, 
C(1)Ar(4)H), 7.68 (1H, d, J 15.4, C(2)H), 7.95-7.97 (2H, m, C(1)Ar(2,6)H), 8.48 (1H, br. s, 
NH). All data in accordance with literature.[194] 
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(E)-1-(4-nitrophenyl)-3-(1H-pyrrol-2-yl)prop-2-en-1-one 
 
 
 
 
Following general procedure S, pyrrole carboxaldehyde (4.79.00 g, 50.4 mmol), aq. NaOH (5 
mL, 10% w/v in H2O) and 4-nitroacetophenone (8.32 g, 50.4 mmol) in EtOH (20 mL) gave the 
title compound as a black solid (7.93 g, 66%); mp 151-152 °C; νmax (ATR)/cm−1 1514, 1568, 
3300 (C-H); 1H NMR (500 MHz, CDCl3) 6.26 (1H, dt, J 2.3, 3.6, pyrrolyl(4)H), 6.81 (1H, br. s, 
pyrrolyl(3)H), 7.21 (1H, br. s, pyrrolyl(5)H), 7.57 (1H, d, J 15.3, C(2)H), 7.66 (1H, d, J 15.3, 
C(3)H), 8.22 (2H, d, J 8.9, Ar(2,6)H), 8.39 (2H, d, J 8.9, Ar(3,5)H); 13C NMR (125 MHz, 
CDCl3) 111.0 (pyrrolylC(3)H), 114.2 (pyrrolylC(4)H), 117.5 (pyrrolylC(5)H), 123.9 
(ArC(2,6)H), 125.3 (C(2)H), 129.1 (pyrrolylC(2)), 129.2 (ArC(3,5)H), 135.7 (C(3)H), 143.4 
(ArC(1)), 149.5 (ArC(4)), 187.2 (C(1)); HRMS (NSI+), C13H11N2O3 [M+H]+, requires 243.0764, 
found 243.0762 (−0.9 ppm). 
9.6.4 N-Alkylation of Pyrrolyl Enones 
Methyl (E)-3-(2-(3-oxo-3-phenylprop-1-en-1-yl)-1H-pyrrol-1-yl)propanoate 
 
 
 
 
Following general procedure T, pyrrolyl enone 690 (5.00 g, 25.6 mmol), potassium tert-
butoxide (29 mg, 0.26 mmol) in methyl acrylate (135 mL) gave the title compound as a yellow 
oil (6.74 g, 93%); νmax (ATR)/cm−1 1213, 1566, 1583, 1732 (ester C=O), 2951 (C-H); 1H NMR 
(500 MHz, CDCl3) 2.78 (2H, t, J 6.9, C(2)H2), 3.69 (3H, s, CO2CH3), 4.39 (2H, t, J 6.9, 
C(3)H2), 6.23-6.24 (1H, m, pyrrolyl(4)H), 6.85-6.86 (1H, m, pyrrolyl(3)H), 6.91-6.92 (1H, m, 
pyrrolyl(5)H), 7.33 (1H, d, J 15.1, pyrrolyl(2)C(2)H), 7.48-7.51 (2H, m, C(O)Ar(3,5)H), 7.55-
7.58 (1H, C(O)Ar(4)H), 7.79 (1H, d, J 15.1, pyrrolyl(2)C(1)H), 8.01-8.02 (2H, C(O)Ar(2,6)H); 
13C NMR (75 MHz, CDCl3) 36.3 (C(2)H2), 42.7 (C(3)H2), 52.2 (CO2CH3), 110.4 
(pyrrolylC(4)H), 112.8 (pyrrolylC(3)H), 117.2 (pyrrolyl(2)C(2)H), 127.2 (pyrrolylC(5)H), 
128.4 (C(O)ArC(2,6)H), 128.7 (C(O)ArC(3,5)H), 129.4 (pyrrolylC(2)), 131.7 
(pyrrolyl(2)C(1)H), 132.6 (C(O)ArC(4)H), 138.8 (C(O)ArC(1)), 171.2 (CO2Me), 189.8 
(pyrrolyl(2)C(3)); HRMS (NSI+), C17H17NO3Na [M+Na]+, requires 306.1101, found 306.1094 
(−2.2 ppm). 
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Methyl (E)-3-(2-(3-(naphthalen-2-yl)-3-oxoprop-1-en-1-yl)-1H-pyrrol-1-yl)propanoate 
 
 
 
 
 
Following general procedure T, pyrrolyl enone 691 (3.00 g, 12.1 mmol), potassium tert-
butoxide (27 mg, 0.24 mmol) in methyl acrylate (64 mL) gave the title compound as a yellow 
oil (2.53 g, 63%); νmax (ATR)/cm−1 1170, 1570, 1730 (ester C=O), 2951 (C-H); 1H NMR (300 
MHz, CDCl3) 2.80 (2H, t, J 6.9, C(2)H2), 3.69 (3H, s, CO2CH3), 4.42 (2H, t, J 6.9, C(3)H2), 
6.25-6.27 (1H, m, pyrrolyl(4)H), 6.92-6.94 (2H, m, pyrrolyl(3)H and pyrrolyl(5)H), 7.49 (1H, d, 
J 15.1, pyrrolyl(2)C(2)H), 7.52-7.63 (2H, m, 2×C(O)ArH), 7.82-8.02 (4H, m, pyrrolyl(2)C(1)H 
and 3×C(O)ArH), 8.11 (1H, dd, J 1.7, 8.6, C(O)ArH), 8.53 (1H, br. s, C(O)ArH); 13C NMR (75 
MHz, CDCl3) 36.3 (C(2)H2), 42.7 (C(3)H2), 52.2 (CO2CH3), 110.4 (pyrrolylC(4)H), 112.9 
(pyrrolylC(3)H), 117.3 (pyrrolyl(2)C(2)H), 124.6 (C(O)ArCH), 126.8 (C(O)ArCH), 127.2 
(C(O)ArCH), 127.9 (C(O)ArCH), 128.3 (C(O)ArCH), 128.6 (C(O)ArCH), 129.5 
(pyrrolylC(2)), 129.6 (C(O)ArCH), 129.6 (C(O)ArCH), 131.7 (pyrrolyl(2)C(1)H), 132.8 
(C(O)ArC), 135.5 (C(O)ArC), 136.1 (C(O)ArC(1)), 171.2 (CO2Me), 189.6 (pyrrolyl(2)C(3)); 
HRMS (NSI+), C21H19NO3Na [M+Na]+, requires 356.1257, found 356.1255 (−0.6 ppm). 
 
Methyl (E)-3-(2-(3-(naphthalen-1-yl)-3-oxoprop-1-en-1-yl)-1H-pyrrol-1-yl)propanoate 
 
 
 
 
 
Following general procedure T, pyrrolyl enone 692 (1.06 g, 4.47 mmol), potassium tert-
butoxide (5 mg, 0.043 mmol) in methyl acrylate (22.5 mL) gave the title compound as a yellow 
oil (922 mg, 62%); νmax (ATR)/cm−1 1280, 1570, 1732 (ester C=O), 2961 (C-H); 1H NMR (500 
MHz, CDCl3) 2.70 (2H, t, J 6.8, C(2)H2), 3.65 (3H, s, CO2CH3), 4.28 (2H, t, J 6.8, C(3)H2), 
6.21-6.22 (1H, m, pyrrolyl(4)H), 6.80 (1H, dd, J 1.2, 3.9, pyrrolyl(3)H), 6.90 (1H, br. s, 
pyrrolyl(5)H), 7.08 (1H, d, J 15.4, pyrrolyl(2)C(2)H), 7.50-7.57 (3H, m, ArH), 7.63 (1H, d, J 
15.4, 7.76-7.77 (1H, m, ArH), 7.89 (1H, d, J 8.3, ArH), 7.96 (1H, d, J 8.2, ArH), 8.37 (1H, d, J 
8.2, ArH); 13C NMR (125 MHz) 36.0 (C(2)H2), 42.5 (C(3)H2), 52.0 (CO2CH3), 110.4 
(pyrrolylC(4)H), 113.3 (pyrrolylC(3)H), 122.0 (pyrrolyl(2)C(2)H), 124.6 (C(O)ArCH), 125.8 
(C(O)ArCH), 126.4 (C(O)ArCH), 126.8 (C(O)ArCH), 127.2 (C(O)ArCH), 127.5 (C(O)ArCH), 
128.4 (C(O)ArCH), 128.8 (pyrrolylC(2)), 130.5 (C(O)ArC), 131.3 (C(O)ArCH), 132.4 
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(pyrrolyl(2)C(1)H), 133.8 (C(O)ArC), 137.9 (C(O)ArC(1)), 170.9 (CO2Me), 194.8 
(pyrrolyl(2)C(3)); HRMS (NSI+), C21H20NO3 [M+H]+, requires 334.1438, found 334.1439 (+0.3 
ppm). 
 
Methyl (E)-3-(2-(3-(4-methoxyphenyl)-3-oxoprop-1-en-1-yl)-1H-pyrrol-1-yl)propanoate 
 
 
 
 
 
 
Following general procedure T, pyrrolyl enone 693 (2.00 g, 8.80 mmol), potassium tert-
butoxide (10 mg, 0.088 mmol) in methyl acrylate (46 mL) gave the title compound as a yellow 
oil (2.56 g, 97%); νmax (ATR)/cm−1 1168, 1581, 1589, 1732 (ester C=O), 2951 (C-H); 1H NMR 
(300 MHz, CDCl3) 2.78 (2H, t, J 6.9, C(2)H2), 3.68 (3H, s, CO2CH3), 3.88 (3H, s, ArOCH3), 
4.39 (2H, t, J 6.9, C(3)H2), 6.21 (1H, m, pyrrolyl(4)H), 6.83 (1H, dd, J 1.3, 3.9, pyrrolyl(3)H), 
6.90 (1H, dd, J 1.6, 2.5, pyrrolyl(5)H), 6.97 (1H, d, J 8.9, C(O)Ar(3,5)H), 7.34 (1H, d, J 15.1, 
pyrrolyl(2)C(2)H), 7.76 (1H, d, J 15.1, pyrrolyl(2)C(1)H), 8.03 (2H, d, J 8.9, C(O)Ar(2,6)H); 
13C NMR (75 MHz) 36.3 (C(2)H2), 42.6 (C(3)H2), 52.1 (CO2CH3), 55.6 (ArOCH3), 110.2 
(pyrrolylC(4)H), 112.4 (pyrrolylC(3)H), 113.9 (C(O)ArC(3,5)H), 117.2 (pyrrolyl(2)C(2)H), 
126.9 (pyrrolylC(5)H), 129.5 (pyrrolylC(2)), 130.6 (C(O)ArC(2,6)H), 131.0 (pyrrolyl(2)C(1)H), 
131.6 (C(O)ArC(1)),  163.3 (C(O)ArC(4)), 171.2 (CO2Me), 188.1 (pyrrolyl(2)C(3)); HRMS 
(NSI+), C18H20NO4 [M+H]+, requires 313.1387, found 313.1379 (−2.6 ppm). 
 
Methyl (E)-3-(2-(3-(4-bromophenyl)-3-oxoprop-1-en-1-yl)-1H-pyrrol-1-yl)propanoate 
 
 
 
 
 
Following general procedure T, pyrrolyl enone 694 (3.00 g, 10.9 mmol), potassium tert-
butoxide (57 mg, 0.26 mmol) in methyl acrylate (57 mL) gave the title compound as a yellow 
oil (3.51 g, 89%); νmax (ATR)/cm−1 1170, 1678, 1732 (ester C=O), 2951 (C-H); 1H NMR (400 
MHz, CDCl3) 2.77 (2H, t, J 6.9, C(2)H2), 3.68 (3H, s, CO2CH3), 4.38 (2H, t, J 6.9, C(3)H2), 
6.23 (1H, m, pyrrolyl(4)H), 6.86 (1H, dd, J 1.1, 4.0, pyrrolyl(3)H), 6.92 (1H, dd, J 1.6, 2.5, 
pyrrolyl(5)H), 7.26 (1H, d, J 15.1, C pyrrolyl(2)C(2)H), 7.62 (2H, d, J 8.7 C(O)Ar(3,5)H), 7.79 
(1H, d, J 15.1, pyrrolyl(2)C(1)H), 7.88 (2H, d, J 8.7 C(O)Ar(2,6)H); 13C NMR (100 MHz, 
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CDCl3) 36.3 (C(2)H2), 42.6 (CO2CH3), 52.2 (C(3)H2), 110.5 (pyrrolylC(4)H), 113.2 
(pyrrolylC(3)H), 116.4 (pyrrolyl(2)C(2)H), 127.5 (pyrrolylC(5)H), 127.5 (C(O)ArC(4)), 129.3 
(pyrrolylC(2)), 129.9 (C(O)ArC(2,6)H), 131.9 (C(O)ArC(3,5)H), 132.1 (pyrrolyl(2)C(1)H), 
137.5 (C(O)ArC(1)), 171.1 (CO2Me), 188.5 (pyrrolyl(2)C(3)); HRMS (NSI+), 
C17H16Br79NO3Na [M+Na]+, requires 384.0206, found 384.0207 (+0.3 ppm). 
 
Methyl (E)-3-(2-(3-(3-bromophenyl)-3-oxoprop-1-en-1-yl)-1H-pyrrol-1-yl)propanoate 
 
 
 
 
 
Following general procedure T, pyrrolyl enone 695 (3.00 g, 10.9 mmol), potassium tert-
butoxide (122 mg, 1.09 mmol) in methyl acrylate (57 mL) gave the title compound as a yellow 
oil (1.62 g, 41%); νmax (ATR)/cm−1 1560, 1578, 1734 (ester C=O), 2953 (C-H); 1H NMR (500 
MHz, CDCl3) 2.78 (2H, t, J 6.9, C(2)H2), 3.69 (3H, s, CO2CH3), 4.40 (2H, t, J 6.9, C(3)H2), 
6.24-6.25 (1H, m, pyrrolyl(4)H), 6.89 (1H, dd, J 1.3, 3.9, pyrrolyl(3)H), 6.93-6.94 (1H, m, 
pyrrolyl(5)H), 7.24 (1H, d, J 15.1, pyrrolyl(2)C(2)H), 7.37 (1H, t, J 7.9, C(O)Ar(5)H), 7.68 
(1H, ddd, J 1.0, 1.9, 7.9, C(O)Ar(6)H), 7.79 (1H, d, J 15.1, pyrrolyl(2)C(1)H), 7.93 (1H, dt, J 
1.2, 7.7, C(O)Ar(4)H), 8.13 (1H, m, C(O)Ar(2)H); 13C NMR (125 MHz, CDCl3) 36.3 (C(2)H2), 
42.6 (CO2CH3), 52.2 (C(3)H2), 110.6 (pyrrolylC(4)H), 113.4 (pyrrolylC(3)H), 116.3 
(pyrrolyl(2)C(2)H), 123.0 (C(O)ArC(3)), 126.8 (C(O)ArC(4)H), 127.7 (pyrrolylC(5)H), 129.2 
(C(O)ArC(2)), 130.3 (C(O)ArC(5)H), 131.4 (C(O)ArC(2)H), 132.4 (pyrrolyl(2)C(1)H), 135.4 
(C(O)ArC(6)H), 140.6 (C(O)ArC(1)), 171.1 (CO2Me), 188.3 (pyrrolyl(2)C(3)); HRMS (NSI+), 
C17H16Br79NO3Na [M+Na]+, requires 384.0206, found 384.0201 (−1.2 ppm). 
 
Methyl (E)-3-(2-(3-oxo-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-pyrrol-1-yl)propanoate 
 
 
 
 
 
Following general procedure T, pyrrolyl enone 696 (3.00 g, 14.8 mmol), potassium tert-
butoxide (166 mg, 1.48 mmol) in methyl acrylate (78 mL) gave the title compound as a yellow 
oil (1.28 g, 30%); νmax (ATR)/cm−1 1410, 1570, 1635, 1734 (ester C=O), 2951, 3103 (C-H); 1H 
NMR (300 MHz, CDCl3) 2.77 (2H, t, J 6.9, C(2)H2), 3.69 (3H, s, CO2CH3), 4.39 (2H, t, J 6.9, 
C(3)H2), 6.22-6.24 (1H, m, pyrrolyl(4)H), 6.85 (1H, dd, J 1.1, 4.0, pyrrolyl(3)H), 6.91 (1H, dd, 
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J 1.6, 2.5, pyrrolyl(5)H), 7.15-7.21 (2H, m, C(O)thienyl(4)H and pyrrolyl(2)C(2)H), 7.64 (1H, 
dd, J 1.1, 5.0, C(O)thienyl(3)H), 7.77 (1H, d, J 15.0, pyrrolyl(2)C(1)H), 7.82 (1H, dd, J 1.1, 3.8, 
C(O)thienyl(5)H); 13C NMR (75 MHz, CDCl3) 36.3 (C(2)H2), 42.7 (CO2CH3), 52.2 (C(3)H2), 
110.4 (pyrrolylC(4)H), 112.9 (pyrrolylC(3)H), 117.0 (pyrrolyl(2)C(2)H), 127.3 
(pyrrolylC(5)H), 128.3 (C(O)thienylC(5)H), 129.2 (pyrrolylC(2)), 131.0 (pyrrolyl(2)C(1)H), 
131.2 (C(O)thienylC(4)H), 133.3 (C(O)thienylC(3)H), 146.2 (C(O)thienylC(2)), 171.2 
(CO2Me), 181.8 (pyrrolyl(2)C(3)); HRMS (NSI+), C15H15NO3SNa [M+Na]+, requires 312.0665, 
found 312.0665 (0.0 ppm). 
 
Methyl (E)-3-(2-(3-oxobut-1-en-1-yl)-1H-pyrrol-1-yl)propanoate 
 
 
 
 
Following general procedure T, pyrrolyl enone 697 (2.97 g, 22.0 mmol), potassium tert-
butoxide (25 mg, 0.22 mmol) in methyl acrylate (116 mL) gave the title compound as a yellow 
oil (4.18 g, 90%); νmax (ATR)/cm−1 1174, 1627, 1740 (ester C=O), 2964 (C-H); 1H NMR (300 
MHz, CDCl3) 2.30 (3H, s, pyrrolyl(2)C(4)H3), 2.73 (2H, t, J 6.8, C(2)H2), 3.66 (3H, s, 
CO2CH3), 4.32 (2H, t, J 6.8, C(3)H2), 6.18 (1H, ddd, J 0.5, 2.7, 3.9, pyrrolyl(4)H), 6.50 (1H, d, 
J 15.6, pyrrolyl(2)C(2)H), 6.69-6.71 (1H, m, pyrrolyl(3)H), 6.86 (1H, dd, J 1.7, 2.5, 
pyrrolyl(5)H), 7.44 (1H, d, J 15.6, pyrrolyl(2)C(1)H); 13C NMR (75 MHz, CDCl3) 28.3 
(pyrrolyl(2)C(4)H3) 36.2 (C(2)H2), 42.5 (CO2CH3), 52.1 (C(3)H2), 110.3 (pyrrolylC(4)H), 112.7 
(pyrrolylC(3)H), 122.0 (pyrrolyl(2)C(2)H), 126.9 (pyrrolylC(5)H), 130.2 (pyrrolylC(2)), 171.1 
(CO2Me), 197.7 (pyrrolyl(2)C(3)); C12H16NO3 [M+H]+, requires 222.1125, found 222.1123 
(−0.9 ppm). 
 
Methyl (E)-3-(2-(3-oxo-3-phenylprop-1-en-1-yl)-4,5,6,7-tetrahydro-1H-indol-1-
yl)propanoate 
 
 
 
 
 
Following general procedure T, pyrrolyl enone 591 (1.26 g, 5.01 mmol), potassium tert-
butoxide (6 mg, 0.05 mmol) in methyl acrylate (26 mL) gave the title compound as a red oil 
(1.90 g, 95%); νmax (ATR)/cm−1 1549, 1581, 1732 (ester C=O), 2926 (C-H); 1H NMR (500 
MHz, CDCl3) 1.71-1.76 (2H, m, C(3)C(6)H2), 1.83-1.88 (2H, m, C(3)C(5)H2), 2.52 (2H, m, 
592
N O
Ph
CO2Me
705
N O
Me
CO2Me
Chapter 9: Experimental 
 
 264 
C(3)C(4)H2), 2.61 (2H, t, J 6.1, C(3)C(7)H2), 2.70 (2H, t, J 6.5, C(2)H2), 3.70 (3H, s, CO2CH3), 
4.27 (2H, t, J 6.1, C(3)H2), 6.69 (1H, s, C(3)pyrrolyl(3)H), 7.24 (1H, d, J 15.1, 
C(3)Ar(2)C(2)H), 7.46-7.49 (2H, m, C(O)Ar(3,5)H), 7.51-7.56 (1H, m, C(O)Ar(4)H), 7.79 (1H, 
d, J 15.0, C(3)Ar(2)C(1)H), 7.99-8.01 (2H, m, C(O)Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 
22.6 (C(3)C(7)H2), 23.1 (C(3)C(4)H2), 23.1 (C(3)C(5)H2), 23.4 (C(3)C(6)H2), 36.0 (C(2)H2), 
36.9 (C(3)H2), 52.2 (CO2CH3), 111.8 (C(3)ArC(3)H), 114.8 (C(3)Ar(2)C(2)H), 121.1 
(C(3)C(4a)), 128.3 (C(O)ArC(2,6)H), 128.3 (C(3)ArC(2)), 128.6 (C(O)ArC(3,5)H), 132.0 
(C(3)Ar(2)C(1)H), 132.3 (C(O)ArC(4)H), 135.6 (C(3)Ar(2)C(2)), 139.2 (C(O)C(1)), 171.1 
(CO2Me), 189.7 (C(3)Ar(2)C(3)); HRMS (NSI+), C21H23NO3Na [M+Na]+, requires 360.1576, 
found 360.1541 (−9.7 ppm). 
 
Methyl (E)-3-(2-(3-(4-bromophenyl)-3-oxoprop-1-en-1-yl)-5-chloro-1H-pyrrol-1-
yl)propanoate 
 
 
 
 
 
To a solution of pyrrolyl enone-ester 571 (2.20 g, 6.08 mmol) in CH2Cl2 (87 mL) at 0 °C was 
added N-chlorosuccinimide (975 mg, 7.30 mmol) portionwise. The reaction was allowed to 
warm to rt and stirred for 4 h. Reaction was quenched with saturated aq. NaCO3, extracted with 
CH2Cl2 (×3), dried over MgSO4 and concentrated under reduced pressure to crude reaction 
mixture. Column chromatography (EtOAc:hexane 15:85) gave the title compound as a brown 
oil (600 mg, 25%) ; νmax (ATR)/cm−1 1555, 1587, 1739 (ester C=O), 2998 (C-H); 1H NMR (300 
MHz, CDCl3) 2.74 (2H, t, J 6.9, C(2)H2), 3.71 (3H, s, CO2CH3), 4.42 (2H, t, J 6.9, C(3)H2), 
6.21 (1H, d, J 4.2, pyrrolyl(4)H), 6.83 (1H, d, J 4.2, pyrrolyl(3)H), 7.26 (1H, d, J 15.1, 
pyrrolyl(2)C(2)H), 7.61-7.65 (2H, m, C(O)Ar(3,5)H), 7.76 (1H, d, J 15.1, pyrrolyl(2)C(1)H), 
7.86-7.90 (2H, m, C(O)Ar(3,5)H); 13C NMR (75 MHz, CDCl3) 35.2 (C(2)H2), 39.8 (CO2CH3), 
52.2 (C(3)H2), 109.7 (pyrrolylC(4)H), 112.6 (pyrrolylC(3)H), 116.5 (pyrrolyl(2)C(2)H), 127.8 
(), 129.3 (pyrrolylC(2)), 129.9 (C(O)ArC(2,6)H), 132.0 (pyrrolyl(2)C(1)H), 132.0 
(C(O)ArC(3,5)H), 137.4 (pyrrolylC(5)), 170.6 (CO2Me), 188.4 (pyrrolyl(2)C(3)); 
C17H1877BrClNO3 [M+H]+, requires 397.9974, found 397.9970 (−1.1 ppm). 
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9.6.5 Hydrolysis of Pyrrolyl Enone-Esters 
(E)-3-(2-(3-Oxo-3-phenylprop-1-en-1-yl)-1H-pyrrol-1-yl)propanoic acid 
 
 
 
 
Following general procedure U, pyrrole enone ester 699 (8.00 g, 28.4 mmol) and LiOH (3.57 g, 
85.2 mmol) in H2O/ethanol (105 mL:105 mL) gave the title compound as a brown solid (4.96 g, 
65%); mp 103-104 °C; νmax (ATR)/cm−1 1641 (C=O), 1732 (C=O), 3157 (C-H); 1H NMR (500 
MHz, CDCl3) 2.85 (2H, t, J 7.1, C(2)H2), 4.41 (2H, t, J 7.1, C(3)H2), 6.25-6.26 (1H, m, 
pyrrolyl(4)H), 6.88 (1H, dd, J 1.3, 3.9, pyrrolyl(3)H), 6.94 (1H, m, pyrrolyl(5)H), 7.35 (1H, d, J 
15.1, pyrrolyl(2)C(2)H), 7.48-7.51 (2H, m, C(O)Ar(3,5)H), 7.56-7.59 (1H, C(O)Ar(4)H), 7.86 
(1H, d, J 15.1, pyrrolyl(2)C(1)H), 8.01-8.03 (2H, C(O)Ar(2,6)H); 13C NMR (100 MHz, CDCl3) 
36.1 (C(2)H2), 42.5 (C(3)H2), 52.2 (CO2CH3), 110.6 (pyrrolylC(4)H), 113.1 (pyrrolylC(3)H), 
116.9 (pyrrolyl(2)C(2)H), 127.4 (pyrrolylC(5)H), 128.5 (C(O)ArC(2,6)H), 128.7 
(C(O)ArC(3,5)H), 129.5 (pyrrolylC(2)), 132.4 (pyrrolyl(2)C(1)H), 132.8 (C(O)ArC(4)H), 138.7 
(C(O)ArC(1)), 174.5 (CO2H), 190.3 (pyrrolyl(2)C(3)); HRMS (NSI+), C16H15NO3Na [M+Na]+, 
requires 292.0944, found 292.0947 (+1.0 ppm). 
 
(E)-3-(2-(3-(4-Methoxyphenyl)-3-oxoprop-1-en-1-yl)-1H-pyrrol-1-yl)propanoic acid 
 
 
 
 
 
Following general procedure U, pyrrole enone ester 702 (2.43 g, 7.75 mmol) and LiOH (978 
mg, 23.3 mmol) in H2O/ethanol (29 mL:29 mL) gave the title compound as a brown solid (1.90 
g, 82%); mp 147-148 °C; νmax (ATR)/cm−1 1634 (C=O), 1730, (C=O), 3084 C-H); 1H NMR 
(500 MHz, d6-DMSO) 2.69 (2H, t, J 6.9, C(2)H2), 3.86 (3H, s, OCH3), 4.33 (2H, t, J 6.9, 
C(3)H2), 6.18-6.20 (1H, m, pyrrolyl(4)H), 7.04-7.08 (3H, m, pyrrolyl(3)H and C(O)Ar(3,5)H), 
7.11-7.12 (1H, m, pyrrolyl(5)H), 7.56 (1H, d, J 15.1, pyrrolyl(2)C(2)H), 7.70 (1H, d, J 15.1, 
pyrrolyl(2)C(1)H), 8.07-8.12 (m, 2H, C(O)ArC(2,6)H), 12.38 (1H, br. s., OH); 13C NMR (125 
MHz, d6-DMSO) 36.0 (C(2)H2), 42.1 (C(3)H2), 55.5 (OCH3), 109.6 (pyrrolylC(4)H), 112.9 
(pyrrolylC(3)H), 113.9 (C(O)ArC(3,5)H), 116.3 (pyrrolyl(2)C(2)H), 127.3 (pyrrolylC(5)H), 
128.94 (pyrrolylC(2)), 130.5 (C(O)ArC(2,6)H) 131.0 (C(O)ArC(1)), 131.1 (pyrrolyl(2)C(1)H), 
555
N O
Ph
CO2H
560
N O
OMe
CO2H
Chapter 9: Experimental 
 
 266 
162.8 (C(O)ArC(1)), 172.0 (C(1)), 186.7 (pyrrolylC(2)C(3)); HRMS (NSI+), C17H16NO4 
[M−H]−, found 298.1085, requires 298.1081 (−1.3 ppm). 
 
(E)-3-(2-(3-(4-Bromophenyl)-3-oxoprop-1-en-1-yl)-1H-pyrrol-1-yl)propanoic acid 
 
 
 
 
 
Following general procedure U, pyrrole enone ester 571 (4.11 g, 11.4 mmol) and LiOH (1.44 g, 
34.2 mmol) in H2O/ethanol (48 mL:48 mL) gave the title compound as a yellow solid (3.57 g, 
90%); mp 110-112 °C; νmax (ATR)/cm−1 1636 (C=O), 1726 (C=O), 3059 (C-H); 1H NMR (500 
MHz, d6-DMSO) 2.69 (2H, t, J 6.9, C(2)H), 4.33 (2H, t, J 6.9, C(3)H), 6.20-6.22 (1H, m, 
pyrrolyl(4)H), 7.10 (1H, dd, J 4.0, 1.5, pyrrolyl(3)H), 7.14-7.16 (1H, m, pyrrolyl(5)H), 7.54 
(1H, d, J 15.1, pyrrolyl(2)C(2)H), 7.73-7.78 (3H, m, pyrrolyl(2)C(1)H and C(O)Ar(3,5)H), 
8.02-8.06 (2H, m, C(O)Ar(2,6)H), 12.4 (1H, br. s., OH); 13C NMR (125 MHz, d6-DMSO) 36.0 
(C(2)H2), 42.0 (C(3)H2), 110.0 (pyrrolylC(4)H), 113.6 (pyrrolylC(3)H), 115.7 
(pyrrolyl(2)C(2)H), 128.0 (C(O)ArC(4)), 130.0 (pyrrolylC(2)), 130.2 (C(O)ArC(2,6)H), 131.7 
(C(O)ArC(3,5)H), 132.40 (pyrrolyl(2)C(1)H), 137.2 (C(O)ArC(1)), 172.0 (CO2H), 187.3 
(pyrrolyl(2)C(3)); HRMS (NSI+), C16H15Br79NO3 [M+H]+, requires 348.0230, found 348.0233 
(+0.9 ppm). 
 
(E)-3-(2-(3-(3-Bromophenyl)-3-oxoprop-1-en-1-yl)-1H-pyrrol-1-yl)propanoic acid 
 
 
 
 
 
Following general procedure U, pyrrole enone ester 703 (1.40 g, 3.87 mmol) and LiOH (487 
mg, 11.6 mmol) in H2O/ethanol (14 mL:14 mL) gave the title compound as a yellow solid (1.07 
g, 81%); mp 138-140 °C; νmax (ATR)/cm−1 1584, 1728 (C=O), 3096 (C-H); 1H NMR (400 MHz, 
d6-DMSO) 2.69 (2H, t, J 6.9, C(2)H2), 4.33 (2H, t, J 6.9, C(3)H2), 6.21-6.22 (1H, m, 
pyrrolyl(4)H), 7.14-7.16 (2H, m, pyrrolyl(3)H and pyrrolyl(5)H), 7.50-7.57 (2H, m, 
pyrroly(2)C(2)H and C(O)Ar(5)H), 7.77 (1H, d, J 15.0, pyrrolyl(2)C(2)H), 7.83 (1H, dd, J 1.1, 
8.0, C(O)Ar(5)H), 8.09 (1H, dt, J 1.1, 7.8, C(O)Ar(4)H), 8.23 (1H, t, J 1.8, C(O)Ar(2)H); 13C 
NMR (125 MHz, d6-DMSO) 36.0 (C(2)H), 42.1 (C(3)H), 110.0 (pyrrolyl(4)H), 113.9 
(pyrrolyl(3)H), 115.6 (pyrrolyl(2)C(2)H), 122.3 (C(O)ArC(3)), 127.2 (C(O)ArC(6)H), 128.2 
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(C(O)ArC(6)H), 128.9 (C(O)ArC(5)H), 130.6 (CO)ArC(2)H), 130.9 (pyrrolylC(2)), 132.7 
(C(O)ArC(4)H), 135.2 (pyrrolyl(2)C(1)H), 140.3 (C(O)ArC(1)), 172.0 (CO2H), 186.9 
(pyrrolyl(2)C(3)); HRMS (NSI+), C16H15Br79NO3 [M+H]+, requires 276.0501, found 276.9886 
(+0.9 ppm). 
 
(E)-3-(2-(3-Oxobut-1-en-1-yl)-1H-pyrrol-1-yl)propanoic acid 
 
 
 
 
Following general procedure U, pyrrolyl enone ester 705 (4.41 g, 19.9 mmol) and LiOH (2.51 
g, 59.7 mmol) in H2O/ethanol (74 mL:74 mL) gave the title compound as a brown solid (1.12 g, 
92%); mp 122-124 °C; νmax (ATR)/cm−1 1591, 1714 (C=O), 2906 (C-H); 1H NMR (500 MHz, 
CDCl3) 2.27 (3H, s, C(O)CH3), 2.65 (2H, t, J 6.8, C(2)H2), 4.30 (2H, d, J 6.8 C(3)H2), 6.13-6.15 
(1H, m, pyrrolyl(4)H), 6.45 (1H, d, J 15.6, pyrrolyl(2)C(2)H), 6.77 (1H, dd, J 1.4, 3.9, 
pyrrolyl(3)H), 7.06-7.07 (1H, m, pyrrolyl(5)H), 7.53 (1H, d, J 15.9, pyrrolyl(2)C(1)H); 13C 
NMR (125 MHz, CDCl3) 27.1 (C(O)CH3), 36.2 (C(2)H2), 42.1 (C(3)H2), 109.8 (pyrrolylC(4)H), 
112.1 (pyrrolylC(3)H), 122.2 (pyrrolyl(2)C(2)H), 127.2 (pyrrolylC(5)H), 128.2 (pyrrolylC(2)), 
131.5 (pyrrolyl(2)C(1)H), 172.3 (CO2H), 197.5 (pyrrolyl(2)C(3)); C11H12NO3 [M−H]−, requires 
206.0823, found 206.0823 (0.0 ppm). 
 
(E)-3-(2-(3-(Naphthalen-2-yl)-3-oxoprop-1-en-1-yl)-1H-pyrrol-1-yl)propanoic acid 
 
 
 
 
 
Following general procedure U, pyrrolyl enone ester 700 (2.53 g, 7.57 mmol) and LiOH (952 
mg, 22.7 mmol) in H2O/ethanol (28 mL:28 mL) gave the title compound as a brown solid (1.35 
g, 56%); mp 120-122 °C; νmax (ATR)/cm−1 1556, 1728 (C=O), 3047 (C-H); 1H NMR (400 MHz, 
d6-DMSO) 2.72 (2H, t, J 6.9, C(2)H2), 4.36 (2H, t, J 6.9, C(3)H2), 6.23-6.24 (1H, m, 
pyrrolyl(4)H), 7.12-7.16 (2H, m, pyrrolyl(3)H and pyrrolyl(5)H), 7.61-7.69 (2H, m, ArH), 7.74 
(1H, d, J 15.1, pyrrolyl(2)C(2)H), 7.81 (1H, d, J 15.1, pyrrolyl(2)C(1)H), 7.96-8.05 (2H, m, 
ArH), 8.10-8.16 (2H, m, ArH), 8.83 (1H, s, ArH), 12.4 (1H, br. s, CO2H); 13C NMR (100 MHz, 
d6-DMSO) 36.0 (C(2)H2), 42.1 (C(3)H2), 109.8 (pyrrolylC(4)H), 113.3 (pyrrolylC(3)H), 116.3 
(pyrrolyl(2)C(2)H), 124.2 (C(O)ArCH), 126.9 (C(O)ArCH), 127.7 (C(O)ArCH), 127.7 
(C(O)ArCH), 128.3 (C(O)ArCH), 128.4 (pyrrolylC(5)H), 129.0 (C(O)ArCH), 129.5 
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(C(O)ArCH), 129.6 (pyrrolylC(2)), 131.8 (C(O)ArC), 132.4 (pyrrolyl(2)C(1)H), 134.9 
(C(O)ArC), 135.5 (C(O)ArC), 172.0 (CO2H), 188.2 (pyrrolyl(2)C(3)); HRMS (NSI−), 
C20H16NO3 [M−H]−, requires 318.1136, found 318.1131 (−1.5 ppm). 
 
(E)-3-(2-(3-(Naphthalen-1-yl)-3-oxoprop-1-en-1-yl)-1H-pyrrol-1-yl)propanoic acid 
 
 
 
 
 
Following general procedure U, pyrrolyl enone ester 701 (1.68 g, 5.04 mmol) and LiOH (634 
mg, 15.1 mmol) in H2O/ethanol (19 mL:19 mL) gave the title compound as a crude residue of 
80% purity; 1H NMR (400 MHz, d6-DMSO) 2.65 (2H, t, J 6.9, C(2)H2), 4.24 (2H, t, J 6.9, 
C(3)H2), 6.18-6.19 (1H, m, pyrrolyl(4)H), 6.98-6.98 (1H, m, pyrrolyl(3)H), 7.13-7.14 (1H, m, 
pyrrolyl(5)H), 7.17 (1H, d, J pyrrolyl(2)C2)H), 7.55-7.63 (5H, m, C(O)ArH ×3 and 
pyrrolyl(2)C(1)H), 7.88-7.89 (1H, m, C(O)ArH), 8.02-8.03 (1H, m, C(O)ArH), 8.10-8.11 (1H, 
m, C(O)ArH), 8.29-8.30 (1H, m, C(O)ArH) 12.3 (1H, br. s, CO2H). The crude residue was 
carried forward immediately into the next step without further characterisation. 
 
(E)-3-(2-(3-oxo-3-(Thiophen-2-yl)prop-1-en-1-yl)-1H-pyrrol-1-yl)propanoic acid 
 
 
 
 
 
Following general procedure U, pyrrole enone ester 704 (1.28 g, 4.42 mmol) and LiOH (319 
mg, 13.3 mmol) in H2O/ethanol (16 mL:16 mL) gave the title compound as a yellow solid (1.12 
g, 92%); mp 122-124 °C; νmax (ATR)/cm−1 1558, 1627 (C=O), 1726 (C=O), 2910 (C-H); 1H 
NMR (400 MHz, CDCl3) 2.84 (2H, t, J 7.2, C(2)H2), 4.33 (2H, t, J 6.9, C(3)H2), 6.24-6.26 (1H, 
dd, J 2.7, 3.5, pyrrolyl(4)H), 6.88 (1H, dd, J 1.2, 4.0, pyrrolyl(3)H), 6.94 (1H, dd, 1.6, 2.5, 
pyrrolyl(5)H), 7.16-7.22 (2H, m, pyrrolyl(2)C(2)H and C(O)thienyl(4)H), 7.66 (1H, dd, J 1.1, 
4.9, C(O)thienyl(3)H), 7.84-7.88 (2H, m, C(O)thienyl(5)H and pyrrolyl(2)C(1)H); 13C NMR 
(100 MHz, CDCl3) 36.1 (C(2)H2), 42.5 (C(3)H2), 110.7 (pyrrolylC(4)H), 113.1 (pyrrolylC(3)H), 
116.8 (pyrrolyl(2)C(2)H), 127.5 (pyrrolylC(5)H), 128.4 (C(O)thienylC(4)H), 129.3 
(pyrrolylC(2)), 131.6 (C(O)thienylC(5)H), 131.7 (pyrrolyl(2)C(1)H), 133.7 
(C(O)thienylC(3)H), 146.0 (C(O)thienylC(2)), 174.6 (CO2H), 182.3 (pyrrolyl(2)C(3)); HRMS 
(NSI−), C14H12NO3S [M−H]−, requires 274.0543, found 274.0536 (−2.7 ppm). 
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(E)-3-(2-(3-oxo-3-phenylprop-1-en-1-yl)-4,5,6,7-tetrahydro-1H-indol-1-yl)propanoic acid 
 
 
 
 
 
Following general procedure U, pyrrolyl enone ester 592 (1.90 g, 5.63 mmol) and LiOH (709 
mg, 16.9 mmol) in H2O/ethanol (21 mL:21 mL) gave the title compound as a crude residue of 
80% purity; 1H NMR (400 MHz, d6-DMSO) 1.74-1.77 (2H, m, indolyl(6)H2), 1.81-1.87 (2H, m, 
indolyl(5)H2), 2.50-2.53 (2H, m, indolyl(4)H2), 2.59-2.62 (2H, m, indolyl(7)H2), 2.70 (2H, t, J 
6.8, C(2)H2), 4.26 (2H, t, J 6.8, C(3)H2), 6.69 (1H, s, indolyl(3)H), 7.23 (1H, d, J 14.9, 
indolyl(2)C(2)H), 7.44-7.54 (3H, m, C(O)Ar(3,5)H and C(O)Ar(4)H), 7.79 (1H, d, J 14.9, 
indolyl(2)C(1)H), 7.98-8.00 (2H, m, C(O)Ar(2,6)H). The crude residue was carried forward 
immediately into the next step without further characterisation. 
 
(E)-3-(2-(3-(4-bromophenyl)-3-oxoprop-1-en-1-yl)-5-chloro-1H-pyrrol-1-yl)propanoic acid 
 
 
 
 
 
 
Following general procedure U, pyrrolyl enone ester 572 (496 mg, 1.24 mmol) and LiOH (156 
mg, 3.72 mmol) in H2O/ethanol (4.6 mL:4.6 mL) gave the title compound as a brown solid (327 
mg, 69%); mp 160-162 °C; νmax (ATR)/cm−1 1558, 1575, 1641 (C=O), 1741 (C=O), 3086 (C-
H); 1H NMR (300 MHz, CDCl3) 2.79 (2H, t, J 6.9, C(2)H2), 4.46 (2H, t, J 6.9, C(3)H2), 6.23 
(1H, d, J 4.2, pyrrolyl(4)H), 6.87 (1H, d, J 4.1, pyrrolyl(3)H), 7.28 (1H, d, J 15.1, 
pyrrolyl(2)C(2)H), 7.63 (2H, d, J 8.5, C(O)Ar(3,5)H), 7.85-7.90 (3H, m, pyrrolyl(2)C(1)H and 
C(O)Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 34.8 (C(2)H2), 39.5 (C(3)H2), 109.8 
(pyrrolylC(4)H), 112.8 (pyrrolylC(3)H), 116.3 (pyrrolyl(2)C(2)H), 122.5 (C(O)ArC(4)), 128.0 
(C(O)ArC(1)), 129.4 (), 130.0 (C(O)ArC(3,5)H), 132.0 (C(O)ArC(2,6)H), 132.7 
(pyrrolyl(2)C(1)H), 137.2 (pyrrolylC(5)), 173.1 (CO2H), 188.9 (pyrrolyl(2)C(3)O); HRMS 
(NSI−), C16H12Br79Cl35NO3 [M−H]−, requires 379.9694, found 379.9695 (0.25 ppm). 
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9.6.6 Intramolecular Isothiourea-Catalysed Michael Addition-Lactonisation 
(4aS,9aR)-3-Phenyl-4a,9a-dihydro-1H,9H-pyrano[4,3-a]pyrrolizin-1-one 
 
 
 
 
Pyrrolyl enone-acid 555 (50.0 mg, 0.19 mmol), i-Pr2NEt (97 µL, 0.56 mmol), pivaloyl chloride 
(69 µL, 0.56 mmol) in CH2Cl2 (2 mL), (+)-BTM 48 (4.7 mg, 0.019 mmol) and i-Pr2NEt (49 µL, 
0.28 mmol) gave crude product (>95:5 dr). Purification by column chromatography 
(EtOAc:petrol ether 10:90) afforded the title compound (>95:5 dr) as a yellow oil (39 mg, 
84%); 
€ 
α[ ]D
20 +52.2 (c 0.5 CHCl3); Chiral HPLC analysis; ChiralPak AD-H (90:10 hexane:IPA, 
flow rate 1.0 mlmin-1, 270 nm, 30 °C) tR 14.3 (major) and tR 16.4 (minor), >99% ee; νmax 
(ATR)/cm−1 3028 (C-H), 1728 (C=O), 1H NMR (500 MHz, CDCl3) 3.91 (1H, td, J 8.0, 5.0, 
C(9a)H), 4.27 (1H, dd, J 4.6, 4.3, C(4a)H), 4.37 (1H, dd, J 10.8, 8.0, C(9)Ha), 4.55 (1H, dd, J 
10.8, 5.0, C(9)Hb), 5.90 (1H, d, J 4.6, C(4)H), 5.95 (1H, dt, J 3.3, 1.1, C(5)H), 6.27 (1H, t, J 
3.1, C(6)H), 6.67 (1H, dd, J 2.8, 1.1, C(7)H), 7.36-7.42 (3H, m, C(3)ArC(3,5)H and 
C(3)ArC(4)H), 7.63-7.66 (2H, m, C(3)ArC(2,6)H); 13C NMR (126 MHz, CDCl3) 35.8 (C(4a)H), 
45.2 (C(9a)H), 49.0 (C(9)HaHb), 99.6 (C(4)H), 100.0 (C(5)H), 113.8 (C(6)H), 115.2 (C(7)H), 
125.2 (C(3)ArC(2,6)H), 128.9 (C(3)ArC(4), 129.7 (C(3)ArC(3,5)H), 132.4 (C(4b)), 136.6 
(C(3)ArC(1)), 148.7 (C(3)), 168.3 (C(1)); HRMS (NSI+), C16H13NO2Na [M+Na]+, requires 
274.0838, found 274.0843 (+1.8 ppm). 
9.6.7 Intramolecular Isothiourea-Catalysed Michael Addition-Lactonisation/Ring 
Opening 
Methyl (1S,2R)-1-(2-oxo-2-phenylethyl)-2,3-dihydro-1H-pyrrolizine-2-carboxylate 
 
 
 
 
Following general procedure V, pyrrolyl enone-acid 555 (50 mg, 0.19 mmol), i-Pr2NEt (97 µL, 
0.56 mmol), pivaloyl chloride (69 µL, 0.56 mmol) in CH2Cl2 (2 mL), (+)-BTM 48 (2.4 mg, 
0.0095 mmol) and i-Pr2NEt (49 µL, 0.28 mmol) gave the crude product (>95:5 dr). Purification 
by column chromatography (EtOAc:petrol 10:90) gave the title compound (>95:5 dr) as a 
yellow oil (45 mg, 86%); 
€ 
α[ ]D
20 –54.3 (c 1.0 in CHCl3); Chiral HPLC analysis ChiralPak AD-H 
(90:10 hexane:IPA, flow rate 1.0 mlmin-1, 220 nm), tR 10.6 (minor) and tR 12.2 (major), >99% 
ee; νmax (ATR)/cm−1 2953 (C-H), 1730 (C=O), 1684 (C=O); 1H NMR (400 MHz, CDCl3) 3.19-
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3.34 (2H, m, pyrrolizine(1)CHaHb and pyrrolizine(1)CHaHb), 3.58 (3H, s, CO2CH3), 4.00 (1H, 
dd, J 16.2, 7.6, pyrrolizine(2)H), 4.15 (1H, dd, J 11.7, 7.6, pyrrolizine(3)HaHb), 4.19-4.26 (1H, 
m, pyrrolizine(1)H), 4.33 (1H, dd, J 11.4, 7.2, pyrrolizine(3)HaHb), 5.80-5.82 (1H, dt, J 3.4, 1.0, 
pyrrolizine(7)H), 6.18-6.22 (1H, m, pyrrolizine(6)H), 6.61 (1H, dd, J 2.6, 1.2, pyrrolizine(5)H), 
7.43-7.49 (2H, m, C(O)ArC(3,5)H), 7.53-7.58 (1H, m, C(O)ArC(4)H), 7.94-7.90 (2H, m, 
C(O)ArC(2,6)H); 13C NMR (125 MHz, CDCl3) 35.3 (pyrrolizineC(1)H), 39.8 
(pyrrolizine(1)CHaHb), 47.5 (pyrrolizineC(3)HaHb), 49.6 (pyrrolizineC(2)H), 51.8 (CO2CH3), 
99.7 (pyrrolizineC(7)H), 112.3 (pyrrolizineC(6)H), 113.9 (pyrrolizineC(5)H), 127.8 
(C(O)ArC(2,6)H), 128.5 (C(O)ArC(3,5)H), 133.1 (C(O)ArC(4)H), 136.7 (pyrrolizineC(7a)), 
137.6 (C(O)ArC(1)), 172.1 (CO2Me), 197.7 (C(O)Ar); HRMS (NSI+), C17H18NO3 [M+H]+, 
requires 284.1281, found 284.1284 (+1.1 ppm). 
 
1-Phenyl-2-((1S,2R)-2-(pyrrolidine-1-carbonyl)-2,3-dihydro-1H-pyrrolizin-1-yl)ethan-1-
one 
 
 
 
 
 
Following general procedure V, pyrrolyl enone-acid 555 (100 mg, 0.37 mmol), i-Pr2NEt (195 
µL, 1.12 mmol), pivaloyl chloride (138 µL, 1.12 mmol) in CH2Cl2 (3.7 mL), (+)-BTM 48 (4 mg, 
0.019 mmol), i-Pr2NEt (65 µL, 0.37 mmol) and pyrrolidine (126 µL, 1.51 mmol) gave, after 
purification by column chromatography (EtOAc:petrol 15:85) to afford the title compound as a 
yellow oil (119 mg, quant.,); 
€ 
α[ ]D
20 –83.0 (c 1.0 in CHCl3); Chiral HPLC analysis ChiralPak IB 
(90:10 hexane:IPA, 1.0 mlmin-1, 211 nm), tR 13.0 (major) and tR 15.6 (minor), >99% ee; νmax 
(ATR)/cm−1 1610 (C=O), 1682 (C=O), 2951 (C-H); 1H NMR (500 MHz, CDCl3) 1.75 (2H, p, J 
7.0, C(O)NC(3)H2), 1.90-2.04 (2H, m, C(O)NC(4)H2), 2.97-3.04 (2H, m, ArC(O)CHa and 
C(O)NC(2)Ha), 3.29-3.36 (1H, m, C(O)NC(2)Hb), 3.46-3.52 (1H, m, C(O)NC(5)Ha), 3.56 (1H, 
dd, J 9.8, 8.6, ArC(O)CHb), 3.69-3.74 (1H, m, C(O)NC(5)Hb), 4.01-4.10 (2H, m, C(1)H and 
C(3)Ha), 4.24-4.29 (1H, m, C(2)H), 4.49-4.56 (1H, m, C(3)Hb), 5.80-5.82 (1H, m, C(7)H), 6.21 
(1H, t, J 3.0, C(6)H), 6.62 (1H, dd, J 2.7, 1.3, C(5)H), 7.41-7.45 (2H, m, C(O)ArC(3,5)H), 7.51-
7.55 (1H, m, C(O)ArC(4)H), 7.89-7.91 (2H, m, C(O)ArC(2,6)H); 13C NMR (125 MHz, CDCl3) 
24.3 (C(O)NC(3)H2), 26.1 (C(O)NC(4)H2), 34.2 (C(2)H), 40.6 (ArC(O)CHaHb), 46.0 
(C(O)NC(2)HaHb), 46.7 (C(O)NC(5)HaHb), 48.2 (C(3)HaHb), 49.4 (C(1)H), 99.3 (C(7)H), 112.4 
(C(6)H), 114.1 (C(5)H), 128.2 (C(O)ArC(2,6)H), 128.7 (C(O)ArC(3,5)H), 133.2 
(C(O)ArC(4)H), 136.9 (C(7a)), 138.6 (C(O)ArC(1)), 168.6 (CO2NR), 198.3 (C(O)Ar); HRMS 
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(NSI+), C20H23N2O2 [M+H]+, requires 323.1754, found 323.1754 (+0.0 ppm). 
 
2-((1S,2R)-2-(Morpholine-4-carbonyl)-2,3-dihydro-1H-pyrrolizin-1-yl)-1-phenylethan-1-
one 
 
 
 
 
 
 
Following general procedure V, pyrrolyl enone-acid 555 (150 mg, 0.56 mmol), i-Pr2NEt (293 
µL, 1.68 mmol), pivaloyl chloride (207 µL, 1.68 mmol) in CH2Cl2 (5.6 mL), (+)-BTM 48 (7 mg, 
0.028 mmol) and i-Pr2NEt (98 µL, 0.56 mmol) gave, after purification by column 
chromatography (EtOAc:petrol 10:90) the title compound (>95:5 dr) as a brown oil (29 mg, 
66%); 
€ 
α[ ]D
20 –26.2 (c 0.5 in CHCl3); Chiral HPLC analysis: ChiralPak IA (80:20 hexane:IPA, 
1.0 mlmin-1, 220 nm), tR 13.3 (major) and tR 16.6 (minor), >99:1 er; νmax (ATR)/cm−1 1633 
(C=O), 1681 (C=O), 2974, 3064 (C-H); 1H NMR (500 MHz, CDCl3) 3.04 (1H, dd, J 4.8, 18.1, 
pyrrolizine(2)H), 3.32-3.39 (1H, dd, J 6.8, 10.3, pyrrolizine(1)CHaHb), 3.41-3.48 (3H, m, 
pyrrolizine(1)CHaHb and 2×C(O)NCHaHb), 3.55-3.59 (2H, m, 2×C(O)NCHaHb), 3.63-3.73 (2H, 
2×C(O)CH2CHaHbO), 3.79-3.82 (1H, m, pyrrolizine(1)H), 4.07 (1H, dd, J 7.4, 10.1, 
pyrrolizine(3)HaHb), 4.13-4.19 (2H, m, 2×C(O)CH2CHaHbO), 4.52-4.55 (1H, m, 
pyrrolizine(3)HaHb), 5.80 (1H, d, J 2.8, pyrrolizine(7)H), 6.20 (1H, t, J 2.8, pyrrolizine(6)H), 
6.61 (1H, br. s, pyrrolizine(5)H), 7.42-7.45 (2H, m, C(O)Ar(3,5)H), 7.53-7.56 (1H, m, 
C(O)Ar(4)H), 7.91 (2H, d, J 7.5, C(O)Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 34.9 
(pyrrolizineC(1)H), 40.3 (pyrrolizine(1)CHaHbCOAr), 42.1 (pyrrolizineC(2)H), 46.2 
(C(O)NCaH2), 47.2 (C(O)NCbH2), 48.4 (pyrrolizineC(3)HaHb), 66.4 (C(O)NCH2CaH2O), 66.6 
(C(O)NCH2CbH2O), 99.5 (pyrrolizineC(7)H), 112.4 (pyrrolizineC(6)H), 114.2 
(pyrrolizineC(5)H), 128.2 (C(O)ArC(2,6)H), 128.7 (C(O)ArC(3,5)H), 133.4 (C(O)ArC(4)H), 
136.7 (pyrrolizineC(8)), 138.2 (C(O)ArC(1)), 169.0 (C(O)NR), 198.0 (C(O)Ar); HRMS (NSI+), 
C20H22N2O3Na [M+H]+, requires 361.1523, found 361.1522 (−0.2 ppm). 
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Tert-butyl 4-((1S,2R)-1-(2-oxo-2-phenylethyl)-2,3-dihydro-1H-pyrrolizine-2-
carbonyl)piperazine-1-carboxylate 
 
 
 
 
 
 
Following general procedure V, pyrrolyl enone-acid 555 (100 mg, 0.37 mmol), i-Pr2NEt (193 
µL, 1.11 mmol), pivaloyl chloride (137 µL, 1.11 mmol) in CH2Cl2 (3 mL), (+)-BTM 48 (4 mg, 
0.019 mmol), i-Pr2NEt (293 µL, 1.68 mmol) and N-Boc piperazine (276 mg, 1.48 mmol) gave, 
after purification by column chromatography (EtOAc:petrol 20:80) the title compound (>95:5 
dr) as a brown oil (121 mg, 75%); 
€ 
α[ ]D
20 –31.6 (c 0.5 in CHCl3); Chiral HPLC analysis: 
ChiralPak AD-H (90:10 hexane:IPA, 1.0 mlmin-1, 211 nm), tR 23.0 (major) and tR 30.3 (minor), 
>99:1 er; νmax (ATR)/cm−1 1163, 1633 (C=O), 1681 (C=O), 2927, 2974 (C-H); 1H NMR (300 
MHz, CDCl3) 1.47 (9H, s, C(CH3)3), 2.99-3.06 (1H, m, pyrrolizine(2)H), 3.25-3.31 (3H, m, 
pyrrolizine(1)CHaHbCOAr and BocNCH2), 3.40-3.70 (6H, m, 2×NCH2 and BocNCH2), 4.04-
4.20 (3H, m, pyrrolizine(3)HaHb and pyrrolizine(1)H and pyrrolizine(1)CHaHbCOAr), 4.50-4.56 
(1H, m, pyrrolizine(3)HaHb); 13C NMR (75 MHz, CDCl3) 28.5 (C(CH3)3), 35.0 
(pyrrolizineC(1)H), 40.4 (pyrrolizineC(2)H), 41.6 (NCH2), 45.7 (BocNCH2), 47.5 
(pyrrolizine(1)CHaHbCOAr), 48.4 (pyrrolizineC(3)H2), 80.4 (C(CH3)3), 99.5 
(pyrrolizineC(7)H), 112.4 (pyrrolizineC(6)H), 114.3 (pyrrolizineC(5)H), 128.2 
(C(O)ArC(2,6)H), 128.2 (C(O)ArC(3,5)H), 133.4 (C(O)ArC(4)H), 136.8 (pyrrolizineC(7a)), 
138.2 (C(O)ArC(1)), 154.6 (NC(O)C(CH3)3), 168.9 (CO2Me), 198.1 (C(O)Ar); HRMS (NSI+), 
C25H32N3O4 [M+CH2+H]+, requires 438.2387, found 438.2394 (1.5 ppm). 
 
(1S,2R)-N-Allyl-1-(2-oxo-2-phenylethyl)-2,3-dihydro-1H-pyrrolizine-2-carboxamide 
 
 
 
 
 
Following general procedure V, pyrrolyl enone-acid 555 (150 mg, 0.56 mmol), i-Pr2NEt (293 
µL, 1.68 mmol), pivaloyl chloride (207 µL, 1.68 mmol) in CH2Cl2 (5.6 mL), (+)-BTM 48 (7 mg, 
0.028 mmol), i-Pr2NEt (293 µL, 1.68 mmol) and allyl amine (168 µL, 2.24 mmol) gave, after 
purification by column chromatography (EtOAc:petrol 15:85) the title compound (>95:5 dr) as 
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a brown oil (140 mg, 81%); 
€ 
α[ ]D
20 –41.0 (c 0.5 in CHCl3); Chiral HPLC analysis: ChiralPak 
AD-H (80:20 hexane:IPA, 1.0 mlmin-1, 254 nm), tR 9.1 (minor) and tR 11.7 (major), 98.5:1.5 er; 
νmax (ATR)/cm−1 1637(C=O), 1683 (C=O), 3290 (C-H); 1H NMR (500 MHz, CDCl3) 3.33 (1H, 
dd, J 5.3, pyrrolizine(1)CHaHbCOAr), 3.42 (1H, dd, J 8.6, 18.5, pyrrolizine(1)CHaHbCOAr), 
3.59-3.64 (1H, m, C(O)NHCHaHb), 3.72-3.80 (2H, m, pyrrolizine(2)H and C(O)NHCHaHb), 
4.09-4.18 (2H, m, pyrrolizine(3)HaHb and pyrrolizine(1)H), 4.37 (1H, dd, J 6.0, 10.6, 
pyrrolizine(3)HaHb), 4.96-5.06 (2H, m, =CHaHb and =CHaHb), 5.61 (1H, ddt, J 6.0, 10.2, 16.3, 
CH=CH2), 5.79-5.80 (2H, m, pyrrolizine(7)H and C(O)NHR), 6.20 (1H, t, J 3.0, 
pyrrolizine(6)H), 6.61 (1H, br. s, pyrrolizine(5)H), 7.44-7.47 (2H, m, C(O)Ar(3,5)H), 7.55-7.58 
(1H, m, C(O)Ar(4)H), 7.93-7.94 (2H, m, C(O)Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 35.6 
(pyrrolizineC(1)H), 40.3 (pyrrolizine(1)CHaHbC(O)Ar), 42.1 (C(O)NHCHaHb), 48.2 
(pyrrolizineC(3)HaHb), 51.4 (pyrrolizineC(2)H), 99.4 (pyrrolizineC(7)H), 112.6 
(pyrrolizineC(6)H), 114.1 (pyrrolizineC(5)H), 117.1 (=CHaHb), 128.2 (C(O)ArC(2,6)H), 128.7 
(C(O)ArC(3,5)H), 133.5 (C(O)ArC(4)H), 133.7 (CH=CH2), 136.7 (pyrrolizineC(8)), 138.1 
(C(O)ArC(1)), 170.8 (C(O)NHR), 199.4 (C(O)Ar); HRMS (NSI+), C20H21N2O2 [M+H]+, 
requires 321.1598, found 321.1589 (−0.1 ppm). 
 
1-Phenyl-2-((1S,2R)-2-(4,5,6,7-tetrahydrothieno[2,3-c]pyridine-6-carbonyl)-2,3-dihydro-
1H-pyrrolizin-1-yl)ethan-1-one 
 
 
 
 
 
Following general procedure V, pyrrolyl enone-acid 555 (100 mg, 0.37 mmol), i-Pr2NEt (193 
µL, 1.11 mmol), pivaloyl chloride (137 µL, 1.11 mmol) in CH2Cl2 (3 mL), (+)-BTM 48 (4 mg, 
0.019 mmol), i-Pr2NEt (293 µL, 1.68 mmol) and 4,5,6,7-tetrahydrothieno[3,2-c] pyridine (260 
mg, 1.48 mmol) gave, after purification by column chromatography (EtOAc:petrol 15:85) the 
title compound (90:10 dr, 50:50 rotameric mixture) as a brown oil (87 mg, 60%); 
€ 
α[ ]D
20 –50.6 (c 
0.5 in CHCl3); Chiral HPLC analysis: ChiralPak AD-H (90:10 hexane:IPA, 1.0 mlmin-1, 220 
nm), tR 35.3 (major) and tR 46.5 (minor), >99:1 er; νmax (ATR)/cm−1 1660 (C=O), 1734 (C=O), 
2951, 3089 (C-H); data for single rotamer; 1H NMR (500 MHz, CDCl3) 2.64 (1H, dt, J 5.2, 
16.0, CH), 2.95-2.99 (1H, m, CH), 3.03-3.12 (2H, m, 2×CH), 3.57 (1H, ddd, J 4.7, 7.4, 12.6, 
CH), 3.90 (1H, dt, J 5.1, 12.8, CH), 4.05-4.13 (4H, m, 4×CH), 4.57-4.64 (2H, m, 4×CH), 5.83-
5.85 (1H, m, pyrrolizine(7)H), 6.22 (1H, t, J 3.0, pyrrolizine(6)H), 6.64-6.65 (1H, m, 
pyrrolizine(5)H), 6.74 (1H, d, J 5.2, thienyl(3)H), 7.14 (1H, d, J 5.2, thienyl(2)H), 7.40-7.44 
N
O
Ph
599
N
O
S
Chapter 9: Experimental 
 
 275 
(2H, m , Ar(3,5)H), 7.51-7.56 (1H, m, Ar(4)H), 7.82-7.83 (2H, m, Ar(2,6)H); 13C NMR (125 
MHz, CDCl3) 24.7 (CH), 34.9 (CH), 40.2 (CH), 43.0 (CH), 46.0 (CH), 48.1 (CH), 48.4 (CH), 
99.6 (pyrrolizineC(7)H), 112.4 (pyrrolizineC(6)H), 114.2 (pyrrolizineC(5)H), 123.7 
(thienylC(2)H), 124.7 (thienylC(3)H), 128.1 (ArCH), 128.7 (ArCH), 132.4 (ArC), 133.3 (ArC), 
134.3 (ArCH), 136.7 (ArC), 138.3 (ArC), 169.1 (C(O)NR), 197.9 (C(O)Ar); HRMS (NSI+), 
C22H21N2O2S [M+H]+, requires 377.1318, found 377.1295 (−6.1 ppm). 
 
Methyl (1S,2R)-1-(2-(4-bromophenyl)-2-oxoethyl)-2,3-dihydro-1H-pyrrolizine-2-
carboxylate 
 
 
 
 
 
 
Following general procedure V, pyrrolyl enone-acid 561 (60 mg, 0.17 mmol), ), i-Pr2NEt (90 
µL, 0.52 mmol), pivaloyl chloride (64 µL, 0.52 mmol) in CH2Cl2 (2 mL), (+)-BTM 48 (2.2 mg, 
0.009 mmol) and i-Pr2NEt (45 µL, 0.24 mmol) gave the crude product (>95:5 dr). Purification 
by column chromatography (EtOAc:petrol 10:90) gave the title compound (>95:5 dr) as a 
brown solid (49 mg, 78%); mp 120-121 °C; 
€ 
α[ ]D
20  –50.8 (c 0.5 in CHCl3); Chiral HPLC 
analysis: ChiralPak AD-H (90:10 hexane:IPA, 1.0 mlmin-1, 254 nm), tR 14.5 (minor) and tR 17.4 
(major), >99% ee; νmax (ATR)/cm−1 1689 (C=O), 1732 (C=O), 2889, 2951 (C-H); 1H NMR (400 
MHz, CDCl3) 3.14-3.30 (2H, m, pyrrolizine(1)CHaHbC(O)Ar and pyrrolizine(1)CHaHbC(O)Ar), 
3.59 (3H, s, CO2CH3), 3.98 (1H, dd, J 8.1, 7.8, pyrrolizine(2)H), 4.12-4.23 (2H, m, 
pyrrolizine(3)HaHb and pyrrolizine(1)H)), 4.32 (1H, dd, J 10.7, 7.4, pyrrolizine(3)HaHb), 5.78-
5.81 (1H, m, pyrrolizine(7)H), 6.19 (1H, t, J 3.0, pyrrolizine(6)H), 6.60 (1H, dd, J 2.8, 1.2, 
pyrrolizine(5)H), 6.57-6.61 (2H, m, C(O)ArC(3,5)H), 7.76-7.81 (2H, m, C(O)ArC(2,6)H); 13C 
NMR (125 MHz, CDCl3) 35.7 (pyrrolizineC(1)H), 40.3 (pyrrolizine(1)CHaHbC(O)Ar), 48.0 
(pyrrolizineC(3)HaHb), 50.0 (pyrrolizineC(2)H), 52.4 (CO2CH3), 100.3 (pyrrolizineC(7)H), 
112.8 (pyrrolizineC(6)H), 114.2 (pyrrolizineC(5)H), 128.7 (C(O)ArC(4)), 129.9 
(C(O)ArC(2,6)H), 132.3 (C(O)ArC(3,5)H), 135.9 (pyrrolizineC(7a)), 137.9 (C(O)ArC(1)), 
172.47 (CO2Me), 197.2 (C(O)Ar); HRMS (NSI+), C17H1777BrNO4 [M+H]+, requires 362.0386, 
found 362.0378 (−2.3 ppm). 
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Methyl (1S,2R)-1-(2-(3-bromophenyl)-2-oxoethyl)-2,3-dihydro-1H-pyrrolizine-2-
carboxylate 
 
 
 
 
 
Following general procedure V, pyrrolyl enone-acid 562 (100 mg, 0.29 mmol), i-Pr2NEt (151 
µL, 0.87 mmol), pivaloyl chloride (107 µL, 0.87 mmol) in CH2Cl2 (2 mL), (+)-BTM 48 (4 mg, 
0.016 mmol) and i-Pr2NEt (76 µL, 0.44 mmol) gave the crude product (>95:5 dr). Purification 
by column chromatography (EtOAc:petrol 10:90) gave the title compound (>95:5 dr) as a 
brown oil (84 mg, 80%); 
€ 
α[ ]D
20 –53.4 (c 0.5 in CHCl3); Chiral HPLC analysis: ChiralPak OD-H 
(90:10 hexane:IPA, 1.0 mlmin-1, 220 nm), tR 15.6 (minor) and tR 17.6 (major), >99% ee; νmax 
(ATR)/cm−1 1695 (C=O), 1771 (C=O), 2980 (C-H); 1H NMR (500 MHz, CDCl3) 3.19 (1H, dd, 
J 6.6, 17.8, pyrrolizine(1)CHaCOAr), 3.28 (1H, dd, J 7.6, 17.8, pyrrolizine(1)CHbCOAr), 3.61 
(3H, s, CO2CH3), 3.99 (1H, q, J 7.8, pyrrolizine(2)H), 4.14-4.21 (2H, m, pyrrolizine(3)Ha and 
pyrrolizine(1)H), 4.32 (1H, dd, J 7.4, 10.6, pyrrolizine(3)Hb), 5.80 (1H, d, J 3.4, 
pyrrolizine(7)H), 6.19 (1H, t, J 3.0, pyrrolizine(6)H), 6.61 (1H, dd, J 1.2, 2.6, pyrrolizine(5)H), 
7.33 (1H, t, J 7.8, C(O)Ar(5)H), 7.68 (1H, ddd, 0.9, 1.8, 7.9, C(O)Ar(4)H), 7.83 (1H, dt, J 1.1, 
7.8, C(O)Ar(6)H), 8.04 (1H, t, J 1.7, C(O)Ar(2)H); 13C NMR (125 MHz, CDCl3) 35.4 
(pyrrolizineC(1)H), 40.2 (pyrrolizine(1)CHaHbCOAr), 47.8 (pyrrolizineC(3)HaHb), 49.8 
(pyrrolizineC(2)H), 52.2 (CO2CH3), 100.1 (pyrrolizineC(7)H), 112.6 (pyrrolizineC(6)H), 114.2 
(pyrrolizineC(5)H), 123.2 (C(O)ArC(3)), 126.6 (C(O)ArC(6)H), 130.4 (C(O)ArC(5)H), 131.2 
(C(O)ArC(2)), 136.2 (C(O)ArC(4)H), 137.6 (pyrrolizineC(8)), 138.6 (C(O)ArC(1)), 172.2 
(CO2Me), 196.7 (C(O)Ar); HRMS (NSI+), C17H17Br79NO3 [M+H]+, requires 362.0386, found 
362.0386 (−0.1 ppm). 
 
Methyl (1S,2R)-1-(2-oxo-2-(thiophen-2-yl)ethyl)-2,3-dihydro-1H-pyrrolizine-2-carboxylate 
 
 
 
 
 
Following general procedure V, pyrrolyl enone-acid 566 (100 mg, 0.29 mmol), i-Pr2NEt (151 
µL, 0.87 mmol), pivaloyl chloride (107 µL, 0.87 mmol) in CH2Cl2 (2 mL), (+)-BTM 48 (4 mg, 
0.016 mmol) and i-Pr2NEt (76 µL, 0.44 mmol) gave, after purification by column 
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chromatography (EtOAc:petrol ether 10:90) the title compound (>95:5 dr) as a brown oil (84 
mg, 80%); 
€ 
α[ ]D
20  –75.2 (c 0.5 in CHCl3); Chiral HPLC analysis: ChiralPak OD-H (90:10 
hexane:IPA, 1.0 mlmin-1, 270 nm), tR 18.3 (minor) and tR 30.9 (major), 99:1 er; νmax (ATR)/cm−1 
1661 (C=O), 1724 (C=O), 2895, 2951 (C-H); 1H NMR (400 MHz, CDCl3) 3.20 (2H, dq, J 7.2, 
17.2, pyrrolizine(1)CHaHb), 3.60 (3H, s, CO2CH3), 3.97 (1H, q, J 7.8, pyrrolizine(2)H), 4.14 
(1H, dd, J 7.8, 10.7, pyrrolizine(3)Ha), 4.20 (1H, q, J 7.5, pyrrolizine(1)H), 4.33 (1H, dd, J 7.3, 
10.7, pyrrolizine(3)Hb), 5.80 (1H, d, J 3.4, pyrrolizine(7)H), 6.19 (1H, t, J 3.0, pyrrolizine(6)H), 
6.60 (1H, dd, J 1.2, 2.6, pyrrolizine(5)H), 7.11 (1H, dd, J 3.9, 4.9, C(O)thienyl(4)H), 7.62-7.65 
(2H, m, C(O)thienyl(3)H and C(O)thienyl(5)H); 13C NMR (100 MHz, CDCl3) 35.5 
(pyrrolizineC(1)H), 40.7 (pyrrolizine(1)CHaHbCO), 47.7 (pyrrolizineC(3)HaHb), 49.8 
(pyrrolizineC(2)H), 52.1 (CO2CH3), 100.0 (pyrrolizineC(7)H), 112.6 (pyrrolizineC(6)H), 114.2 
(pyrrolizineC(5)H), 128.3 (C(O)thienylC(4)H), 132.1 (C(O)thienylC(3)H), 133.8 
(C(O)thienylC(5)H), 137.6 (pyrrolizineC(8)), 144.2 (C(O)thienylC(2)), 172.2 (CO2Me), 190.7 
(C(O)thienyl); HRMS (NSI+), C15H15NO3SNa [M+Na]+, requires 312.0665, found 312.0660 
(−1.6 ppm). 
 
Methyl (1S,2R)-1-(2-(4-methoxyphenyl)-2-oxoethyl)-2,3-dihydro-1H-pyrrolizine-2-
carboxylate 
 
 
 
 
 
 
Following general procedure V, pyrrolyl enone-acid 560 (42 mg, 0.13 mmol), i-Pr2NEt (70 µL, 
0.40 mmol), pivaloyl chloride (50 µL, 0.40 mmol) in CH2Cl2 (2 mL), (+)-BTM 48 (1.7 mg, 
0.007 mmol) and i-Pr2NEt (35 µL, 0.20 mmol) gave the crude product (>95:5 dr). Purification 
by column chromatography (EtOAc:petrol 10:90) gave the title compound (>95:5 dr) as a 
yellow oil (41 mg, 98%); %); 
€ 
α[ ]D
20 –61.3 (c 0.5 in CHCl3); Chiral HPLC analysis: ChiralPak 
AD-H (90:10 hexane:IPA, flow rate 1.0 mlmin-1, 270 nm) tR 20.0 (minor) and tR 25.1 (major) 
>99:1 er; νmax (ATR)/cm−1 2953 (C-H), 1734 (C=O), 1676 (C=O); 1H NMR (500 MHz, CDCl3) 
3.12-3.29 (2H, m, pyrrolizine(1)CHaHbC(O)Ar and pyrrolizine(1)CHaHbC(O)Ar), 3.57 (3H, s, 
CO2CH3), 3.86 (3H, s, C(O)Ar(4)OCH3), 3.94-4.02 (1H, m, pyrrolizine(2)H), 4.11-4.25 (2H, m, 
pyrrolizine(3)HaHb and pyrrolizine(1)H), 4.33 (1H, dd, J 7.1, 10.6, pyrrolizine(3)HaHb), 5.80 
(1H, dt, J 1.0, 3.4, pyrrolizine(7)H), 6.19 (1H, m, pyrrolizine(6)H), 6.60 (1H, dd, J 1.3, 2.6, 
pyrrolizine(5)H), 6.92 (2H, d, J 8.9, C(O)ArC(3,5)H), 7.90 (2H, d, J 9.0, C(O)ArC(2,6)H); 13C 
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NMR (125 MHz, CDCl3) 35.7 (pyrrolizineC(1)H), 39.7 (pyrrolizine(1)CHaHb), 47.8 
(pyrrolizineC(3)HaHb), 49.9 (pyrrolizineC(2)H), 52.1 (CO2CH3), 55.6 (C(O)Ar(4)OCH3), 99.9 
(pyrrolizineC(7)H), 112.5 (pyrrolizineC(6)H), 113.8 (C(O)ArC(2,6)H), 114.0 
(pyrrolizineC(5)H), 130.1 (C(O)ArC(1)), 130.4 (C(O)ArC(3,5)H, 138.0 (C(O)ArC(4)), 163.6 
(pyrrolizineC(7a)), 172.3 (CO2Me), 196.4 (C(O)Ar); HRMS (NSI+), C18H20NO4 [M+H]+, 
requires 314.1389, found 314.1388 (+0.3 ppm). 
 
Methyl (1S,2R)-1-(2-(naphthalen-2-yl)-2-oxoethyl)-2,3-dihydro-1H-pyrrolizine-2-
carboxylate 
 
 
 
 
 
 
Following general procedure V, pyrrolyl enone-acid 565 (100 mg, 0.31 mmol), i-Pr2NEt (162 
µL, 0.93 mmol), pivaloyl chloride (115 µL, 0.93 mmol) in CH2Cl2 (3 mL), (+)-BTM 48 (4 mg, 
0.016 mmol) and i-Pr2NEt (82 µL, 0.47 mmol) gave the crude product (>95:5 dr). Purification 
by column chromatography (EtOAc:petrol 10:90) gave the title compound (>95:5 dr) as a white 
solid (84 mg, 81%); mp 108-110 °C; 
€ 
α[ ]D
20 –64.1 (c 0.5 in CHCl3); Chiral HPLC analysis 
ChiralPak OD-H (90:10 hexane:IPA, flow rate 1.0 mlmin-1, 220 nm, 30 °C), tR 19.3 (minor) and 
tR 26.5 (major), >99:1 er; νmax (ATR)/cm−1 1674 (C=O), 1720 (C=O), 3021 (C-H) ; 1H NMR 
(400 MHz, CDCl3) 3.35 (1H, dd, J 7.8, 17.6, pyrrolizine(1)CHaHbC(O)Ar), 3.46 (1H, dd, J 7.8, 
17.6, pyrrolizine(1)CHaHbC(O)Ar), 3.58 (3H, s, CO2CH3), 4.03 (1H, q, J pyrrolizine(2)H), 4.18 
(1H, dd, J 7.8, 10.5, pyrrolizine(3)HaHb), 4.29 (1H, q, J 7.3, pyrrolizine(1)H), 4.37 (1H, dd, J 
7.2, 10.5, pyrrolizine(3)HaHb), 5.85 (1H, br. s, pyrrolizine(7)H), 6.21 (1H, br. s, 
pyrrolizine(6)H), 6.63 (1H, br. s, pyrrolizine(5)H), 7.54-7.62 (2H, m, ArH), 7.86-8.03 (4H, m, 
ArH), 8.42 (1H, br. s, ArH); 13C NMR (125 MHz, CDCl3) 35.7 (pyrrolizineC(1)H), 40.2 
(pyrrolizine(2)CHaHbC(O)Ar), 47.8 (pyrrolizineC(3)HaHb), 49.9 (pyrrolizineC(2)H), 51.8 
(CO2CH3), 100.0 (pyrrolizineC(7)H), 112.6 (pyrrolizineC(6)H), 114.1 (pyrrolizineC(5)H), 
123.8 (ArCH), 127.0 (ArCH), 127.9 (ArCH), 128.6 (ArCH), 128.6 (ArCH), 129.7 (ArCH), 
129.8 (ArCH), 132.6 (ArC), 134.2 (ArC), 135.8 (pyrrolizineC(7a)), 137.9 (C(O)ArC(1)), 172.4 
(CO2Me), 197.9 (C(O)Ar); HRMS (NSI+), C21H19NO3Na [M+Na]+, requires 356.1257, found 
356.1250 (−1.1 ppm). 
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Methyl (1S,2R)-1-(2-(naphthalen-1-yl)-2-oxoethyl)-2,3-dihydro-1H-pyrrolizine-2-
carboxylate 
 
 
 
 
 
Following general procedure V, pyrrolyl enone-acid 566 (100 mg, 0.31 mmol), i-Pr2NEt (162 
µL, 0.93 mmol), pivaloyl chloride (115 µL, 0.93 mmol) in CH2Cl2 (3 mL), (+)-BTM 48 (4 mg, 
0.016 mmol) and i-Pr2NEt (82 µL, 0.47 mmol) gave the crude product (>95:5 dr). Purification 
by column chromatography (EtOAc:petrol 10:90) gave the title compound (>95:5 dr) as a white 
solid (74 mg, 72%); 
€ 
α[ ]D
20 –55.2 (c 0.5 in CHCl3); Chiral HPLC analysis ChiralPak AD-H 
(90:10 hexane:IPA, flow rate 1.0 mlmin-1, 211 nm, 30 °C), tR 12.5 (minor) and tR 14.2 (major), 
>99:1 er; νmax (ATR)/cm−1 1165, 1670 (C=O), 1732 (C=O), 2951 (C-H); 1H NMR (400 MHz, 
CDCl3) 3.36 (2H, d, J 7.2, pyrrolizine(1)CHaHbC(O)Ar and pyrrolizine(1)CHaHbC(O)Ar), 3.57 
(3H, s, CO2CH3), 4.05 (1H, q, J pyrrolizine(2)H), 4.18 (1H, dd, J 7.8, 10.6, pyrrolizine(3)HaHb), 
4.30 (1H, q, J 7.5, pyrrolizine(1)H), 4.35 (1H, dd, J 7.1, 10.6, pyrrolizine(3)HaHb), 5.86 (1H, d, 
J 3.4, pyrrolizine(7)H), 6.20 (1H, J 3.0, pyrrolizine(6)H), 6.62 (1H, dd, J 1.2, 2.5, 
pyrrolizine(5)H), 7.46-7.49 (1H, m, ArH), 7.52-7.56 (1H, m, ArH), 7.61 (1H, ddd, J 1.3, 6.9, 
8.5, ArH), 7.81-7.83 (1H, m, ArH), 7.87-7.88 (1H, m, ArH), 7.98 (1H, br. d, J 8.2, ArH), 8.61 
(1H, br. d, J 8.6, ArH); HRMS (NSI+), C11H12NO3 [M+H]+, requires 206.0823, found 206.0823 
(0.0 ppm). 
 
Methyl (1S,2R)-1-(2-oxo-2-phenylethyl)-2,3,5,6,7,8-hexahydro-1H-pyrrolo[1,2-a]indole-2-
carboxylate 
 
 
 
 
Following general procedure V, pyrrolyl enone-acid 593 (100 mg, 0.31 mmol), i-Pr2NEt (162 
µL, 0.93 mmol), pivaloyl chloride (115 µL, 0.93 mmol) in CH2Cl2 (3 mL), (+)-BTM 48 (4 mg, 
0.016 mmol) and i-Pr2NEt (54 µL, 0.31 mmol) gave, after purification by column 
chromatography (EtOAc:petrol 10:90) the title compound (>95:5 dr) as a brown oil (55 mg, 
53%); 
€ 
α[ ]D
20 – 33.1 (c 0.5 in CHCl3); Chiral HPLC analysis: ChiralPak IC (90:10 hexane:IPA, 
1.0 mlmin-1, 211 nm), tR 14.7 (major) and tR 17.4 (minor), >99% ee; νmax (ATR)/cm−1 1665 
(C=O), 1730 (C=O), 2841, 2927, 2953 (C-H); 1H NMR (500 MHz, CDCl3) 1.68-1.74 (2H, m, 
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pyrroloindolyl(7)H2), 1.76-1.84 (2H, m, pyrroloindolyl(6)H2), 2.47-2.55 (4H, m, 
pyrroloindolyl(8)H2 and pyrroloindolyl(5)H2), 3.18 (1H, dd, J 6.5, 17.8, 
pyrroloindolyl(1)CHaHbCOAr), 3.57 (3H, s, CO2CH3), 3.92-4.01 (2H, m, pyrroloindolyl(2)H 
and pyrroloindolyl(3)Ha), 4.14 (1H, dd, J 7.0, 9.9, pyrroloindolyl(3)Hb), 4.19 (1H, q, J 7.4, 
pyrroloindolyl(1)H), 5.59 (1H, s, pyrroloindolyl(9)H), 7.43-7.46 (2H, m, C(O)Ar(3,5)H), 7.53-
7.57 (1H, m, C(O)Ar(4)H), 7.91-7.93 (C(O)Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 21.9 
(pyrroloindolylC(9)H2), 23.4 (pyrroloindolylC(8)H2), 23.7 (pyrroloindolylC(5)H2), 23.8 
(pyrroloindolylC(6)H2), 35.6 (pyrroloindolylC(1)H), 40.5 (pyrroloindolyl(1)CHaHbCOAr), 45.4 
(pyrroloindolylC(3)HaHb), 49.6 (pyrroloindolylC(2)H), 52.1 (CO2CH3), 98.4 
(pyrroloindolylC(9)H), 121.3 (pyrroloindolylC(8a)), 122.9 (pyrroloindolylC(4a)), 128.1 
(C(O)ArC(3,5)H), 128.7 (C(O)ArC(2,6)H), 133.3 (C(O)ArC(4)H), 135.5 (pyrroloindolylC(9a)), 
137.0 (C(O)ArC(1)), 172.5 (CO2Me), 198.1 (C(O)Ar); In our hands this compound proved to be 
unstable to mass spectrometry analysis. 
 
Methyl (1S,2R)-1-(2-(4-bromophenyl)-2-oxoethyl)-5-chloro-2,3-dihydro-1H-pyrrolizine-2-
carboxylate 
 
 
 
 
 
 
Following general procedure V, pyrrolyl enone-acid 573 (40 mg, 0.11 mmol), i-Pr2NEt (55 µL, 
0.32 mmol), pivaloyl chloride (39 µL, 0.32 mmol) in CH2Cl2 (1 mL), (+)-BTM 48 (1 mg, 0.005 
mmol) and i-Pr2NEt (18 µL, 0.11 mmol) gave, after purification by column chromatography 
(EtOAc:petrol 10:90) the title compound (94:6 dr) as a brown oil (29 mg, 66%); 
€ 
α[ ]D
20 –40.1 (c 
0.5 in CHCl3); Chiral HPLC analysis: ChiralPak OD-H (90:10 hexane:IPA, 1.0 mlmin-1, 211 
nm), tR 18.0 (minor) and tR 21.4 (major), >99:1 er; νmax (ATR)/cm−1 1584 (C=O), 1688 (C=O), 
2926, 2951 (C-H); 1H NMR (500 MHz, CDCl3) 3.18 (1H, dd, J 7.1, 17.7, 
pyrrolizine(1)CHaHbCOAr), 3.24 (1H, dd, J 7.2, 17.7, pyrrolizine(1)CHaHbCOAr), 3.62 (3H, s, 
CO2CH3), 3.97 (1H, q, J 7.8, pyrrolizine(2)H), 4.12 (1H, dd, J 7.9, 10.9, pyrrolizine(3)HaHb), 
4.17-4.27 (2H, m, pyrrolizine(1)H and pyrrolizine(3)HaHb) 5.74 (1H, dd, J 0.8, 3.6, 
pyrrolizine(7)H), 5.97 (1H, d, J 3.6, pyrrolizine(6)H), 7.60 (2H, d, J 8.6, C(O)Ar(3,5)H), 7.77 
(1H, d, J 8.6, C(O)Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 36.4 (pyrrolizineC(1)H), 39.9 
(pyrrolizine(1)CHaHbCOAr), 46.4 (pyrrolizineC(3)HaHb), 49.3 (pyrrolizineC(2)H), 52.3 
(CO2CH3), 100.9 (pyrrolizineC(7)H), 109.6 (pyrrolizineC(6)H), 127.5 (C(O)ArC(4)Br), 128.7 
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(pyrrolizineC(8)), 129.6 (C(O)ArC(3,5)H), 132.1 (C(O)ArC(2,6)H), 135.5 (C(O)ArC(1)), 136.4 
(pyrrolizineC(5)Cl), 171.8 (CO2Me), 196.8 (C(O)Ar); HRMS (NSI+), C17H16Br79ClNO3 
[M+Na]+, requires 397.9974, found 397.9974 (0.0 ppm). 
9.6.8 Derivatisations 
Tert-butyl 5-methoxy-2-(4-(2-((1S,2R)-2-(methoxycarbonyl)-2,3-dihydro-1H-pyrrolizin-1-
yl)acetyl)phenyl)-1H-indole-1-carboxylate 
 
 
 
 
A flame-dried schlenk flask, under inert atmosphere, was charged with Pd(PPh3)4 (16 mg, 0.014 
mmol), pyrrolizine 603 (50 mg, 0.14), Na2CO3 (45 mg, 0.42 mmol) and N-Boc-5-methoxy-2-
indolylboronic acid (49 mg, 0.17 mmol). Degassed DME (2.2 mL) was added and reaction 
stirred at 80 °C for 16 h. Reaction cooled to rt and dilute with EtOAc, washed with brine (×3), 
dried over MgSO4 and concentrated under reduced pressure to give crude reaction mixture that, 
following column chromatography (EtOAc:Petrol 20:80), gave the title compound (>95:5 dr) as 
a brown oil (45 mg, 60%); 
€ 
α[ ]D
20 –22.0 (c 0.5 in CHCl3); Chiral HPLC analysis ChiralPak AD-
H (90:10 hexane:IPA, 1.0 mlmin-1, 254 nm), tR 42.6 (major) and tR 52.0 (minor), >99:1 er; νmax 
(ATR)/cm−1 1607, 1681 (C=O), 1726 (C=O), 2929, 2951 (C-H); 1H NMR (300 MHz, CDCl3) 
1.35 (9H, s, NCO2C(CH3)3), 3.20-3.38 (2H, m, pyrrolizine(1)CHaHbC(O)indole), 3.62 (3H, s, 
CO2CH3), 3.87 (3H, s, ArOCH3), 3.97-4.05 (1H, m, pyrrolizine(2)H), 4.14-4.27 (2H, m, 
pyrrolizine(1)H and pyrrolizine(3)HaHb), 4.35 (1H, dd, J 7.2, 10.6, pyrrolizine(3)HaHb), 5.81 
(1H, d, J 3.3, pyrrolizine(7)H), 6.19-6.21 (1H, m, pyrrolizine(6)H), 6.55 (1H, s, indolyl(3)H), 
6.61 (1H, dd, J 1.2, 2.6, pyrrolizine(5)H), 6.95-7.03 (2H, m, indolyl(6)H and indolyl(7)H), 7.50 
(2H, d, J 8.4, C(O)Ar(3,5)H), 7.95 (2H, d, J 8.5, C(O)Ar(2,6)H), 8.08 (1H, d, J 9.0, 
indolyl(4)H); 13C NMR (100 MHz, CDCl3) 27.9 (C(CH3)3), 35.6 (pyrrolizineC(1)H), 40.2 
(pyrrolizine(1)CHaHbC(O)Ar), 47.8 (pyrrolizineC(3)HaHb), 49.9 (pyrrolizineC(2)H), 52.1 
(CO2CH3), 55.9 (ArOCH3), 84.0 (NCO2C(CH3)3), 100.1 (pyrrolizineC(7)H), 103.2 
(indolylC(3)H), 111.2 (pyrrolizineC(7)H), 112.2 (pyrrolizineC(6)H), 113.9 (indolylC(4)H), 
114.1 (indolylC(6)H), 116.3 (pyrrolizineC(5)H), 127.7 (C(O)ArC(3,5)H), 128.9 
(C(O)Ar(2,6)H), 130.0 (indolylC(2)), 132.6 (indolylC(7a)), 135.8 (indolylC(3a)), 137.9 
(pyrrolizineC(8)), 139.8 (C(O)ArC(1)), 140.0 (C(O)ArC(4)), 150.1 (NCO2t-Bu), 156.3 
(indolylC(5)), 172.3 (CO2Me), 197.5 (C(O)Ar); HRMS (NSI+), C31H32N2O6Na [M+Na]+, 
requires 551.2158, found 551.2138 (−3.6 ppm). 
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Methyl (1S,2R)-5-chloro-1-(2-oxo-2-phenylethyl)-2,3-dihydro-1H-pyrrolizine-2-
carboxylate 
 
 
 
 
 
To a solution of pyrrolizine 594 in CH2Cl2 (5 mL) at 0 °C, under inert atmosphere was added N-
chlorosucinimide (47 mg, 0.35 mmol) and reaction stirred for 2 h. Reaction was dilute with 
CH2Cl2 (5 mL), washed with Na2CO3 (×3), dried over MgSO4 and concentrated under reduced 
pressure to give crude reaction mixture that, following column chromatography (EtOAc:Petrol 
20:80), gave the title compound (>95:5 dr) as a brown oil (86 mg, 79%); 
€ 
α[ ]D
20 –31.2 (c 0.5 in 
CHCl3); Chiral HPLC analysis ChiralPak OD-H (90:10 hexane:IPA, 1.0 mlmin-1, 211 nm), tR 
24.2 (minor) and tR 39.7 (major), >99:1 er. νmax (ATR)/cm−1 1681 (C=O), 1730 (C=O), 3001 (C-
H); 1H NMR (500 MHz, CDCl3) 3.18-3.30 (2H, m, pyrrolizine(1)CHaHbC(O)Ar and 
pyrrolizine(1)CHaHbC(O)Ar), 3.61 (3H, s, CO2CH3), 3.98 (1H, q, J 7.8, pyrrolizine(2)H), 4.12 
(1H, dd, J 7.8, 10.9, pyrrolizine(3)HaHb), 4.19-4.27 (2H, m, pyrrolizine(3)HaHb and 
pyrrolizine(1)H), 5.75 (1H, d, J 3.5, pyrrolizine(7)H), 5.97 (1H, d, J 3.5, pyrrolizine(6)H), 7.44-
7.47 (2H, m, C(O)Ar(3,5)H), 7.55-7.58 (1H, m, C(O)Ar(4)H), 7.90-7.92 (2H, m, 
C(O)Ar(2,6)H); 13C NMR (125 MHz, CDCl3) 36.5 (pyrrolizineC(1)H), 39.9 (pyrrolizineC(2)H), 
46.5 (pyrrolizine(1)CHaHbC(O)Ar), 49.3 (pyrrolizineC(3)H), 52.2 (CO2CH3), 100.9 
(pyrrolizineC(7)H), 109.5 (pyrrolizineC(6)H), 110.1 (), 128.1 (C(O)ArC(3,5)H), 128.8 
(C(O)ArC(2,6)H), 133.4 (pyrrolizineC(8)). 136.6 (C(O)ArC(1)), 136.8 (pyrrolizineC(5)Cl), 
171.9 (CO2Me), 197.7 (C(O)Ar); HRMS (NSI+), C17H17ClNO3 [M+H]+, requires 318.0891, 
found 318.0893 (+0.6 ppm). 
9.6.9 X-Ray Structure Determination 
Crystal data for 602: C17H16BrNO3, M = 362.22, colourless prism, orthorhombic space group 
P21/c; a = 7.5275(14) Å, b = 13.374(3) Å, c = 15.278(3) Å, α = β = γ = 90°, V = 1538.1(5) Å3, Z 
= 4, Dc = 1.564 g cm−3, flack parameter = 0.003(1), R = 0.0449, RW = 0.0740 for 2746 data with 
I> 2σ(I) and 200 parameters. Data were recorded at 93 K on Rigaku XtaLAB P200 
diffractometer using multi-layer mirror monochromated Mo-Kσ radiation and the structures 
were solved by direct methods and refined using full-matrix least square analysis. 
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9.7 Experimental for Chapter 7 
9.7.1  General Experimental Procedures 
General procedure W: Isothiourea-Catalysed Michael Addition-Lactamisation 
 
 
 
 
 
 
To a solution of requisite carboxylic acid (1.0 eq) CH2Cl2 (0.06 M) were added i-Pr2NEt (1.5 eq) 
and pivaloyl chloride (1.5 eq) at 0 °C. The reaction mixture was allowed to stir at 0 °C for 10 
min then cooled to −78 °C. The requisite Michael acceptor (1.0 eq), (2R,3S)-HyperBTM 53 (5 
mol%), and i-Pr2NEt (1.0 eq) were added and reaction stirred at −78 °C until complete by TLC 
analysis. The reaction mixture was quenched with aq. HCl (0.1 M) and extracted with CH2Cl2 
(×3). The combined organics were dried over MgSO4, filtered and concentrated under reduced 
pressure to give the crude reaction mixture. Products were purified by Biotage® IsoleraTM 4 in 
the solvent system reported. 
9.7.2 Preparation of Sulfonyl Imine Substrates 
3-Methylbenzo[d]isothiazole 1,1-dioxide 
 
 
 
 
Following literature procedure,[63] to a solution of saccharin (2.00 g, 10.9 mmol) in THF (109 
mL) at 0 °C was added methyl magnesium bromide (3.0 M in Et2O, 7.27 mL, 21.8 mmol) 
dropwise. The reaction was warmed to rt and stirred for 16 h before being quenched with sat. 
aq. NH4Cl, extracted with CH2Cl2 (×3). Combined organics were washed with brine, dried over 
MgSO4, filtered and concentrated under reduced pressure to give crude reaction product. 
Recrystallisation (CH2Cl2) gave the title compound as a white solid (600 mg, 20%); mp 210-212 
°C {lit.[196] 213-213.5 °C}; 1H NMR (500 MHz, CDCl3) 2.67 (3H, s, CH3), 7.73-7.76 (2H, m, 
Ar(5)H and Ar(6)H), 7.91-7.93 (1H, m, Ar(4)H and Ar(7)H). All data in accordance with 
literature.[196] 
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(E)-3-Styrylbenzo[d]isothiazole 1,1-dioxide 
 
 
 
 
Following literature procedure,[156] to a solution of sulfonyl imine 633 (600 mg, 2.23 mmol), in 
EtOH (7.4 mL) at 80 °C was added benzaldehyde (0.5 mL, 4.91 mmol) followed by piperidine 
(22 µL, 0.22 mmol), and acetic acid (13 µL, 0.22 mmol). Reaction was stirred at 80 °C for 16 h 
before being filtered, washed with petrol to give the title compound as a yellow solid (325 mg, 
54%); mp 247-248 °C {lit.[197] 245-247 °C}; 1H NMR (500 MHz, CDCl3) 7.31 (1H, d, J 15.6, 
C(3)H), 7.48-7.49 (3H, m, ArH), 7.70-7.72 (2H, m, ArH), 7.77-7.78 (2H, m, ArH), 7.89-7.91 
(1H, m, ArH), 7.97-7.99 (1H, m, ArH), 8.34 (1H, d, J 15.6, C(2)H). All data in accordance with 
literature.[156] 
9.7.3 Isothiourea-Catalysed Michael Addition-Lactamisation 
(8S,9S)-8,9-diphenyl-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-one 5,5-dioxide 
 
 
 
 
Following general procedure W, phenyl acetic acid (26 mg, 0.19 mmol), pivaloyl chloride (36 
µL, 0.29 mmol) and i-Pr2NEt (51 µL, 0.29 mmol) in CH2Cl2 (3.2 mL), (2R,3S)-HyperBTM 53 
(3 mg, 0.01 mmol), cyclic sulfonyl imine 617 (50 mg, 0.19 mmol), i-Pr2NEt (33 µL, 0.19 mmol) 
at −78 °C gave crude reaction mixture (85:15 dr). Purification by Biotage® IsoleraTM 4 [SNAP 
25 g, 75 mL−1, hexane:EtOAc (97:3 4 CV, 97:3 to 50:50 10 CV, 50:50 1 CV)] gave the title 
compound (53 mg, 73%) as a white solid (91:9 dr). mp 230-232 °C {Lit.[156] 232-233 °C}; 
€ 
α[ ]D
20 +134.0 (c 1.0 CHCl3) {Lit.[156] 
€ 
α[ ]D
20 −177.0 (c 1.03 CH2Cl2) for 99% ee}; Chiral HPLC 
analysis, Chiralpak AD-H (60:40 hexane:IPA, flow rate 1 mLmin−1, 254 nm, 30 °C) tR (8S,9S): 
13.1 min, tR (8R,9R): 23.0 min; 95% ee; 1H NMR (500 MHz, CDCl3) 4.06 (1H, d, J 7.4, C(8)H), 
4.17 (1H, dd, J 4.5, 6.9, C(9)H), 6.14 (1H, d, J 4.1, C(10)H), 7.10-7.17 (4H, m, ArH), 7.26-7.30 
(6H, m, ArH), 7.65 (1H, m, ArH), 7.72-7.79 (2H, m, ArH), 7.88-7.92 (1H, m, ArH). All data in 
accordance with literature.[156] 
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(8S,9S)-8-(4-Bromophenyl)-9-phenyl-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-
7-one 5,5-dioxide 
 
 
 
 
 
Following general procedure W, 4-bromophenyl acetic acid (80 mg, 0.37 mmol), pivaloyl 
chloride (69 µL, 0.56 mmol) and i-Pr2NEt (98 µL, 0.56 mmol) in CH2Cl2 (6 mL), (2R,3S)-
HyperBTM 53 (5 mg, 0.019 mmol), cyclic sulfonyl imine 617 (100 mg, 0.37 mmol), i-Pr2NEt 
(64 µL, 0.37 mmol) at −78 °C gave crude reaction mixture (89:11 dr). Purification by Biotage® 
IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (97:3 4 CV, 97:3 to 50:50 10 CV, 50:50 1 
CV)] gave the title compound (129 mg, 75%) as a white solid (>95:5 dr). mp 182-184 °C; 
€ 
α[ ]D
20 
+78.7 (c 0.1 CHCl3); Chiral HPLC analysis, Chiralpak AD-H (80:20 hexane:IPA, flow rate 1 
mLmin−1, 211 nm, 30 °C) tR (8S,9S): 44.6 min, tR (8R,9R): 51.5 min; 97% ee; νmax (ATR)/cm−1 
1724, 1735, 3028 (C-H); 1H NMR (500 MHz, CDCl3) 4.00 (1H, d, J 9.0, C(8)H), 4.17 (1H, dd, 
J 3.8, 9.0, C(9)H), 6.12 (1H, d, J 3.8, C(10)H), 6.99 (2H, d, J 8.4, ArH), 7.07 (2H, d, J 6.6, 
ArH), 7.24-7.30 (3H, m, ArH), 7.38 (2H, d, J 8.4, ArH), 7.65-7.69 (1H, m, ArH), 7.73-7.75 
(2H, m, ArH), 7.89 (1H, d, J 7.9, ArH); 13C NMR (125 MHz, CDCl3) 47.4 (C(9)H), 55.7 
(C(8)H), 105.9 (C(10)H), 121.9 (ArCH), 121.9 (ArCH), 122.0 (C(8)ArC(4)Br), 126.5 (ArC), 
127.7 (ArCH), 128.0 (ArCH), 129.3 (ArCH), 129.7 (ArC), 130.5 (ArCH), 131.3 (ArCH), 132.0 
(ArCH), 132.8 (ArC), 134.3 (ArCH), 135.0 (C(10a)), 140.3 (ArC), 166.0 (C(7)); HRMS (NSI+) 
C23H1679BrNO3SNa+ [M+Na]+, requires 487.9926, found 487.9913 (−2.8 ppm). 
 
(8S,9S)-8-(4-Methoxyphenyl)-9-phenyl-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-
a]pyridin-7-one 5,5-dioxide 
 
 
 
 
Following general procedure W, 4-methoxyphenyl acetic acid (61 mg, 0.37 mmol), pivaloyl 
chloride (69 µL, 0.56 mmol) and i-Pr2NEt (98 µL, 0.56 mmol) in CH2Cl2 (6 mL), (2R,3S)-
HyperBTM 53 (5 mg, 0.019 mmol), cyclic sulfonyl imine 617 (100 mg, 0.37 mmol), i-Pr2NEt 
(64 µL, 0.37 mmol) at −78 °C gave crude reaction mixture (>95:5 dr). Purification by Biotage® 
IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (97:3 4 CV, 97:3 to 50:50 10 CV, 50:50 1 
CV)] gave the title compound (129 mg, 75%) as a white solid (>95:5 dr). mp 220-222 °C; 
€ 
α[ ]D
20 
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+54.4 (c 0.1 CHCl3); Chiral HPLC analysis, Chiralpak AD-H (60:40 hexane:IPA, flow rate 1 
mLmin−1, 254 nm, 30 °C) tR (8S,9S): 19.3 min, tR (8R,9R): 26.6 min; >99% ee; νmax (ATR)/cm−1  
1366, 1724, 1735, 1751, 2970 (C-H); 1H NMR (500 MHz, CDCl3) 3.76 (3H, s, ArOCH3), 4.01 
(1H, d, J 7.5, C(8)H), 4.13 (1H, dd, J 4.4, 7.5, C(9)H), 6.13 (1H, d, J 4.3, C(10)H), 6.79-6.82 
(2H, m, C(8)Ar(3,5)H), 7.08-7.12 (4H, m, ArH), 7.24-7.31 (3H, m, ArH), 7.66 (1H, ddd, J 2.5, 
5.9, 8.2, ArH), 7.72-7.76 (2H, m, ArH), 7.90 (1H, d, J 7.9, ArH); 13C NMR (125 MHz, CDCl3) 
47.6 (C(9)H), 55.3 (C(9)H), 55.4 (ArOCH3), 105.7 (C(10)H), 114.4 (C(8)ArC(3,5)H), 121.8 
(ArCH), 122.0 (ArCH), 126.7 (ArC), 127.7 (ArCH), 127.9 (ArCH), 128.4 (ArCH), 129.3 
(ArCH), 129.6 (ArCH), 129.6 (ArC), 131.2 (ArCH), 132.9 (ArC), 134.2 (C(10a)), 140.9 (ArC), 
159.2 (C(8)ArC(4)), 166.7 (C(7)); HRMS (NSI+) C24H19NO4SNa+ [M+Na]+, requires 440.0927, 
found 440.0924 (−0.7 ppm). 
 
(8S,9S)-9-Phenyl-8-(m-tolyl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-one 5,5-
dioxide 
 
 
 
 
Following general procedure W, 4-methoxyphenyl acetic acid (56 mg, 0.37 mmol), pivaloyl 
chloride (69 µL, 0.56 mmol) and i-Pr2NEt (98 µL, 0.56 mmol) in CH2Cl2 (6 mL), (2R,3S)-
HyperBTM 53 (5 mg, 0.019 mmol), cyclic sulfonyl imine 617 (100 mg, 0.37 mmol), i-Pr2NEt 
(64 µL, 0.37 mmol) at −78 °C gave crude reaction mixture (94:6 dr). Purification by Biotage® 
IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (97:3 4 CV, 97:3 to 50:50 10 CV, 50:50 1 
CV)] gave the title compound (105 mg, 71%) as a white solid (>95:5 dr). mp 174-177 °C 
{Lit.[156] 177-180 °C}; 
€ 
α[ ]D
20 +166.0 (c 1.0 CHCl3) {Lit.[156] 
€ 
α[ ]D
20 −185.0 (c 1.03 CHCl3) for 
98% ee}; Chiral HPLC analysis, Chiralpak AD-H (70:30 hexane:IPA, flow rate 1 mLmin−1, 254 
nm, 30 °C) tR (8S,9S): 14.6 min, tR (8R,9R): 27.3 min; >99% ee; 1H NMR (400 MHz, CDCl3) 
2.11 (3H, s, ArCH3), 4.17-4.20 (1H, m, C(9)H), 4.29-4.30 (1H, d, J 7.1, C(8)H), 6.14 (1H, d, J 
4.1, C(10)H), 6.27 (1H, d, J 5.2, ArH), 6.45 (1H, br. s, ArH), 6.59 (1H, d, J 7.2, ArH), 6.84-6.85 
(2H, m, ArH), 6.96-7.03 (2H, m, ArH), 7.15-7.22 (3H, m, ArH), 7.67-7.70 (1H, m, ArH), 7.74-
7.80 (2H, m, ArH), 7.92 (1H, d, J 7.8, ArH). All data in accordance with literature.[156] 
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(8S,9S)-9-Phenyl-8-(4-(trifluoromethyl)phenyl)-8,9-dihydro-7H benzo[4,5]isothiazolo [2,3-
a]pyridin-7-one 5,5-dioxide 
 
 
 
 
Following general procedure W, 4-trifluoromethylphenyl acetic acid (76 mg, 0.37 mmol), 
pivaloyl chloride (69 µL, 0.56 mmol) and i-Pr2NEt (98 µL, 0.56 mmol) in CH2Cl2 (6 mL), 
(2R,3S)-HyperBTM 53 (5 mg, 0.019 mmol), cyclic sulfonyl imine 617 (100 mg, 0.37 mmol), i-
Pr2NEt (64 µL, 0.37 mmol) at −78 °C gave crude reaction mixture (>95:5 dr). Purification by 
Biotage® IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (97:3 4 CV, 97:3 to 50:50 10 CV, 
50:50 1 CV)] gave the title compound (108 mg, 64%) as a white solid (>95:5 dr). mp 170-172 
°C; 
€ 
α[ ]D
20 +59.7 (c 0.1 CHCl3); Chiral HPLC analysis, Chiralpak IA (60:40 hexane:IPA, flow 
rate 1 mLmin−1, 254 nm, 30 °C) tR (8S,9S): 12.0 min, tR (8R,9R): 15.9 min; 97% ee; νmax 
(ATR)/cm−1 1321, 1707, 3158 (C-H); 1H NMR (500 MHz, CDCl3) 4.13 (1H, d, J 9.3, C(8)H), 
4.19 (1H, dd, J 3.7, 9.3, C(9)H), 6.16 (1H, d, J 3.7, C(10)H), 7.08-7.12 (2H, m, ArH), 7.25-7.32 
(5H, m, ArH), 7.53 (2H, d, J 8.2, ArH), 7.69 (1H, ddd, J 2.1, 6.3, 8.1, ArH), 7.76-7.80 (2H, m, 
ArH), 7.90 (1H, d, J 7.9, ArH); 13C NMR (125 MHz, CDCl3) 47.4 (C(8)H), 56.0 (C(9)H), 105.9 
(C(10)H), 121.9 (ArCH), 121.9 (ArCH), 124.0 (q, J 272, CF3), 125.7 (q, J 3.6, C(8)ArC(3,5)H), 
126.4 (ArC), 127.7 (ArCH), 128.1 (ArCH), 129.3 (ArCH), 129.3 (ArCH), 129.7 (ArC), 130.1 
(q, J 33.0, C(8)ArC(4)), 131.4 (ArCH), 132.7 (C(10a)), 134.4 (ArCH), 140.0 (ArC), 140.1 
(ArC), 165.8 (C(7)); 19F NMR −62.7; HRMS (NSI+) C24H16F3NO3SNa [M+Na]+, requires 
478.0695, found 478.0686 (−1.9 ppm). 
 
(8S,9S)-8-(1-Methyl-1H-indol-3-yl)-9-phenyl-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-
a]pyridin-7-one 5,5-dioxide 
 
 
 
 
 
Following general procedure W, 1-methyl-3-indoleacetic acid (70 mg, 0.37 mmol), pivaloyl 
chloride (69 µL, 0.56 mmol) and i-Pr2NEt (98 µL, 0.56 mmol) in CH2Cl2 (6 mL), (2R,3S)-
HyperBTM 53 (5 mg, 0.019 mmol), cyclic sulfonyl imine 617 (100 mg, 0.37 mmol), i-Pr2NEt 
(64 µL, 0.37 mmol) at −78 °C gave crude reaction mixture (80:20 dr). Purification by Biotage® 
IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (97:3 4 CV, 97:3 to 50:50 10 CV, 50:50 1 
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CV)] gave the title compound (97 mg, 60%) as a white solid (89:11 dr). mp 236-238 °C; 
€ 
α[ ]D
20 
+69.7 (c 1.0 CH2Cl2); Chiral HPLC analysis, Chiralpak AD-H (60:40 hexane:IPA, flow rate 1 
mLmin−1, 254 nm, 30 °C) tR (8S,9S): 12.0 min, tR (8R,9R): 15.9 min; >99% ee; νmax (ATR)/cm−1 
1333, 1705, 3155 (C-H); 1H NMR (400 MHz, CDCl3) 3.69 (3H, s, NCH3), 4.33 (1H, dd, J 3.7, 
5.6, C(9)H), 4.42 (1H, d, J 3.7, C(8)H), 6.15 (1H, d, J 5.6, C(10)H), 6.94 (1H, s, indolyl(2)H), 
7.16-7.20 (1H, m, ArH), 7.25-7.39 (6H, m, ArH), 7.67-7.70 (2H, m, ArH), 7.25-7.28 (2H, m, 
ArH), 7.92 (1H, d, J 7.8, ArH); 13C NMR (100 MHz, CDCl3) 33.0 (NCH3), 46.7 (C(9)H), 48.0 
(C(8)H), 105.2 (C(10)H), 109.8 (indolylC(7)H), 110.3 (indolylC(3)H), 119.0 (indolylC(4)H), 
119.8 (indolylC(5)H), 121.9 (ArCH), 121.9 (ArCH), 122.3 (ArCH), 126.3 (indolylC(2)H), 
126.6 (ArC), 126.8 (ArC), 127.4 (ArCH), 128.0 (ArCH), 129.5 (ArCH), 131.1 (ArCH), 132.8 
(ArC), 134.2 (ArCH), 137.1 (C(10a)), 141.0 (ArC), 166.4 (C(7)); HRMS (NSI+) 
C26H20N2O3SNa [M+Na]+, requires 463.1087, found 463.1078 (−1.9 ppm). 
 
(8S,9S)-9-Phenyl-8-(thiophen-3-yl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-
one 5,5-dioxide 
 
 
 
 
Following general procedure W, 3-thiopheneacetic acid (53 mg, 0.37 mmol), pivaloyl chloride 
(69 µL, 0.56 mmol) and i-Pr2NEt (98 µL, 0.56 mmol) in CH2Cl2 (6 mL), (2R,3S)-HyperBTM 53 
(5 mg, 0.019 mmol), cyclic sulfonyl imine 617 (100 mg, 0.37 mmol), i-Pr2NEt (64 µL, 0.37 
mmol) at −78 °C gave crude reaction mixture (93:7 dr). Purification by Biotage® IsoleraTM 4 
[SNAP 25 g, 75 mL−1, hexane:EtOAc (97:3 4 CV, 97:3 to 50:50 10 CV, 50:50 1 CV)] gave the 
title compound (112 mg, 77%) as a white solid (>95:5 dr). mp 198-200 °C; 
€ 
α[ ]D
20 +79.3 (c 0.1 
CH2Cl2); Chiral HPLC analysis, Chiralpak AD-H (60:40 hexane:IPA, flow rate 1 mLmin−1, 254 
nm, 30 °C) tR (8S,9S): 21.7 min, tR (8R,9R): 44.0 min; >99% ee; νmax (ATR)/cm−1  1355, 1709, 
3001 (C-H); 1H NMR (500 MHz, CDCl3) 4.16-4.20 (2H, m, C(8)H and C(9)H), 6.15 (1H, d, J 
4.6, C(10)H), 7.04-7.08 (2H, m, ArH), 7.16-7.17 (2H, m, ArH)7.27-7.33 (4H, m, ArH), 7.65 
(1H, m, ArH), 7.72 (2H, m, ArH), 7.84 (1H, d, J 7.8, ArH); 13C NMR (125 MHz, CDCl3) 46.8 
(C(9)H), 51.5 (C(8)H), 105.1 (C(10)H), 121.9 (ArCH), 121.9 (ArCH), 126.6 (ArCH), 127.0 
(ArCH), 127.4 (ArCH), 127.4 (ArCH),  128.0 (ArCH), 129.4 (ArCH), 129.6 (ArC), 131.3 
(ArCH), 132.8 (), 134.3 (ArCH), 136.1 (C(10a)), 140.4 (ArC), 165.9 (C(7)); HRMS (NSI+) 
C21H16NO3S2 [M+H]+, requires 394.0572, found 394.0561 (−2.8 ppm). 
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(8R,9S)-9-Phenyl-8-((E)-styryl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-one 
5,5-dioxide 
 
 
 
 
Following general procedure W, (E)-4-phenylbut-3-enoic acid (60 mg, 0.37 mmol), pivaloyl 
chloride (69 µL, 0.56 mmol) and i-Pr2NEt (98 µL, 0.56 mmol) in CH2Cl2 (6 mL), (2R,3S)-
HyperBTM 53 (5 mg, 0.019 mmol), cyclic sulfonyl imine 617 (100 mg, 0.37 mmol), i-Pr2NEt 
(64 µL, 0.37 mmol) at −78 °C gave crude reaction mixture (95:5 dr). Purification by Biotage® 
IsoleraTM 4 [SNAP 25 g, 75 mL−1, hexane:EtOAc (97:3 4 CV, 97:3 to 50:50 10 CV, 50:50 1 
CV)] gave the title compound (98 mg, 64%) as a white solid (95:5 dr). mp 204-206 °C; 
€ 
α[ ]D
20 
+81.1 (c 1.0 CH2Cl2); Chiral HPLC analysis, Chiralpak AD-H (60:40 hexane:IPA, flow rate 1 
mLmin−1, 254 nm, 30 °C) tR (8R,9S): 15.6 min, tR (8S,9R): 25.8 min; 71% ee; νmax (ATR)/cm−1 
1366, 1728, 1736, 2970 (C-H); 1H NMR (500 MHz, CDCl3) 3.66 (1H, t, J 6.6, C(8)H), 3.96 
(1H, t, J 5.0, C(8)H), 6.10 (1H, d, J 4.5, C(8)C(1)H), 6.17 (1H, dd, J 7.6, 15.9, C(8)C(2)H), 6.42 
(1H, d, J 15.9, C(10)H), 7.20-7.34 (10H, m, ArH), 7.61-7.64 (1H, m, ArH), 7.70-7.72 (2H, m, 
ArH), 7.85 (1H, d, J 7.8, ArH); 13C NMR (125 MHz, CDCl3) 45.9 (C(9)H), 53.3 (C(8)H), 105.0 
(C(8)C(1)H), 121.9 (ArCH), 121.9 (ArCH), 123.4 (C(8)C(2)H), 126.7 (ArCH), 126.7 (ArCH), 
127.7 (ArCH), 128.0 (ArC), 128.2 (ArC), 128.7 (ArCH), 129.4 (ArCH), 129.6 (ArC), 131.2 
(ArCH), 132.8 (ArC), 134.2 (ArCH), 135.3 (ArCH), 136.3 (C(10a)), 140.3 (ArC), 166.2 (C(7)); 
HRMS (NSI+) C25H20NO3S [M+H]+, requires 414.1164, found 414.1139 (−6.0 ppm). 
 
9-Phenyl-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-one 5,5-dioxide 
 
 
 
 
To a solution of acyl imidazole 661 (81 mg, 0.37 mmol) in CH2Cl2 was added cyclic sulfonyl 
imine 617 (100 mg, 0.37 mmol) and DHPB 86 (7 mg, 0.037 mmol) and reaction stirred at rt for 
6 h. Reaction was washed with aq. HCl (2 M) (×3), sat. aq. NaHCO3, dried over MgSO4 and 
concentrated under reduced pressure to give crude reaction product. Recrystallisation (Et2O) 
gave the title compound as a white solid (100 mg, 88%); mp >300 °C; νmax (ATR)/cm−1 1724, 
2895, 2951 (C-H); 1H NMR (500 MHz, d6-DMSO) 6.91 (1H, s, C(10)H), 7.54-7.55 (3H, m, 
ArH), 7.74 (1H, s, C(8)H), 7.83-7.90 (3H, m, ArH), 7.98 (1H, t, J 7.6, ArH), 8.26 (1H, d, J 7.8, 
ArH), 8.47 (1H, d, J 7.9, ArH); 13C NMR (125 MHz, d6-DMSO) 107.8 (C(8)H), 118.1 
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(C(10)H), 122.3 (ArCH), 123.9 (ArCH), 125.1 (ArC), 127.3 (ArCH), 129.1 (ArCH), 130.7 
(ArCH), 131.8 (ArC), 133.0 (ArCH), 135.4 (ArC), 135.5 (ArCH), 135.5 (ArC), 153.2 (ArC), 
158.4 (C(7)); HRMS (NSI+) C17H11NO3S+ [M+H]+, requires 309.0460, found 309.0451 (−1.3 
ppm). 
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